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Abstract 
Optimising medicine reconciliation at the healthcare interface 
By 
Eman A. Hammad BSc MSc 
Keywords: Medicine/ medication reconciliation, care transition, pharmacist service, 
discharge communication, medication discrepancies, health interface 
Background: Medicine reconciliation (MR) is the process of obtaining and maintaining an 
accurate, detailed list of all medicines taken by a patient and using this list anywhere 
within the health care system to ensure that the patient receives the correct medicines. 
This thesis aimed to design an MR intervention and develop a strategy for its evaluation. 
Methods: A health Trust-wide evaluation of the quality of discharge information relative to 
national guidance for the minimum dataset of information transfer was undertaken to 
identify the areas of sub-optimal practice. A systematic review informed the content and 
design of a pharmacy led medicines reconciliation service. A pilot randomised controlled 
trial was conducted to provide an early indication of the intervention’s costs and effects 
and to inform the design of a definitive trial.   
Results: A review of 3,444 discharge summaries in one primary care trust found that 80% 
had at least one medication discrepancy. On average these were considered to cause 
moderate patient harm and to take 15 minutes to address. No studies were found to 
comprehensively assess the cost-effectiveness of pharmacy led medicines reconciliation. 
Interim analysis of a pilot 24 hour MR service showed that only 20% of errors upon 
admission were intercepted before discharge in the control group, compared to 98.6% 
within the intervention arm. The MR service was estimated to contribute to cost savings of 
almost £3,000 per patient.   
Conclusions: The existing process to transfer and process information at the healthcare 
interface is not optimum. Evidence to demonstrate the cost-effectiveness of pharmacy led 
MR services is not currently available. Interim analysis of a pharmacy led 24 hour MR 
service suggests that the service may enhance accuracy and transfer of information and 
reduce overall health resource utilisation. The pilot MR service will inform the feasibility of 
large scale evaluation for the cost-effectiveness.  
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by a wide range of independent contractors, such as GPs, dentists, 
pharmacists and optometrists. NHS walk-in centres. 
Secondary care  The health service provided by medical specialists who generally do not 
have first contact with patients and usually delivered in hospitals  
Department of 
Health 
The division responsible for strategic leadership of both the health and 
social care systems, but no longer the headquarters of the NHS, nor it 
directly manage any NHS organisations.  
The Royal 
Pharmaceutical 
of Great Britain  
The regulatory and professional body for pharmacists and pharmacy 
technicians in England, Scotland and Wales. 
From NHS.choice. Available at: http://www.nhs.uk/NHSEngland/thenhs/about/Pages/authoritiesandtrusts.aspx. 
**National Patient safety agency available at : http://www.npsa.nhs.uk/corporate/about-us/what-we-do/nrls/ 
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University of East Anglia, Norwich, UK  

orwich is situated in the county of 
Norfolk, in the east of England. The city 
has a rich historical background.  During 
the 11th century, Norwich was the largest city in 
England after London.  
Norwich, alongside the rest of the British Isles, 
experiences a temperate maritime climate, and as 
such does not endure extreme temperatures, and 
benefits from fairly evenly spread rainfall 
throughout the year. Some call Norwich the city of 
sun compared to the rest of UK cities.  
Norwich is a very beautiful city with fascinating landscape views, delightful riverside walk 
and lake.  There are also museums, magnificent cathedrals, cobbled streets, half-
timbered houses. Norfolk is a beautiful county; famous for Norfolk Broads. These offer 
uniquely beautiful unspoilt coastline, nature reserves and amazing wildlife. 
The University of East Anglia (UEA) was founded in 1963; UEA will celebrate its 50th 
anniversary in 2013 over the weekend of 28-29 September 2013.  
UEA School of Pharmacy was founded in 2003 and has quickly risen to become one of 
the top pharmacy schools in the UK which was nominated number one in the Guardian 
University Guide (2013). In the 2008 Research Assessment Exercise, UEA came 6th 
overall, top of the new schools of Pharmacy in the UK. 
Most recent, UEA is ranked 5th in the UK for the impact of its research in the 2013 Leiden 
ranking of universities and the Top UK University by the Times Higher Education Student 
Experience Survey 2013.  
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University of Jordan, Jordan 
Eman A. Hammad, the author of this thesis is from Jordan.  
ordan is a small country in the Middle 
East but captures one’s heart the 
minute they get to see the 
mesmerising beauty and contrasts of the 
country as it isa well-travelled bridge 
between sea and desert.  Jordan has grown 
into a modern nation that has enjoyed a 
remarkable measure of peace and stability.  
Jordanians are friendly and open their 
hearts before homes to visitors.  
Jordan is mostly known to westerners for its 
famous ancient Nabataean city of Petra, carved from the rock over a thousand years. 
 
The main duties of community pharmacists in Jordan involve dispensing; the duties of 
hospital pharmacists mainly consist of administrative tasks with dispensing activities 
principally left to pharmacy technicians.  In recent years the role of clinical pharmacist has 
been increasingly recognised and the need for pharmacy profession to develop and strive 
to adopt a more central role in patient care and health policy making is well recognised by 
health care and education bodies in Jordan. This can be achieved by devising 
undergraduate and postgraduate programmes that yield pharmacists with clinical, 
communication and research skills.  
University of Jordan (UJ) is the leading university in Jordan and one of the most 
prestigious in the Arab World.  UJ/ School of Pharmacy enjoys respectable reputation for 
research and innovation; staff at the faculty continually strive for excellence in their 
learning, teaching and research.  The School actively promotes opportunities to allow 
students to add new skills and experiences that can be shared with future students and 
translated into pharmacy research that take the profession of pharmacy in Jordan forward; 
herein the author of this thesis was funded to do her PhD. 
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1.1 Background 
With medication usage increasing by 4% each year it is the primary healthcare 
intervention used in western society, in 2011 it was estimated that an adult is prescribed 
an average of 18 items under the UK National Health Service (NHS) per year.[1]  In June 
2012, the National Reporting and Learning Services / National Patient Safety Agency 
(NPSA) in England and Wales identified adverse drug events as the second most 
common type of patient safety incident and therefore effectively managing the way that 
medicines are prescribed, dispensed and administered is central to patient safety. [2] 
Whilst the number of hospital admissions in England has grown by more than 60% from 
11 million per year to 17.5 million over the past 10 years, the number of hospital beds has 
increased to accommodate only 5% of these admissions.  Consequently, the average 
length of hospital stay over the past five years has reduced significantly and the median 
length is currently one day.[3, 4]  The increase transition of patients between primary and 
secondary care provides an increased opportunity for medication errors.  Between 2003 
and 2007, the NPSA reported 7,070 medication errors involving admission and discharge 
resulting in two fatalities and 30 errors which caused severe patient harm.[5]  Additionally, 
between 2006 and 2009, the NPSA received reports of 27 deaths, 68 severe harms and 
more than 21,000 patient safety incidents related to omitted and delayed medicines upon 
admission.[6]  Noting that the NPSA reporting scheme is a voluntary system, it is likely that 
these figures potentially underestimate greater rates of patient harm.  
The Institute of Healthcare Improvement, based on reports from hundreds of 
organisations around the world, concluded that poor communication of clinical information 
at the health interface is responsible for almost 50% of all medication errors and up to 
20% of averse drug events.[7]  It is also estimated that one in five patients suffer an 
adverse event at discharge, of which 72% are related to medicines.[8]  Additionally, the 
World Health Organisation highlighted the increased risk of preventable morbidity at the 
health interface.[9]   
In the UK, the Audit Commission in 2001 reported that 12% of adverse drug events upon 
hospital admission were related to medicine use.[10]  It is also estimated that each adverse 
event increase hospital stay by 8.5 days on average and the total cost of hospital 
admissions related to preventable medication errors is half of a billion pounds each 
year.[11]  Additionally, within an increasingly litigious society, the NHS Litigation Authority 
reported that the payment for clinical claims is rising substantially each year.  In 
2011/2012 the NHS payment for clinical claims in total was estimated over than one 
billion[12] 
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As a result of increases in the use of medicines, number of hospital admissions, number 
of medication errors and the public desire to pursue compensation, it has become ever 
more necessary to minimise errors occurring at healthcare interfaces and to identify areas 
for improvement in the current practice of care transition. 
1.2 Healthcare transition in the UK 
There are two main transfer points where errors can be introduced; one is on admission 
from primary to secondary care and the other is upon discharge from secondary to 
primary care.  
1.2.1 Primary care to secondary care transition  
1.2.1.1 Planned admissions 
A patient admission to the hospital can be planned or unplanned.  Planned admissions 
might be an outpatient, admitted as day care or inpatient case.  As an outpatient, the 
patient goes to the hospital for an appointment to see a specialist without staying 
overnight.  As a day case, the patient will be given a hospital bed for a test or surgery, but 
will not stay overnight; this can include treatments such as minor surgery, dialysis or 
chemotherapy.  Meanwhile, as an inpatient the patient stays in hospital for one night or 
more.  
With planned admissions, the patient is often involved in the decision regarding the receipt 
of treatment in hospital.  The decision is mutually agreed with the patient’s primary care 
doctor who will be termed the general practitioner (GP).  Patients might have a referral 
letter from their GP which contains information about the patient’s regular medicines, co-
morbidities, and known allergies.  The letter might also include a full list of medicines the 
patient is taking and the contact details of the GP or the nurse who is responsible for the 
patient’s care in the primary care practice.  Additionally, the patient may bring their own 
medicines with them or a copy of their repeat prescription. 
Traditionally, information upon admission is obtained by junior doctors, also called 
foundation year doctors, who have limited experience and knowledge of medicines and 
frequently this process is undertaken unsupervised.[13, 14] 
In some hospitals patients attend a pre-admission clinic which may include an 
appointment with a nurse or doctor, or a telephone assessment.  This might also include a 
pharmacist who obtains information on the patient’s medication history and ensures the 
patient receives clear instructions on medicines to discontinue before admission.   
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1.2.1.2 Unplanned admissions 
Unlike planned admissions, the amount and quality of information available in the case of 
unplanned admissions is less predictable.  Patients frequently access the accident and 
emergency departments with serious injuries or illnesses; this occurs more frequently out 
of working hours
  Therefore, no information may be available with the patient and 
neither the GP nor the community pharmacist might be available to contact.  
In some emergency departments, a pharmacy post is funded to provide services including 
medication history and patient own drugs review; however, in others there is limited or no 
pharmacy input.[15]  Similarly, in some hospitals a dedicated pharmacist is employed in the 
medical assessment units; through which a sizable proportion of patients are admitted.  
The pharmacist is available to quality assure the information collected on admission; 
nevertheless, not all admissions go through the medical assessment units and might 
occur outside normal working hours.  
1.2.2 Secondary care to primary care transition  
The quality of discharge information can depend on the quality of admission information, 
i.e. if errors were introduced at the admission stage they are likely to continue upon 
discharge.[16, 17]  Each hospital has its own discharge policy which should comply with the 
guidance published by the Department of Health in 2003.  The guidance emphasises the 
importance of involving patients and their care providers in hospital discharge planning 
and ensuring effective handover of care.[18]   
Upon discharge from hospital, a discharge summary is produced by the secondary care 
team summarising the key clinical information related to the patient’s hospital stay.  
Ideally, this includes details of the presenting diagnosis, procedures carried out, 
medicines changed, started or stopped.[19]  Discharge summaries can be handwritten or 
produced in an electronic pro-forma; either type might be faxed, posted, emailed or hand 
delivered by the patient to the primary care practice.   
As is the case with admissions, the responsibility for preparing lists of discharge 
medicines lies principally with junior doctors.  A new post has been funded in many 
hospitals for a discharge coordinator who is often from a nursing background.  The 
discharge coordinator is responsible for providing a single communication point for all 
health professionals involved in patient care.  The consultant in charge and the discharge 
coordinator might support junior doctors.[20]  Increasingly, a pharmacist is available also to 
clinically check discharge prescriptions; however, such a service is available in only three 
quarters of UK trusts and mostly during normal working hours only.[21] 
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Following discharge, patients visit primary care practices for follow up, assessment of 
treatment progress and obtaining medicines supplies.  Once a discharge summary is 
received by the primary care practice, information from secondary care should be critically 
reviewed and incorporated in the GP held patient record.  As such, all changes occurring 
during hospital stay are continued as intended by the hospital team.  Ensuring continuity 
of care between health providers at both sides of the health interface is central for patient 
safety; breakdown in communication might result in duplicated medicines or continued 
medicines which might be incompatible with the patient’s condition.[19]   
1.3 Communication deficits at the health interface: hospital admission and 
discharge 
Several NHS reports and a number of UK studies highlight that admission and discharge 
information is often incomplete and inaccurate.   
The audit commission highlighted in 2001 that almost one third of patients receive 
incorrect medicines or have incomplete medicines recorded on admission and outlined 
considerable costs related to patient own drugs that brought upon admission but thrown 
away or left behind upon discharge.[10] 
Gray et al. reviewed 736 medicine charts over three months in an acute medical 
assessment unit in a large teaching hospital in the east of England in 2007 and found that 
45% of charts included at least one prescribing error.  A total of 265 prescribing errors 
were identified of which 15.9% were omissions and 13.2% were incorrect additions of 
medicine.[22]  Additionally, the NPSA published a report in 2010 highlighting the harm 
caused by omitted and delayed medicines upon hospital admission.  Omission of regular 
medicines was the predominating error and often contributed to delays in patients 
receiving their medicines.[23]   
Studies have highlighted that a gold standard medicines list is frequently not available 
when patients transfer between care settings.  A study in the northwest of England in 
2004 conducted by Collins et al. reviewing 126 medical and 51 surgical patients 
highlighted the need for better documentation of medication histories.  One hundred and 
two (16%) inpatient medicines were not documented in medical notes and 40% of 
medicines were omitted.  Collins et al. reviewed different sources of patient information 
and found frequent discrepancies between what is are actually taken, reported by the 
patient, documented on the hospital medical notes and the primary care records.[24]   In 
2010, a similar investigation repeated in the same institution reported similar findings.  
Further insights, however, were reported on the type of discrepancies identified within 
each source of patient information.  Discrepancies were most frequently attributable to 
unintentional omissions by the hospital team, those accounted for 119 (42%) 
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discrepancies.  Additionally, for 28 patients, the GP held list of medicines was found 
inaccurate and inadequate which accounted for 119 discrepancies.  Of those 
discrepancies 30% were medicines described to be used “as directed” where ideally full 
directions should have been included and so the hospital doctor required further contact 
for clarification.[25]   
Allergy information is often insufficiently documented in patient records; Collins et al. 
reported that allergy information was incorrect or incomplete for 41% patients.  For 29% 
patients, allergy status boxes were left empty and for 71% patients allergy was noted but 
with no description of the nature of reaction.[24]  Similarly, allergy information was also 
missing or inaccurate on 13% of medication charts reviewed by Gray et al.[22] 
An audit of 56 trusts reported by the clinical directorate of the East and South East 
England Specialist Pharmacy Services in 2010 included 3,3120 patients; the average 
number of errors per discharge review consisting of five or more medicines was 1.32 
errors.  A total of 11,366 unintentional discrepancies were identified of which 73% 
concerned omitted medicines and 14% were for wrong doses.[26]   
In addition to omissions and inaccuracies of information, legibility may compromise the 
effectiveness of discharge communication.  However, this has been only evaluated by a 
small report in Nottinghamshire in 2007; a comparison of 30 handwritten and 30 electronic 
discharge summaries considered 12 (40%) were illegible.[27]   
These findings from UK reports are of note, however, they are mostly of relatively small 
size, based on a single site and with considerable confounding and methodological 
limitations.  There is no robust UK, large-scale evaluation of the quality of information 
transferred at the health interface. 
Similar to those reported in the UK, deficits within information transfer have been reported 
in USA and Canada.  These were generally of larger, multiple site evaluations, though 
they had similar methodological limitations.[28-31]  In line with the figures from the USA and 
Canada, studies from Europe and Australia have highlighted similar issues.[32-37]  This 
suggests that deficits with information transfer is a worldwide growing challenge across 
health interfaces and health systems of different workflows 
1.4 Deficits in information transferred to primary care 
Maintaining continuity of care has showed a significant association with improved patient 
outcomes and health resource utilisation.[38, 39]  Unless an accurate and complete 
medicines list is obtained upon admission, omissions and unintentional changes will 
persist until discharge. [16, 17]   
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Studies evaluating the quality of information received in primary care have highlighted that 
discharge summaries were often missing essential information.  Of 569 discharge 
summaries audited in Australia in 2001, 36.4% were found to contain information which 
did not accurately reflect the information recorded in hospital notes.[36]  Additionally, GPs 
require comprehensive information following patient discharge to ensure appropriate post 
discharge management and continuity of healthcare.  One hundred and forty nine out of 
465 Dutch GPs responded to post questionnaire in 2010 enquiring about the information 
needed on discharge medication, both regarding content and timing of discharge 
information.  Up to 88% of respondents wished to receive full information about medicines 
stopped and changed during hospital admission and appreciated clinical pharmacist 
advice to inform the post discharge care decision.[40]  
The availability of complete information can help to optimise patient post discharge care; 
in Canada, a study aimed to determine if the availability of discharge summaries at the 
next health provider visit would decrease the risk of hospital readmission.  From 888 
patients discharged in 2002, a discharge summary was available for only 12.2% of 4,639 
post discharge outpatient visits and 27% of these patients were urgently readmitted to 
hospital.  Patients who were seen by a doctor who had received the discharge summary 
trended towards a decreased risk of readmission, relative risk [95% CI] = 0.74 [0.50 to 
1.11] (p>0.05).[39] 
The timeliness of information transfer is also pertinent for continuity of post discharge 
care. An Australian study conducted in 2011 estimated that over 70% of patients visit their 
GP within one month of discharge and 25% visit their GP within 4 days of discharge.[41]  
Discharge summaries, therefore, ideally need to reach primary care practices within this 
timeline, however, a Canadian study in 2002, showed that 542 (68.4%) patients had no 
discharge summary available at the time of their GP visit post discharged.  In 20% of 
cases this was because discharge summaries were not generated on time and in 50% 
they were not sent at all.[42]  Similarly, in the Netherlands in 2010, 25% of GPs experienced 
delays in discharge information and preferred to receive information on the day of 
discharge because they were consulted by patients or family immediately after 
discharge.[40] 
In the UK, the Care Quality Commission in 2009 published the results from a survey of 12 
primary care trusts and highlighted persistent omissions of information related to the 
medicines prescribed upon discharge.  GPs reported that information on allergies was 
infrequent and contact details for enquiries even more rare.[19]  The report also outlined 
concerns around the timeliness of discharge summaries with only 53% of the 12 reviewed 
trusts reporting that discharge summaries were received in enough time to be of use for 
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patient post discharge management.[19]  However, the development of computer 
technology has expedited the production and transfer of electronic discharge summaries 
and resolved legibility issues.[43]  
1.5 Implications of communication deficits at the health interface 
The clinical impact of information deficits at the health interface have been evaluated by a 
number of studies using various tools, but few adopted validated approaches.[31, 32, 35]  In 
the UK and worldwide, the proportions of discrepancies causing moderate to serious harm 
or patient discomfort have ranged between 10% and 50%.[31, 34, 44, 45]  Variances can be 
explained by the variations in discrepancy definition, identification and study settings.  
Studies also differed in the methods used to assess severity in terms of the tool used, 
number of raters and degree of agreement.  Appendix 1 summarises the variations in 
worldwide MR literature with respect to discrepancy definition, classification, clinical 
significance and inter-rater agreement assessment. 
The only large scale UK evaluation of the clinical significance of MR related discrepancies 
was reported by the clinical directorate of the East and South East England Specialist 
Pharmacy Services in 2011.[44]  This audit consisted of 30 acute trusts and reviewed 3,091 
medicines; 4,041 discrepancies were identified.  Across care areas, 30% to 52% were 
considered of moderate or significant potential to increase treatment length or to cause 
non-permanent harm to the patient.  The severity of discrepancies was assessed using a 
non-validated tool developed by the NPSA in 2008.  The development of the NPSA matrix 
was supported by background guidance along with findings from local workshops.[46]  No 
details were also reported regarding assessment of the variability and agreement between 
auditors. 
Medication discrepancies also contributed to increased risks of rehospitalisation.  In a 
USA study of 375 patients, 14.3% with a medication discrepancy were re-admitted to 
hospital within 30 days of discharge compared with only 6.1% of patients with no 
discrepancy (p=0.04).[47]  This was also consistent with the findings from a small UK study 
in 2008.[48]  Communication gaps within discharge information for 108 patients readmitted 
within 28 days in the East Midlands in 2008 we identified frequent occurring in two-thirds 
of discharge documents.  Twenty two (54%) of readmissions were of patients with at least 
one communication gap upon discharge.[48]  
Discharge summaries lacking information not only pose a risk to the patient but also 
create ambiguity in prescribing and therefore cost implications.  These might include 
continuation of unnecessary prescribing or the need for GPs to spend time acquiring 
necessary information from the hospital team using alternative media.  This has been 
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outlined as a concern by the Care Quality Commission report on managing patients after 
discharge in 2009.[19]  Additionally, without comprehensive and timely notification about 
patient treatment during and post hospitalisation GPs might feel unable to continue patient 
care and maintain clinical responsibility.[49, 50] 
Whilst, studies have highlighted the implications of admission and discharge information 
deficits, little has been reported on the quality of information transferred to primary care.  
There is little indication of the magnitude of discharge discrepancies that are translated 
into primary care; neither the outcomes of discrepancies nor the actual patient harm 
perpetuated post discharge.  Additionally, little is known about how primary care practices 
process discharge team recommendations.   
1.6 Contributing factors to the quality of information transfer at health interfaces 
Factors that may influence the quality of communication at health interfaces may be 
patient related such as age, complexity of care and medicines regimen.  They can also be 
related to the process of obtaining or communicating information, such as the discharge 
summary template and whether the document used to transfer information is handwritten 
or electronic.  Additionally, the time available to collect and communicate information can 
influence accuracy and completeness of information depending on whether the admission 
or discharge was planned or unplanned or occurred out of working hours or at weekends.  
Variations may also be related to the professional involved, such as the medical training of 
the person obtaining medication history or completing discharge summary.  Workload and 
ward workflow might vary between care areas and hospitals and thus it might contribute to 
variation in the transferred information.  
1.6.1 Patient related factors  
Patient age can influence the risk of experiencing a discrepancy.  Perren et al. evaluated 
577 consecutively selected discharge summaries in Switzerland in 2008.  The study 
reported that discrepancies were significantly more frequent in females who were also 
significantly older than men plus patients prescribed more medicines.[32]  No regression 
was undertaken in order to estimate the relative effects of these different predictors.  
Unroe et al. in USA in 2010, [32] used multivariate logistic regression analysis to investigate 
factors associated with admission and discharge discrepancies.  The study reported age 
to be a significant predictor of discrepancies.[29]  Given that the average life expectancy of 
females is longer than males, it is likely that age is the predictor of discrepancy frequency 
and not sex as suggested by the Perren et al. study.  
Conversely, Pippins et al. found patients older than 85 years had fewer discrepancies.[28]  
This might be unintuitive, as with increased age patients might be prescribed more 
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medicines and this imposes greater pressure for communication and opportunity of more 
errors.  However, this effect persisted when Pippins et al. adjusted for number, class of 
medicines and the source used to obtain pre-admission medicines lists.  A possible 
explanation might be that older patients aged over 85 tend to be in relatively good general 
health status, i.e. prescribed less medicines and able to self-manage their medicines.  
Additionally, they might have been prescribed the same medicines for many years, thus, 
both the patient and carer are well familiar with medicines prescribed.  This might suggest 
that the actual association seen between risk of discrepancy and age in the earlier studies 
is actually related to the influence of an increased number of prescribed medicines.  
Consistent with this assertion is a study of 120 consecutively selected patients with a 
mean (SD) age of 82.3 (6.8) in a geriatric outpatient clinic in the Netherlands in 2009 
which identified an increased risk of medication discrepancies with an increased number 
of prescribed medicines but not with age.[51]  This is also in concordance with other 
reports.[16, 30, 32, 35, 52-54]  Add to this, a recent retrospective review of 199 discharge 
documents from patients admitted to an acute geriatric department in Belgium estimated 
47% increase in the likelihood of discrepancies for every additional medicine.[55]  Those 
studies might be insightful, however none of them evaluated patients identified via random 
selection and thus their conclusion might be biased by unknown confounding factors.  
An increased risk of discrepancy might actually reflect the increased complexity of patient 
care; Pippins et al. found that patients who had six or more medicines changed during 
their hospital stay were over three times more likely to experience medication 
discrepancies.[28]   
Similarly, the type of prescribed medicines could give an indication of care complexity; 
cardiovascular medicines were most often associated with discrepancies.[28, 29, 56]  Those 
patients are most often elderly and acutely ill; additionally these medicines are the most 
frequently prescribed class of medicine.[1]  Other classes have also been implicated in 
discrepancies such as medicines for the central nervous system ,[31, 33] gastrointestinal [54] 
and respiratory. [31, 33]  Over the counter purchased medicines and vitamin supplements 
were similarly associated with discrepancies in a number of reports.[28, 29, 31, 33]  Of these 
studies, only Unroe et al. and Pippin et al. evaluated the association between 
discrepancies and medication classes whilst taking into account confounding factors 
related to patient and regimen complexity.  Unroe et al. defined a medicine as “high risk” if 
listed in the North Carolina Narrow Therapeutic index;[57] using univariate logistic 
regression, patients prescribed one or more of these medicines were at considerably 
higher risk of experiencing a medication discrepancy, odds ratio [95%CI] = 63.1 [7.93–
502.45] (p<0.001).  Pippins et al. defined the five most “high risk medicines” prescribed 
with the greatest frequency in the study site as gout medicines, muscle relaxants, lipid 
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lowering agents, antidepressants and respiratory medicines.  Four or more of these “high 
risk medicines” at admission increased the odds of a higher number of discrepancies by 
three times (p <0.05).  This association between high risk medicines and discrepancies 
may simply be because they are commonly prescribed or due to being associated with 
complex regimens. [1, 58]  However, in the case of over the counter medicines and vitamins 
or supplements, this might be because they are perceived as safe, with minimal risk of 
adverse event and thus less attention paid to accuracy.[59] 
1.6.2 Process related factors 
1.6.2.1 Type of discharge summary  
Historically, discharge summaries were handwritten and thus their legibility presented a 
potential for errors.  Reports have estimated that 40% to 75% of handwritten discharge 
summaries were completely or partially illegible.[27, 60]  As might be expected, handwritten 
discharge summaries were associated with an increased risk of medication 
discrepancies.[35]  However, with advances in computer technology, the use of electronic 
discharge summaries has evolved and thus the relevance of legibility is diminishing.[43]   
Despite electronic discharge summaries removing the issue of legibility and allowing 
faster and uniform recording of clinical information,[60] evidence is emerging that errors yet 
can be introduced with the use of IT systems.[61, 62]  Thus, electonic discharge summary 
are subject to the same transcription issues as handwritten discharge summaries.[43, 61, 63]  
In line with this, an Australian study reviewing 245 discharge summaries in 2008, 
identified nearly twice as many errors and omissions in electronic compared to 
handwritten discharge summaries.[64]  A larger evaluation conducted by the same author in 
2010, reviewed 966 handwritten and 842 electronic discharge summaries, the study 
aimed to gain further insight in to the nature of errors introduced by electronic discharge 
communication.  The authors found no new types of error introduced by electronic 
discharge summaries with both types exhibiting similar nature and extent of errors.[63]  
However, neither of these studies adjusted for possible patient or process confounders. 
1.6.2.2 Type of admission 
For planned admissions, it might be expected to have more comprehensive information.  
Patients can be asked to bring certain information with them and the GP can help with the 
process by providing a letter or a list of repeat medicines.  Whereas, with unplanned 
admissions obtaining information in a timely manner can be challenging and the amount 
and quality of information can vary.  There is, however, limited evidence to support this 
hypothesis  The UK wide audit conducted by the East and South East England Specialist 
Pharmacy Services in 2011 reported more errors being associated with unplanned 
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admissions in medical areas, but equally highlighted errors in planned surgical 
admissions.[44]  These comments should be only taken as a guide as they are not 
supported by regression analysis and there were incomplete data related to a number of 
planned and unplanned care areas.  Another large study conducted by Bell et al., 
reviewed 1,402 medicine charts of patients discharged from intensive care units in 
Canada.  The study identified patients admitted via emergency department at 1.4 times 
more risk of unintentional discontinuation of pre-admission medicines.[65]  However, this 
was not statistically significant and patients might have been at increased risk of errors 
due to the complexity of their presentation which was not adjusted in the regression 
model.  Therefore, further investigation is needed. 
1.6.3 Individual related factors 
1.6.3.1 Training of healthcare professional 
While discharge information depends on the information collected upon admission, it may 
also be dependent on the training and skills of the person collecting the information upon 
admission and preparing the discharge summary.   
A UK study in 2009 reviewed 124,260 medication orders across 19 hospitals in the 
northwest of England; the aim was to explore the types of errors made by foundation 
doctors in their first year of training.  Foundation doctor training level was identified as a 
contributing factor to increased risk of prescribing error.[13]  A later smaller study but still of 
considerable size, reviewed 7,920 medication orders for 1,038 patients over four weeks in 
the same region.  This also identified foundation doctors as a significant predictor of 
prescribing errors; odds ratio [95% CI] = 2.54 [1.08, 5.99] p = 0.03.[66]  This was also 
indicated by other studies, although of smaller scale, in USA and Europe.[28, 45]   
In contrast to the above, an Australian study retrospectively evaluating 1,808 discharge 
summaries reported that medication errors were similar among doctors of various training 
levels ranging from one year up to three years post-graduate training.[63]  There is 
therefore lack of clarity regarding the effect of practitioner training and experience on the 
quality of discharge summary produced. 
Studies also assessed variances that could arise from differences in training level of 
professional implementing MR at admission.  Those studies compared medication 
histories elicited by various professionals and highlighted that medication histories 
obtained by pharmacists were more accurate and comprehensive compared to those 
obtained by doctors or nurses.[14, 67-69]  However, these are of small size, non-blind and of 
retrospective observational design.  Thus such conclusions might have been biased in 
favour of pharmacist obtained histories.   
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Therefore, further exploration of the effect of profession type across different workflows 
and specialities is necessary.  This should be of large and robust design accounting for 
potential confounders.   
1.6.4 System related factors  
1.6.4.1 Ward speciality  
The complexity of patient care, workload and staff responsibilities differs between wards.  
These variances may contribute to the observed differences between wards with respect 
to the quality of transferred information.  The study conducted by Unroe et al. evaluated 
three wards including general surgery, general medicine and cardiology.  General surgery 
patients experienced more medication discrepancies and of these more were considered 
of high risk for patient harm compared to cardiology and general medicine wards; odds 
ratio [95% CI] = 3.31 [1.4-7.87] (p=0.007).  However, surgical patients in the study had 
higher rates of medicines changed compared to the other wards investigated.  It is also of 
note that besides confounding effects, these conclusions are limited by the inclusion of 
only three wards in the evaluation.  Therefore, further evaluation of ward speciality 
influence on the quality of information is demanded. 
1.6.4.2 Variation between hospitals  
Hospitals vary with respect to medicines management practice, staff and resources which 
may explain some of the differences in the extent and quality of information 
communication.[70]  There is, however, limited evidence regarding the extent to which 
quality of transferred information varies between hospital types such as teaching, 
community or specialist care hospitals.  Bell et al. found patients from an academic 
hospital were at a lower risk of errors with an adjusted odds ratio [95% CI] of 0.70 [0.49 to 
1.0] (p<0.05).  Withstanding that the study adjusted for confounding factors related to type 
of admission, complexity of patient presentation and regimen, with the small number of 
hospital studied (n=3) these conclusions are highly limited.  Wider evaluation of hospitals 
of different workflows with their representative patient population and ward specialities is 
of need.[65]  
1.6.4.3 Time and day of admission 
It might be expected that the completeness and quality of information could be influenced 
by other factors, such as the time and day of admission.  Fewer staff are available at 
weekends and out of hours admissions, plus there is limited access to primary care and 
community pharmacies.  Thus errors can be introduced; however, limited evidence is 
available to support this hypothesis.  
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Overall, the transfer of clinical information at the health interface is a multi-factorial 
process.  The relationships between factors and the quality of communication at the 
health interfaces are unclear and subject to confounding effects.  Careful and robust 
investigation of these factors in a UK context through a wide scale evaluation might 
enhance understanding of contributors and predictors of communication deficit plus 
substandard as well as outstanding practice.   
1.7 Medicine reconciliation (MR) 
1.7.1 Definition  
In response to concerns about patient safety at health transitions, medicine reconciliation 
(MR) was proposed as a solution.[7]  The definition of MR has been widely discussed 
among health professionals; the Joint Commission which is a USA based non-profit 
organization that accredits health care organizations, defines MR as the process of 
comparing the patient's medication orders to all of the medicines that the patient has been 
taking.  MR should be performed at every transition of care which includes changes in 
setting, service, practitioner or level of care.[71]  According to the Joint Commission, the 
MR process comprises five steps 1) develop a list of current medicines; 2) develop a list of 
medicines to be prescribed; 3) compare the medicines on the two lists; 4) make clinical 
decisions based on the comparison and 5) communicate the new list to the next care 
provider and to the patient.[71]  The Institute of Healthcare Improvement described three 
steps for MR: verification, clarification and reconciliation as summarised in BOX 1.1. 
The UK National Prescribing Centre (NPC) developed a similar definition and describes 
MR in two stages; and adopts the 3C approach: collecting, checking and 
communication.[72]  The MR process as described by the NPC is presented in BOX 1.2.   
  
 
BOX 1.1 MR steps defined by the institute of healthcare improvement [73] 
 Verification  
The first step involves collecting of medication histories. 
 Clarification  
Secondly, ensure that medicines and doses are appropriate 
 Reconciliation  
Thirdly, document all changes in inpatient medicine orders or charts 
This process starts when the patient is admitted to the hospital, continues whenever 
the patient is transferred to a different level of care, and occurs again when the patient 
is discharged from the hospital. 
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1.7.2 Terminology  
Whilst MR is currently clearly defined in the literature, historically there have been 
variations within MR terminology.  The growing literature over the past decade employed 
a wide range of terms describing the MR process such as history taking,[24, 74-76] discharge 
planning[77-79], prescribing checking,[58, 80] care transition/continuity,[81-84] medication 
management,[85] and assessment. 
  
 
BOX 1.2 NPC MR process[72] 
 Basic reconciliation (stage 1)  
Basic reconciliation involves the collection and accurate identification of a patient 
current list of medicines. E.g. of basic MR would include medication history taking in 
secondary care upon admission.  
 Full reconciliation (stage 2) 
Full reconciliation involves taking the basic reconciliation information and comparing it 
to the list of medicines that was most recently available for that patient. In addition, it 
involves identifying any discrepancies between the two lists and then acting on that 
information accordingly.  
The NPC “3Cs approach” includes: Collecting, Checking and Communicating 
o Collecting  
The ‘Collecting’ step involves taking a medication history and collecting other relevant 
information about the patient’s medicines which can be collected from a range of 
different sources. 
Medication history should be collected from the most recent and reliable source. Where 
possible, information should be cross-checked and verified by multiple sources. The 
person recording the information should always record the date that the information 
was obtained and the source of the information. Where there appears to be a 
discrepancy between what the patient is currently prescribed, and what the patient is 
actually taking, this should be recorded too. Where they can be established, the 
reasons for any variation should be recorded too. 
o Checking 
The ‘Checking’ step involves ensuring that the medicines and doses that are now 
prescribed for the patient are correct.  
o Communicating  
Communicating’ is the final step in the process, where any changes that have been 
made to the patient’s prescription are documented to the next care provider. 
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1.8 Initiative for MR implementation  
1.8.1 MR initiatives in the UK   
Driven by the increased focus on promoting patient safety across all NHS health 
settings,[86, 87] in September 2000, the Department of Health published Implementing the 
NHS Plan: A programme for pharmacy in the NHS hospitals.  Pharmacy services were 
suggested to be re-engineered and recommendations were placed to extend the clinical 
pharmacist role to mediation history taking.[88]   
The National Service Framework for older people in 2001 outlined that more than 15% of 
hospital admissions are related to problems with prescribed medicines and 50% of older 
people are not taking their medicines as intended upon admission.  Therefore, the report 
set standards to ensure a system is in place to specifically manage admissions of older 
people.  The system aimed to enforce safe prescribing, medicines review and accurate 
documentation of medication history.  In addition, the National Service Framework 
highlighted a need for improved communication between hospital and community health 
professionals following discharge.[89] 
With a similar focus on ensuring appropriate and safe medicine prescribing upon 
admission, the audit commission in 2001 published A Spoonful of Sugar Medicines 
Management in NHS Hospitals.  Pharmacists’ involvement in taking medication histories 
and ensuring the accuracy of admission information was emphasised.[10]  In 2003, the 
Royal Pharmaceutical Society of Great Britain also published guidelines for medicine 
management during admission and discharge.[90, 91]   
 
The NPSA in 2007 published the Fourth Report from the Patient Safety Observatory 
recommending seven actions to improve medicine use and safety of which was the 
accurate and complete documentation of patients’ allergy status.[92]  This was followed by 
national guidance for MR implementation published in collaboration with the National 
Institute for Health and Clinical Excellence (NICE).  The NICE guidance Technical patient 
safety solutions for medicines reconciliation on admission of adults to hospital 
recommended MR implementation for all admitted patients and identified pharmacists as 
the key provider of MR.[93]  In 2008, the NPC further developed the NICE/NPSA 
recommendations by recommending MR for all patients upon discharge, admission and 
ward transfer.  This was recommended within 24 hours of admission and two working 
days following discharge.  This guidance Medicines Reconciliation: A Guide to 
Implementation stipulated the minimum dataset of information that should be 
communicated at all care transitions points.  The NPC minimum datasets are summarised 
in BOX 1.3.[72] 
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In February 2010, The Rapid Response Report: From reporting to learning was issued by 
the NPSA in response to patient safety incidents, it outlined immediate actions to be taken 
by NHS organisations to minimise risks of omitted and delayed medicines in hospital and 
that all staff should be involved in the change.[6] 
More recently in 2011, the Royal Pharmaceutical society produced guidance for 
medication history taking and emphasised the pharmacist role in obtaining medication 
information from different sources and confirming information with the patient or patient’s 
carer.  In addition, greater care was recommended for obtaining information on medicines 
taken as required and recently stopped.[94]  A year after, the report Keeping patients safe 
when they transfer between care providers: getting the medicines right was published by 
the Royal Pharmaceutical society.  This report recommended implementation of 
information technology (IT) systems in hospitals and primary care practices to ensure 
effective transfer of the key content of medicines records required for patient care.  
Community pharmacists were also recommended to be involved in the process of 
information transfer between primary and secondary care.  Taking the MR process 
forward, the report recommended that clinical records should be structured in a nationally 
agreed format to assist interoperability and information transfer between settings.[95] 
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BOX 1.3 NPC minimum dataset 
 Suggested minimum dataset required in primary care 
To be able to reconcile medicines in a primary care setting, it is suggested that the 
minimum dataset of information available to GPs should include: 
o Complete and accurate patient details i.e. full name, date of birth, weight if under 
16 years, NHS/unit number, consultant, ward, date of admission, date of 
discharge 
o The diagnosis of the presenting condition plus co-morbidities 
o Procedures carried out 
o A list of all the medicines prescribed for the patient on discharge from hospital 
(and not just those dispensed at the time of discharge) 
o Dose, frequency, formulation and route of all the medicines listed 
o Medicines stopped and started, with reasons 
o Length of courses where appropriate (e.g. antibiotics) 
o Details of variable dosage regimens (e.g. oral corticosteroids, warfarin, etc.) 
o Known allergies, hypersensitivities and previous drug interactions 
o Any additional patient information provided such as corticosteroid record cards, 
anticoagulant books, etc. 
This information should be clear, unambiguous and legible and should be available to 
the GP (or other primary care prescriber) as soon as possible. Ideally, this should be 
within two working days of the patient’s discharge. 
 Suggested minimum dataset required in secondary care: 
It is suggested that the minimum dataset of information available on admission to 
hospital should include: 
o Complete patient details i.e. full name, date of birth, weight if under 16 years, 
NHS/unit number, GP, date of admission 
o The presenting condition plus co-morbidities 
o A list of all the medicines currently prescribed for the patient, including those 
bought over-the-counter (where this is known) 
o Dose, frequency, formulation and route of all the medicines listed 
o An indication of any medicines that are not intended to be continued 
o Known allergies and previous drug interactions 
This information should be clear and legible and should be available to the hospital 
when the patient is admitted for planned admissions, and within 24 hours of admission 
for unplanned admissions. In addition to the suggestions made here, local agreements 
or policies may require further information to be provided. 
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1.8.2 Worldwide MR initiatives  
In the USA, MR came to the forefront of health care in 2005; when it was designated by 
the Joint Commission as a patient safety goal.  In 2005, the Joint Commission announced 
the National Patient Safety Goal number eight which was to "accurately and completely 
reconcile medicines across the continuum of care".  Accredited organizations were 
required to develop and test processes for MR implementation.[71]  In 2009, in recognition 
of the challenges that an organisation might face to ensure MR processes are in place, 
the Joint Commission removed MR from the accreditation decision criteria.[96]  Instead, the 
National Patient Safety Goal number eight was reviewed and in June 2011; MR was 
retained as a safety goal but in tandem with other medication management requirements.  
The revised goal sets an expectation for maintaining accurate medication information 
while leaving organisations to define their MR process and adopt the workflow to 
encourage better performance in their own institution.[97]  
The World Health Organisation launched the “High 5s project” in 2006 to address major 
concerns about patient safety.[98]  The High 5s name derives from the project’s original 
intent to significantly reduce the frequency of five challenging patient safety problems.  
Accuracy of medicines information upon care transition was recognised as one of High 5s 
challenges.  The World Health Organisation issued in 2009 a standard operating 
procedure to guide implementation of MR.[99]  This was followed by a campaign lunched 
by the Institute of Healthcare Improvement to save 5 Million lives, the campaign named 
MR as a strategy to prevent adverse drug events.  A starting toolkit was published in 2008 
to enhance wide implementation of MR strategies.[100] 
Many tools are currently available for optimisation of MR; in March 2012 the American 
Society of Health System Pharmacists published guidance Improving Care Transitions: 
Optimizing Medication Reconciliation in which pharmacists were recommended to take a 
leadership in the development of MR policies and procedures.[8]  A similar initiative was 
published in 2012 by the Agency for Healthcare Research and Quality titled as 
Medications at Transitions and Clinical Handoffs toolkit for Medication Reconciliation.[101] 
In 2004, MR was adopted by the Canadian council on health services accreditation as a 
patient safety goal.[102]  In 2010 a report was published Seamless Care: Pharmacists 
intervene to prevent adverse drug events and optimize drug therapy reinforcing 
pharmacist role in preventing adverse drug events and optimising drug therapy while 
performing discharge MR.[103] 
Initiatives adapting MR were lunched in Australia too, one of the leading countries in the 
WHO High 5s project.  Admission MR is regarded as a part of standard clinical pharmacy 
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practice that is recommended for every inpatient.  The Society of Hospital Pharmacists of 
Australia outlined MR as a professional practice standard.[104]  Additionally, MR is one of 
the eight clinical practice improvement areas of the Safety and Quality Investment for 
Reform Program, and one of the five standards of the West Australian Process of 
Pharmaceutical Review policy.  These are programmes created in Western Australia to 
empower the Department of Health’s clinical governance and patient safety management 
systems to ensure delivery of safe, high quality, evidence-based health care to patients. 
[105] 
Similarly, in the Netherlands, a Patient Safety Programme was launched in Dutch 
hospitals in 2007, which included a bundle intervention concerning MR at hospital 
admission and discharge.  Since 2011, MR at hospital admission and discharge has been 
made compulsory by the Dutch government for every planned admission and upon 
discharge.[106] 
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1.9 Interventions to improve information transfer at the health interface 
Interventions to improve information transfer have focused on promoting pharmacy led 
MR, multidisciplinary MR packages and incorporating a computer system in the 
production and transfer of information.  Additionally, studies have evaluated the use of 
standardised forms for obtaining and transferring information, discharge planning and post 
discharge follow up. 
1.9.1 Pharmacy led MR 
Pharmacy led MR interventions have frequently been supplemented with other clinical 
activities such as discharge counselling,[78, 107-109] patient education,[110-112] medication 
review,[107, 110, 113-115] adherence aids,[60] participation with ward rounds[14, 116] and telephone 
follow up.[111, 112, 117, 118]  Additionally, MR was evaluated across various settings such as 
emergency department,[76, 110, 119] surgical pre-admission clinic,[120, 121] outpatient[122] and 
ambulatory care.[123, 124]  Pharmacy led MR was implemented at different point of care 
including admission MR [14, 68, 75] or discharge MR alone.[60, 125, 126]  In fewer number of 
studies full MR process was implemented; i.e. at both admission and discharge.[118, 120, 127]  
MR was mostly led by a pharmacist with clinical training; however, less frequently MR was 
implemented by pharmacy technicians [107, 128] or pharmacy students.[111, 117, 129]   
A number of studies in the UK have evaluated the pharmacist role in medication history 
taking and shown improvement in the accuracy of medication histories, inpatient charts, 
discharge prescriptions and allergy information.  Those studies were, however, of small 
size, uncontrolled observational and of before and after design.[14, 76, 80, 116, 130, 131]  Thus 
conclusions, most likely have been biased in favour of the pharmacist intervention.  
Studies outside the UK are relatively larger in size; however they have varied widely in the 
MR intervention, setting, number of providers, comparator and outcomes measured.  A 
USA study in 2012 consisted of 102 patients who received pharmacy led MR compared to 
116 patients who received MR by the doctor.  The MR pharmacist enhanced the 
completeness of medication histories and reduced adverse drug events attributed to 
admission errors.[132]  This agrees with a previous USA study, in which MR was led by a 
pharmacist or pharmacy student who obtained medication histories.[133]  These two studies 
adopted non-random selection of patients admitted to general medical units.  However, 
the findings are consistent with a Canadian study across surgical pre-admission 
assessment which adopted a randomised controlled design.  This latter study of 227 
patients randomised into the intervention group and 237 in the control group compared 
pharmacy led MR with nurse-conducted medication histories plus surgeon-generated 
discharge summaries.  In the intervention group, 20.3% had at least one postoperative 
error related to home medications, compared with 40.2% of control group (p<0.001).  
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Additionally, 29.9% of patients in the control group had at least one postoperative 
medication discrepancy with the potential to cause possible or probable harm compared 
with 12.9% in the intervention group (p<0.001).[121]  The study therefore suggests that 
pharmacy led MR results in a significant reduction in errors and discrepancies, however, 
this difference may not be entirely attributed to the health professional delivering the MR.  
The intervention and control groups differed not only in terms of the professional 
delivering the service but also in the process; the intervention adopted the seamless 
uniprofessional MR process whilst the control group had a more disjointed approach of 
partial delivery by a nurse and doctor which may have introduced greater scope for 
communication issues and thus errors and discrepancies. 
Inconsistent with the findings above, another randomised study conducted by Kripalani et 
al. in 2012 included 860 patients in both groups and reported that the effect of MR on 
preventable adverse drug events and clinically significant medication errors was less 
evident.  Patients were hospitalised with acute coronary syndrome and acute 
decompensated heart failure, potentially those were at a greater risk of adverse drug 
events and required more complex care.[111]  Therefore, the poor clarity about the true 
effects of pharmacy led MR on adverse drug events and clinically significant errors might 
reflect the heterogeneity between these study methods, intervention, provider and setting.  
This limits the ability to draw firm conclusions on this regard. 
The influence of pharmacy led MR on health resource use such as length of hospital stay, 
readmission and emergency department visits is also uncertain.  Optimising therapy and 
medicine use by ensuring an accurate and complete medicine list at admission and 
throughout hospital stay might shorten patient stay.  However, the findings from Mortimer 
et al. [110] were not in agreement with such an assertion.  In an emergency department, 
199 patients were alternately allocated to either the intervention which was receipt of 
pharmacy led MR or the control which was MR from a doctor at admission and MR from a 
ward pharmacist at discharge.  The intervention patients stayed longer in hospital 
compared to control patients (p< 0.01).  The lack of randomisation and thus the risk of 
selection bias might underline the imbalances reported between the two groups; the MR 
pharmacist managed significantly more complex patients compared to the doctors and 
thus they might have stayed longer because of the nature of their presentation.[110]  
Similarly, in Sweden in 2012, a large before and after study, Hellstrom et al., including 
1,216 patients in the intervention group and 2,758 control patients showed no significant 
effect on emergency department visits, rehospitalisation or mortality rates over 6 
months.[134]  In contrast, Scullin et al. and Gillespie et al., two randomised controlled 
studies, showed significantly fewer readmissions and emergency department visits for 
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patients receiving pharmacy led MR compared to standard care.[115, 135]  Additionally, 
Scullin et al. showed a significant reduction in length of hospital stay.  
Scullin et al. 2007 is a study in Northern Ireland including 371 patients in the intervention 
group and 391 in the control group.  The intervention significantly lowered readmission 
rates over 12 months by 10%.  It also delayed the time at which readmissions occurred; 
intervention patients took 20 days longer on average to be readmitted compared to control 
patients (p = 0.036).  A more recent Swedish study conducted by Gillespie et al evaluated 
readmissions and emergency department visits combined for 199 patients in the 
intervention group and 201 patients randomised to the control group.  Intervention patients 
showed a significant reduction in readmissions and emergency department visits 
compared to control patients.  Hellstrom et al.[134] evaluated the effect of the addition of 
admission MR in wards which had already implemented discharge MR process as a part 
of the usual care; an important difference between these three studies is that, thus the 
effect of the intervention might have partially masked by the benefit of usual care MR.  
Whereas, Scullin et al.[115] and Gillespie et al.[135] evaluated the effect of full MR process at 
both admission and discharge compared to absence of MR at the control group.  
Additionally, in the latter two studies, patients were counselled on discharge, and in the 
study by Gillespie et al. they were also followed up by a telephone call five to seven days 
post discharge to ensure all medicines were being taken as intended.  Discharge 
counselling and follow up by a phone call are non-MR care activities and may have 
enhanced post discharge care continuity and thus reduced risk of readmissions and 
emergency department visits on their own.  Thus, conclusions on the true effect of MR on 
health resource use are not definitive and the extent to which MR contributed to the 
observed findings cannot be established without further work. 
MR can aid in optimising prescribing such as stopping unnecessary medicines, switching 
formulation and managing patient own drugs, thus it would be plausible to assume that 
this might contribute to considerable savings.  However, this can be established only 
through studies adopting a robust economic evaluation design.  Unfortunately, studies that 
have attempted to estimate costs and savings related to pharmacy led MR, have generally 
considered only costs of medicine use without any estimates of other costs or savings 
such as health resource use and cost of harm associated with errors.[14, 68]  Little evidence 
was available for the effects of pharmacy led MR on quality of life and thus further 
research is necessary. 
In UK, the NICE/NPSA guidance in 2007 recommended pharmacist involvement in MR at 
admission based on findings from one randomised controlled trial, two before and after 
and five observational studies presented in a systematic review conducted by the 
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university of Sheffield which described the effect and cost-effectiveness of interventions 
aimed at preventing errors upon admission.[136]  Pharmacy led MR appeared to be 
beneficial in reducing medication discrepancies, however none of the included studies 
assessed the effect of MR on adverse drug events and health resource use.  Thus, the 
NICE/NPSA conclusion on pharmacy led MR may have been biased by the limited 
number of studies and methodological limitations of the included studies.   
Two recent systematic reviews attempted to collate the available evidence on hospital 
based MR; Mueller et al.[137] and Kwan et al.[138]  Both reviews highlighted that the quality 
of the evidence available for MR interventions is poor but indicated that the most rigorous 
research support the pharmacist related interventions
This indicates that the quality 
of the available evidence for pharmacy led MR has advanced little over time.   
Recommendations supporting pharmacy led MR are informed by a number of existing 
randomised controlled studies,[111, 115, 135] however majority of the recommendations are 
derived from less rigorous designs.  Those randomised controlled studies varied widely in 
interventions and outcomes measured.  Additionally, Limited number of studies evaluated 
pharmacy led MR within UK settings.  Up to the time of this thesis synthesis, all the 
randomised controlled studies, those assumed to inform the most robust evidence, are 
based outside the UK.  And therefore, these recommendations are of limited 
generalisability due to differences between the UK NHS and other health care systems.  
This highlights insufficiency of the evidence and the need of UK relevant evidence. 
1.9.2 Multidisciplinary package to implement MR   
Studies described multidisciplinary MR packages including a pharmacy led MR 
implemented in a multidisciplinary core of various healthcare professionals such as 
doctors, nurses, GPs or community pharmacists.  The workflow within these packages 
was supported by meetings and discussion between the team members, periodic reviews 
to ensure standardised implementation plus regular audits.  The multidisciplinary MR 
packages described in the literature are highly heterogeneous and responsibilities are 
widely varying between professions based on the study setting, staffing capacity and 
workflow.   
Two USA studies highlighted a favourable effect of multidisciplinary MR packages.  The 
first study was an observational uncontrolled study of 102 patients.  The study included 
nurses, pharmacists, and physicians as well as family medicine residents reconciling 
medicines at admission and discharge.  The mean number of medication discrepancies at 
both admission and discharge was reduced significantly, p <0.05.[139]  The second study 
was of before and after design.  In addition to doctors, nurses and pharmacist, the study 
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included occupational therapists, nutritionist, pharmacist and social workers developing 
collaboratively a care plan upon admission.  GPs were also notified by patient admission 
and informed promptly upon discharge.  In addition, discharge planning meeting was held 
with the nurse, doctor and patient to optimise care transition.  No pharmacist input was at 
discharge.  For 185 patients in the intervention group compared to 237 control patients, 
emergency visits were three times less likely to occur at 3 days of discharge, odds ratio 
[95% CI] =0.25 [0.10–0.62] (p<0.05).  This effect was sustained at 30 days with 
emergency visits and readmissions, odds ratio [95% CI] =0.61 [0.36–1.03] (p=0.06).[140]   
Both studies showed a significant reduction in discrepancies, readmissions and 
emergency visits, however their small size and non-randomised design, leaves plenty for 
further work.  Subsequent studies need to assess acceptability of multidisciplinary MR 
packages by health professionals and application across institutions and trusts of different 
staff and resources.  
Additionally, given the limited number of studies and the heterogeneity of MR packages, it 
is unclear how MR tasks can be divided optimally between professionals and what would 
be the most effective approach by which MR can be optimised.  
1.9.3 IT based information transfer initiatives 
Implementing computerised IT is considered a solution to ensure effective and timely 
communication at health interfaces; it is well accepted that employing an electronic pro-
forma has expedited and enhanced legibility of discharge summaries.[60, 62]  However, the 
risk of user selection and human errors is increasingly seizing attention.[43, 61]  In addition 
to IT based production and transfer of information, the use of IT applications to integrate 
MR with medicine entry orders and medicine management software might hold potential 
for further enhancing patient care.   
A web-based application that enabled GPs to visualise information regarding their 
patients' emergency department visits was implemented in Canada 2007 for 2,022 
emergency department visits.  GPs found information more useful, they could manage 
patient better and initiated actions more often following the receipt of information.  
However, though those could highlight the benefit on ensuring accuracy and continuity of 
care, these were not reflected as a reduction in GPs visits post discharge.[141]  Similarly the 
use of a more sophisticated computerised MR tool integrating medicines list from several 
electronic sources and enabled other clinicians to review medicines reported to decrease 
unintentional discrepancies which were considered of potential harm with adjusted relative 
risk [95%CI]= 0.72; [0.52-0.99].  Nevertheless, the benefits on readmissions and 
emergency department visits were not apparent.   
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Worth noting, the later study was conducted in two hospitals with significant benefit on 
medication discrepancies seen at hospital 1 but not at hospital 2.  No significant effect 
was shown in healthcare resources use in both hospitals.  Variation in intervention 
success could reflect the extent of the MR tool integration into the existing computer 
system in the study hospitals.  The system in hospital 1 was reported being set in an 
easier manner to input information and match patient medicine lists compared to the 
system of hospital 2. [142] 
In 2007, the UK Patient safety advisory committee regarded that the evidence is 
insufficient to make recommendations on the use of IT based applications.[93]  Since then, 
there is a range of new and developing technologies that appear to have benefits on 
reducing medicine errors and improving accuracy and usefulness of communication.[141, 
142]  However, it is not well established whether these improved healthcare resources 
use.[141, 142]  Additionally, IT application features and the advances with the technology 
would widely vary between settings; this places a question on the applicability of these 
applications for wide scale implementation.  It would be also uncertain whether similar 
outcomes would be yielded across different institutions and trusts.   
1.9.4 The use of a standardised reconciliation document  
The use of a standardised MR form to ensure optimum MR implementation could 
contribute to better communication of information.  Research evaluating their effect is 
limited; however, those reported have shown a significant reduction in both discharge 
summary omissions and medication errors with the potential to decrease health resource 
utilisation.  However, it did not report whether health resource use in the intervention 
group was significantly lower than control.  A standardised discharge medication report 
was employed to document medicines changed and rationales.  The report was sent to 
GPs and handed to patients at discharge.  Eleven out of 248 (4.4%) patients in the 
standardised report group compared with 16 out of 179 (8.9%) patients needed medical 
care because of medication errors p = 0.049.[143] 
The use of standardised MR forms might appear of low complexity and place limited 
demands on new or additional costly resources such as pharmacist or computer 
technology.  It is important however, to obtain consensus between professionals on the 
use and the responsibility for the form completion.  Otherwise, benefits might not be 
possible to achieve.  In Canada, data related to a total of 3,275 medicines before 
implementation of a MR standardised form were compared to 3,240 medicines after form 
implementation.  No particular profession was responsible for the completion of 
medication history forms whilst a doctor were assigned responsibility for form completion 
at discharge.  Quality of medication information was comparable between groups (p= 
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0.86) on admission whist on discharge, there was a significant improvement in the quality 
of information P < 0.001.[144]  Assigning the responsibility of form completion to a 
nominated profession might have enhanced the completion and utilisation of discharge 
forms, consequently this might have improved the quality of discharge information.  
Nonetheless, there was no overall improvement in the quality of information transfer. 
Developing and incorporating a standardised MR form within the routine workflow is not 
free of challenges.  Underutilisation of the form and unfamiliarity of the staff with the form 
may be problematic.[144]  Employing a standardised form might be perceived by the care 
team as time consuming and thus contribute to increased complexity in care transition.[144]  
Therefore, more studies are needed to determine the effect of standardised MR forms on 
health resource use and the time needed to collect information and complete the form.  It 
might be, however, of note that over time, experience with the form would build up and 
thus form completion might improve and become faster.[145] 
1.9.5 Discharge planning and post discharge follow up 
MR can be embedded within discharge planning which involves the development of an 
individualised discharge plan for the patient prior to leaving hospital and arranging follow 
up programmes with the GP or home nurse.[146, 147]  A discharge program in USA in 2009, 
involving a nurse and a clinical pharmacist showed a positive impact on readmissions and 
emergency department visits.  The nurse acted as a discharge advocate, arranging a post 
discharge follow up appointment, confirming MR and sending an individualised instruction 
booklet to GPs.  The clinical pharmacist followed up patients via phone call or visit to 
reinforce discharge plans and review post discharge medicines.  Within 30 days of 
discharge, intervention patients (n= 370) had significantly lower rates of readmission and 
emergency department visits compared to usual care (n= 368) with an odds ratio [95% CI] 
of 0.70 [0.515 to 0.937] (p= 0.009).[112]  The true effect of MR on these findings is hard to 
establish as discharge planning might by itself optimise patient post discharge care and 
ensure continuity of care.  This might have augmented MR benefits on readmissions and 
emergency department visits.  However, a recent Cochrane review concluded that 
discharge planning has limited impact on readmission rates, hospital length of stay or 
health outcomes.[146]  Therefore, further research is demanded to enable firm conclusions. 
1.9.6 Education and training health care staff involved with care transition  
Possible causes for deficiencies in care transition communication might be related to 
insufficient MR related training or education of health professionals.  Thus, a possible 
intervention might aim to enhance care team awareness of the significance of accurate 
and complete information transfer on patient outcomes and continuity of care.   
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One study conducted an educational campaign targeting junior doctors.  The campaign 
included teaching, posters and placing reminders in the hospital notes.  For 580 patients, 
the discrepancy rate per patient discharge summary significantly reduced from 2.6 in the 
first two weeks of the study, i.e. pre-educational intervention, to 1.0 by the end of the 
study at 18 weeks.  This decline in discrepancy rate also remained significant when only 
clinically important discrepancies were included.  The proportion of admissions with one or 
more clinically important discrepancies also significantly decreased during the study from 
46% to 24% (p = 0.023).[148]  This study of note, however, more work is needed. 
1.10 Barriers for implementation of medicines reconciliation  
While MR appeared generally accepted at a conceptual level, wide implementation has 
not yet been achieved.[73, 149]  Initiatives for MR optimisation have existed over the past 15 
to 20 years in the UK and worldwide, so the lack of progress in MR practice is of concern.  
The institute of healthcare improvement stated in 2011, that frequently there is no 
standardised process to ensure a comprehensive patient‘s medicine list is available to all 
providers and compared with the most recent list of medicines as the patient moves 
through different levels of care.[73]  There is also no clear agreement about the 
professional responsible for MR across settings and there is no wide national guide on 
who, where and when to implement MR.[149, 150] 
Accurate sources of information may be difficult to identify at the time of care transition 
unless one has taken the time to explore and test different methods to collect 
information.[8, 73]  Since the most rigorous evidence is supporting an increased involvement 
of the pharmacist in care transitions tasks, the extra time commitment to perform MR 
should be precisely estimated.[14, 76, 140]  However, due to the variation between studies in 
the design, patients, complexity of interventions and MR process, a reliable estimate of 
the pharmacist time commitment is difficult to ascertain.  The time needed has ranged 
from 10 minutes to 45 minutes.[17, 67, 80, 112, 133, 151, 152]  Additionally, with interventions 
consisting of multi-components, the time and thus costs related to other health 
professionals, developing policies, forms, IT application and training should be also 
considered.  The cost of pharmacist and other professional time is probably the main cost 
drive to consider before accepting wide application of MR.  
Health professionals might resist IT based MR application, this might be heavily 
influenced by inadequate computer literacy and difficulties in layout.  Additionally, the use 
of IT application might introduce user and selection errors.[64]  Therefore, the needs for 
training, IT support, education of health professionals are key requirements for successful 
IT based MR implementation.  Noteworthy, variances in the resources available to support 
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IT interventions and the feasibility of integrating MR with the existing computerised system 
might lead to different outcomes and acceptability between settings.[142] 
Healthcare professionals may resist also changes in the existing practice; this is partially 
due to time or workload concern and insufficient training or education.[129, 144, 150]  
Additionally, continuous evaluation, auditing and feedback of MR process are time 
consuming.[140, 153, 154] 
Finally, effective MR implementation might also be hindered by the lack of obligatory 
legislations which formalise wide MR implementation and the lack of collaboration 
between secondary care and primary care at national and organisational level.[150]   
1.11 A place for evidence  
The literature search presented earlier suggests that MR might improve care transition 
and patient outcomes plus health resource use.  Yet, evidence is needed to draw these 
conclusions with confidence.  This thesis aimed to design an MR intervention and develop 
a strategy for its evaluation.  To fulfil this aim, three projects were conducted; an audit of 
discharge summaries to identify current deficits in information transfer to primary care, a 
systematic review to identify the most effective features of MR interventions and 
appropriate outcome measures for evaluation, plus design and interim analysis of a pilot 
randomised controlled study informed by the audit and systematic review.  The work on 
these projects aimed to answer the questions presented in BOX 1.4.  In answering these 
questions progress has been made in describing the optimum use of MR at the heath 
interface. 
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BOX 1.4 Areas for key research questions 
1.12.1 What is the extent of practice adherence to the UK guidance on 
information transfer at the healthcare interface? 
The quality of admission and discharge discrepancies has been extensively 
investigated; however, there is no large scale report on the quality of information 
received in primary care following patient discharge. Additionally, there has been no 
evaluation of the extent to which discharge summaries adhere to the minimum dataset 
recommend by the NPC. Thus, there is no indication of this recommendation impact on 
the quality of practice.  
1.12.2 What are the factors contributing to better practice upon care transition 
and which are the ones implicated into poor performance?   
Whilst poor practice is often highlighted, there is little information about the predictors of 
good practice. Additionally with sparse NHS resources, the identification of patient 
related risk factors which contribute to discrepancies would be useful for prioritising 
patients at high risk. Therefore, further investigation is warranted. 
1.12.3 What is the best practice to implement MR?  
It is difficult to describe the best approach to implement MR. Studies widely varied with 
respect to MR interventions, patients and outcomes measured. More studies are 
needed on the adoption and implementation of effective MR. A well-defined pharmacy 
led MR intervention must be developed to identify the best practice for MR. More 
studies of randomised design are needed to address the feasibility and effectiveness of 
MR in UK context. 
1.12.4 What are the resources necessary to implement pharmacy led MR?  
The cost of implementing pharmacy led MR is uncertain. Implementing pharmacy led 
MR might be constrained due to lack of resources. Accepting of pharmacy led MR 
service across trusts requires a precise estimation of the resources and the cost 
associated with MR implementation. 
1.12.5 Is pharmacy led MR cost-effective? 
Cost avoidance resulting from MR might be a challenging figure to capture. Potential 
cost saving might result from mitigating patient harm, improving prescribing and 
reducing health resource use. An evaluation of the cost-effectiveness of pharmacy led 
MR intervention compared with the current practice at care transition is needed to 
enable an answer whether health commissioners should accept pharmacy led MR 
services across NHS health interfaces. This however cannot be assumed without full 
economic evaluation. 

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1.12 Thesis purpose  
1.12.1 Conducting a Trust-wide evaluation of information received in primary care  
An in-depth investigation review of the factors that influence the quality of discharge 
information communicated to primary care is lacking.  It was recognised that a view on the 
current practice and the quality of discharge summary information should be obtained.  A 
Trust-wide evaluation would enable to highlight areas of improvement and inform the need 
for future interventions.  
It was almost three years since the NPC guidance was issued, therefore, it was an 
appropriate time to audit current practice across Norfolk to improve understanding of 
discharge communication across the Trust.  An evaluation of the potential harm 
associated with post discharge discrepancies by using a scientifically rigorous approach 
was also regarded appropriate.   
Clinical governance is a system through which NHS organisations are accountable to 
safeguard high standards of care by creating an environment in which excellence in 
clinical care can flourish.[155]  Clinical audit was integrated into clinical governance systems 
by the Department of Health in 1997.[156]  The NHS took this further and proposed in 2008 
a mandatory participation of all health staff in clinical audits.[157]  Audits are the heart of 
clinical governance and aimed to be introduced within the NHS normal practice.[158]   
All clinical audits conducted within NHS organisations follow the principles of Best 
Practice in Clinical Audit issued by NICE in 2008.[158]  NICE defines audit as a quality 
improvement process that seeks to improve patient care and outcomes through a 
systematic review of care against explicit criteria.[158]  Clinical audit is seen as a continuous 
cycle of a systematic process for establishing best practice, measuring care against 
criteria, taking action to improve care and monitoring practice to sustain improvement.  
Figure 1.1 illustrates the audit cycle and BOX 1.5 summarises the stages of a clinical 
audit. 
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Figure 1.1 The clinical Audit cycle[158]  
NICE encourages NHS organisations to undertake baseline data collection to determine 
whether practice is in accordance with guidance.[159]  A Trust-wide audit would be the first 
part of the clinical audit cycle and where practice deviating from the guidance is identified, 
changes would be recommended.  Therefore, a Trust-wide audit was carried out; 
discharge summaries received in primary care practices across Norfolk were audited 
against the NPC minimum dataset of information transferred on discharge.   
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BOX 1.5 Clinical audit steps (NICE, 2008)[158] 
Stage 1 - Preparation 
 Choose a topic:  
o Preferably one which is a high priority for the organisation. 
o This may involve areas in which there is a high volume of work, high risks or 
high costs of care, or an area identified as a priority by patients. 
 Identify available resources such as:  
o Organisations may have a local audit lead or office. 
o There may be existing guidelines defining desired standards for the topic 
chosen. 
Stage 2 - Select criteria 
 Define the criteria 
o This should be in the form of a statement, e.g. All patients with hypertension 
who smoke should be offered smoking cessation advice. 
 Define the standard which is usually a target as a percentage 
o This may be a minimum standard or an optimal one, depending on the clinical 
scenario. 
Stage 3 - Measuring level of performance 
 Collect the data:  
o May be from computerised records, manual collection, or both. 
o May be retrospective or prospective. 
 Analyse the data collected:  
o Compare actual performance with the set standard. 
o Discuss how well the standards were met. 
o If the standards were not met, note the reasons for this (if known) 
Stage 4 - Making improvements 
 Present the results and discuss them with the relevant teams in your 
organisation. 
 The results should be used to develop an action plan, specifying what needs to 
be done, how it will be done, who is going to do it and by when. 
Stage 5 - Maintaining improvements 
 This follows up the previous stages of the audit, to determine whether the actions 
taken have been effective, or whether further improvements are needed. 
 It involves repeating the audit (i.e. targets, results, discussion); hence the terms 
'audit cycle' or 'audit spiral'. 
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1.12.2 Developing and evaluating an innovative pharmacy led MR intervention  
MR contains several interacting components and a range of possible outcomes, variability 
in population and implementation between settings; thus it is believed to be an example of 
complex health intervention.[160]  The Medical Research Council published a framework to 
help researchers and research funders to recognise and adopt appropriate methods for 
the development, evaluation and implementation of complex interventions.[160]  BOX 1.6 
summarises the main elements of the Medical Research Council’s guidance.  
 
  
BOX 1.6 The Medical Research Council process for the development, evaluation 
and implementation of complex interventions  
The Medical Research Councils’ process includes developing, piloting, evaluating, 
reporting and implementing  
 Developing  
o Identifying the evidence base 
Identifying the relevant, existing evidence base, ideally by carrying out a systematic 
review  
o Identifying/developing appropriate theory 
Identify what changes are expected, and how change is to be achieved.  For example 
interviews with ‘stakeholders’, i.e. those targeted by the intervention, or involved in its 
development or delivery. This should be done whether to develop an intervention or to 
evaluate an intervention that has already been developed and/or implemented. There 
may be lots of competing or partly overlapping theories and finding the most 
appropriate ones will require expertise in the relevant disciplines.  
o Modelling process and outcomes 
Obtain information about the design of both the intervention and the evaluation. One 
useful approach to modelling is to undertake a pre-trial economic evaluation.  This may 
identify weaknesses and lead to refinements, or it may show that a full-scale evaluation 
is unwarranted, for example because the effects are so small that a trial would have to 
be infeasible large  
 Piloting and feasibility 
Ensure intervention can be delivered as intended, it is also important to develop an 
estimation of the effect sizes, variability and rates of recruitment and retention in a 
large scale evaluation. 
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BOX 1.6 The Medical Research Council process for the development, evaluation 
and implementation of complex interventions (continued) 
 Evaluating  
o Assessing effectiveness 
Randomisation should be considered as it is the most robust method of preventing the 
selection bias.  A crucial aspect of the design of an evaluation is the choice of outcome 
measures; which outcomes are most important, and which are secondary, and how to 
deal with multiple outcomes in the analysis. Sources of variation in outcomes are 
important to be considered as well as subgroup analyses. 
o Understanding processes 
Evaluation is often highly valuable in providing insight into why an intervention fails 
unexpectedly or has unanticipated consequences or why a successful intervention 
works and how it can be optimised.  Process evaluation nested within a trial can also be 
used to assess fidelity and quality of implementation, clarify causal mechanisms and 
identify contextual factors associated with variation in outcomes.  Process evaluations 
should be conducted to the same high methodological standards and reported just as 
thoroughly as evaluation of outcomes. However, they are not a substitute for an 
outcome evaluation, and interpreting the results is crucially dependent on knowledge of 
outcomes. 
o Assessing cost-effectiveness 
An economic evaluation should be included if at all possible, as this will make the 
results far more useful for decision-makers. Ideally, economic considerations should be 
taken fully into account in the design of the evaluation, to ensure that the cost of the 
study is justified by the potential benefit of the evidence it will generate, appropriate 
outcomes are measured, and the study has enough power to detect economically 
important differences. The main purpose of an economic evaluation is estimation rather 
than hypothesis testing, so it may still be worth including one even if the study cannot 
provide clear cost or effect differences. However, it is of most importance to handle 
uncertainty appropriately. 
 Reporting and implementing 
o Getting evidence into practice 
Findings are made available using methods that are accessible and convincing to 
decision-makers in order to allow them to be translated into routine practice or policy.  
Information needs to be provided in accessible formats and disseminated actively 
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BOX 1.6 The Medical Research Council process for the development, evaluation 
and implementation of complex interventions (continued) 
o Getting evidence into practice (continued) 
Approaches for effective implementation are: 
• To involve stakeholders in the choice of question and design of the research  
• To provide evidence in an integrated and graded way as reviews not individual 
studies and with variable length summaries to allow for rapid scanning 
• To take account of context, and identify the elements relevant to decision-
making, such as benefits, harms and costs 
• To make specific recommendations as possible 
• To use a multifaceted approach involving a mixture of interactive rather than 
didactic educational meetings, audit, feedback, reminders, and local consensus 
processes 
Successful implementation depends on changing behaviour and often of a wide range 
of people. This requires understanding of the behaviours that need to change, factors 
maintaining current behaviour, barriers and facilitators to change.  Further research 
may be needed to assist the process of implementation. 
o Surveillance, monitoring and long term outcomes 
Effects are likely to be smaller and more variable once the intervention becomes 
implemented more widely, and unanticipated consequences may begin to emerge. 
Long-term follow-up may be needed to determine whether short-term changes persist. 
It is worth thinking about how to measure rare or long-term impacts, for example 
through routine data sources and record linkage, or by re-contacting study participants.  
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1.12.2.1 Identifying the evidence base for pharmacy led MR studies 
The quality of discharge information communication largely depends on the quality of 
information obtained on admission.  At least half of discrepancies at discharge originate 
from discrepancies in medication histories and 72% of all potentially harmful 
discrepancies in admission or discharge orders were due to errors related to compiling 
pre-admission medicines list.[17, 28]  Therefore, improving the continuity and quality of 
information received in primary care can be enhanced by optimum implementation of MR 
during hospital stay.  
The Institute of Healthcare Improvement states in 2008 that the term MR has been 
occasionally not fully implemented; in some contexts, MR is widely accepted as a 
medication history taking task and in others it includes only discharge reconciliation.[161]  
Two years later, the Institute of Healthcare Improvement reported that MR is continuing to 
be a challenge for many hospitals and care settings.  However, there were some 
examples of effective implementation.[73]  The Institute of Healthcare Improvement also, 
highlighted the lack of clear ownership of the process and the need for a standardised 
approach to implement MR.  In some cases, the collection of medication history is 
completed by a nurse, or by a pharmacist or a doctor in other cases.  There is still no 
widely agreed defined process to communicate therapy changes and treatment plans 
between healthcare providers.[73] 
Considering the pharmacist’s knowledge of medicine use, increasingly many hospitals 
allocate pharmacists to quality assure the clinical information collected on admission 
and/or discharge.  Pharmacist involvement and the time spent in MR differ between 
hospitals depending on the available resources and staff.[8]  A UK study reported that 
pharmacy led clinical advice, medication history taking and discharge check are only 
provided in 40% of emergency departments.[15]  In East of England pharmacy led MR is 
provided for only 50-60% of patients.[26, 162]  Variations in the extents of pharmacy led MR 
also exist in the USA, Australia and Ireland.[163-165] 
The impact of pharmacy led MR is not fully understood and the associated cost of 
expanding MR services to all admissions is uncertain.  Therefore, without robust evidence 
on the effects and associated costs it is not possible to expand pharmacy led MR across 
all NHS healthcare interfaces.[166, 167]   
Primary studies of various design, settings and measurements have been published in 
recent years evaluating hospital based pharmacy led MR.  Therefore, a systematic search 
to summarise the published evidence which would progress to provide a rigorous 
summary of the existing evidence is of value.   
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The two recent systematic reviews of hospital based MR conducted by Mueller et al.[137] 
and Kwan et al.[137]  identified that the most successful interventions relied on pharmacists 
and outlined that MR appears to be a potentially promising intervention to improve 
information transition.[138]  Those systematic reviews, however, only described the clinical 
effect related to MR interventions and thus a collative review focusing on acquiring the 
evidence for the cost is warranted. 
Therefore, an exhaustive systematic review to summarise all the relevant research 
evaluating the full MR process led by a pharmacist, pharmacy technician or pharmacy 
student was undertaken.   
1.12.2.2 Development and evaluation of a novel pharmacy MR intervention 
Both reviews on hospital based MR supported pharmacy led interventions.[137, 138]  
However, they showed varying conclusions with respect to the effect of MR on medication 
discrepancies and the use of health resources.  Mueller et al. found a consistent reduction 
in medication discrepancies, meanwhile the reduction in resource use was less 
evident.[137]  Kwan et al. found no effect of MR on reducing discrepancies which were 
considered clinically significant; however, a significant reduction in emergency department 
visits and readmissions was identified at 30 days post discharge.[138]  Kwan et al. 
presumed the observed difference resulted from methodological differences between the 
two reviews; mainly in the selection criteria.  Reviewing the bibliography of both reviews, 
both identified a different set of relevant studies.  Kwan et al. identified studies that 
assessed the clinical significance of unintentional discrepancies, required a clear 
distinction between intentional and unintentional discrepancies and performed the 
assessments of clinical significance by at least one clinician independent from the study 
process.  Mueller et al. included studies with MR being the primary focus of the 
intervention with no criteria of selection based on the outcomes measured.  Nevertheless, 
both reviews derived conclusions from interventions that included non-MR aspects, those 
are of potential to improve admission and discharge process and enhance post discharge 
care coordination.  As such, the degree to which MR contributed to the reported findings is 
unclear and the answer to the question regarding the true effect of MR remains unclear 
and warrants further investigation. 
The systematic review in 2007 of interventions aimed to prevent medication errors at 
admission,[136] reported that NHS cost avoidance from pharmacy led MR was £106 per 
MR review ranging between £63 and £148.[44]  Those costs, however, were only related to 
preventing medication errors.  An economic model was informed by the aforementioned 
review; the cost-effectiveness of pharmacy led MR strategies on reducing adverse drug 
events was estimated with £10,000 per quality-adjusted life-year (QALY).  The authors 
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also estimated the cost of implementing pharmacy led MR at £1,897 per 1000 prescription 
orders.  However, there was uncertainty surrounding the model assumptions in estimating 
and identifying the proportion of errors leading to preventable adverse drug events.[168]  
Additionally, other costs associated with use of health resources and medicine use were 
not estimated.  Those unmeasured costs are essential to obtain a precise estimate of 
pharmacy led MR cost-effectiveness.  Therefore, further evidence to determine the cost-
effectiveness of pharmacy led MR interventions is needed.   
The use of theory and evidence from systematic reviews and undertaking feasibility and 
pilot studies is essential in the development and evaluation of interventions, those are 
highly recommended prior large scale evaluation.[160]  MR is a complex intervention, as 
described earlier, and so a randomised controlled study would be the most robust method 
to evaluate and assess the effects and costs.[160]  A pilot study would play an important 
role in providing information for the planning and justification of a large scale randomised 
controlled study evaluating a pharmacy led MR intervention.  A pilot study is a version of 
the main study that is run in miniature scale to test whether the components of the 
intervention can all work together.[169]  The Medical Research Council’s guide recommends 
a feasibility and piloting stage to test acceptability, estimate the likely rates of recruitment 
and retention of subjects, and the calculate appropriate sample sizes.  It also emphasises 
the role of the pilot in anticipating problems with acceptability, compliance, delivery of the 
intervention, recruitment and a very small effect size.[160]   
Although, piloting is vital preparatory work, it is often skipped and poorly reported.[170, 171]  
Piloting data is also misinterpreted by some investigators; a pilot study is mainly 
descriptive and should be interpreted cautiously when making assumptions or using 
hypothesis testing.[169, 171] 
Within this thesis, a pilot study was developed to provide an insight into the potential value 
of expanding the pharmacist MR service and to determine whether a larger scale trial 
would be feasible.  If the patient recruitment rate was poor, the effect size negligible, or 
the impact from the service was minimal; further trials would be regarded as unnecessary.   
1.13 Cost-effectiveness 
In order for a new intervention to achieve cost-effectiveness, it should generate more 
health gain to the NHS patients than the existing alternative as a result of the additional 
cost imposed on the system.  NICE, in assessing cost-effectiveness, is concerned with 
making decisions which are consistent with maximising patient health gains subject to the 
NHS budget constraint.[172] 
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Cost-effectiveness is a type of economic evaluation defined as a comparative analysis of 
alternative courses of action in terms of both their costs and consequences.[173]  BOX 1.7 
describes the four types of economic evaluation [173]   
 
BOX 1.7 Types of economic evaluation (Drummond, 2005)[173] 
 Cost-minimisation analysis  
Cost-minimisation analysis describes the evaluation where the consequences of two or 
more interventions are broadly equivalent. In this type of analysis only costs are analysed, 
and the least costly alternative is chosen, provided that outcomes are known to be equal 
among alternatives.  
E.g. For a number of medicines to treat hypertension; If the dose required to cause a 10 
mmHg reduction in systolic blood pressure was known for several different medicines, the 
acquisition costs of the medicines could be calculated and the cheapest one identified. 
 Cost-effectiveness analysis  
A cost-effectiveness analysis is used when the costs and outcomes of different 
services/treatments are compared using an outcome that is bespoke to the intervention  
E.g. Two medicines to treat hypertension (A and B); drug A causes a 10 mmHg drop in 
blood pressure and costs £120 per year, while drug B causes a 15 mmHg drop in blood 
pressure but costs £180 per year.  
 Cost-utility analysis  
It shares many similarities to cost-effectiveness analysis with particular attention on quality 
of the health gained or forgone. It is usually used to compare medicines or services for 
which success is measured using different outcomes using a generic outcome, usually 
expressed as QALY, which can be used to assess the effectiveness of interventions for 
different conditions 
E.g. Knowing that £500 can prevent a fall while £200 can reduce pain by 50%  
 Cost-benefit analysis  
Within cost-benefit analysis the main outcome is valuated in monetary terms, as the 
patients’ perceived value of a service or medicine measured as their willingness to pay for 
it.  
Cost-utility analysis is frequently criticised for its narrow focus on health outcomes. 
Improvement in patient satisfaction, access to services or improve outcomes in other 
sectors of the economy, these can be measured by Cost-benefit analysis 
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The core components of a cost-effectiveness analysis include an estimation of the costs 
and the consequences associated with the intervention and its comparator(s).  A 
comparator could be another intervention or the existing practice.[173]  NICE recommends 
the “reference case” analysis for the purpose of the Technology Appraisals Programme.  
The reference case is a set of methodological requirements that NICE considers to be the 
most appropriate for the Technology Appraisal’s Committee’s purpose and consistent with 
the NHS objective of maximising health gain from limited resources.[172]    
1.13.1 Costs  
A cost is defined as the amount of resources consumed multiplied by its unit value.[172]  
Unit costs are defined as the value of each unit of resource such as medicine cost per 
dose or staff cost per hour. [172]  
For the reference case, costs should be related to the use of NHS and personal and social 
services (PSS) resources.  These resources should be valued using the prices relevant to 
the NHS and Department of Health.[174, 175]  NICE required resource use and cost data to 
be identified systematically and all costing assumptions to be clearly defined.  
The steps of an economic evaluation of any type are to identify, measure, value and 
compare the cost and consequences of the alternatives being considered.[173]  Costing as 
a method is common to all types, but the range of costs is determined by the viewpoint of 
the analysis.[173]  There are three stages for cost estimation: identification, measurement 
and valuation.  BOX 1.8 describes the stages of cost estimation. 
 
BOX 1.8 Stages of cost estimation (Drummond, 2005)[173] 
 Identification  
Identify the resources that might be consumed by the intervention.  This is determined by 
the perspective of the study (1.13.3). Costs could be: 
o Fixed costs( also called capital costs) 
Costs which do not vary with the quantity of output and frequently needed to setup the 
intervention, e.g. rent, equipment, wages and salary  
o Variable costs (also called operational costs) 
Costs which vary with the level of output and required to deliver the intervention, e.g. time 
o Knock on or consequence costs  
Cost that are likely to be influenced by the intervention, this consists of patient’s health 
status and value of resources saved. 
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 BOX 1.8 Stages of cost estimation (continued) [173] 
 Measurement  
This stage include measuring/recoding the level of resources use. This could be 
performed by: patient questionnaire, diaries or the review of medical records.[176]  
 Valuation  
Assign a monetary value to the resources used by multiplying the quantities by the 
relevant prices. There are two main costing strategies[177]:  
o Micro-costing 
To identify, count, and price out every single health care service item consumed by 
each patient. 
o Gross-costing
To identify, count, and price out health care encounters or other health care units that 
represent some aggregate of a bundle of service items (e.g. the average cost per 
hospital day or average cost per hospital admission  
 
1.13.2 Effectiveness   
For the reference case, cost-effectiveness, specifically cost–utility analysis, is the 
preferred form of economic evaluation.  Health effects should be expressed in terms of 
QALY.  QALY is an index of survival that is adjusted to account for the patient's quality of 
life during this time.  QALYs incorporate changes in both quantity (longevity/mortality) and 
quality (morbidity, psychological, functional, social, and other factors) of life.[172] 
The effectiveness of an intervention is assessed by comparing the incremental cost per 
QALY gained against the cost-effectiveness threshold which acts as a proxy for the cost 
consumed.  NICE recommend the measurement of changes in health related quality of life 
to be reported directly from patients and the utility of change in the quality of life to be 
based on public preferences.  Given the need for consistency across appraisals, one 
measurement method, the EQ-5D, is preferred for the measurement of health related 
quality of life in adults.[172] 
 
 
 
	

The EQ-5D is a standardised and validated generic instrument.  The EQ-5D comprises 
five dimensions of health: mobility, ability to self-care, ability to undertake usual activities, 
pain and discomfort, anxiety and depression.  For each of these dimensions it has three 
levels of severity (no problems, some problems and severe problems).  The system has 
been designed so that people can describe their own health related quality of life using a 
standardised descriptive system.  A set of preference values elicited from a large UK 
population study is available for the EQ-5D health state descriptions.  The York A1 tariff is 
usually used to assign scores to each EQ-5D health state description; the York A1 tariff is 
the most influential valuation work to date on the EQ-5D which has been undertaken by 
the Measurement and Valuation of Health group at York, UK through a large-scale survey 
in 1997.  Their work elicited values for 243 health states defined by the EQ-5D using 
2,997 interviews of members of the general population.[178]  This set of values obtained by 
York A1 tariff can be applied to health related quality of life measurements to generate 
health-related utility value on a scale of 0 (death) to 1 (perfect health).   
The conventional approach to calculate QALY is area under the curve.[173] This can be 
seen in Figure 1.2.  The quality adjustment for each health status is multiplied by the time 
in the state and then summed to calculate total QALYs.   
 
Figure 1.2 Quality-adjusted life-years gained from an intervention. (Drummond, 
2005)[173] 
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In Figure 1.2, without the health intervention an individual’s health related quality of life 
would deteriorate and he/she would die at the time of Death 1.  With the intervention, 
however, the individual would deteriorate more slowly, live longer and die at the time of 
Death 2.  The area between the two curves is the number of QALY gained by the 
intervention.  Area A, in the amount of QALY gained due to quality improvement, 
meanwhile the area B is the amount of QALY gained due to quantity improvement, i.e. the 
amount of life extension.[173] 
1.13.3 Perspective  
An economic evaluation can be carried out from different perspectives such as that of the 
society, health care payer, hospital, or patient.  The perspective describes and determines 
the categories of costs and outcomes to be identified, measured, and valued.  For 
example, an “NHS perspective” would imply that only costs to the NHS are to be included 
whereas the term “societal perspective” implies that all categories of cost should be 
included irrespective of whose responsibility it is to pay for the costs.[173] 
NICE’s perspective for the reference case is based on the costs to the NHS and PSS use.  
Only the costs that fall within the remit of these two organisations should be included.  In 
addition, NICE regarded it as appropriate to consider the cost of the time spent by family 
members, friends or a partner providing informal care to the patient, otherwise it would 
have been provided by the NHS or PSS workers.  A range of valuation methods exist to 
cost this type of care and therefore the method chosen should be clearly described.[175]  . 
1.13.4 Making decision using economic evaluation  
The Technology Appraisal Committee is an independent advisory team which makes 
recommendations to NICE regarding the clinical and cost-effectiveness of treatments for 
use within the NHS.  
When considering the cost-effectiveness of an intervention, dominance of the intervention 
or the control should be evaluated.  Graphically this can be illustrated by the cost-
effectiveness plane[179] presented in Figure 1.3.  A new intervention is said to dominate 
control being less costly and more effective if it is located in the southeast quadrant.  Vice 
Versa, a control dominates an intervention if it is located in the northwest quadrant, i.e. the 
new intervention is less effective and more costly.[180] 
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NW: northwest. NE: northeast. SW: southwest. SE: southeast 
Figure 1.3 Cost-effectiveness plane 
In the case of dominance, it is clearly appropriate to implement the least costly and most 
effective (or dominant) option and no recourse to calculate the cost-effectiveness ratio 
would be required.  However, far more common is for a new intervention to be more 
effective and more costly.  A decision should be made in such circumstances whether the 
additional health benefit is worth the additional cost.[180] 
An Incremental Cost-effectiveness Ratio (ICER) is calculated as the difference in costs 
between alternatives divided by the difference in outcomes measured.[173]  If the ICER of 
the new intervention is less than the acceptable cost-effectiveness threshold (i.e. the 
value a decision maker is willing to pay for a unit of health gained) then the treatment 
should be adopted.  The graphical illustration of the decision for cost-effectiveness can be 
seen in Figure 1.4.  
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NW: northwest. NE: northeast. SW: southwest. SE: southeast 
Figure 1.4 Decision for cost-effectiveness compared to the cost- effectiveness 
threshold 
In the NICE reference case, an additional QALY receives the same weight regardless of 
any other characteristics of the people receiving the health benefit.  NICE considers a 
value less than £20,000 and no more than £30,000 per QALY gained as acceptable for 
intervention adoption, i.e. the NHS cost-effectiveness threshold.[172] 
NICE emphasises the importance of quantifying the uncertainty associated with the 
intervention cost-effectiveness decision.  One method that is used to assess the 
uncertainty is to consider the likelihood that the intervention would be cost-effective if the 
threshold cost was changed.  The probability that an intervention is cost-effective at 
different thresholds can be plotted to produce the cost-effectiveness acceptability curve 
(CEAC).[173] 
In addition, the robustness of results should be tested by conducting a sensitivity analysis 
to account for uncertainty of the key estimates and the assumptions made during 
identification, measurement, and valuation of costs and outcomes.[172]   
Herein, to gain insight into the cost-effectiveness value of a pharmacy led MR intervention 
in hospital, an economic evaluation was warranted. 
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This thesis titled as “Optimising medicine reconciliation at the healthcare interface” 
consists of three projects; an audit, a systematic review, and an interim analysis of a 
pilot randomised controlled study.  This chapter describes the methods for each project. 
2.1 Audit of current practice on discharge information transferred to primary 
care 
A Primary Care Trust-wide audit was conducted in order to describe the quality of 
information received in primary care upon patient discharge.  This was to highlight areas 
of improvement in discharge information communication and inform the need for future 
interventions. 
2.2 Systematic review of the effects and costs of pharmacy led medicine 
reconciliation (MR) interventions 
A systematic review summarising relevant research on the effects and the associated 
costs with the implementation of pharmacy led MR interventions was conducted.  This 
helped to identify the most effective approach to implement MR and informed the 
development of a pharmacy led MR intervention. 
2.3 Development and evaluation of a novel pharmacy led medicine 
reconciliation study 
A pilot randomised controlled study, the MedRec study, was designed and implemented 
to estimate the effects and cost-effectiveness of a pharmacy led MR intervention within 
inpatient setting.  The MedRec pilot study aims to inform the optimum design of a 
pharmacy led MR intervention and to determine whether a larger scale trial is warranted 
and feasible. 
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2.1 Quality of 
discharge 
information upon 
hospital discharge: 
an audit at primary 
care 
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The literature review in chapter one highlighted that the quality of admission and 
discharge discrepancies has been extensively investigated; however, there is no large 
scale report on the quality of information received in primary care following patient 
discharge.  Additionally, there has been no evaluation of the extent to which discharge 
summaries adhere to the minimum dataset recommend by the National Prescribing 
Centre (NPC).  Thus, there is no indication of the impact of this recommendation on the 
quality of practice.  Additionally, the transfer of clinical information at the health interface is 
a multi-factorial process.  The relationships between factors and the quality of 
communication at the health interfaces are unclear and subject to confounding effects.  
Robust investigation of these factors in a UK context through a large scale evaluation was 
needed to enhance understanding of the predictors of communication deficit.   
A Trust-wide audit would be the first part of the clinical audit cycle to identify where 
practice is deviating from the guidance.  At the time of this thesis, it was almost three 
years since the NPC guidance was issued, therefore, it was an appropriate time to audit 
current practice across Norfolk to improve understanding of discharge communication 
across the Trust.  An evaluation of the potential harm associated with post discharge 
discrepancies by using a scientifically rigorous approach was also warranted as the 
evidence summarised in chapter one demonstrates that frequently discrepancies were 
evaluated using non-validated tools.  Additionally, there were insufficient details on the 
extent of agreement between raters. 
Therefore, a Trust-wide audit was carried out; discharge summaries received in primary 
care practices across Norfolk were audited against the NPC minimum dataset of 
information that should be transferred on discharge.  An investigation of predictors of 
adherence and medication discrepancies was carried out and consequently changes were 
proposed to optimise information transfer at the health interface. 
Within NHS Norfolk, all discharge summaries were audited against NPC minimum dataset 
from January 2011 to April 2011.  This audit was a joint collaboration between the 
University of East of Anglia (UEA) medicine management research team/ School of 
pharmacy and the NHS Norfolk primary care trust prescribing team.  
As an audit, no ethical approval was sought.  However, appropriate trust authorization to 
conduct the audit was obtained.  Aim and Objectives of the audit are described in BOX 
2.1.1 
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2.1.1 Audit site 
Within the UK, there are three main types of hospital; teaching, district and community.  
Teaching hospitals combines assistance to patients with teaching to medical or pharmacy 
students and nurses, often they are affiliated to a university.  Teaching hospitals 
frequently offer a wide and highly specialised range of specialities.  District hospitals 
typically are the major health care facility in a local community or a region and don’t have 
an affiliation to educational institution.  These often of smaller number of beds and less 
specialised services.  Whereas community hospital are often for intermediate or long term 
care, i.e. care for patients who are can be cared for out of acute care trust or primary care 
but yet independent to be cared at home.  Those hospitals frequently care for elderly 
patients and required long recovery or rehabilitation.  Health professionals in community 
hospitals are experienced with general care provisions.   
In urban areas teaching hospitals predominate, whereas for more rural areas district and 
community hospitals predominately provide secondary care services.  Norfolk is mainly 
rural with one large city and 21 market towns.  The health of the Norfolk population is 
generally better than the England average; deprivation is lower and life expectancy is 
higher.  However, Norfolk is served by one large teaching hospital, two district hospitals 
and 20 community hospitals.  A Trust-wide audit thus offers a unique representation of the 
BOX 2.1.1 Aim and objectives of the discharge information audit 
 Aim 
The aim of this audit was to describe the quality of clinical information transferred upon 
patient discharge in one UK primary care trust. 
 Objectives 
The audit was designed to: 
o Describe adherence of discharge summary content to the NPC minimum dataset 
of information transferred upon hospital discharge 
o Evaluate the extent and the nature of discrepancies upon hospital discharge 
o Estimate the clinical significance of discharge information discrepancies 
o Identify the factors which increase the likelihood of discharge information and 
medication discrepancies 
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quality of discharge summaries generated from these three different types of secondary 
care organisation. 
2.1.2 Audit tool 
An audit tool was developed incorporating the NPC minimum dataset which is 
summarised in Table 2.1.1, for which 100% adherence was expected. 
The NPC minimum dataset of information recommended in primary care following discharge 
from hospital 
 
1. Complete and accurate patient details, i.e. full name, date of birth, weight if under 16 year, 
NHS/unit number, consultant, ward, date of admission, date of discharge. 
2. The diagnosis of the presenting condition plus co-morbidities 
3. Procedures carried out 
4. A list of all medicine prescribed for the patient on discharge from hospital (and not just 
those dispensed at the time of discharge) 
5. Dose, frequency, formulation and route of all the medicine listed 
6. Medicine stopped and started, with reasons 
7. Length of courses where appropriate (e.g. antibiotics)  
8. Details of variable dosage regimens (e.g. oral corticosteroids, warfarin, etc.) 
9. Known allergies, hypersensitivities and previous drug interactions 
10. Any additional patient information provided such as corticosteroid record cards, 
anticoagulant books. 
11. This information should be clear, unambiguous and legible and should be available to the 
GP as soon as possible. Ideally, this should be within 2 working days of the patient’s 
discharge 
NHS: national health services. NPC: National Prescribing Centre. GP: General-Practitioner 
 
Table 2.1.1 The NPC minimum dataset of information recommended in primary care 
following discharge from hospital 
All the NPC minimum dataset elements listed above were included in the audit standards 
except “procedures carried out” and additional information related to corticosteroid record 
cards or anticoagulant books.  It was not possible to identify whether procedures were 
carried or not when there was no information recorded in the discharge summary on this 
regard.  The audit was conducted retrospectively, it was not possible to identify whether a 
patient was provided with the relevant record card or logbook.   
The audit tool was formulated into a Microsoft Excel spreadsheet (Appendix 2).  The 
auditors selected either “yes” or “no” by checking the option box when the information was 
present and /or accurate as appropriate.  Free text boxes were included to allow auditors 
recording further information or comments when appropriate.  
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In addition to the NPC minimum dataset, the audit tool recorded the following information:  
 Patient information related to age, gender, hospital, co-morbidities, ward speciality, 
length of hospital stay, admission type (planned vs. unplanned) and type of discharge 
summary (handwritten vs. electronic) 
 Number of working days between discharge date and the receipt of the discharge 
summary by primary care 
 Clinical information related to laboratory results, post admission complications 
 Contact and role of the person responsible for discharge summary completion 
From each hospital represented in the audit, a copy of the discharge summary template 
was obtained.  For some hospitals more than one template was used; the template 
representing the majority of the discharge summaries from that hospital was selected. 
2.1.3 Data collection 
The audit period was conducted between January 2011 and April 2011.  All 91 primary 
care practices across NHS Norfolk primary care trust were invited to participate in the data 
collection.  Each practice was requested to sequentially collect a defined number of 
discharge summaries; this was based on a 5% proportion of the practice list size.  A total 
sample of 3,761 discharge summaries was anticipated.  The practice itself identified a 
member of staff to conduct the audit.  The audit was part of the primary care trust quality 
and outcomes framework incentive scheme for 2010/2011. 
2.1.4 Pilot  
A sample of 200 discharge summaries sequentially selected of patients discharged to nine 
primary care practices in Norfolk during August 2010; those were audited using the initial 
version of the audit tool. 
The pilot enabled the refinement of the tool and development of the audit process. The 
following amendments were informed by the audit:  
 Inclusion of check boxes to simplify data entry 
 Altered ordering of data entry to ensure ease & flow while completing the audit tool 
 Simplification of the basic audit tool from three to one Microsoft Excel spreadsheet 
 Inclusion of a field to collect data on allergy status 
 Addition of free commentary text fields 
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2.1.5 Inclusion and exclusion criteria 
A discharge summary was eligible if the patient was hospitalised for at least 24 hours on 
an inpatient ward.  Discharge summaries of patients who were deceased before 
discharge, deceased prior to data collection or transferred to another NHS trust were 
excluded.  
2.1.6 Audit communication  
The audit was communicated to primary care practices via the lead prescribers’ meeting 
held in September 2010 which included GPs, primary care administrative staff and 
pharmacists from almost all primary care practices across Norfolk.  A brief overview of the 
audit aims, process and the audit tool was presented in a 20 minutes PowerPoint 
presentation which followed by discussion and comments.  In addition, practices were 
informed about the audit by one to one communication, phone calls and emails. 
2.1.7 Audit distribution and recall 
Practices were emailed the audit guidance (Appendix 3) which included detailed guide for 
the completion of the audit tool and contact details for enquires.  Each practice was sent 
the specified number, based on 5% of practice size, of audit tools using a secure NHS 
email.  Some practices requested paper copies in preference to electronic; these were 
sent to them which were then returned by post to UEA team.  
2.1.8 Confidentiality 
No patient identifiable details were collected or attached with the audit tools.  Discharge 
summaries were given unique audit identifiers; a list of patients’ NHS numbers and their 
audit identifiers was generated and held in the practices.  This list was maintained in the 
practice until the audit period ended. 
A sample of handwritten discharge summaries was photocopied to assess variation in 
legibility assessment; these copies were anonymised.  
2.1.9 Outcomes measurement 
2.1.9.1 Adherence to NPC minimum dataset  
The extent of discharge summary adherence to the NPC minimum dataset was 
estimated by scoring each discharge summary against a set of criteria described in Table 
2.1.2.  Discharge summaries for patients with no medication history or had no medicine 
changed, initiated or discontinued were scored only against the applicable criteria and 
therefore the extent of adherence to the NPC minimum dataset was estimated as a 
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percentage.  BOX 2.1.2 describes the method for estimating the extent of adherence to 
the NPC minimum dataset. 
 
 
 
 
 
 
 
Discharge summaries were scored 1 point when a criterion was successfully fulfilled (i.e. 
the information was provided and/or accurate) and 2 points when it failed to fulfil the 
criterion.  A total score for each discharge summary was calculated by adding all points 
assigned for each criterion (S).  T is the score representing complete adherence to all 
criteria applicable to a given discharge summary.  E.g. if a discharge summary had at 
least one medicine and there was at least one therapy change, including initiation, 
discontinuation or dose, formulation or route alternation, all 14 criteria would have been 
relevant and therefore ‘T’ = 14.   
NPC minimum dataset criteria were organised into three categories: patient, admission 
and discharge information, medication information and therapy change information 
(Table 2.1.2).  Discharge summaries were also scored with respect to each of the three 
categories and the extent of adherence to each category was estimated using similar 
method to which shown in BOX 2.1.2. 
  
BOX 2.1.2 Method for estimating discharge summary adherence to the NPC 
minimum dataset 
Discharge summary adherence to NPC minimum dataset is estimated as:  
Extent of adherence to NPC minimum dataset = [1-((S – T)/T)] ×100% 
o Discharge summary adherence score (S)= Sum of the point(s) assigned to each 
applicable criterion 
o T= score representing complete adherence to all applicable criteria 
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Categories Criteria 
Patient, admission & 
discharge details  
1. Correct patient name  
2. Correct date of birth  
3. Consultant name  
4. Ward  
5. Date of admission  
6. Date of discharge 
7. Presenting diagnosis  
8. Complete past medical history (PMH) and co-morbidities   
9. Complete drug history 
10. Known allergic or hypersensitivities,  
11. Discharge summary is legible  
12. Received within 2 days post discharge (weekends and 
public holidays were excluded). 
Medication related 
information  
13. Full list of all medicines  
a. All doses 
b. All frequencies 
c. All routes of administration  
d. All formulations  
e. Therapy duration when a medication was initiated by 
hospital  
Therapy changes 
related information  
14. List of all medication altered 
a. All medicines initiated with reason(s) 
b. All medicines discontinued with reason(s) 
c. All medicines changed with reason(s) 
Table 2.1.2 Audit scoring criteria
2.1.9.2 Discharge discrepancies identification  
A sample of discharge summaries was reviewed to identify discharge discrepancies.  
Practices were self-selected to take apart in the process of discharge discrepancies 
identification.  From each practice a consecutive sample of discharge summaries were 
selected based on again 5% of the practice list size. 
Primary care records were reviewed to identify discharge discrepancies using a 
reconciliation sheet (Appendix 4); the sheet incorporated information on patient pre-
admission and discharge medicines.  These were matched to identify discrepancies.  
Information related to therapy durations, titration and monitoring plans were recorded for a 
set of medicines; those included: clopidogrel, anticoagulants, antibiotics, corticosteroids, 
analgesic and proton pump inhibitors.  These medicines were identified following 
discussions with primary and secondary care pharmacists and with reference to national 
guidelines.[181, 182]  It was agreed that these medicines would contribute to an increased 
risk of patient harm when associated with inaccuracies or omissions.   
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Types of discharge discrepancies are described in BOX 2.1.3.  The identification of 
discharge discrepancies was undertaken by five researchers from the UEA; the thesis 
author (EH) and four final year pharmacy students.  Prior the audit, the UEA auditors were 
trained on the tool completion, the use of the practices’ computer system and process of 
discrepancies identification.  Discussion led the development of standard operating 
procedures for discrepancies identification and classification.  Weekly feedback meetings 
and discussions were held, this also aimed to minimise variation between auditors. 
BOX 2.1.3 Type of discharge discrepancies 
Discharge discrepancies included medication and reconciliation discrepancies. 
 Medication discrepancies  
Medication discrepancies were defined as any undocumented differences between 
discharge summaries and patients’ most updated pre-admission medicines as recorded 
in the GP notes.  Medication discrepancy classification was adapted from various studies 
[31, 34, 121, 127]
 and categorised as:  
 Omission of pre admission medication  
 Undocumented changes (dose, frequency, formulation or route)  
 Undocumented medication substitutions ( generic substitution was not 
considered a discrepancy)  
 Failure to report reasons or indications for medication initiations 
 Failure to report reasons or indications for medication discontinuations 
 Reconciliation discrepancies  
A reconciliation discrepancy was considered when there was no recorded evidence of an 
explicit discharge summary recommendation being implemented in the GP held patient 
notes.  
GP held patient records were reviewed and the extent to which hospital 
recommendations were implemented was recorded.   
Auditors discussed, clarified and resolved each discrepancy with GPs or the practice 
based pharmacist.  Medicines were categorised as described in the British National 
Formulary 59. 
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2.1.9.3 Clinical significance of discharge discrepancies  
Medication and reconciliation discrepancies were stratified according to the following 
criteria: 
o Discrepancy category  
o Being explicitly recommended by the discharge summary  
o Prescription only medication or over the counter medication 
o Recommendation implemented by the GP 
Resources were available to enable assessment of a sample of discrepancies; this was 
discussed with Norfolk prescribing team, it was estimated that 20 discrepancies would 
place reasonable burden on each assessor.  Thus, a random sample of 20 discrepancies 
was evaluated by a clinical expert panel.  The panel included one of each of the following 
professions: GP, consultant, primary care and hospital pharmacists.  The Dean and 
Barber visual analogue scale (VAS) [183] was used to assess severity of discharge 
discrepancies.  The method proposed by Dean and Barber does not require the 
knowledge of patient outcomes, where 0 represents a discrepancy with no potential effect 
and 10 for a discrepancy that may result in death.  Dean and barber reported that a 
generalisable score for the severity of a medication error can be produced from at least 
four judges of experienced UK pharmacy, medical staff and nursing staff.  The mean 
score from all assessors was estimated; mean score of each discrepancy was categorised 
as minor (<3), moderate (3-7) or severe (>7).   
The time needed by GPs to confirm necessary actions was also estimated using a scale 
of 0, 15 min and > 30 min.  The time scores assigned for discrepancies were categorised 
further into three categories; 1 (<15 min), 2 (15-30 min) and 3 (>30 min) and the median 
(IQ) was reported. 
2.1.10 Validity and reliability 
2.1.10.1 Face validity of the audit process and tool 
Face validity of the audit tool was assessed prior the audit Trust-wide distribution by 
presenting the audit tool to two senior research pharmacists (DW and DB), a GP and two 
practice based pharmacists.  Refinements were subsequently made to the language and 
the layout of the audit tool. 
After the audit completion, two GPs, two primary care pharmacists and pharmacy 
technicians who were involved in the audit conduct from different practices were invited 
for one to one discussion.  This was to gain insight on the quality of audit data and 
variations in the audit tool completion.  
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Auditors were self-selected; practices were contacted requesting two of each profession 
above who were directly involved with the audit completion.  Discussions were structured 
and led by a set of open questions related to: 
 Clarity of audit aims 
 Ease of audit tool completion and handling. 
 Nature and ambiguity with of the audit questions 
 Time needed for audit completion 
 Ambiguity with legibility rating 
2.1.10.2 Quality assurance of the audit data 
Practices were requested to retain hard copies of the audited discharge summaries.  
Practices were stratified by list size and five practices were randomly selected from each 
stratum.  Twenty discharge summaries were randomly selected from each practice and 
re-audited.  This would yield a total of 100 discharge summaries. 
Agreement across the audit questions was evaluated using kappa statistics.  Kappa 
scores ranging from 0.01-0.40 were considered of slight to fair agreement, 0.41- 0.60 of 
moderate agreement, 0.061-0.80 good and > 0.81 of substantial agreement.[35] 
2.1.10.3 Legibility rating agreement  
Legibility of handwritten discharge summaries was assessed using a four point scale: 
o 'Legible’; all words clear ‘  
o 'Some words illegible’; but report can be understood by a clinician  
o 'Most words are illegible’; meaning of the whole unclear 
o 'Illegible’; most or all words impossible to identify  
This rating scale was informed by reviewing studies evaluated the legibility of doctors’ 
handwriting in medical records and demonstrated considerable agreement between 
assessors.  Additionally, the scale was believed reasonably objective and with minimum 
or limited ambiguity.[184, 185] 
To ensure uniform legibility rating, the UEA auditors were trained until reasonable 
agreement was achieved.  The UEA auditors scored a random sample of 20 handwritten 
discharge summaries collected during the pilot and discussed disagreements until 
consensus. Subsequently, the process was standardised to ensure minimum variation 
between UEA auditors. 
After the audit completion, a random sample of 20 handwritten discharge summaries was 
selected from 14 practices and a GP independently re-rated them.  This was to assess 
agreement in legibility assessment between auditors among various practices.   
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Being an ordinal rating scale, i.e. the differences between categories carry a meaningful 
message, therefore, the Inter-rater agreement for legibility was assessed using weighted 
kappa statistics.  Weighted kappa statistics had similar interpretations to unweighted 
kappa scores.  Cells were weighted according to the magnitude of disagreement; the 
method used to weight cells is the absolute error weight.  All cells in the diagonal were 
given a weight of 1, those which deviated by one category were weighted with 2/3 and 
those deviating by two categories were weighted with 1/3.  Total disagreement was 
weighted with 0.[186]   
2.1.11 Statistical analysis 
Data were processed using the Statistical Package for Social Science (SPSS version 18).  
Descriptive statistics were reported as a mean 95% [CI] and median (IQ) as appropriate.   
In order to investigate the contributors and identify predictors of the quality of discharge 
information, regression analysis was deemed appropriate.  Regression analysis and 
generalised linear model analysis (GLM) were utilised to estimate the relationships among 
variables and to model the effect of those variables on the outcomes, i.e. adherence to the 
NPC minimum dataset and medication discrepancies.  As such, significant predictors of 
good practice and factors associated with substandard practice were identified at a 
significance level of P < 0.05.   
Regression via enter method was used to explore the influence of patient demographics, 
admission type (planned vs. unplanned), discharge summary template, discharge 
summary type (handwritten or electronic), hospital, ward speciality and profession type.  
These factors were selected as they were widely reported in the literature (chapter one) 
as potentially influencing the quality of discharge information.   
The influence of variables and the potential confounding effect of contributing factors 
needed to be examined thus regression models were adjusted; both adjusted and 
unadjusted models were reported.   
Stepwise backward elimination was used to reach the most parsimonious GLM models; 
those models highlighted significant predictors and assessed the change in the outcome 
with a unit change in the predictor.  GLM analysis was also used to determine the effect of 
ward speciality on discharge summary adherence to the NPC minimum dataset.  
Community and specialist care hospitals such as mental health hospitals were excluded 
from this analysis as they do not have the breadth of different ward specialities 
demonstrated by general hospitals.  Similar analysis using regression and GLM was used 
across the three categories of the NPC minimum dataset.   
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All regression models were checked for assumptions of linearity, multicollinearity and 
Homoscedasticity (Appendix 5).  Correlation matrixes were checked to identify any 
substantial association between predictors.  Additionally, age, hospital stay and no. of 
medicines were checked for linearity, those were fitted in the regression models as 
categorical variables.  There was consistent decreasing monotonic trend through levels.  
The Best fitting models were presented and discussed in this thesis. 
It was decided that a linear relationship between the number of medication discrepancies 
per discharge summary and any predictors of medication discrepancies would not exist.  
Therefore discharge summaries were dichotomised into those with at least one 
discrepancy or no discrepancy at all.  Logistic regression using enter method was used to 
identify the contributing factors to medication discrepancies.  Assumption of logistic 
regression was checked, those are presented in Appendix 5. 
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2.2 Pharmacy led 
medicine 
reconciliation in 
hospital care: A 
systematic review 
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Following the discharge information audit, a systematic search was conducted to collate 
the available evidence on the effects and costs associated with pharmacy led medicine 
reconciliation (MR) interventions in hospital setting. 
Aims and objectives of pharmacy led MR systematic review are described in BOX 2.2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BOX 2.2.1 Aims and objectives of pharmacy led MR systematic review 
 Aims  
The systematic review aimed to: 
o Evaluate the published literature on the effects and costs associated with 
pharmacy led MR interventions in inpatient setting 
o Identify the optimal methods for delivering a pharmacy led MR service in inpatient 
setting.  
 Objectives  
The objectives were to: 
o Describe pharmacy led MR service with respect to: 
• The person or team providing MR 
• The setting where MR is delivered 
• The time to implement MR  
o Describe the targeted patient population  
o Describe outcomes measured such   
o Determine the resources needed to implement pharmacy led MR 
o Determine the costs and consequences associated with pharmacy led MR 
interventions and the process used for measurement and valuation of these costs 
and consequences 
o Describe the quality and design of studies evaluating the effects and costs of 
pharmacy led MR interventions 
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2.2.1 Literature search strategy 
Studies were identified through comprehensive electronic and manual search that aimed 
to identify all the reports of published and unpublished studies.  The search were carried 
out on 23rd March 2012 and completed by 3rd May 2012. 
A comprehensive range of databases was searched:  
 EMBASE & MEDLINE Ovid; search date in 23.03.2012 
 CINAHL; search date in 19.04.2012 
 Cochrane library which included Cochrane Database of Systematic Review, 
Database of Abstracts of Reviews of Effects  and the NHS Economic Evaluation 
Database; search date in 26.04.2012 
 The Centre of Reviews and Dissemination; search date in 28.04.2012 
 PHARMLINE provided by the National electronic Library for Medicines; search date 
in 2/05/2012 
Scoping search was conducted prior to finalising the search to identify all relevant search 
terms.  Search strategy combining terms for medicine, reconciliation, hospital and 
pharmacist were used in combination with truncations (*), wild cards ($), adjacent search 
options (e.g. adj2), hyphens and other relevant boolean operators where allowed by the 
databases.  The search strategies applied into the various databases are summarised in 
Appendix 6 (A-E).  
Bibliographies of the included studies were also reviewed to identify additional references.  
Citation searching using SCOPUS database was performed.  Additionally, authors and 
key institutions involved with research on MR evaluation and implementation were 
contacted by email to obtain any relevant work.  This included the UK National Patient 
Safety Agency and NPC, Institute of healthcare improvement and Joint commission in 
USA.  One month was allowed for authors and institutions to response.  
2.2.2 Software to manage references 
References were managed using Endnote X4 software 
2.2.3 Inclusion criteria 
2.2.3.1 Populations and sites 
Studies evaluating adults and children receiving pharmacy led MR within inpatient 
settings.  All type of admissions and ward specialities were considered.  
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2.2.3.2 Intervention type  
Any study evaluating all of the following tasks of MR implemented by a pharmacist or 
pharmacy technician or pharmacy student was included: 
 Collecting medicine history and other relevant information about patient medicines or 
any information that might affect the treatment choice such as allergies and 
hypersensitivities. 
 Comparing collected information with inpatient medicine chart to ensure that patient 
medicines are complete and accurate 
 Comparing inpatient information with discharge document to ensure all changes are 
documented and communicated clearly and accurately 
 Pharmacist intervening to resolve and clarify any identified discrepancies with the 
medical team  
 Documenting changes made to patient’s medicines and communicate them clearly to 
the next care provider 
 
2.2.3.3 Study design 
All study designs were considered including randomised clinical trials (RCTs), non-
randomised comparative studies, observational studies and before and after studies.  
Systematic reviews reference lists were checked to ensure that all relevant articles had 
been identified. 
2.2.3.4 Language 
No language restrictions were applied. 
2.2.4 Exclusion criteria 
Studies evaluating a pharmacy led MR via qualitative approach were excluded.  
2.2.5 Screening and selection 
The relevance of each study to the research question was assessed in three stages as 
described by figure 2.2.1.  Screening was performed using a screening tool developed for 
the purpose of the review (Appendix 7). 
Independent screening of titles and abstracts for relevance was performed by the thesis 
author (EH) and verified by a second senior researcher (AB).  Discrepancies were 
discussed to obtain consensus.  Any remaining disagreement was resolved by a third 
reviewer (DB).  Authors were contacted when it was necessary for clarification or to obtain 
further information relating to the included studies.   
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Figure 2.2.1 Pharmacy led MR systematic review screening stages 
 
2.2.6 Data extraction 
The thesis author (EH) extracted the relevant data from the included articles using a data 
extraction tool which was in a Microsoft Excel spreadsheet format (Appendix 8).  The 
extraction tool incorporated the following details: 
 Details related to study design, authors, country of correspondence, year of 
publication and setting 
 Details related to study population, number of participant, speciality, recruitment, 
demographics and baseline comparability if applicable  
 Details related to study intervention including feature of the intervention, the team 
providing MR, timing to provide the intervention, comparators and follow up.  
 Details related to study outcomes including process and patient outcome data 
The data extraction tool was piloted and face validated.  Two relevant articles were 
presented to researchers with systemic review experience from different disciplines; those 
were invited to extract data using the tool.  Interactive feedback was obtained through 
group and one to one discussions. 
  
Title 
screening
•Initial screening of titles against the inclusion criteria to 
identify potentially relevant papers for abstract retrieval
Abstract 
screening
•Screening of abstracts to identify papers for full text 
retrieval
Full text 
assessment
•Assessment of full papers for inclusion into the review
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2.2.7 Outcome measurements 
Information relating to the following measures was recorded: 
 Process oriented outcomes: 
o Medication discrepancy rate  
o Pharmacy intervention to intercept discrepancies 
o Clinical significance of medication discrepancy 
o Resources necessary to implement MR such as time and training 
 Patient oriented outcomes 
o Health resource use  
o Health related quality of life 
o Mortality rate   
 Associated costs  
Data related to cost measurment and valuation including fixed, variable and knocked on 
consequence costs was extracted.  Cost outcome data were related to:  
o Health care resource use such as length of hospital stay, readmission, emergency 
department visits  
o Operating costs related to cost consumed in the MR intervention delivery, e.g. time 
commitment 
o Fixed costs related to setting up the intervention, e.g. training or education 
sessions 
o Cost savings or avoidance contributed by MR interventions  
2.2.8 Quality assessment 
Studies were not excluded based on quality.  The thesis author (EH) assessed the quality 
of the included studies using a tool adapted from several sources including Cochrane 
guidance [23], the Critical Appraisal Skills Programme [50] and the Review Body for 
Interventional Procedures.[187]  The tool adapted the Cochrane collaboration’s table for 
assessing risk of bias; few modifications were introduced to enable the evaluation of non-
RCT studies as well as RCTs and economic evaluations.  
The handbook of Cochrane recommended assessing the risk of bias for non-randomised 
studies using six domains; those also recommended for RCTs.   The Cochrane domains 
are: selection, performance, attrition, detection and reporting bias.  The Cochrane tool 
was developed without having non-randomised studies in mind; thus it is stated that the 
six domains are not necessarily all appropriate for non-randomised study designs.[23]  
However, the general structure of the tool was believed useful and thus adopted by the 
pharmacy led MR systematic review. 
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The risk of bias assessment tool was piloted and face validated.  Two relevant articles 
were presented to researchers with systemic review experience from different disciplines; 
those were invited to extract data using the tool.  Feedback was obtained through group 
and one to one discussions. 
Domains were assessed by providing a description of what happened in the study and 
providing a judgement on the adequacy of the study with regard to the domain.  The 
judgement is formulated by answering a pre-specified question, such that an answer of 
‘Yes’ indicates low risk of bias, an answer of ‘No’ indicates high risk of bias, and an 
answer of ‘Unclear’ indicates unclear or unknown risk of bias.     
The tool employed in this systematic review incorporated nine domains in total (Appendix 
9); additional domains related to clarity of study question and design, baseline 
comparability between groups, standardised intervention delivery and outcome 
measurement plus sample size calculation were assessed.  Three additional domains 
assessing the validity of economic evaluation studies were also included; those related to 
well-defined perspective, appropriate cost identification, measurement and valuation and 
assessment of variability associated with the cost and cost-effectiveness estimate. 
Detection bias related to blinding of outcomes measurement was considered of 
importance in assessing the measurement of medication discrepancies and their clinical 
significance.  However, blinding of outcome assessors was considered less pertinent 
when less subjective outcomes were under question such as rate of readmissions and 
emergency department visits.  In these, risk of bias was assessed whether studies 
obtained outcome data by using a standardised reporting system such as hospital data or 
self-report data.   
2.2.9 Reporting  
Reporting of the systematic review was based on the PRISMA statement 2009 which 
details the Preferred Reporting Items for Systematic Reviews and Meta-analysis.[188]  
A protocol was developed and registered on the international database of prospectively 
registered systematic reviews (PROSPERO) in May 2012.  The review registration 
number is CRD42012002386.  
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2.3 Medicine 
reconciliation at the 
health interface: The 
MedRec Study  
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The Medical research council’s guide recommends “Identifying the relevant, existing 
evidence base, ideally by carrying out a systematic review”, it also emphasises the use of 
piloting and feasibility before large scale evaluation (BOX 1.6).  The systematic search to 
identify the relevant, existing evidence base on the effects and costs associated with 
pharmacy led MR was followed by a pilot randomised study of the cost-effectiveness of a 
pharmacy led MR service.  MR is a complex intervention, as described earlier, and so a 
randomised controlled study would be, as recommended by the Medical research 
council’s guide, the most robust method to evaluate and assess the effects and costs of a 
complex health intervention.[160]  Randomisation is the most robust method of preventing 
selection bias and matching groups with respect to known and unknown confounding 
factors.  A pilot study would play an important role in providing information for the planning 
of a large scale randomised controlled study if warranted including provision of data to 
inform the sample size calculation for a definitive study.  
The pharmacy led MR systematic review informed the design and outcomes measures of 
the pilot RCT presented in this section.  Having not received MR by a pharmacist within 
24 hours of admission, patients were randomised to either receiving MR from the study 
pharmacist or receiving standard care.  Standard care may or may not include receipt of 
MR as this was dependent on work load and staff availability and thus not available to all 
patients.  
The pharmacy led MR study, the MedRec study, aim and objectives are descried in BOX 
2.3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BOX 2.3.1 The MedRec pilot study aim and objectives 
 Aim  
The aim of the pilot study was to determine the optimum design of a larger scale RCT 
and evaluate a novel pharmacy led MR service within inpatient settings.  
 Objectives 
The study objectives were to: 
o Estimate the possible effect size of an extended pharmacy led MR 
service  
o Determine recruitment and follow up rates 
o Describe the appropriate approach to recruitment 
o Identify patients who might receive the most benefit from pharmacy led 
MR  
o Identify resources necessary to implement pharmacy led MR  
o Assess the MedRec intervention cost-effectiveness 
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2.3.1 Study development  
2.3.1.1 Study management committee 
The study management committee consisted of a collaborative research team from UEA 
and Cambridge University Hospital Foundation Trust.  UEA team included the author 
thesis (EH), David Wright (DW), Ian Nunney (IN) and James Desborough (JD) from the 
school of Pharmacy and Richard Holland (RH) and Garry Barton (GB) from the Medical 
School.  Cambridge University Hospital Foundation Trust team included Brit Cadman (BC) 
who is the study principal investigator (PI), Amanda Bale (AB) who is the senior 
researcher, Kellie Hempstead (KH) an assistant researcher, Helen Howe a chief 
pharmacist and two patient representatives.  The study management committee met 
every three to four months to oversee the study progress. 
2.3.1.2 Patient and public involvement 
The medical research council recommends identifying and developing appropriate theory, 
this can be done by interviewing with ‘stakeholders’, i.e. those targeted by the 
intervention, or involved in its development or delivery.  Prior the study commencement, 
the study protocol was presented to health professionals including doctors, nurses, 
pharmacists and patients.  Feedback was received regarding the study design and 
process via a series of meetings.  Each meeting started with a brief overview of the study 
and was structured around a list of pre-determined questions related to the study design, 
recruitment process and outcome measurements.  Opinions on the study information 
leaflet and lay summary were also obtained.   
2.3.1.3 Ethical review and approval  
This study was funded by the Research for Patient and Benefit programme and was 
approved by the Essex ethics committee REC#12/EE/0143.  The study registry number at 
ISRCTN.org, a non-profitable organisation that serves as a platform for registry of clinical 
trials, is ISRCTN23949491. 
2.3.2 Study setting 
The study was conducted at Cambridge University Hospital Foundation Trust which is a 
large university-affiliated teaching hospital.  It took place in five adult medical wards in the 
medicine division comprising a range of medical specialities including gastroenterology, 
renal and endocrinology and two medicines for older people wards.  The study wards 
were selected pragmatically (out of a total of 16 medical wards) following discussion with 
the lead pharmacist for medicine at the study site and the clinical services manager who 
was also principal investigator. 
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The selection criteria were the number of admissions, type of pharmacy service allocated 
to the ward and likelihood of ward closure during the study period.  In terms of number of 
admissions, wards with the highest turnover were preferentially selected to increase the 
likelihood of recruiting the target number of patients.  In terms of type of pharmacy 
service, those wards receiving specialist pharmacy services provided by senior 
pharmacists such as critical care, transplant, paediatrics, oncology and haematology were 
excluded.  This was because the costs of delivering these services was significantly 
higher than the majority of wards due to the higher salary of the pharmacist and increased 
time spent per patient.  Thus the selected wards had pharmacy service cover typical to 
routine care in the Trust and other similar trusts in the region.[26]  In addition, wards which 
were anticipated to close during the study period were excluded. 
The profile of the pharmacy service in the study wards was maintained at the same 
routine level during the study period.  At the times of staff shortage due to vacancies and 
annual leave, the level of the service was reduced to a basic clinical safety service.  This 
was applied across all wards in the Trust.   
The specialities covered by the study wards were general medicine, renal, 
gastroenterology, endocrine and medicine for older people.  
The study intervention was implemented seven days a week during working hours with 
the support of three MR pharmacists who followed a rota to ensure the extended service 
cover over week days as well as weekends.  
2.3.3 Study communication  
Pharmacy staff who were not involved in the study as well as medical and nursing staff in 
the study wards were informed about the study and the MR pharmacist role through 
educational meetings and one to one communication.   
2.3.4 Patient recruitment and consent 
Study recruitment started on 5th of July 2012 and extended until 6th April 2013.  It was 
envisaged that 5-8 patients a week would be recruited and therefore nine months 
anticipated to complete patient recruitment.[189] 
The study researchers were trained to consent patients and obtain consultee decision for 
patients under the Mental Capacity Act 2005.[190]   
A nurse on the ward assessed the mental capacity of patients.  When a patient was 
considered mentally competent to consent for a study the nurse asked whether the patient 
was comfortable to be approached by the study researcher.  If agreeable, patients were 
approached by the study researcher and a written informed consent was obtained.  
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Patients were invited to take part in the study within 24 hours of their admission.  This time 
window was considered from the time the patient is admitted to the ward excluding the 
time spent in the emergency department prior to transfer to inpatient wards.   
Each participant was provided with a copy of the study information leaflet (Appendix 10) 
which included full details on the purpose of the study and the study process.  The study 
information leaflet was analysed for ease of reading using the Flesch Reading Ease score 
[191]
 and demonstrated a score of 59 which described as ‘fairly difficult to read’.  This score 
is accounted for a 15 years old school reading level.  There was a group of three syllable 
words frequently used in the study information leaflet such as pharmacist, participant, 
information, hospital, medicines, and questionnaire, these three syllable words were 
considered unchangeable as this might affect the quality and the clarity of the information 
leaflet.  A score of 78 was found when these words were taken out.  This accounted for 
‘fairly easy to read’ with a level of 12 years old reading.  However, the feedback on the 
study information leaflet from the patient stakeholder meeting and the patient 
representative members expressed satisfactory ease of reading. 
As the intervention is non-invasive and aimed to be provided within 24 hours of admission, 
it was not possible to allow patients two days to consider the study participation.  
However, patients were given at least 2 hours to read the study information leaflet.  They 
were welcomed to ask questions and offered any support they needed before consenting 
to the study (Appendix 11).  Following patient consent, a letter was sent to the patient GP 
to inform him/her about the patient’s participation.   
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2.3.4.1 Inclusion & Exclusion criteria 
 Inclusion criteria 
Patients who met all the following criteria were eligible for the study: 
o Adult (≥18 years of age) 
o Admitted within the previous 24 hours. 
o Admitted with at least one regular or over the counter medicine to one of the study 
wards 
o Have not received MR services from any member of the clinical team as part of the 
control care up to the point of recruitment 
 Exclusion criteria 
Patients were excluded if they met any of the following: 
o Admitted via elective admission, this was to ensure that patients had not received 
MR during pre-admission clinic 
o A study participant who was readmitted during the course of the study 
2.3.4.2 Recruitment of patients under the Mental Capacity Act 2005  
To ensure a representative sample, the study included patients who were admitted in a 
state of reduced consciousness which may be or not related to their illness and thus they 
lacked the mental capacity to consent.  The MedRec intervention study is a low risk 
intervention, no or little disadvantage or burden to those patients was believed. 
When the patient was considered mentally incompetent to consent, a patient consultee 
under the Mental Health Act 2005, section 32 was identified.  When it was not possible to 
identify a consultee from the participant relatives or friends, an independent mental 
capacity advocate was to be nominated according to the local policy in CUHFT.  The 
independent mental capacity advocate was independent from the research team and the 
study.  A member of the nursing team asked whether a patient relative or friend is willing 
to advice the study researcher with regard the patient wishes about the study.  If 
agreeable, the study researcher asked the consultee to offer an advice as whether he/she 
believed that the patient’s wishes would be to take part in the study if they have not been 
mentally incapacitated.  In such cases, the consultee was given a consultee information 
leaflet and allowed the time to consider the study participation (Appendix 12).  In addition 
to full details on the study purpose and process, the consultee information leaflet included 
information with regard to the consultee role and responsibilities as specified under the 
Mental Capacity Act 2005.  When a decision was made to take a part in the study, the 
consultee signed a consultee declaration form (Appendix 13).   
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Following the consultee consent, a letter was sent to the patient’s GP to inform him/her 
about the study participation.  
To safeguard patient confidentiality, the consultees were not asked about the patient’s 
regular medicines.  This information was obtained from elsewhere such GPs, previous 
admissions or repeat prescriptions. 
When a patient lacked the mental capacity initially upon recruitment and his/her mental 
capacity was recovered during a later courses of the study, an informed decision was then 
sought from the patient him/herself. 
2.3.5 Randomisation 
Patients were randomised either into the intervention or control group using an automated 
randomisation system.  The allocation to either intervention or control group was obtained 
using a centralised randomisation function built into the study database.  Randomisation 
was stratified by wards; patients were randomised in a ratio of 1:1; intervention: control.  
The randomisation details were emailed to BC and AB.  The intervention was a 
standardised service provided to patients across the study wards by a team of MR 
pharmacists who had a rota to ensure weekend cover of the service.  There were three 
MR pharmacists delivering the intervention across five wards, thus it was impractical to 
randomise at a ward level.  Additionally, a wash over effect of the intervention, i.e. the 
practice of the ward staff influencing or improving due to witnessing the intervention was 
unlikely because the nursing and medical team provided no MR as a part of the routine 
care.  Additionally, the study pharmacists were informed not to discuss the study MR 
process with the ward pharmacy staff.  Therefore, limited benefit was anticipated for 
cluster randomisation by ward, furthermore cluster randomisation would imply consenting 
patients after allocation to the study groups; this potentially might bias the study selection.  
Cluster randomisation also requires relatively large sample sizes to observe an effect; with 
a pilot design aiming to assess feasibility of the study process such an approach was 
considered inappropriate use of extra resources. 
2.3.6 Blinding  
The nature of the MedRec intervention precluded blinding of the study team; i.e. study 
researchers, PI, ward doctors and MR pharmacists as well as patients.  However, ward 
nursing and medical team providing standard care to patients were blinded to the study 
allocation.   
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2.3.7 Study groups 
The MedRec recruitment chart is summarised in Figure 2.3.1. 
2.3.7.1 Intervention group  
The study researcher informed the MR pharmacist to visit the patient when the allocation 
was for the intervention group; the MR pharmacist visited the patient within 24 hours of 
admission to implement a standardised MR and record the duration of MR tasks using a 
form developed for the purpose of the study (Appendix 14). 
 The MedRec intervention  
The MedRec intervention included a comprehensive reconciliation of patient medication 
list performed by a pharmacist within 24 hours of patient admission to identify 
discrepancies and resolve unintentional errors.  The MR pharmacist also documented all 
medicines changed and communicated complete and comprehensive information clearly 
to the next health provider upon discharge. BOX 2.3.2 describes the MedRec intervention.  
 
BOX 2.3.2 The MedRec intervention  
The MR pharmacist: 
 Verified medication histories and collated a comprehensive accurate list of all 
medicines the patient is taking using different sources of patient information. 
 Compared the collated list with the patient active inpatient medicines list written by the 
medical team upon admission.   
 Identified discrepancies between the above two lists were reviewed and discussed with 
the medical team to determine whether they were intentional or unintentional.  
 Ensured that unintentional discrepancies resolved and all intentional changes 
documented clearly in the medical notes and discharge summary.  
 
 
In addition to information obtained from the patient interview, the MR pharmacist used at 
least two source of information.  Those included, but not limited to, patient own drugs, 
home medication list obtained from the GP, previous discharge summary or copy of 
repeat prescription.   
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Prior the study commencement, each MR pharmacist provided MR to at least 30 patients.  
The study PI observed each MR pharmacist undertaking at least three MR; this was to 
ensure a standardised and uniform delivery of the MedRec intervention between MR 
pharmacists.   
2.3.7.2 Control group 
Control group consisted of standard care provided to the patient by Cambridge University 
Hospital Foundation Trust staff who were independent from the study.  Standard care 
included MR occasionally depending on resources and staff availability.   
 Control MR 
MR in the control group was defined as MR provided by a pharmacy staff who is 
independent from the study as a part of the usual care.  In Cambridge University Hospital 
Foundation Trust at the time of the study, primarily MR was provided by pharmacy 
technicians and was provided typically after more than 24 hours of patient admission.  In 
addition, there was rarely a significant opportunity for direct patient/carer interaction and 
limited contact with primary care for the purpose of obtaining or clarifying patient 
information.  Nevertheless, there was also limited or no follow up of discrepancies and 
communication with the next health provider. 
The study did not interfere with the clinical services provided for control patients.  
Pharmacy staff who were independent from the study were asked to record if and when a 
patient received control MR.  Data were recorded using a form developed for this purpose.  
The form was advertised to the ward staff and placed in the ward pharmacy folder 
(Appendix 15).  
2.3.8 Data management and collection  
A study database was developed by the UEA clinical trials research unit which collated all 
information relating to patient admission, discharge and follow up.  Identifiable patient data 
including name or contact details such as address, phone number, NHS number and 
information relating patient to the study number were kept in a separate, password 
protected database held by the study senior researcher and PI at the study site Hospital 
Foundation Trust.   
The UEA research team accessed no patient identifiable information.  The study database 
was kept on password protected drives, stored and processed on computers for research 
purposes only and it was accessed from a series of web-based data entry forms.  Each 
user was assigned a username and password allowing different levels of data viewing 
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based on the role within the study and the blindness toward patient allocation.  All web 
traffic was encrypted.  Table 2.3.1 describes the MedRec study data collection process. 
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Time point  Data collection 
The study researcher at the following time points of the study: 
Pre-randomisation  Maintained a daily list of: 
• All newly admitted patients 
• Number of patients approached and recruited 
• Reason(s) for study decline or withdrawal if stated by the 
patient 
Admission  
(pre- intervention) 
• Recorded all relevant patient information upon admission 
• Photocopied inpatient medication chart(s) written by the 
medical team upon admission  
• Contacted the patient’s GP to obtain a faxed list of medicines  
• Photocopied all medicine labels of patient own drugs  
• Asked the patient to complete a health related quality of life 
questionnaire  
Admission post 
intervention 
(Intervention group only) 
Photocopied post intervention medication chart(s) and medical 
note(s) 
During hospital stay 
• Photocopied all changes/amendments to the medication 
chart(s) during hospital stay 
• Recorded all relevant information to the MR pharmacist 
interventions and discrepancies’ follow up 
• Recorded medical team action(s) in response to the MR 
pharmacist interventions  
• Recorded information related to MR (if any) received in the 
control group 
Discharge  
(pre- intervention) 
Photocopied medication chart(s) and medical notes upon 
discharge  
Discharge post 
intervention 
(Intervention group only) 
• Photocopied medication chart(s) and medical notes following 
MR pharmacist intervention 
• Recorded all relevant information to the MR pharmacist 
interventions upon discharge 
Three months post 
discharge • Obtained a list of medicines the patient is taking three month 
post discharge 
• Sent the health related quality of life & health resource use 
questionnaire to patients 3 months post discharge 
• Recorded relevant information related to readmission 
episodes; ward admitted to, date, duration and reason(s) 
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Table 2.3.1 The MedRec study data collection process 
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2.3.9 Outcomes measurement  
The MedRec study investigated a broad scope of study design, patient and process 
oriented outcomes, costs and consequences: 
 Study feasibility outcomes 
o Outcomes informing the design of a future larger scale trial: 
• Recruitment and follow up rates 
• Feasibility of the study process 
• Feasibility of data collection 
• Feasibility of data analysis  
• Acceptability of the intervention 
 Process oriented outcomes 
o Rate and nature of medication discrepancies 
o Clinical significance of medication errors 
o MR pharmacist interventions  
 Patient oriented outcomes  
o Length of hospital stay  
o Post discharge health resource use of NHS and personal social service (PSS) 
services 
o Health related quality of life  
o Mortality  
 Cost-effectiveness outcomes 
o Consumed costs  
• Time commitment to implement MR 
• Costs of medication errors 
o Consequence costs 
• Length of hospital stay 
• Post discharge health care resource use of NHS and PSS services 
• Use of social care and informal care 
o Effectiveness 
• Change in utility score over three months, e.g. EQ-5D scores 
• Incremental quality-adjusted life year (QALY) gain/loss  
• Incremental cost effectiveness ratio (ICER) 
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2.3.10 Process oriented outcomes 
In chapter one, it was shown that MR pharmacist involvement can be useful in detecting 
and rectifying medication errors as well as preventing error recurrence upon discharge.  It 
was also demonstrated that 30% to 50% of errors have the potential to cause clinically 
significant consequences.  Thus, medication errors are an appropriate outcome to 
measure.
2.3.10.1 Identification of medication discrepancies 
Medication discrepancies were evaluated at three time points: admission, discharge and 
three months post discharge.   
The patients’ active medical chart at each time point was reviewed to identify 
discrepancies by comparing these charts with the most comprehensive updated list of 
medicines the patient should be taking.  When discrepancies existed, the medical record 
was searched for an explanation.   
 Medication discrepancies upon admission 
Any differences between the most updated comprehensive list, constructed by the study 
researcher for control patients or by the MR pharmacists for the intervention patients, and 
the inpatient medicine chart written upon admission i.e. within the first 24 hours of 
admission.   
 Medication discrepancies upon discharge 
Any undocumented differences between the active inpatient medicine chart upon 
discharge and discharge summary.   
 Medication discrepancies three months post discharge 
Any differences between the discharge summary and the list of patient medicines three 
months post discharge held by the GP.   
Discrepancies were identified by a retrospective review.  Figure 2.3.2 illustrates 
medication discrepancies identification process in both study groups.  
Unintentional medication error rate in both study groups at admission, discharge and at 3 
months post discharge were recorded.  Number of patients experiencing at least one 
medication discrepancy at each time point was determined too.  Discrepancies which 
identified three months post discharge were screened by the study principal investigator 
and discussed with GPs to determine the most appropriate action. 
Medication discrepancies identification was performed by EH.  To assess the consistency 
of discrepancies identification, ten medicine charts were reviewed independently by the 
study principal investigator and agreement was assessed using kappa analysis. 
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Figure 2.3.2 Medication discrepancy identification in both study groups.  
2.3.10.2 Classification of medication discrepancies 
Classification of medication discrepancies was adapted from Pippins et al;[28] each 
discrepancy was classified according to prescriber intention, location and type as 
described in figure 2.3.3.   
Hence, medication discrepancy identification in the control care group was carried out 3 
months post discharge; it was not possible to establish the intention with the medical 
team.  Medical notes of control patients were reviewed for a documented evidence or 
clinical explanation for the rational of discrepancies.  In some cases the discrepancy was 
obviously unintentional such as methotrexate prescribed once daily instead of once a 
week.  In other instances, discrepancies were obviously intentional such as dalteparin 
given subcutaneously in a deep vein thrombosis prophylaxis dose while inpatient stay and 
discontinued upon patient discharge.   
A set of assumptions were considered to establish the intention of prescriber, those were 
agreed after discussion with the study team.  Assumptions are summarised in BOX 2.3.3. 
  
Intervention group
Within 24 hours of admission 
discrepancies
The pre-randomisation prescription chart 
and the amended prescription chart by 
the MR pharmacist were compared to 
identify any discrepancies
Discharge discrepancies
The inpatient medication chart amended by 
the MR pharmacist was compared with the 
discharge summary. If discrepancies 
identified, the MR pharmacist resolved 
discrepancies and amended discharge 
summary 
3. Three months post discharge 
discrepancies
The amended discharge letter was 
compared with the GP record at three 
months post discharge 
Control group
1. Within 24 hours of admission  
discrepancies
The pre-randomisation prescription 
charts and the subsequent chart 
were compared with the list 
constructed by the study researcher
2. Discharge discrepancies
The inpatient medication charts was  
compared with the discharge 
summary.  
3. Three month post dischrge 
discrepancies
The discharge summary was 
compared with the GP record at three 
months post discharge 
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BOX 2.3.3 Assumptions agreed to establish prescriber’s intention 
In order to establish the intention of prescribers and define a discrepancy whether 
intentional or unintentional in the control group, the following assumptions were agreed: 
 The change of intravenous and subcutaneous medicine route of administration into 
oral forms upon discharge were considered intentional change, e.g. meropenem 
injection that was continued upon discharge to complete 5 days course with oral co-
Amoxiclav tablets 
 Medicines prescribed as required in inpatient and omitted upon discharge was 
considered intentional discontinuation, e.g. senna 2 tablets ON as required 
 Analgesics, laxatives, indigestion products, nausea and vomiting relief product and 
sleeping aids prescribed inpatient for regular use and discontinued upon discharge 
or for short term were considered intentional discontinuation/change in duration, 
e.g. metoclopramide or cyclizine prescribed for nausea 
  Analgesics, laxatives, indigestion products, nausea and vomiting relief product and 
sleeping aids prescribed inpatient as required and continued for long term upon 
discharge were considered unintentional addition  
 Medicines which were prescribed for regular use pre-admission or those been 
prescribed for regular use inpatient and discontinued upon discharge with patient 
prescribed other medicines from the same class were agreed to be intentional 
substitutions, e.g. patient prescribed senna tablets inpatient which omitted upon 
discharge but he/she was prescribed Movicol sachets to take home  
 Pre-admission medicines that is listed for patient regular use by at least two source 
of patient information and were omitted inpatient with no documented evidence to 
indicate those had been stopped or held while hospital stay were considered 
unintentional omissions, e.g. Seretide Accuhaler listed for regular patient use in 
GP list and previous discharge summary but not transcribed in inpatient chart 
 Generic and brand names of a medicine were considered interchangeable and thus 
this was not deemed as a discrepancy  

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Discrepancy classification was undertaken by EH supported by DW.  In case of 
uncertainties or ambiguities, discrepancies classification was discussed and agreed with a 
clinical hospital pharmacist (BC). 
 
 
Figure 2.3.3 Medication discrepancy classification  
2.3.10.3 Clinical significance of medication errors 
Intentional medication discrepancies were not considered medication errors.  In the 
intervention group, the MR pharmacist resolved intentional discrepancies and ensured 
comprehensive and accurate documentation in medical records and discharge 
summaries.  Unintentional medication discrepancies were considered medication errors 
and therefore the severity and potential for patient harm were evaluated.  Medication 
errors were stratified according to the type of discrepancy and the time point occurred (i.e. 
admission, discharge or 3 months post discharge).  As a pilot study with an embedded 
feasibility component, a random selection of 20 discrepancies was clinically assessed for 
potential patient harm in order to estimate the feasibility of this process.  The clinical 
significance of medication errors was assessed using the Dean and barber VAS.[183]  The 
mean score for all assessor for each discrepancy was categorised as minor (<3), 
moderate (3-7) or severe (>7).[35]  
  
Medication 
discrepancies
Intentional 
(not  medication error)) 
Documented
Undocumented
Unintentional (medication error) 
Omission
Addition
Change to
(Dose, frequency, route 
or formulation )
Discontinuation
Substitution 
(i.e. with medication in 
the same class)
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2.3.11 Patient oriented outcomes 
2.3.11.1 Length of hospital stay  
The literature review in chapter one highlighted the lack of firm evidence for the effect of 
MR on hospital stay or other health resource use.  For an intervention to be widely 
adopted, it is essential that it demonstrates cost-effectiveness.  The beneficial effects of 
MR have been frequently cited, however, evidence of its impact on costs is less widely 
researched.  Length of hospital stay was the primary outcome as MR might be expected 
to shorten length of hospital stay by optimising medicine prescribing upon admission and 
preventing adverse drug events.  This would contribute to considerable cost savings for 
NHS trusts.  Therefore, length of hospital stay was considered an appropriate patient 
oriented outcome to investigate.   
Hospital stay period was estimated from the time a patient was admitted to the ward until 
discharge time from the hospital.  When patients were transferred to other wards or 
inpatient services the period was included until discharge from the hospital.  
2.3.11.2 Post discharge health resource use  
MR could be expected to improve patient use of health resources.  This might be 
influenced by the role of the MR pharmacist in optimising patient care during hospital stay 
and preventing unintentional drug adverse events.  This would potentially improve post 
discharge care and reduce the burden of preventable unplanned readmissions.  
Additionally, this might improve patient quality of life and reduce health resource use. 
 Readmissions 
Readmission details were obtained from hospital records and via self-report by patients or 
consultees.  Hospital records were reviewed to obtain details on readmissions episodes at 
three months post discharge.  Self-report readmission details were obtained via postal 
questionnaire (Appendix 16) sent to patients three months post discharge. 
 Post discharge use of NHS and PSS services 
Details on patients’ use of health resources were obtained via a postal questionnaire sent 
to patients three months post discharge (Appendix 16); details were obtained on: 
o Health resource use in community; i.e. NHS and PSS worker in community 
o Health resource use in hospital; i.e. NHS and PSS worker in hospital 
o Use of social and informal care 
Non-responders were followed up once by post and then by phone.  Consultees were 
asked to complete the questionnaire on behalf of the study participants. 
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2.3.11.3 Health related quality of life  
Patients were asked to complete health related quality of life questionnaire (Appendix 16) 
at the time of recruitment and at three months post discharge.  The questionnaire consists 
of two parts including the EQ-5D descriptive system and the EuroQol VAS.[192]  The 
EuroQol VAS recorded the respondents self-rated health statues from 0 representing the 
worst imaginable health to 100 representing the best imaginable health.  York A1 tariff was 
used to assign a value to each EQ-5D health state description.[178] 
The hospital computer system was checked to ensure that the questionnaire was not be 
sent to participants who had died or readmitted (i.e. in hospital at the time of three month).  
The study was registered with the EuroQol group, an authorisation for the use of EQ-5D 
was obtained.   
2.3.11.4 Mortality 
At three months post discharge, primary care practices were contacted to identify patients 
who were deceased in both groups. 
2.3.12 Cost-effectiveness 
2.3.12.1  Cost estimation  
NICE recommends costs from the perspective of the NHS and PSS.[172]  It is also 
considered appropriate by NICE to include costs of informal care by family members, 
friends who live or do not live with the patient.  Accordingly, the health resource use 
questionnaire attempted to capture details related to NHS and PSS worker visits, hospital 
services use, social care and informal carer.  In addition to this, patients were also asked 
to report out of pockets expenses, those which were paid by patients as a result of their 
health over the three months period post discharge. 
Using micro-costing valuation, a unit cost was specified for every resource consumed/ 
saved in healthcare service provision.  The unit costs reported by personal social services 
research units and Department of Health reference costs, financial year 2011/2012, were 
assigned to each NHS and PSS use.[174, 175]  The total costs were calculated for each cost 
unit by summing all single cost components that contributed to the MR intervention and 
patient use of health resouces.  The mean incremental cost of the intervention was 
calculated by subtracting the estimated mean cost per patient of all NHS and PSS costs, 
time commitment and medication errors costs for control group from that for the 
intervention group. 
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The method to estimate the cost of informal carer time was based on Patal et al.[193]  The 
opportunity cost defind as the value of the opportunities forgone by care givers as a result 
of time spent on care giving was used to estimate the cost of informal care.  The UK 
minimum wage for the year 2011/2012 was £4.38 per hour; this was used as a proxy 
valuation of carer time.[194]  Travel cost of informal carer who do not live with the patient 
was assigned the the avergage cost of return trip using public trasport in Great Britain in 
2011/2012 in non-metropolitan reagions.[195] 
In order to estimate the cost of MR received by control patients, it was assumed that on 
average control MR took 20 minutes and was provided by pharmacy technicians.  The unit 
cost assigned to one hour employment of pharmacy technician taken from the National 
Career Service information and based on an average earning of £23,000 per year [196] was 
£11.64 per hour. 
Medication errors costs were estimated based on published studies in USA and UK.  The 
USA study reported that 4.8% 95%CI [3.7-6.1] of discrepancies upon patient transfer of 
hospital lead to adverse drug events.[197]  From a prospective analysis of 18, 820 patients 
admitted to hospitals in UK and assessed for the prevelence of admissions due to an 
adverse drug event, it was estimated that patients admitted with an adverse drug event 
had a median stay (IQ) of 8 [4,18].[11].  
Costs estimates were based on mean (SD); this was drawn based on the 
recommendations from Drummond et al and the NICE guidance for the Method of 
Technology Apprasial programme.  Using the median will not allow policy makers to 
determine the total cost of treatment for a group of patients.  For this, the mean is required 
because total cost for a group is the mean cost multiplied by number of patients in the 
group.[172, 173] 
Costing was based on “Available- case analysis”; the mean for the available cases for 
each variable was estimated.  Missing data were not imputed. 
2.3.12.2 Effectiveness 
In line with NICE recommendations for the reference case analysis, the York A1 tariff was 
used to estimate the utility weight scores.[178]  QALY was used as the effectiveness 
measure and the health realted quality of life element was measured using EQ-5D 
scores.[198] 
Area under the curve method without baseline adjustment was used to estimate the 
incremental QALY gain/loss.[173]  However, baseline adjusment was warranted,[199] 
therefore the area under the curve method with baseline adjustment was also used to 
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estimate the mean change in QALY over three months post discharge for both groups, 
along with the mean incremental QALY gain/loss for the intervention.[200] 
Providing the intervention dominance was not apparent as if the intervention was less 
costly and more effective than the control,[201] the incremental cost per QALY gain/lose, 
ICER associated with the intervention would be calculated.  In line with NICE guidance, if 
an ICER to be calculated it would be compared with the NICE cost-effectiveness threshold 
of £20,000–30,000 per QALY.[172] 
2.3.13 Statistical analysis (the MedRec interim analysis) 
The present thesis reports the interim analysis of the MedRec study; comprising the data 
collected over the first three months, 5th July 2012 to 6th October 2012, for 60 patients 
equally distributed between the study groups.  The MedRec study full protocol was 
developed by the thesis author (EH) with the support of the MedRec study research team.  
The MedRec study is due to be completed in August 2013.  The interim analysis aimed to 
inform the full pilot analysis and provide insight in the initial findings
All data were processed using the statistical package for social science (SPSS version 18, 
Chicago, USA software), descriptive data have been reported as mean ± SD or median 
(IQR) as appropriate.   
Recruitment rate was estimated out of patient approached.  The rate was also estimated 
out of eligible patient.  The latter rate was estimated after deducting ineligible patients 
identified after conversing with the patient or the nurse, i.e. prescribed no medicine or 
seen by the ward pharmacist.   
The study cover, the days the MR pharmacists and the study researchers were available, 
was calculated.  Uncovered days were adjusted for holidays, weekends and annual leave. 
The response rate of obtaining three month post discharge outcome data, i.e. the GP held 
medicine lists and health related quality of life questionnaires was estimated accounting 
for patients lost to follow up due to death.  The response rates of primary care practices 
and patients were estimated for the first contact as well as the follow up contact(s). 
The intervention effect size were estimated.[202]  The time took for readmission to occur 
was estimated applying the Kaplan–Meier survival analysis log-rank test.  Number to treat, 
the number of patients needed to receive MR intervention in order to prevent one 
readmission was also calculated.[203] 
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Hence, this is an interim anlysis of a pilot study, a sensitivity analysis to assess changes 
in the key assumptions was believed not warranted at this stage.  Sensitivity analysis and 
the assessment of uncerantity associated with the decision regarding cost-effectiveness 
using cost-effectivness accepality curve (CEAC) was warranted for the full pilot 
analysis.[204] 
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This chapter presents findings from the Trust-wide audit.  The magnitudes of adherence to 
the total NPC minimum dataset and the categories related to admission, discharge and 
patient information, medication information and therapy change information were 
evaluated.  
Additionally, contributing factors to the quality of discharge information were investigated; 
predictors of discharge summary adherence to the NPC minimum dataset and those 
associated with increased risk of discrepancy were also identified.  The potential influence 
of these factors was investigated adjusting for possible confounding and covariate effects.  
Therefore, predictors of non-adherence to the NPC minimum dataset and the 
characteristics associated with an increased risk of discrepancy were described and 
recommendations to improve the current practice were developed.  Figure 3.1 presents 
summary of audit data collected.  
3.1 Audit sample  
A total of 3,444 discharge summaries were audited from 84 primary care practices across 
NHS Norfolk representing 12 hospitals.  Discharge summaries were primarily from two 
teaching hospitals (H1 and H4) which accounted for 2,421 (70.3%) and three district 
hospitals (H2, H3 and H5) accounting for 910 (26.4%).  The remainder included private, 
mental health trusts, community hospitals and hospitals beyond the Norfolk/Suffolk/ 
Cambridgeshire region.  The majority of discharge summaries represented unplanned 
admissions which accounted for 2,168 (63.0%) and for 365 (10.6 %) no information was 
available regarding admission type.  The remainder were planned admissions.  Discharge 
summaries were mainly electronic 2,570 (74.6%) and for patients discharged mostly in 
January; 1,666 (48.4%) and February; 950 (27.6%).  There was a relatively even gender 
distribution; 1,753 (50.9%) were female.  The median (IQ) age of patients was 66 (46, 80) 
years and the median duration of hospital stay was 4 (2, 8) days.  Discharge summaries 
listed no medicines for 446 (13.5%) patients and the median (IQ) number of medicines 
prescribed per patient was 5 (2, 8).   
Table 3.1 presents the audit sample characteristics.  High proportion of the discharge 
summaries were from medicine for elderly wards 564 (16.4%), followed by urology 403 
(11.7%) and general surgery 321 (9.3%) wards.   
The role of the healthcare professional responsible for preparing the discharge summary 
was not indicated in 758 (22.0%) of the cases.  When the profession type was provided, 
doctors accounted for 2,504 (72.7%).  Of the discharge summaries prepared by doctors, 
foundation year doctors accounted for 853 (34.1%), whereas 1113 (41.4%) were prepared 
by doctors of unknown training.  The second frequent profession type completing 
discharge summaries were specialised nurse practitioners with 146 (4.2%). 
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*Based on 5% of the practice size  
Figure 3.1 Summary of the audit data  
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  Hospitals 
Characteristics 
Measure H1 
n=2,368 
H2 
n=715 
H3 
n=136 
H4 
n=57 
H5 
n=55 
Community 
hospitals  
n=52 
Tertiary 
hospital 
n=29 
Mental trust 
n=21 
Patient demographics 
         
Age  Median 
(IQ) 
66 (46,79) 67 (45,81) 60.5 (39.3,76.8) 59 (46,70) 73 (57,80) 76 (70.3,84.8) 65.5 (56.3-79.0) 70(44,47) 
Female  N (%) 1,194 (50.4) 371 (51.9) 81 (59.6) 22 (38.6) 27 (49.1) 26 (50.0) 13 (44.8) 13 (61.9) 
No. of medicines Median 
(IQ) 
6 (2,8) 5 (2,8) 6 (3,10) 6 (2,8) 5 (3,8) 6 (3,10) 6 (3.5,9.5) 4 9(2,5) 
Hospital stay Median 
(IQ) 
4.5 (2,8) 4 (2,8) 3 (2,6) 3 (1.5,8) 4.5 (2,13) 13 (5,36) 6 (2,8) 8 (2,17) 
Time of discharge 
summary arrival  
Median 
(IQ) 
2 (1,3) 2 (2,8) 1 (0,2) 2 (2,4) 2 (1,2.5) 2 (2,4) 2 (1,3) 2 (1,5) 
Type of discharge 
summary 
         
Electronic discharge 
summaries 
N (%) 2,211 (93.4) 110 (15.4) 126 (92.6) 29 (50.9) 25 (45.5) 30 (57.7) 21 (72.4) 14 (66.7) 
Type of admission  
Unplanned admission  N (%) 1591 (67.2) 433 (60.6) 20 (14.7) 28 (49.1) 41 (74.5) 30(57.7) 9 (31.0) 13 (61.9) 
Unspecified type of 
admission 
N (%) 128 (5.4) 106 (14.8) 92 (67.6) 10 (17.5) - 14 (26.9) 8 (27.6) 2 (9.5) 
Ward specialities  
Medicine for Elderly N (%) 454 (19.2) 73 (10.2) 21 (15.4) 3 (5.3) 1 (1.8) 7 (13.5) 3 (10.3) 2 (9.5) 
Urology N (%) 292 (12.3) 76 (10.6) 25 (18.4) 4 (7.0) 2 (3.6) 2 (3.8) 1 (3.4) 1 (4.8) 
General surgery N (%) 244 (10.3) 54 (7.6) 1 (0.7) 8 (14.0) 10 (18.2) 3 (5.8) - - 
Thoracic N (%) 210 (8.9) 27 (3.8) 5 (3.7) 1 (1.8) - - - - 
Cardiology N (%) 195 (8.2) 24 (3.4) 5 (3.7) 4 (7.0) 3 (5.5) 1 (1.9) 7 (24.1)  
Orthopaedic N (%) 137 (5.8) 62 (8.7) 3 (2.2) 4 (7.0) 7 (12.7) 3 (5.8) 1 (3.4)  
Paediatrics N (%) 131 (5.5) 63 (8.8) 6 (4.4) 2 (3.5) - 1 (1.9) -  
General medicine N (%) 65 (2.7) 70 (9.8) 40 (29.4) 1 (1.8) 9 (16.4) 2 (3.8) -  
Gynaecology N (%) 105 (4.4) 21 (2.9) 13 (9.6) 4 (7.0) 2 (3.6) - 2 (6.9)  
Oncology N (%) 121 (5.1) 10 (1.4) 1 (0.7) 6 (10.5) - 2 (3.8)  - 
Gastroenterology N (%) 90 (3.8) 26 (3.6) 2 (1.5) 2 (3.5) 4 (7.3) - 2 (6.9)  
Ear, nose& throat N (%) 56 (2.4) 5 (0.7) 6 (4.4) - - 1 (1.9) -  
Neurology N (%) 48 (2.0) - 2 (1.5) 5 (8.8) - 1 (1.9) -  
Nephrology N (%) 52 (2.2) 1 (0.1) - - - - - - 
Endocrinology N (%) 42 (1.8) 8 (1.1) - - - - - - 
Others* N (%) 68 (2.9) 51 (7.1) 1 (0.7) 10 (17.5) 15 (27.3) 7 (13.5) 4 (13.8) 8 (38.1) 
Unspecified specialities  N (%) 58 (2.4) 144 (20.1) 5 (3.7) 3 (5.3) 2 (3.6) 22 (42.3) 9 (31.0) 10 (50.0) 
*E.g. Dermatology, Rheumatology, Ophthalmology, Maternity care and Neonatal, rehabilitation 
Table 3.1 Characteristics of the audit sample 
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  Hospitals 
Characteristics Measure H1 
n=2,368 
H2 
n=715 
H3 
n=136 
H4 
n=57 
H5 
n=55 
Community 
hospitals 
n=52 
Tertiary hospital 
n=29 
Mental trust 
n=21 
Profession type           
Doctors+ N (%) 1,026 (43.3) 28 (3.9) 15 (11.0) 8 (14.0) 12 (21.8) 11 (21.2) 6 (20.7) 6 (28.6) 
Foundation years N (%) 363 (15.3) 435 (60.8) 4 (2.9) 18 (31.6) 12 (21.8) 10 (19.2) 5 (17.2) 6 (28.6) 
Core medical training N (%) 165 (7.0) 88 (12.3) - 6 (10.5) 4 (7.3) 2 (3.8) 1 (3.4) - 
Speciality training  N (%) 71 (3.0) 25 (3.5) 1 (0.7) 6 (10.5) 3 (5.5) 2 (3.8) 9 (31.0) 2 (9.5) 
Consultant  N (%)  95 (4.0) 25 (3.5) 2 (1.5) 2 (3.5) 2 (3.6) 2 (3.8) 1 (3.4) 1 (4 .8) 
Registrar  N (%) 8 (0.3) 1 (0.1) - - - 11 (21.2) - 1 (4.8) 
Pharmacists N (%) 36 (1.5) - - - - - - - 
Specialist nurse 
practitioners 
N (%) 135 (5.7) 5 (0.7) - 2 (3.5) - 1 (1.9) 3 (10.3) - 
Unspecified profession  N (%) 469 (19.8) 108 (15.1) 114 (83.8) 15 (26.3) 22 (40.0) 13 (25.0) 4 (13.8) 5 (23.8) 
+unspecified training level  
 
 
Continued  
Table 3.1 Characteristics of the Audit sample 
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3.2 Adherence to the NPC minimum dataset 
Mean [95% CI] discharge summary adherence to the total National prescribing centre 
(NPC) minimum dataset was 71.7% [70.21-73.2].  Table 3.2 illustrates the range of 
discharge summary adherence with different procedural characteristics. 
 
 
Discharge summary adherence 
 
Total NPC  
Dataset 
Patient, admission 
& discharge 
information 
Medication 
information 
Therapy change 
information 
Type of admission 
Planned 
 
71.3% [70.6-72.1] 
 
77.2% [76.5-78.0] 
 
63.9% [62.2-65.6] 
 
46.3% [43.8-48.9]. 
Unplanned  71.8% [71.3-72.3] 77.5% [77.1-78.0] 62.9% [61.9-64.0] 49.0% [47.3-50.8] 
Unspecified  72.6% [71.2-74.1] 76.4% [75.0-77.8] 70.8% [68.5-73.1] 55.4% [51.2-59.7] 
Type of discharge summary   
Electronic 73.7% [73.3-74.1] 79.5% [79.1-79.9] 67.2% [66.3.-68.2] 50.9% [49.4-52.3] 
Handwritten 67.0% [65.2-66.8] 71.0% [70.2-71.9] 54.8% [53.4-56.3] 40.2% [36.9-43.7]. 
Hospital     
H1 73.5% [73.1-74.0] 79.3% [79.0-79.7] 66.4% [65.4-67.4] 50.6% [49.0-52.1] 
H2 65.0% [64.1-65.9] 69.8% [68.9-70.7] 54.3% [52.9-55.8] 41.8% [37.8-45.9] 
H3 81.4% [79.7-83.2] 85.4% [83.9-87.0] 83.0% [80.0-86.0] 65.5% [60.0-71.0] 
H4 73.5% [70.6-76.8] 79.7% [76.2-83.1] 69.1% [62.5-75.8] 46.9% [34.7-59.1] 
H5 71.7% [68.3-75.1] 79.4% [76.7-82.1] 48.2% [40.2-56.2] 26.4% [14.6-38.2] 
Community hospital 62.4% [58.1-66.9] 68.6% [64.3-72.9] 58.5% [49.5-67.5] 27.7% [15.8-39.6] 
Tertiary hospital  68.3%[63.4-73.3] 73.8% [68.8-78.8] 58.9% [47.5-70.4] 31.0% [17.3-44.7] 
Mental health trust 65.7% [60.6-70.8] 71.8% [66.1-77.5] 52.7% [63.4-41.9] 22.6% [8.7-36.7] 
Ward speciality     
Medicine for Elderly 73.5% [72.6-74.4] 79.7% [78.8-80.6] 64.7% [62.8-66.7] 53.0% [49.7-56.2] 
Urology 73.3% [72.2-74.4] 78.4% [77.1-79.1] 67.6% [65.3-69.9] 52.0% [48.3-56.2] 
General surgery 71.1% [69.9-72.4] 78.1% [76.9-79.3] 58.8% [55.7-61.9] 42.3% [37.7-46.9] 
Thoracic 73.3% [72.0-74.6] 78.7% [77.5-80.0] 67.2% [64.4-69.7] 51.5% [46.6-56.4] 
Cardiology 73.0% [71.5-74.5] 78.9% [77.4-80.4] 65.2% [62.3-68.1] 50.7% [46.5-54.9] 
Orthopaedic 68.6% [67.1-70.2] 75.0% [73.5-76.5] 63.5% [60.5-66.6] 34.9% [29.0-40.7] 
Paediatrics 71.4% [69.7-73.1] 76.6% [74.9-78.2] 64.7% [61.0-68.3] 46.8% [40.8-52.8] 
General medicine 72.0% [70.3-73.7] 75.8% [73.9-77.5] 64.8% [61.1-68.6] 58.3% [51.5-64.9] 
Gynaecology 72.2% [70.1-74.3] 78.9% [77.1-80.6] 64.0% [59.4-68.5] 49.6% [42.0-56.9] 
Oncology 73.9% [72.1-75.7] 77.8% [76.2-79.4] 68.2% [64.4-72.1] 58.9% [52.6-65.3] 
Gastroenterology 69.6% [67.7-71.6] 75.7% [73.7-77.7] 60.2% [56.1-64.2] 48.1% [41.0-55.3] 
Ear, nose& throat 75.6% [73.1-78.1] 79.7% [77.6-81.8] 57.7% [49.5-65.8] 30.2%[21.6-38.8] 
Neurology 73.5% [70.6-76.3] 79.4% [76.7-82.0] 56.6% [48.1-65.0] 34.5% [26.6-42.4] 
Nephrology 70.0% [66.9-73.1] 76.9% [73.8-80.0] 53.0% [43.7-62.2] 35.8% [26.2-45.5] 
Endocrinology 74.4% [70.9-77.9] 82.0% [79.6-84.4] 47.9% [37.7-58.0] 32.7%[22.6-42.8] 
Others* 71.4% [69.6-73.1] 76.9% [75.3-78.5] 49.5% [44.4-54.6] 21.3% [16.2-26.4] 
Unspecified  64.4% [62.7-66.1] 68.8% [67.1-70.5] 60.2% [56.0-62.5] 49.0% [43.2-54.9] 
*E.g. Dermatology, Rheumatology, Ophthalmology, Maternity care and Neonatal, rehabilitation. NPC: National prescribing 
centre
Table 3.2 Discharge summary adherence to the NPC minimum dataset  
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Discharge summaries adherence 
 
Total NPC  
Dataset 
Patient, admission 
& discharge 
information 
Medication 
information 
Therapy change 
information 
Profession type 
    
Doctors+ 72.8% [72.2-73.5] 79.0% [78.4-79.6] 58.8% [57.0-60.6] 36.0% [33.94-38.1] 
Foundation years 68.7% [67.9-69.5] 73.7% [72.9-74.5] 52.8% [51.0-53.2] 26.3% [23.9-28.7] 
Core medical 
training 
70.9% [69.6-72.2] 76.5% [75.1-77.8] 54.7% [51.2-58.1] 34.7% [30.1-39.4] 
Speciality training  68.9% [66.7-71.2] 75.3% [73.0-77.5] 50.0% [44.5-55.5] 30.5% [23.7-37.2] 
Consultant  71.9% [69.7-74.1] 77.3% [75.6-79.0] 52.1% [46.5-57.7] 31.4% [23.7-37.2] 
Registrar  71.4% [65.6-77.2] 74.2% [68.5-79.9] 42.9% [26.7-59.1] 28.6% [12.0-45.2] 
Pharmacists 74.6% [71.7-77.5] 80.1% [77.6-82.6] 69.1% [61.2-77.0] 51.5% [38.4-64.6] 
Specialist nurse 
practitioners 
74.5% [72.5-76.6] 79.8% [78.1-81.5] 65.6% [61.0-70.3] 53.0% [46.8-59.2] 
Unspecified  73.6% [72.6-74.4] 79.1% [78.3-79.9] 67.5% [65.7-69.3] 50.5% [47.8-53.2] 
+unspecified training level. NPC: National prescribing centre 
Continued  
Table 3.2 Discharge summary adherence to NPC minimum dataset  
Adherence rates of discharge summaries arising from planned and unplanned admissions 
were similar.  Electronic discharge summaries, however, were associated with a notably 
higher adherence rates compared to handwritten discharge summaries.  Variation can be 
seen between hospitals, with H3 demonstrating the greatest adherence, whilst H2 and 
community hospitals demonstrating a substantially lower adherence rates than the other 
hospitals.   
Wards exhibited a wide range of adherence rates with orthopaedic wards demonstrating 
the lowest adherence.  Discharge summaries written by pharmacists and specialist nurse 
practitioners demonstrated better adherence rates compared to discharge summaries 
written by doctors.  Discharge summaries prepared by foundation year doctors 
demonstrated the lowest adherence rate. 
3.2.1 Adherence to the NPC minimum dataset relating to patient, admission and 
discharge information  
Figure 3.2 illustrates adherence rates for patient, admission and discharge information.  
Mean [95% CI] discharge summary adherence was 77.3% [77.0-77.7] with co-morbidities, 
medication history and allergy status contributing to the most frequent omissions. 
When reviewing a random selection of 100 discharge summaries, it was found that the 
omitted co-morbidities were frequently related to depression 62%, osteoporosis 53%, 
stroke 40%, history of acute MI 36%, skin conditions such as eczema and psoriasis 46%, 
plus asthma and chronic obstructive pulmonary disease 59%.  Additionally, the most 
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omissions with medication histories were for analgesics 79%, laxatives 76%, antacids 
64%, sleeping aids 48%, aspirin 63%, antihistamines 43% and vitamin supplements 44%.   
A random selection of 100 discharge summaries for which the discharge teams recorded 
no information with respect to allergy status was reviewed.  For 18% of patients there were 
no known allergies held in the GP records, whereas for the remainder one or more known 
allergens were recorded. 
 
Figure 3.2 Magnitudes of discharge summaries adherence to NPC minimum dataset 
A review of allergies documented in the GP records identified that frequently those were 
adverse drug reactions or intolerances; this was seen for 50 (61.0%) patients.  adverse 
drug reactions are classified into Type A and B; Type A adverse drug reactions are due to 
an exaggerated response to the expected action of the drug, e.g. bradycardia with beta-
blockers, whereas Type B adverse drug reactions are usually unpredicted reactions 
unrelated to the conventional pharmacology of the drug and occur only in susceptible 
individuals, e.g. Type B adverse drug reactions include anaphylaxis with penicillin.[205]  Drug 
allergy is a type of adverse drug reaction to drugs encompasses a spectrum of 
immunologically-mediated hypersensitivity reactions with varying mechanisms and clinical 
presentations. Type B adverse drug reactions closely describe what is conventionally 
called a drug allergy. [206, 207]  Reviewing the nature of allergy reaction described in primary 
care notes identified 17 (20.7%) patients being allergic to antibiotics, 8 (9.8%) patients 
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allergic to non-steroidal anti-inflammatory drugs or analgesics and 4 (4.9%) patients 
allergic to other medication groups such as immunosuppressant.  Table 3.3 presents 
examples of allergies recorded in GP held records with their classification. 
 
Medication/allergen   Nature of allergy as recorded in 
the GP held record 
Classification** 
Tamsulosin Tamsulosin causes paraesthesia, 
swelling hot leg 
Unpredictable ADR (type B) 
Amlodipine  Certain moderate intolerance to 
Amlodipine oedema and lip swelling 
Predictable ADR (type A) 
Beta-blockers (Atenolol) Airway obstruction Predictable ADR (type A) 
Dihydrocodeine Nightmares Predictable ADR (type A) 
Clarithromycin Nausea, Diarrhoea and abdominal 
pain 
Predictable ADR (type A) 
Hazelnut  S, swelling Food allergy 
Egg  local reaction face Food allergy  
Amoxicillin  Overspread body rash  Unpredictable ADR (type B) 
Aspirin Likely moderate allergy to causing 
intracranial haemorrhage 
Predictable ADR (type A) 
Metformin  Diarrhoea and abdominal pain  Predictable ADR (type A) 
Bendroflumathiazide likely moderate allergy to 
bendroflumathiazide causing 
impotence 
Predictable ADR (type A) 
Allopurinol Widespread rash and limbs swelling Unpredictable ADR (type B) 
Simvastatin  Nausea and vomiting Predictable ADR (type A) 
Ciprofloxacin  Fever, rash Unpredictable ADR (type B) 
Trimethoprim/co-trimoxazole Fatal allergy to Septrin Unpredictable ADR (type B)  
**Classification based Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and 
management. The Lancet 2000;356 (9237):1255-59.[205] 
Table 3.3 Examples of allergies recorded in primary care records  
It can be seen that the majority of patients were mislabelled as having a known allergy; 
meanwhile this was a drug side effect or intolerance (type A).  However, when a definite 
allergy existed it can be seen that, antibiotics were the most frequent allergens. 
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3.2.2 Adherence to the NPC minimum dataset relating to medication information  
In general, discharge summaries demonstrated lower adherence to medication information 
compared to patient admission and discharge information.  Mean [95% CI] discharge 
summary adherence to medication information was 64.0% [63.2-64.8].  Figure 3.1 
illustrates adherence rates for medication information; particular deviations are manifested 
with formulation and duration information. 
Exceptions to the deficits with formulation information were topical preparation, inhalers, 
eye drops and oral solutions which were often recorded in discharge summaries.   
3.2.3 Adherence to the NPC minimum dataset relating to therapy change 
information  
Discharge summaries reporting of therapy change information demonstrated the lowest 
adherence rates among the three categories of the NPC minimum dataset.  Mean [95% CI] 
adherence was 48.9% [47.5-50.3] with particular omissions for the rationales of the 
medicines initiated, discontinued or changed.  Figure 3.1 illustrates adherence rates for 
therapy change information.  
3.3 Adherence to the NPC minimum dataset between admission and discharge 
summary types 
Table 3.4 to 3.6 provide comparisons of discharge summaries adherence to the categories 
of the NPC minimum dataset with respect to admission and discharge summary types: 
planned admission, unplanned admission, electronic and handwritten.  The lowest 
performance is indicated by bold type face.   
No discernible differences were observed between planned and unplanned admissions 
across all categories of the NPC minimum dataset.  However, unplanned admissions were 
more likely to report the rationales for therapy changes (Table 3.6).   
Conversely, handwritten discharge summaries consistently demonstrated lower adherence 
rates across all categories of the NPC minimum dataset.  With respect to handwritten 
discharge summary legibility, the majority of discharge summaries were electronic and 
thus legible.  However, 374 (42.8%) 95%CI [39.5-46.1] of the handwritten discharge 
summaries were considered partially illegible and the clinical message regarded 
unaffected, 33 (8.8%) 95%CI [6.9-10.7] were considered mostly illegible with the meaning 
of the clinical message unclear and 13 (1.5%) 95%CI [0.69-2.3] were regarded completely 
illegible.  
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3.4 Adherence to the NPC minimum dataset between hospitals 
Table 3.7 to 3.9 compare adherence rates across the three categories of the NPC 
minimum dataset between hospitals with the lowest performance indicated by bold type 
face.  Persistent deviations were apparent with community hospitals discharge summaries, 
notable omissions were with the information related to consultant, ward name, presenting 
diagnosis and rationales of medicines initiated.  
H2 showed particular deviations with medication histories, legibility, route of administration 
and details of medicines discontinued.  Mental health trusts demonstrated notable 
deviations with allergy status, formulation and rationales of medicines changed.  Table 
3.10 presents the content of the discharge summary templates used by hospitals 
representing the majority of the audit sample.  No two templates were identical and the 
extent of template adherence followed a similar pattern to discharge summary adherence 
rates to the NPC minimum dataset.  The template adherence score was generated through 
recording the percentage of NPC criteria represented by the template fields.  The template 
of H3 exhibited greatest adherence to the NPC minimum dataset whilst the template of H2 
and community hospitals demonstrated the lowest adherence. 
Expectedly, the variables of hospital and template were highly correlated; r=0.93 
(p=<0.001), Spearman Rho.  
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 Admission type Discharge summary type 
Patient, admission & discharge 
information 
Planned 
admission 
n=911  
N (%) 
Unplanned admission 
n=2,168  
N (%) 
Electronic  
n=2,570 
N (%) 
 
Handwritten  
n=874 
N (%) 
 
Correct patient name 901 (98.9) 2,149 (99.1) 2,551 (99.3) 858 (98.2) 
Correct date of birth 905 (99.3) 2,146 (99.0) 2,551 (99.3) 860 (98.4) 
Consultant name  818 (89.8) 2,011 (92.8) 2,452 (95.4) 697(79.7) 
Ward 822 (90.2) 1,987 (91.7) 2,440 (94.9) 678 (77.6) 
Admission date 898 (98.6) 2,145 (98.9) 2,544 (99.0) 855 (97.8) 
Discharge date 864 (94.8) 2,091 (96.4) 2,475 (96.3) 822 (94.1) 
Allergy status 77 (8.5) 157 (7.2) 256 (10.0) 75 (8.6) 
Presenting diagnosis 851 (93.4) 2,094 (94.6) 2,436 (94.8) 804 (92.0) 
Complete past medical history 468 (51.4) 1,155 (53.3) 1,482 (57.7) 318 (36.4) 
Complete drug history  393 (43.2) 933 (43.1) 1,102 (42.9) 354 (40.5) 
legible  809 (88.8) 1,902 (87.7) 2,495 (97.1) 514 (58.8) 
Received within 2 working days  599 (66.9) 1,404 (65.4) 1,675 (66.1) 578 (66.6) 
# Bold type face indicates lowest adherence to the criterion.  
Table 3.4 Adherence to patient, admission and discharge information by admission and discharge summary types 
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 Admission type Discharge summary type 
Medication information  Planned 
admission 
n=771 
N (%) 
Unplanned admission 
n=1,908  
N (%) 
Electronic  
n=2,216 
N (%) 
Handwritten  
n=782 
N (%) 
Dose for all medications 653 (84.7) 1,585 (83.1) 1,837 (82.9) 681 (87.1) 
Frequency for all medications  657 (85.2) 1,634 (85.6) 1,890 (85.3) 693 (88.6) 
Route for all medications 507 (65.8) 1,248 (65.4) 1,750 (79.0) 209 (26.7) 
Formulation for all medications  79 (10.2) 150 (7.9) 262 (11.8) 59 (7.5) 
Duration for all medications * 174 (35.2) 487 (37.6) 572 (35.8) 150 (38.6) 
 
*All discharge summaries (n=1,989), planned (n= 495), unplanned (n= 1,295), electronic (n=1,598) and handwritten (n=391) 
# Bold type face indicates lowest adherence to the criterion 
 
 
Table 3.5 Adherence to medication information by admission and discharge summary types 
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 Admission type Discharge summary type 
Therapy change information  
Planned 
admission 
N (%) 
 
Unplanned 
admission 
N (%) 
 
Electronic  
N (%) 
 
Handwritten  
N (%) 
 
n=518 n=1,300 n=1,593 n=396 
Medications initiated 348 (67.2) 910 (70.0) 1,180 (72.9) 228 (57.6) 
Reasons for initiation 116 (22.4) 387 (29.8) 485 (30.0) 89 (22.7) 
 
n=319 n=786 n=1,045 n=201 
Medications changed 238 (74.6) 570 (72.5) 791 (75.7) 118 (58.7) 
Reasons for changes 39 (12.2) 183 (23.3) 214 (20.5) 37 (18.4) 
 
n=290 n=710 n=949 n=178 
Medications discontinued 221 (76.2) 537 (75.6) 753 (79.3) 96 (53.9) 
Reasons for discontinuation 41 (14.1) 170 (23.9) 198 (20.9) 32 (17.9) 
# Bold type face indicates lowest adherence to the criterion 
 
Table 3.6 Adherence to therapy change information by admission and discharge summary types 
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 Hospitals 
NPC patient, admission & 
discharge information 
H1 
n=2,368 
N (%) 
H2 
n=715 
N (%) 
H3 
n=136 
N (%) 
H4  
n=57 
N (%) 
H5 
n=55 
N (%) 
Community 
n=52 
N (%) 
Tertiary 
hospital 
n=29 
N (%) 
Mental 
health trust  
n=21 
N (%) 
Correct patient name 2,352 (99.3) 700 (97.9) 134 (98.5) 57 (100) 55 (100 ) 52 (100) 29 (100) 19 (90.5) 
Correct date of birth 2,349 (99.2) 705 (98.6) 136 (100) 56 (98.2) 55 (100) 50 (96.2) 29 (100) 20 (95.2) 
Consultant name  2,264 (95.6) 570 (79.7) 134 (98.5) 51 (89.5) 51 (92.7) 29 (55.8) 25 (86.2) 15 (71.4) 
Ward 2,270 (95.9) 554 (77.5) 131 (96.3) 51 (89.5) 41 (74.5) 26 (50.0) 21 (72.4) 18 (85.7) 
Admission date 2,342 (98.9) 700 (97.9) 136 (100) 57 (100) 55 (100) 49 (94.2) 29 (100) 21 (100) 
Discharge date 2,290 (96.7) 667 (93.3) 135 (99.3) 52 (91.2) 52 (94.5) 48 (92.3) 26 (89.7) 18 (85.7) 
Allergy status 160 (6.8) 50 (7.0) 70 (51.5) 22 (38.6) 4 (7.3) 13 (25.0) 7 (24.1) 1 (4.8) 
Presenting diagnosis 2,235 (94.4) 660 (92.3) 20 (95.2) 55 (96.5) 54 (98.2) 26 (50.0) 54 (98.2) 20 (95.2) 
Complete past medical history 1,373 (58.0) 230 (32.2) 85 (62.5) 33 (57.9) 33 (60.0) 18 (34.6) 13 (44.8) 12 (57.1) 
Complete drug history  1,022 (43.2) 278 (38.9) 50 (36.8) 27 (47.4) 36 (65.5) 20 (39.2) 12 (41.4) 8 (38.1) 
legible  2,295 (96.9) 400 (55.9) 123 (97.1) 46 (80.7) 46 (83.6) 43 (82.7) 23 (97.3) 17 (81.0) 
Received within 2 working days  1,525 (65.3) 459 (65.0) 119 (87.5) 36 (64.3) 44 (80.0) 31 (59.6) 17 (58.6) 13 (61.9) 
# Bold type face indicates lowest adherence to the criterion. 
Table 3.7 Adherence to patient, admission and discharge details between hospitals  
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 Hospitals 
Medication information   
H1 
n=2,024 
N (%) 
H2 
n=643 
N (%) 
H3 
n=131 
N (%) 
H4  
n=49 
N (%) 
H5 
n=53 
N (%) 
Community 
n=45 
N (%) 
Tertiary 
hospital  
n=24 
N (%) 
Mental 
health trust  
n=19 
N (%) 
Dose for all medications 1,673 (82.7) 563 (87.6) 123 (93.9) 42 (85.7) 35 (66.0) 37 (82.2) 22 (91.7) 18 (94.7) 
Frequency for all medications  1,718 (84.9) 580 (90.2) 125 (95.4) 43 (87.8) 34 (64.2) 37 (82.2) 23 (95.8) 18 (94.7) 
Route for all medications 1,598 (79.0) 129 (20.1) 114 (87.0) 33 (67.3) 32 (60.4) 28 (62.2) 13 (54.2) 11 (57.9) 
Formulation for all medications  164 (8.1) 47 (7.3) 91 (69.5) 11 (22.4) 2 (3.8) 3 (6.7) 2 (8.3) 0 (0) 
Duration for all medications * 536 (36.3) 116 (40.4) 19 (21.6) 14 (45.2) 12 (29.3) 15 (51.7) 2 (12.5) 4 (33.3) 
*H1 (n=1,478), H2 (n= 287), H3 (n=88), H4 (n= 31), H5 (n=41), Mental health trusts (n=12), tertiary care hospital (n=16) and community hospitals (n=29) 
# Bold type face indicates lowest adherence to the criterion 
 
Table 3.8 Adherence to medication information between hospitals   
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 Hospitals 
Therapy change information  H1  
N (%) 
H2 
N (%) 
H3 
N (%) 
H4 
N (%) 
H5 
N (%) 
Community 
N (%) 
Tertiary 
hospitals 
N (%) 
Mental health 
trust  
N (%) 
n=1,514 n=286 n=78 n=32 n=42 n=28 n=18 n=11 
Medications initiated 1,107 (73.1) 168 (58.7) 64 (82.1) 20 (62.5) 15 (35.7) 12 (42.9) 13 (72.2) 8 (72.7) 
Reasons for initiation 437 (28.9) 66 (23.1) 46 (59.0) 9 (28.1) 8 (19.0) 2 (7.1) 5 (27.8) 1 (9.1) 
n=967 n=145 n=75 n=20 n=8 n=15 n=8 n=9 
Medications changed 720 (74.5) 77 (53.1) 71 (91.0) 15 (75.0) 7 (87.5) 9 (60.0) 3 (37.5) 5 (55.6) 
Reasons for changes 198 (20.5) 27 (18.6) 21 (28.0) 3 (15.0) 0 (0) 2 (13.3) 0 (0) 0 (0) 
n=881 n=121 n=64 n=19 n=7 n=16 n=9 n=8 
Medications discontinued 689 (78.2) 57 (47.1) 62 (96.9) 16 (84.1) 5 (71.4) 8 (50.0) 5 (55.6) 5 (62.5) 
Reasons for discontinuation 186 (21.1) 23 (19.0) 13 (20.3) 4 (21.1) 0 (0) 2 (12.5) 1 (11.1) 1 (12.5) 
# Bold type face indicates lowest adherence to the criterion 
 
Table 3.9 Adherence to therapy change information between hospitals  
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 Electronic template Handwritten template 
Information H1  H3 H4 H2 H5 Community 
hospital 
template 
Tertiary  
hospital 
template 
Mental 
trust 
Patient details 
Name           
Date of birth          
NHS number          
Past medical history        × × 
Allergy and 
hypersensitivities 
×   × × ×  × 
Admission date          
Discharge date          
Presenting diagnosis         
Procedures and 
investigation  
     × × × 
Discharge medicine details 
Name          
Dose         
Frequency          
Route     ×    × 
Formulation ×  × × × × × × 
Duration  × ×     × 
Therapy change 
Medication started   × × × × × × × 
Reason for medication 
started 
× × × × × × × × 
Medication stopped    × × × × × × 
Reason for medication 
stopped  
× × × × × × × × 
Medication changes  ×  × × × × × × 
Reason for medication 
changed 
× × × × × × × × 
Ward details  
Consultant name         
Ward name          
% Template 
adherence to NPC 
minimum dataset 
73.9% 78.3% 65.2% 60.9% 65.2% 60.9% 58.3%% 45.8% 
NPC: National prescribing centre. NHS: National Health Services 
Table 3.10 Templates of the primary medium of discharge summary   
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3.5 Adherence to NPC minimum dataset between wards  
Table 3.11 to 3.14 compare wards adherence across the three categories of the NPC 
minimum dataset with the lowest performance indicated by bold type face. 
Wards exhibited considerable variations in the extents of adherence to all categories of the 
NPC minimum dataset.  No wards demonstrated better adherence across all categories. 
3.6 Adherence to NPC minimum dataset between profession types 
Tables 3.14 to 3.16 illustrate adherence to the categories of the NPC minimum dataset 
between profession types with the lowest performance indicated by bold type face.   
It can be seen, that no healthcare professional performed better adherence rates across all 
categories.  However, discharge summaries prepared by foundation doctors demonstrated 
the lowest performance with deviations predominantly in co-morbidities and medication 
histories, route of administration and duration.  
Noticeably, discharge summaries prepared by consultants frequently lacked details on 
rationales of therapy changes (Table 3.16) 
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Patient, admission and discharge information 
Wards  Correct 
patient 
name 
Correct 
DOB 
Consultant 
name 
Ward Admission 
date 
Discharge 
date 
Allergy 
status 
Presenting 
diagnosis 
Complete 
co-
morbidities 
Medication 
history  
Legible  Within  
two 
working 
days  
Medicine for 
Elderly 
N 
(%) 
558 
(98.9) 
557 
(98.8) 
525  
(93.1) 
528 
(93.6) 
558  
(98.9) 
554  
(98.2) 
53 
(9.4) 
534  
(94.8) 
326  
(57.8) 
276  
(98.9) 
522 
(92.6) 
429 
(76.5) 
Urology N 
(%) 
399 
(99.0) 
401 
(99.5) 
389 
(96.5) 
378 
(93.8) 
402  
(99.8) 
390  
(96.8) 
37  
(9.2) 
374  
(92.8) 
203 
(50.4) 
167  
(41.4) 
361 
(89.6) 
278 
(69.8) 
General surgery N 
(%) 
319 
(99.4) 
318 
(99.4) 
289  
(90.0) 
300 
(93.5) 
318  
(99.1) 
311  
(96.9) 
27  
(8.4) 
298  
(92.8) 
172 
(53.6) 
144  
(44.9) 
286 
(89.1) 
230 
(72.3) 
Thoracic N 
(%) 
243 
(100) 
240 
(98.8) 
233 
(95.9) 
233 
(95.9) 
241  
(99.2) 
235  
(96.7) 
19  
(7.8) 
232  
(95.5) 
135 
(55.6) 
99 
(40.7) 
223 
(91.8) 
155 
(62.8) 
Cardiology N 
(%) 
235 
(100) 
234 
(99.6) 
217 
(92.3) 
219 
(93.2) 
235 
(100) 
224 
(95.3) 
23  
(9.8) 
224  
(95.3) 
144 
(61.3) 
98 
(41.7) 
219 
(93.2) 
117 
(50.6) 
Orthopaedic N 
(%) 
219 
(98.2) 
222 
(99.6) 
201 
(90.1) 
201 
(90.1) 
219  
(98.2) 
199  
(89.2) 
25 
(11.2) 
208  
(93.3) 
98 
(43.9) 
87 
(39.0) 
187 
(83.9) 
114 
(54.0) 
Paediatrics N 
(%) 
201 
(99.0) 
199 
(98.0) 
179 
(88.2) 
185 
(91.1) 
201  
(99.0) 
194  
(95.6) 
9 
(4.4) 
190  
(93.6) 
120 
(59.1) 
95 
(46.8) 
165 
(81.8) 
130 
(64.0) 
General 
medicine 
N 
(%) 
183 
(96.8) 
188 
(99.5) 
174 
(92.1) 
162 
(85.7) 
188  
(99.5) 
177  
(93.7) 
25 
(13.2) 
180  
(95.2) 
79 
(41.8) 
73 
(38.6) 
148 
(78.3) 
138 
(73.8) 
Gynaecology N 
(%) 
148 
(99.3) 
147 
(98.7) 
135 
(90.6) 
142 
(95.3) 
140 
(94.0) 
146  
(98.0) 
22 
(14.8) 
143  
(96.0) 
77 
(51.7) 
53 
(35.8) 
137 
(83.5) 
110 
(73.8) 
Oncology N 
(%) 
141 
(100) 
139 
(98.6) 
131 
(92.9) 
134 
(95.0) 
137 
(97.2) 
137  
(97.2) 
14  
(9.9) 
135  
(95.7) 
73 
(51.8) 
51 
(36.2) 
131 
(92.9) 
71 
(51.1) 
Gastroenterology N 
(%) 
131 
(99.2) 
132  
(100) 
126  
(95.5) 
118 
(89.4) 
129  
(97.7) 
124  
(93.9) 
10  
(7.6) 
121  
(91.7) 
60 
(45.5) 
56 
(42.4) 
113 
(85.6) 
82 
(62.1) 
DOB: date of Birth 
Table 3.11 Adherence to patient, admission and discharge information between wards 
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Patient, admission and discharge information 
Wards  Correct 
patient 
name 
Correct 
DOB 
Consultant 
name 
Ward Admission 
date 
Discharge 
date 
Allergy 
status 
Presenting 
diagnosis 
Complete 
co-
morbidities
Medication 
history  
legible Within  
two 
working 
days  
Ear, nose& 
throat 
 N  
(%) 
66  
(95.7) 
69  
(100) 
65 
(94.3) 
67  
(97.1) 
69 
(100) 
68 
(98.6) 
8  
(11.6) 
68  
(98.6) 
35 
(50.7) 
31 
(44.9) 
67 
(97.1) 
56 
(81.2) 
Neurology  N  
(%) 
55  
(96.5) 
56 
(98.2) 
53 
(93.0) 
54  
(94.7) 
57 
(100) 
55 
(96.5) 
4 
(7.0) 
54 
(94.7) 
38 
(66.7) 
30 
(52.6) 
55 
(96.5) 
31 
(54.4) 
Nephrology N  
(%) 
52 
(98.1) 
53 
(100) 
48 
(90.6) 
50  
(94.3) 
51 
(96.2) 
53  
(100) 
1 
(1.9) 
50 
(94.3) 
32 
(60.4) 
19 
(35.8) 
48 
(90.6) 
39 
(73.6) 
Endocrinology N  
(%) 
50 
(100) 
49 
(98.0) 
49 
(98.0) 
50  
(100) 
50 
(100) 
50 
(100) 
4 
(8.0) 
49  
(98.0) 
29 
(58.0) 
25 
(52.1) 
49 
(98.0) 
31  
(62.0) 
Others* N  
(%) 
163 
(99.4) 
161  
(98.2) 
142 
(86.6) 
147 
(89.6) 
164  
(100) 
158 
(96.3) 
20  
(12.2) 
157  
(95.7) 
88 
(53.7) 
57 
(35.0) 
137 
(83.5) 
96 
(59.3) 
Unspecified  N 
(%) 
246 
(99.2) 
246  
(99.2) 
193 
(77.8) 
150 
(60.5) 
240  
(96.8) 
222  
(89.5) 
30  
(12.1) 
223  
(89.9) 
91 
(36.7) 
95 
(38.3) 
160 
(64.5) 
152 
(62.8) 
*E.g. Dermatology, Rheumatology, Ophthalmology, Maternity care and Neonatal, rehabilitation. DOB: date of Birth 
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Medication information 
Wards n 
Dose for all 
medications 
N (%) 
Frequency 
for all 
medications 
N (%)  
Route for all 
medications 
N (%) 
Formulation 
for all 
medications 
N (%) 
Duration for 
all 
medications 
 
N (%) 
Medicine for 
Elderly 524 448 (85.5) 451 (86.1) 383 (73.1) 48 (9.2) 114 (33.0) 
Urology 343 305 (88.9) 314 (91.6) 261 (76.1) 46 (13.4) 79 (36.4) 
General surgery 286 220 (76.9) 231 (80.8) 149 (52.1) 16 (5.6) 70 (33.5) 
Thoracic 213 165 (77.5) 171 (80.3) 144 (67.6) 15 (7.0) 68 (44.2) 
Cardiology 195 174 (89.2) 174 (89.2) 138 (70.8) 18 (9.2) 46 (31.7) 
Orthopaedic 191 164(85.9) 165 (86.4) 111 (58.1) 17 (8.9) 43 (35.2) 
Paediatrics 157 139 (88.5) 137 (87.3) 87 (55.4) 28 (17.8) 45 (40.5) 
General 
medicine 
168 
145 (86.3) 146 (86.9) 86 (51.2) 48 (28.6) 34(37.4) 
Gynaecology 131 111 (84.7) 111 (84.7) 82 (62.6) 17 (13.0) 30 (38.5) 
Oncology 120 97 (80.1) 102 (85.0) 90 (75.0) 19 (15.8) 25 (29.8) 
Gastroenterology 120 97 (80.1) 102 (85.0) 69 (57.5) 4 (3.3) 27 (34.2) 
Ear, nose& 
throat 
56 47 (83.9) 50 (89.3) 49 (87.5) 10 (17.9) 15 (42.9) 
Neurology 47 38 (80.9) 41 (87.2) 39 (83.0) 12 (4.3) 12 (33.3) 
Nephrology 45 29 (64.4) 30 (66.7) 31 (68.9) 1 (2.2) 13 (37.1) 
Endocrinology 44 52 (72.7) 34 (77.3) 33 (75.0) 4 (9.1) 13 (41.9) 
Others* 135 106 (78.5) 113 (83.7) 72 (53.3) 15 (11.1) 33 (43.4) 
Unspecified  
223 201 (90.1) 211 (94.6) 91 (40.8) 13 (5.8) 55 (41.7) 
*E.g. Dermatology, Rheumatology, Ophthalmology, Maternity care and Neonatal, rehabilitation 
Medicine for Elderly (n=354), urology (n=217), general surgery (n=209), thoracic (n=154), cardiology (n=154), orthopaedic 
(n=122), paediatric (n=111), general medicine (n=91), gynaecology (n=78), oncology (n=84), gastroenterology (n=79), Ear, 
nose& throat (n=35), neurology (n=36), nephrology (n=35), endocrinology (n=32), others (n=76), speciality not indicated 
(n=132) 
Table 3.12 Adherence to medication information between wards   
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Therapy change information 
Wards Medications 
initiated 
N (%) 
Reasons 
for 
initiation 
N (%) 
Medications 
changed 
N (%) 
Reasons 
for 
changes 
N (%) 
Medications 
discontinued 
N (%)  
Reasons for 
discontinue 
N (%) 
 n=346  n=229  n=214  
Medicine for 
Elderly 244 (70.5) 116 
(33.5) 
169 (73.8) 64 (28.0) 170 (79.4) 54 (25.2) 
 n=229  n=160  n=153  
Urology 182 (79.5) 72 (31.4) 127 (79.4) 32 (20.0) 118 (77.1) 23 (15.0) 
 n=213  n=109  n=93  
General surgery 124 (58.2) 54 (25.4) 75 (68.8) 20 (18.3) 70 (75.3) 17 (18.3) 
 n=161  n=94  n=79  
Thoracic 126 (78.3) 50 (31.1) 65 (69.1) 15 (16.0) 59 (74.7) 13 (16.5) 
 n=148  n=112  n=100  
Cardiology 116 (78.4) 33 (22.3) 91 (81.3) 13 (11.6) 83 (83.0) 14 (14.0) 
 n=117  n=67  n=57  
Orthopaedic 35 (29.9) 16 (13.6) 43 (64.2) 11 (16.5) 40 (70.2) 10 (17.5) 
 n=116  n=60  n=56  
Paediatrics 80 (69.0) 26 (22.4) 43 (71.7) 9 (15.0) 38 (67.6) 9 (16.1) 
 n=85  n=63  n=53  
General 
medicine 
62 (72.9) 35 (41.2) 51 (80.9) 18 (28.6) 46 (86.8) 22 (41.5) 
 n=85  n=45  n=38  
Gynaecology 61 (71.8) 25 (29.4) 31 (68.9) 10 (22.2) 22 (57.9) 6 (15.8) 
 n=91  n=59  n=52  
Oncology 72 (79.1) 36 (39.6) 49 (83.1) 18 (30.5) 45 (86.5) 16 (30.8) 
 n=77  n=35  n=40  
Gastroenterology 52 (67.5) 23 (29.9) 21 (60.0) 3 (8.6) 29 (72.5) 10 (25.0) 
 n=37  n=22  n=18  
Ear, nose& 
throat 
27 (73.0) 12 (32.4) 18 (81.8) 5 (22.7) 13 (72.2) 2 (11.1) 
 n=36  n=25  n=21  
Neurology 23 (63.9) 4 (11.1) 23 (92.0) 5 (20.0) 19 (90.5) 2 (9.5) 
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Therapy change information 
Wards 
Medications 
initiated 
N (%) 
Reasons 
for 
initiation 
N (%) 
Medications 
changed 
N (%) 
Reasons 
for 
changes 
N (%) 
Medications 
discontinued 
N (%)  
Reasons for 
discontinue 
N (%) 
 n=32  n=22  n=19  
Nephrology 23 (71.9) 9 (28.1) 16 (72.7) 2 (9.1) 16 (84.2) 4 (21.1) 
 n=32  n=19  n=20  
Endocrinology 21 (65.6) 7 (21.9) 8 (42.1) 2 (10.5) 11 (55.0) 7 (35.0) 
 n=82  n=42  n=41  
Others* 45 (54.9) 18 (21.9) 26 (61.9) 7 (17.1) 25 (61.0) 6 (14.6) 
 n=128  n=83  n=73  
Unspecified  93 (72.7) 34 (26.6) 53 (63.9) 17 (20.5) 45 (61.6) 15 (20.5) 
*E.g. Dermatology, Rheumatology, Ophthalmology, Maternity care and Neonatal, rehabilitation 
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 Profession type 
NPC patient, 
admission & 
discharge 
information 
 Not 
indicated  
n=758 
Doctor a 
n=1113 
Foundation 
years 
n=853 
Core 
medical 
training b 
n=266 
Specialty 
training c 
n=120 
Registrars 
n=21 
Consultant 
n=131 
Pharmacist 
n=36 
Specialist 
nurse 
practitioner 
n=146 
Correct patient 
name 
N (%) 751 (99.2) 1105 (99.3) 839 (98.4) 262 (98.5) 120 (100) 21 (100) 129 (98.5) 36 (100) 145 (99.3) 
Correct date of 
birth 
N (%) 750 (98.9) 1103 (99.1) 846 (99.2) 262 (98.5) 118 (99.2) 21 (100) 130 (99.2) 36 (100) 145 (99.3) 
Consultant name  N (%) 690 (91.0) 1048 (94.2) 746 (87.5) 247 (92.9) 103 (85.8) 12 (57.1) 124 (94.7) 36 (100) 143 (97.9) 
Ward N (%) 690 (91.0) 1047 (94.1) 733 (85.9) 236 (88.7) 102 (85.0) 16 (76.2) 119 (90.8) 36 (100) 139 (95.2) 
Admission date N (%) 753 (99.3) 1103 (99.1) 834 (97.8) 263 (98.9) 120 (100) 20 (95.2) 131 (100) 36 (100) 139 (95.2) 
Discharge date N (%) 731 (96.4) 1072 (96.3) 801 (93.9) 258 (97.0) 113 (94.2) 20 (95.2) 125 (95.4) 35 (97.2) 142 (97.3) 
Allergy status N (%) 112 (14.8) 102 (9.2) 57 (6.7) 21 (7.9) 12 (10.0) 1 (4.8) 12 (9.2) - 14 (9.6) 
Presenting 
diagnosis 
N (%) 705 (93.1) 1061 (95.3) 798 (93.6) 250 (94.0) 112 (93.3) 21 (100) 123 (93.9) 35 (97.2) 135 (92.5) 
Complete co-
morbidities 
N (%) 423 (55.8) 650 (58.4) 351 (41.1) 121 (45.0) 61 (50.8) 9 (42.9) 74 (56.5) 21 (58.3) 90 (61.6) 
Complete 
medication history  
N (%) 332 (43.8) 445 (40.1) 299 (35.1) 126 (47.5) 44 (36.7) 13 (61.9) 49 (37.4) 18 (50.0) 64 (43.8) 
legible  N (%) 674 (88.9) 1074 (96.5) 632 (74.1) 214 (80.5) 102 (85.0) 19 (90.5) 116 (88.5) 36 (100) 142 (97.3) 
Received within 2 
working days  
N (%) 511 (69.5) 701 (63.6) 564 (66.4) 171 (64.3) 82 (68.9) 13 (65.0) 93 (71.5) 15 (41.7) 109 (74.7) 
a
 Unspecified training level, b: Core medical training 1&2, speciality doctor 1&2, c: speciality doctor 3 & Fellow. # Bold type face indicates lowest adherence to the criterion 
Table 3.14 Adherence to patient, admission & discharge details between profession types   
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 Profession type 
Medication information  
Measure Not indicated 
n= 635 
Doctor 
a 
n= 971 
Foundation 
years 
n= 766 
Core 
medical 
training 
b 
n= 236 
Specialty 
training c 
n= 105 
Registrars 
n= 16 
Consultant 
n= 114 
Pharmacist 
n= 33 
Specialist 
nurse 
practitioners 
n= 122 
Dose for all medications N  
(%) 
551  
(86.8) 
812  
(83.6) 
651 
(85.0) 
188  
(79.7) 
82 
(78.1) 
14 
(87.5) 
90 
(78.9) 
30  
(90.9) 
100  
(82.0) 
Frequency for all medications  N  
(%) 
561  
(88.3) 
833  
(79.0) 
667 
(87.1) 
197 
(83.4) 
83 
(79.0) 
13 
(81.3) 
94 
(82.5) 
30  
(90.0) 
105 
(86.1) 
Route for all medications N 
(%) 
450 
(70.9) 
761  
(78.4) 
347 
(45.3) 
130 
(55.1) 
59  
(56.2) 
10  
(62.5) 
75 
(65.8) 
30  
(90.9) 
98 
(80.3) 
Formulation for all medications  N  
(%) 
132 
(20.8) 
93  
(9.6) 
48 
(6.3) 
16 
(6.8) 
5 
(4.8) 
- 8 
(7.0) 
3  
(9.1) 
16 
(13.1) 
Duration for all medications * N  
(%) 
142 
(32.4) 
246  
(35.0) 
110 
(25.9) 
62 
(38.5) 
31 
(41.9) 
5 
(50.0) 
31 
(41.9) 
9 
(39.1) 
51  
(39.3) 
a
 Unspecified training level, b: Core medical training 1&2, speciality doctor 1&2, c: speciality doctor 3 & Fellow. # Bold type face indicates lowest adherence to the criterion 
*Not indicated (n=438), doctor (n= 703), foundation year (n=424), core medical training (n= 161), specialty training (n=74), consultant (n=72), Specialist nurse practitioners 
(n=84), pharmacist (n=23) and registrar (n=10) 
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 Profession type 
Therapy change 
information  
Not 
indicated  
Doctor a Foundatio
n years 
Core 
medical 
training b 
Specialty 
training c 
Registrars Consultant Pharmacis
t 
Specialist 
nurse 
practitioners 
n=439 n=711 n=424 n=160 n=77 n=11 n=78 n=25 n=90 
Medications initiated 308 (70.2) 517 (72.7) 281 (66.3) 114 (71.3) 40 (51.9) 8 (72.7) 56 (71.8) 18 (72.0) 66 (73.3) 
Reasons for initiation 142 (32.3) 190 (26.7) 115 (27.1) 49 (30.6) 22 (28.6) 3 (27.3) 13 (16.0) 6 (23.1) 31 (34.4) 
n=340 n=466 n=203 n=77 n=35 n=7 n=55 n=10 n=53 
Medications changed 280 (82.4) 319 (68.5) 133 (65.5) 57 (74.0) 23 (65.7) 5 (71.4) 40 (72.7) 10 (100) 42 (79.2) 
Reasons for changes 64 (18.8) 88 (18.9) 48 (23.6) 22 (28.6) 7 (20.0) 1 (14.3) 10 (18.2) 1 (10.0) 10 (18.7) 
n=304 n=417 n=187 n=64 n=28 n=6 n=51 n=12 n=58 
Medications discontinued 248 (81.6) 308 (731.9) 122 (65.2) 52 (81.3) 19 (67.9) 6 (100) 38 (74.5) 12 (100) 44 (75.9) 
Reasons for 
discontinuation 49 (16.1) 82 (19.7) 46 (24.6) 23 (35.9) 5 (17.6) 
2 (33.3) 
6 (10.7) 5 (41.7) 11 (19.0) 
a
 Unspecified training level b: Core medical training 1&2, speciality doctor 1&2, c: speciality doctor 3 & Fellow # Bold type face indicates lowest adherence to the criterion 
Table 3.16 Adherence to therapy change information between profession types  
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3.7 Investigating contributing factors to discharge summary adherence to the 
total NPC minimum dataset 
Tables 3.17-3.20 illustrate the adjusted models exploring the contributing factors to 
discharge summary adherence to the total and three categories of the NPC minimum 
dataset.  Factors influencing discharge summary adherence to the total NPC minimum 
dataset is presented in Table 3.17.  Contributors to good adherence included discharge 
summaries from H3, written by registrars or specialist nurse practitioners and unplanned 
admissions.  It can be presumed from Table 3.17 that a discharge summary from H3 
improves adherence to the total NPC minimum dataset by 7.61%.  Additionally, a 
discharge summary prepared by a registrar or specialist nurse practitioner improves 
adherence to the total NPC minimum dataset by 7.6% and 2.51% respectively.   
Contributors to lower adherence were discharge summaries from community, mental 
health trusts and H2 hospitals plus nephrology and orthopaedic wards.  It can be seen 
that, discharge summaries from community, mental health trusts and H2 hospitals trended 
to demonstrate lower adherence rates by 10.5%, 6.19% and 5.49% respectively.  
Similarly, discharge summaries from nephrology and orthopaedic wards exhibited lower 
rated by 4% and 2% respectively.  
Additionally, handwritten discharge summaries were more likely to exhibit lower rates 
approximately by 3% and with increased number of medicines the likelihood of good 
adherence potentially decreases. 
3.7.1 Contributing factors to patient, admission and discharge information  
Factors influencing discharge summary adherence to patient, admission and discharge 
information are presented in Table 3.18.  The strongest contributing factor to better 
adherence was H3 accounting for an increase in adherence rate of 6.8%.  Endocrinology 
and medicine for elderly wards as well as discharge summaries written by specialist nurse 
practitioners were also contributors to good adherence accounting for an increase in 
adherence rate by 5.2%, 3.1% and 2.2% respectively.   
Conversely, community hospitals, mental health trusts and H2 as well as handwritten 
discharge summaries were contributors to poor adherence.  Those trended to reduce 
adherence rate by 8.3%, 4.8%, 5.5% and 3.1% respectively.  Increased number of 
medicines was associated with lower adherence rates too. 
  


3.7.2 Contributing factors to medication infromation 
It can be seen in Table 3.19 that, H3 and H4 are the strongest contributors to good 
adherence, contributing to better adherence by 11.4% and 7.6% respectively.  This is 
followed by discharge summaries prepared by speciality training doctors accounting to an 
increase of 4.9%.  Meanwhile, H5, community hospitals as well as H2 were contributors to 
poor adherence.  Those attributed to lower adherence rates by 11.6%, 7.3% and 5.5% 
respectively. 
Despite being a contributor to good adherence for patient, admission and discharge 
information, endocrinology wards were identified as a contributor to poor adherence with 
respect to medication information by 13.5%.  In addition, general surgery wards, 
handwritten plus discharge summaries of older patients were contributing to poor 
adherence.  Discharge summaries which were from general surgery wards exhibited lower 
adherence rate by 6.5%, whereas handwritten contributed to lower adherence rate by 8%. 
3.7.3 Contributing to factors therapy changes infromation 
There were no clear factors contributing to better adherence to therapy change 
information.  There were, however, some very strong contributors to poor adherence with 
orthopaedic wards being the strongest contributor accounting to 21.7% reduction in 
adherence rate.   
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 Univariate analysis Multivariate analysis 
Variable B 95%CI p B 95%CI p 
Patient demographics 
      
Age -0.02 [-0.03-0.0] <0.001 -0.02 [-0.04- 0.02] 0.17 
No. of medications -0.21 [-0.30-0.12] <0.001 -0.25 [-0.34- -.15] <0.001 
Hospital stay -0.04 [-0.07-0.0] 0.03 -0.02 [-0.05-0.02] 0.33 
Type of discharge summary 
      
Handwritten discharge 
summaries 
-7.71 [-8.58- -6.84] <0.001 -2.96 [-4.28- -1.64] <0.001 
Type of admission a 
Admitted via unplanned 
admission  
0.05 [-7.64-0.87] 0.89 
1.03 [0.11-1.94] 0.03 
Unspecified type of admission 1.0 [-0.28-2.27] 0.13 2.37 [0.79-3.92] 0.003 
Hospitals b 
      
Discharges from H2 -8.48 [-9.40- -7.55] <0.001 -5.49 [-6.99- -4.0] <0.001 
Discharges from H3  10.06 [8.06-12.06] <0.001 7.61 [5.09-10.14] <0.001 
Discharges from H4 2.02 [-1.07-5.12] 0.20 1.29 [-1.80-4.38] 0.41 
Discharges from H5 -0.05 [-3.20-3.10] 0.97 0.02 [-3.04-3.08] 0.99 
Discharges from tertiary hospital -3.46 [-7.78-0.85] 0.12 -2.82 [-6.96-1.33] 0.18 
Discharges from mental health 
trusts 
-6.09 [-11.15- -1.02] 0.02 -6.19 [-11.13-1.26] 0.01 
Discharges from community 
hospitals 
-9.39 [-12.61- -6.17] <0.001 -10.50 [-14.12- -6.89] <0.001 
Ward specialities c 
      
Discharges from Medicine for 
elderly wards 
2.08 [1.01-3.14] <0.001 1.46 [-0.59-3.51] 0.16 
Discharged from Orthopaedic 
wards 
-3.31 [-4.91- -1.71] <0.001 -2.11 [-4.48-0.26] 0.008 
Discharged from General surgery 
wards 
-0.66 [-2.02-0.69] 0.34 -1.04 [-3.16-1.07] 0.33 
Discharged from Urology wards 1.76 [0.54-2.99] 0.01 0.38 [-1.7-2.47] 0.72 
Discharged from 
Gastroenterology wards 
-2.19 [-4.25-0.14] 0.04 -2.45 [-5.03-0.12] 0.06 
Discharged from Cardiology 
wards 
1.31 [-0.26-2.88] 0.10 0.01 [-2.27-2.28] 0.99 
Discharged from Thoracic wards 1.70 [0.15-3.24] 0.03 0.82 [-1.44-3.08] 0.48 
Discharged from Paediatric wards  -0.36 [-2.04-1.32] 0.67 -1.32 [-3.89-1.25] 0.32 
Discharged from Oncology wards 2.24 [0.25-4.24] 0.04 0.71 [-1.86-3.28] 0.59 
Discharged from Nephrology 
wards 
-1.76 [-4.96-1.45] 0.28 -4.10 [-7.62-0.59] 0.02 
Discharged from Ear, nose& 
throat wards 
3.95 [1.13-6.76] 0.01 1.44 [-1.75-4.63] 0.38 
Discharged from Endocrinology 
wards 
2.67 [-0.64-5.96] 0.11 1.78 [-1.74-5.31] 0.32 
Discharged from Gynaecology 
wards 
0.52 [-1.42-2.46] 0.60 -0.36 [-2.89-2.18] 0.78 
Discharged from Neurology wards 1.75 [-1.34-4.84] 0.27 -0.63 [-4.04-2.78] 0.72 
Discharged from other ward 
Specialties  
-0.39 [-2.24-1.47] 0.68 0.57 [-1.88-3.02] 0.65 
Unspecified speciality   -7.90 [-9.41- -6.40] <0.001 -4.22 [-6.52- -1.92] <0.001 
B: The estimate of change in the outcome with one unit change of the predictor  
Table 3.17 Factors contributing to discharge summary adherence to the total NPC minimum 
dataset   


 
 
 Univariate analysis Multivariate analysis 
Variable B 95%CI P B 95%CI p 
Role of person responsible for 
discharge d 
      
Core medical training doctors -0.90 [-2.38-0.58] 0.23 0.37 [-1.20-1.93] 0.64 
Speciality training doctors -2.93 [-5.08- -0.78] 0.008 -1.88 [-4.06-0.20] 0.09 
Registrars  -0.36 [-0.36-4.70] 0.89 7.60 [2.06-13.15] 0.01 
Consultants  0.20 [-1.86-2.27] 0.84 -0.05 [-2.14-2.04] 0.96 
Doctors of unknown training level  1.64 [0.80-2.48] <0.001 -0.42 [-1.56-0.72] 0.47 
Pharmacists 2.88 [-1.0-6.76] <0.15 1.53 [-2.24-5.29] 0.43 
Specialist nurse practitioners 2.9 [0.96-4.87] 0.01 2.51 [041-4.62] 0.02 
Unspecified profession  2.33 [1.38-3.28] <0.001 0.26 [-1.02-1.55] 0.69 
Constant B= 78.4, Std error=1.5, P <0.001. R square =0.16, adjusted R square= 0.15, Std error of the 
estimate=10.76. a Compared against planned admission, b Compared to H1,  c Compared to general medicine 
wards, d Compared to foundation year doctors. B: The estimate of change in the outcome with one unit 
change of the predictor 
# Bold type face indicates statistically significant model predictors (i.e. p<0.05)  
Continued  
Table 3.17 Factors contributing to discharge summary adherence to the total NPC minimum 
dataset 
Of note, the unadjusted model in Table 3.17 identified age, some type of ward specialities 
and professions as contributors to the quality of discharge information.  However, those 
were not significant contributors when the model was adjusted.  This most likely due to the 
confounding effect exerted by number of medicines and type of discharge summary. 


 
 Univariate analysis  Multivariate analysis 
Variable B 95%CI P B 95%CI p 
Patient demographics 
      
Age -0.01 [-0.02-0.01] 0.59 -0.01 [-0.03-0.01] 0.47 
No. of medications 0.15 [0.06-0.24] 0.01 0.11 [0.02-0.20] 0.01 
Hospital stay -0.02 [-0.06-0.01] 0.14 -0.01 [-0.04-0.02] 0.41 
Type of discharge summary 
      
Handwritten discharge 
summaries 
-8.46 [-9.29- -7.64] <0.001 -3.1 [-4.34- -1.85] <0.001 
Type of admission a 
Admitted via unplanned admission  0.51 [-0.28-1.29] 0.21 0.55 [-0.31-1.41] 0.21 
Unspecified type of admission -1.02 [-2.26-0.21] 0.11 0.30 [-1.18-1.77] 0.70 
Hospitals b 
      
Discharges from H2 -9.49 [10.37- -8.6] <0.001 -5.52 [-6.93- -4.11] <0.001 
Discharges from H3  8.42 [6.49-10.35] 0.001 6.77 [-4.39-9.15] <0.001 
Discharges from H4  2.39 [-0.59-5.36] 0.12 1.60 [-1.32-4.51] 0.30 
Discharges from H5 2.09 [-0.93-5.13] 0.17 2.27 [-0.62-5.16] 0.12 
Discharges from mental health 
trusts 
-5.54 [-10.41- -0.67] 0.03 -4.74 [-9.4- -0.08] 0.05 
Discharges from tertiary hospitals -3.51 [-7.66-0.64] 0.10 -3.10 [-7.01-0.82] 0.12 
Discharges from community 
hospitals 
-8.87 [-11.97- -5.78] <0.001 -8.29 [-11.69- -4.88] <0.001 
Ward specialities c 
      
Discharges from Medicine for 
elderly wards 
0.78 [1.78-3.80] <0.001 3.13 [1.19-5.06] 0.002 
Discharged from Orthopaedic 
wards 
-2.49 [-4.03- -0.95] 0.002 0.22 [-2.02-2.45] 0.85 
Discharged from General surgery 
wards 
0.84 [-0.47-2.14] 0.21 1.89 [-.11-3.89] 0.07 
Discharged from Urology wards 0.87 [-0.31-2.06] 0.15 1.33 [-0.64-3.29] 0.19 
Discharged from Gastroenterology 
wards 
-1.70 [-3.68-0.28] 0.09 -0.36 [-2.79-2.07] 0.77 
Discharged from Cardiology wards 1.69 [0.18-3.19] 0.03 2.06 [-0.083-4.21] 0.06 
Discharged from Thoracic wards 1.52 [0.03-2.99] 0.05 1.88 [-0.25-4.02] 0.08 
Discharged from Paediatric wards  -0.78 [-2.39-0.84] 0.35 1.10 [-1.32-3.53] 0.37 
Discharged from Oncology wards 0.47 [-1.45-2.38] 0.63 0.47 [-1.95-2.89] 0.71 
Discharged from Nephrology wards -0.45 [-3.5-2.6] 0.78 -1.34 [-4.66-1.97] 0.43 
Discharged from Ear, nose& throat 
wards 
2.43 [-0.28-5.14 0.08 1.94 [-1.07-4.95] 0.21 
Discharged from Endocrinology 
wards 
4.74 [1.57-7.91] 0.003 5.17 [1.84-8.50] 0.002 
Discharged from Gynaecology 
wards 
1.60 [-0.27-3.46] 0.09 2.19 [-0.21-4.58] 0.07 
Discharged from Neurology wards 2.09 [-0.88-5.06] 0.17 1.23 [-1.99-4.44] 0.46 
Discharged from other ward 
Specialties  
-0.42 [-2.2-1.36] 0.65 2.51 [0.20-4.82] 0.03 
Unspecified speciality  -9.17 [-10.6- -7.74] <0.001 -3.79 [-5.95- -1.62] 0.001 
B: The estimate of change in the outcome with one unit change of the predictor 
Table 3.18 Factors contributing to discharge summary adherence to patient, admission and 
discharge information 


 
 
Univariate analysis Multivariate analysis 
Variable B 95%CI P B 95%CI p 
Role of person responsible for 
discharge d 
      
Core medical training doctors -0.93 [-2.35-0.49] 0.20 0.56 [0.92-2.03] 0.46 
Speciality training doctors -2.13 [-4.20- -0.06] 0.04 -0.94 [-2.99-1.11] 0.37 
Registrars  -3.14 [-8.02-1.73 0.21 4.26 [-0.98-9.49] 0.11 
Consultants  -0.04 [-2.03-1.94] 0.96 0.03 [-1.95-1.99] 0.98 
Doctors of unknown training level  2.45 [1.64-3.26] <0.001 0.39 [0.69-1.46] 0.48 
Pharmacists 2.79 [-0.94-6.52] 0.14 1.08 [-2.47-4.63] 0.55 
Specialist Nurse Practitioners 2.57 [0.69-4.45] 0.05 2.24 [0.25-4.22] 0.03 
Unspecified profession  2.28 [1.36-3.19] <0.001 0.40 [-0.82-1.61] 0.52 
Constant B= 80.19, Std error=1.4, P <0.001. R square =0.179, adjusted R square= 0.169, Std error of the 
estimate=10.16. a Compared against planned admission, b Compared to H1, c Compared to general medicine 
wards, d Compared to foundation year doctors.  # Bold type face indicates statistically significant model 
predictors (i.e. p<0.05). B: the estimate of change in the outcome with one unit change of the predictor  
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Table 3.18 Factors contributing to discharge summary adherence to Patient, admission and 
discharge information  
Similarly in Table 3.18, the unadjusted analysis identified some type of ward specialities 
and professions as contributors to the quality of discharge information; however this effect 
was not significant when the model was adjusted to number of medicines and type of 
discharge summary and admission.   
  


 
 
Univariate analysis Multivariate analysis 
Variable B 95%CI P B 95%CI p 
Patient demographics    
   
Age 0.05 [-0.11-0.94] 0.01 -0.07 [-0.12-0.24] 0.003 
No. of medications 2.56 [2.34-2.70] <0.001 -0.05 [-0.26-0.17] 0.66 
Hospital stay 0.06 [-0.03-0.14] 0.21 0.04 [-0.03-0.10] 0.32 
Type of discharge summary    
   
Handwritten discharge 
summaries 
-9.13  [-11.44- -6.81] <0.001 -8.03 [-10.87- -5.19] <0.001 
Type of admission a 
Admitted via unplanned 
admission  51.99 [51.23-52.75] <0.001 -0.36 [-2.34-1.63] 0.72 
Unspecified type of 
admission 
53.26 [51.0-55.51] <0.001 6.79 [3.34-10.25] <0.001 
Hospitals b    
   
Discharges from H2 42.03 [40.42-43.64] <0.001 -5.45 [-8.67- -2.23] 0.001 
Discharges from H3  72.27 [68.54-75.99] <0.001 11.40 [6.06-16.73] <0.001 
Discharges from H4  51.45 [45.56-57.33] <0.001 7.58 [0.88-14.28] 0.03 
Discharges from H5 38.45 [32.45-44.46] <0.001 -11.59 [-17.95- -5.23] <0.001 
Discharges from mental health 
trusts 
50.89 [41.16-60.61] <0.001 2.46 [-7.93-12.85] 0.64 
Discharges from tertiary 
hospitals 
44.66 [36.39-52.94] <0.001 -0.62 [-9.78-8.52] 0.89 
Discharges from community 
hospitals 
42.64 [36.47-48.82] <0.001 -7.30 [-9.78-8.52] <0.07 
Ward specialities c    
   
Discharges from Medicine for 
elderly wards 
53.35 [-51.57-55.13] <0.001 -0.67 [-5.09-3.75] 0.77 
Discharged from Orthopaedic 
wards 
46.78 [43.84-49.73] <0.001 -1.92 [-7.03-3.18] 0.46 
Discharged from General 
surgery wards 
44.94 [42.51-47.39] <0.001 -6.52 [-11.10- -1.94] 0.005 
Discharged from Urology wards 50.27 [48.12-52.42] <0.001 0.90 [-3.62-5.43] 0.70 
Discharged from 
Gastroenterology wards 
46.87 [43.02-50.72] <0.001 -5.44 [-10.96-0.75] 0.05 
Discharged from Cardiology 
wards 
46.48 [43.61-49.35] <0.001 0.71 [-5.67-4.25] 0.78 
Discharged from Thoracic 
wards 
51.34 [48.52-54.14] <0.001 1.15 [-3.75-6.05] 0.65 
Discharged from Paediatric 
wards  
42.20 [39.19-45.39] <0.001 2.81 [-8.53-2.90] 0.34 
Discharged from Oncology 
wards 
50.28 [46.56-53.99] <0.001 -0.52 [-6.15-5.11] 0.86 
Discharged from Nephrology 
wards 
44.98 [38.86-51.09] <0.001 -5.63 [-13.29-2.03] 0.15 
Discharged from Ear, nose& 
throat wards 
49.72 [44.38-55.07] <0.001 0.77 [-6.35-7.88] 0.83 
Discharged from 
Endocrinology wards 
39.86 [33.56-46.16] <0.001 -13.54 [-21.15- -5.92] 0.001 
Discharged from Gynaecology 
wards 
48.46 [44.84-52.07] <0.001 -2.14 [-7.60-3.33] 0.44 
Discharged from Neurology 
wards 
48.61 [42.72-54.49] <0.001 -1.35 [8.86-6.17] 0.73 
Discharged from other ward 
Specialties  
41.74 [38.28-45.19] <0.001 -2.91 [-8.33-2.51] 0.29 
Unspecified speciality  46.57 [43.78-49.36] <0.001 1.62 [-3.34-6.58] 0.52 
B: the estimate of change in the outcome with one unit change of the predictor 
Table 3.19 Factors contributing to discharge summary adherence to medication information 
	

 
 
Univariate analysis Multivariate analysis 
Variable B 95%CI P B 95%CI p 
Role of person responsible for 
discharge d 
      
Core medical training doctors 47.13 [44.44-49.82] <0.001 1.42 [-1.96-4.81] 0.41 
Speciality training doctors 42.16 [38.11-46.21] <0.001 4.91 [-9.63-0.18] 0.04 
Registrars  34.83 [25.09-44.57] <0.001 -9.68 [-22.75-3.39] 0.15 
Consultants  44.28 [40.40-48.15] <0.001 3.38 [-7.92-1.15] 0.14 
Doctors of unknown training 
level  
53.19 [52.0-54.38] <0.001 3.04 [0.59-5.49] 0.02 
Pharmacists 55.36 [47.94-62.77] <0.001 6.58 [-1.47-14.64] 0.11 
Specialist Nurse Practitioners 47.06 [43.40-50.72] <0.001 3.07 [-1.58-7.73] 0.20 
Unspecified profession  50.04 [48.53-51.57] <0.001 1.69 [-1.07-4.44] 0.23 
Constant B= 79.23, Std error=3.28, P <0.001. R square =0.118, adjusted R square= 0.106, Std error of the 
estimate=21.95. a Compared against planned admission, b Compared to H1, c Compared to general medicine 
wards, d Compared to foundation year doctors.  # Bold type face indicates statistically significant model 
predictors (i.e. p<0.05). B: the estimate of change in the outcome with one unit change of the predictor 
 
Continued  
Table 3.19 Factors contributing to discharge summary adherence to medication information 
Similarly in Table 3.19, the unadjusted analysis identified some type of hospitals, ward 
specialities and professions as contributors to the quality of discharge information; 
however this effect was not significant when the model was adjusted to number of 
medicines and type of discharge summary and admission.   
  


 
 
Univariate analysis Multivariate analysis 
Variable B 95%CI P B 95%CI p 
Patient demographics    
   
Age 0.04 [-0.01-0.09] 0.146 -0.02 [-0.07-0.10] 0.65 
No. of medications 0.56 [0.28-0.84] <0.001 -0.31 [0.66-0.05] 0.09 
Hospital stay -0.07 [-0.17-0.04] 0.23 -0.14 [0.27- -0.01] 0.05 
Type of discharge summary    
   
Handwritten discharge 
summaries 
-17.9 [-20.61- -15.20] <0.001 -8.73 [-13.05- -3.49] 0.001 
Type of admission a 
Admitted via unplanned 
admission  31.30 [30.61-31.99] <0.001 2.87 [-0.56-6.49] 0.10 
Unspecified type of admission 29.81 [27.98-31.64] <0.001 10.54 [4.10-10.98] 0.001 
Hospitals b    
   
Discharges from H2 14.94 [13.61-16.27 <0.001 -3.80 [-9.96-2.36] 0.23 
Discharges from H3  41.62 [38.62-44.61] <0.001 8.29 [-1.71-18.29] 0.10 
Discharges from H4 26.52 [21.84-31.20] <0.001 -1.67 [-13.89- -10.54] 0.79 
Discharges from H5 15.36 [10.59-20.1] <0.001 -17.0 [-27.95- -5.96] <0.003 
Discharges from mental health 
hospitals 
17.81 [10.09-25.53] <0.001 -5.40 [-24.91-14.09] 0.59 
Discharges from tertiary hospital 26.24 19.68-32.8] <0.001 -4.39 [-20.28-11.49] 0.59 
Discharges from community 
hospitals 
11.71 [6.79-16.62] <0.001 -20.41 [-34.42- -6.40] 0.004 
Ward specialities c    
   
Discharges from Medicine for 
elderly wards 
34.02 [32.57-35.46] <0.001 -3.42 [-12.04-5.19] 0.44 
Discharged from Orthopaedic 
wards 
17.39 [15.02-19.75] <0.001 -21.65 [-31.56-11.73] <0.001 
Discharged from General 
surgery wards 
27.29 [25.34-29.25] <0.001 -13.07 [-21.84- -4.29] 0.004 
Discharged from Urology wards 30.56 [28.82-32.29] <0.001 -5.34 [-14.15-3.47] 0.24 
Discharged from 
Gastroenterology wards 
28.16 [25.09-31.28] <0.001 -7.83 [-18.31-2.65] 0.14 
Discharged from Cardiology 
wards 
34.35 [32.07-36.62] <0.001 -5.82 [-15.06-3.42] 0.22 
Discharged from Thoracic wards 33.24 [30.99-35.48] <0.001 -6.80 [-16.07-2.17] 0.15 
Discharged from Paediatric 
wards  
25.81 [23.34-28.28] <0.001 -11.53 [-22.11- -0.94] 0.03 
Discharged from Oncology wards 37.18 [34.23-40.23] <0.001 1.47 [-8.84-11.77] 0.78 
Discharged from Nephrology 
wards 
26.24 [26.24-35.94] <0.001 -14.12 [-27.38- -0.85] 0.04 
Discharged from Ear, nose& 
throat wards 
25.44 [21.19-29.69] <0.001 -8.75 [-21.87-4.37] 0.19 
Discharged from 
Endocrinology wards 
27.9 [22.9-32.89] <0.001 -17.55 [-30.86- -4.24] 0.01 
Discharged from Gynaecology 
wards 
26.21 [23.32-29.10] <0.001 -8.55 [-19.09-1.99] 0.11 
Discharged from Neurology 
wards 
29.75 [25.07-34.43] <0.001 -16.48 [-29.28-3.67] 0.01 
Discharged from other ward 
Specialties  
16.58 [13.82-19.34] <0.001 -14.64 [-25.29- -3.99] 0.007 
Unspecified speciality  24.08 [-21.85-26.08] <0.001 0.60 [-10.45-9.25] 0.90 
B: the estimate of change in the outcome with one unit change of the predictor 
Table 3.20 Factors contributing to discharge summary adherence to therapy change 
information 


 
 
Univariate analysis Multivariate analysis 
Variable B 95%CI P B 95%CI p 
Role of person responsible for 
discharge d 
   
   
Core medical training doctors 30.23 [28.08-32.37] <0.001 2.37 [-3.73-8.48] 0.45 
Speciality training doctors 25.79 [22.57-29.01] <0.001 6.51 [-14.68-1.66] 0.12 
Registrars  23.76 [16.04-31.48] <0.001 0.65 [-19.94-21.23] 0.95 
Consultants  26.75 [23.67-29.83] <0.001 5.49 [-13.65-2.68] 0.19 
Doctors of unknown training level  32.74 [31.73-33.74] <0.001 2.43 [-6.76-1.89] 0.27 
Pharmacists 35.27 [29.39-41.16] <0.001 2.18 [-15.45-11.08] 0.75 
Specialist Nurse Practitioners 32.76 [29.86-35.67] <0.001 0.65 [-7.16-8.46] 0.87 
Unspecified profession  31.81 [30.57-33.06] <0.001 -1.67 [-6.63-3.29] 0.51 
Constant B= 70.46, Std error=6.01, P <0.001. R square =0.068, adjusted R square= 0.051, Std error of the 
estimate=33.6. a Compared against planned admission, b Compared to H1, c Compared to general medicine 
wards, d Compared to foundation year doctors 
# Bold type face indicates statistically significant model predictors (i.e. p<0.05). B: the estimate of change in 
the outcome with one unit change of the predictor 
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Table 3.20 Factors contributing to discharge summary adherence to therapy change 
information  
In Table 3.20, the unadjusted analysis identified some type of hospitals, ward specialities 
and professions as contributors to the quality of discharge information; however this effect 
was not significant when the model was adjusted to number of medicines and type of 
discharge summary and admission.   
 
 


3.8 Predictors of adherence to the NPC minimum requirements 
The regression models presented earlier, Table 3.17-3.20, have outlined an association 
between discharge summary adherence to the NPC minimum dataset and factors such as 
number of medicines, type of discharge summary, hospital and ward speciality plus 
profession type.   
Such influences should be examined while accounting for potential covariates and 
confounding effects between factors.  Therefore, further insights to identify the predictors 
of non-adherence plus the characteristics associated with increased adherence to the NPC 
minimum dataset was investigated using ANCOVA-GLM analysis.  The audit data was 
modified prior to implementing ANCOVA-GLM.  These modifications are described in BOX 
3.1 summarises.  
 
 
 
 
 
  
BOX 3.1 Modifications to the audit dataset prior ANCOVA-GLM analysis 
 Association between hospitals and the quality of discharge template (section 4.1.4) 
believed to represent a potential confounding effect.  Both factors are highly 
correlated and as such one factor should be retained in the model.  Discharge 
summary template was included in the ANCOVA-GLM analysis  
 
 In order to employ the ANCOVA-GLM analysis, it was believed that the wide 95% CIs 
associated with subgroups with very small number of data points would not allow 
comparative conclusions to be drawn and therefore subgroups were combined: 
o Subgroups of hospitals with less than 50 data points was merged into 
“others” category 
o Subgroups of ward speciality of less than 100 was merged into “others” 
category 
o Doctors of different training levels were combined 


Table 3.21 examines the significant predictors of discharge summary adherence to the 
total NPC minimum dataset.   
Factors related to discharge summary template, number of medicines, ward speciality and 
discharge summary type exhibited significant influences on discharge summary adherence 
to the total NPC minimum dataset, all p <0.05.  It can be seen from Table 3.21 that  
discharge summary template accounted for the largest proportion of variation within the 
adherence to the total NPC minimum dataset, sum of squares df=6=7512.50. 
 
Variables 
Type III Sum 
of Squares Df Mean Square F p 
Corrected Model 84120.76a 198 424.90 3.60 <0.001 
Intercept 31966.70 1 31966.70 272.40 <0.001 
Age 125.30 1 125.30 1.10 0.30 
No. of medicines 3015.70 1 3015.70 25.70 <0.001 
Hospital stay 46.80 1 46.80 0.40 0.53 
Type of discharge summary  519.70 1 519.70 4.40 0.04 
Type of admission  265.20 2 132.60 1.10 0.32 
Discharge summary template 7512.50 6 7512.50 64.0 <0.001 
Ward speciality 2859.10 12 238.30 2.0 0.02 
Profession type  299.40 3 99.80 0.9 0.47 
Error 339973.70 2897 117.40   
Total 1600000.0 3096    
Corrected Total 424094.4 3095    
df: degree of freedom 
Table 3.21 Predictors of discharge summary adherence to the total NPC minimum dataset 
Stepwise backward elimination resulted in the model presented in Table 3.22.  The effect 
of discharge summary template on discharge summary adherence to the total NPC 
minimum dataset adjusted for number of medicines and discharge summary type identified 
template of community hospitals and H2 as significant predictors of lower adherence rates; 
whereas, H3 template attributed to better adherence.   
  


 
Variables B 
Std. 
Error t p 
95% CI  
Lower 
limit 
Upper  
Limit 
Constant 78.60 0.75 104.77 <0.001 77.13 80.07 
No. of medicines -0.24 0.04 -5.53 <0.001 -0.33 -0.16 
Type of discharge 
summary 
      
Handwritten  -3.51 0.63 -5.58 <0.001 -4.749 -2.28 
Electronic 0      
Discharge summary template  
     
Template of H1 0      
Template of H2 -5.83 0.68 -8.59 <0.001 -7.17 -4.50 
Template of H3 8.14 0.70 8.40 <0.001 6.24 10.05 
Template of H4 1.66 1.50 1.11 0.27 -1.28 4.59 
Template of H5 -0.13 1.53 -0.09 0.93 -3.13 2.87 
Template of community 
hospitals 
-9.47 1.56 -6.09 <0.001 -12.53 -6.42 
Template of other 
hospitals 
-6.61 1.45 -4.60 <0.001 -9.43 -3.80 
*Final step of stepwise backward elimination  
R2 = 0.14, adjusted R2= 0.137 
Table 3.22 Effect of discharge summary templates on adherence to the total NPC minimum 
dataset adjusting for number of medicines and discharge summary type* 
Significant predictors of discharge summary adherence across the three categories of the 
NPC minimum dataset are identified in Tables 3.23-3.28.   
3.8.1 Predictors of adherence to patient, admission and discharge information 
Table 3.23 examines predictors of discharge summary adherence to patient, admission 
and discharge information. 
Similarly, discharge summary template accounted for the largest amount of variation in 
patient, admission and discharge information, sum of squares df=6 =7832.90.  Stepwise 
backward elimination resulted in the table presented in Table 3.24.  The effect of discharge 
summary template on discharge summary adherence to patient, admission and discharge 
information adjusting for the influence of discharge summary type and number of 
medicines outlined template of community hospitals as the strongest predictor of poor 
adherence.   

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Variables 
Type III Sum 
of Squares df Mean Square F p 
Corrected Model 69674.39 93 749.19 7.12 <.001 
Intercept 401996.10 1 401996.10 3821.15 <0.001 
No. of medicines 547.81 1 547.81 5.21 0.02 
Age 1.80 1 1.80 0.02 0.90 
Hospital stay 35.30 1 35.30 0.34 0.56 
Type of discharge summary 497.27 1 497.27 4.73 0.03 
Type of admission 40.56 2 20.28 0.19 0.83 
Discharge summary template 7832.90 6 1305.48 12.41 <0.001 
Profession type  146.050 3 48.68 0.46 0.71 
Error 315819.45 3002 105.20   
Total 18890000 3096    
Corrected Total 385493.83 3095    
df: degree of freedom 
Table 3.23 Predictors of discharge summary adherence to patient, admission and discharge 
information 
 
Variables B 
Std. 
Error t p 
95% CI 
Lower  
limit  
Upper  
limit 
Intercept 79.05 0.32 249.04 <0.001 78.43 79.67 
No. of medicines 0.11 0.04 2.71 0.01 0.03 0.20 
Type of discharge summary  
      
Handwritten  -4.77 .86 -5.55 <0.001 -6.46 -3.09 
Electronic 0 . . . . . 
Discharge summary template 
      
Template of H1 0      
Template of H2 -8.54 1.02 -8.39 <0.001 -10.54 -6.54 
Template of H3 6.33 0.96 6.63 <0.001 4.46 8.21 
Template of H4 3.92 1.95 2.01 0.04 0.10 7.74 
Template of H5 -0.58 2.10 -0.28 0.78 -4.70 3.53 
Template of community 
hospitals 
-9.49 1.92 -4.95 <0.001 -13.24 -5.73 
Template of other hospitals -4.293 1.683 -2.550 .011 -7.594 -0.99 
*Final step of stepwise backward elimination  
R2=0.18, adjusted R2=0.16 
Table 3.24 Effect of discharge summary template on adherence rate to patient, admission 
and discharge information adjusting for number of medicine and discharge summary type* 
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
3.8.2 Predictors of adherence to medication information 
Table 3.25 examines predictors of discharge summary adherence to medication 
information.  Likewise, discharge summary templates accounted for the largest amount of 
variation in medication information,sum of squaresdf=6 =10412.39.   
Variables 
Type III Sum 
of Squares df Mean Square F p 
Corrected Model 193120.94 92 2099.14 4.33 <0.001 
Intercept 282267.09 1 282267.09 582.17 <0.001 
No. of medicines 351.87 1 351.86 0.73 0.39 
Age 3195.47 1 3195.47 6.59 0.01 
Hospital stay 208.91 1 208.91 0.43 0.51 
Type of discharge summary 3143.89 1 3143.89 6.48 0.01 
Type of admission 3800.18 2 1900.09 3.92 0.02 
Discharge summary template 10412.39 6 1735.40 3.58 0.002 
Profession type  997.0 3 332.33 0.69 0.56 
Error 1404044.28 2957 474.82   
Total 13870000  2997 
Corrected Total 1589687.27 2996 
df: degree of freedom 
Table 3.25 Predictors of discharge summary adherence to medication information 
 
The effect of the discharge summary template adjusting for age, discharge summary type 
and admission type (Table 3.26) identified handwritten discharge summary the strongest 
predictor of poor adherence. H3 template is the only significant predictor of good 
adherence to medication information. 
It can also be seen that when the effects of the template and the type of discharge 
summary were adjusted in the model, no significant influence was exhibited by admission 
type. 
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Variables B 
Std. 
Error t p 
95% CI 
Lower 
limit 
Upper  
limit 
Intercept 70.13 1.43 49.11 <0.001 67.33 72.93 
Age -0.04 0.02 -2.14 0.03 -0.069 -0.003 
Type of discharge 
summary  
      
Handwritten  -13.47 3.62 -3.72 <0.001 -20.58 -6.37 
Electronic 0      
Type of admission 
      
Unspecified type of 
admission  
2.74 2.75 0.99 0.32 -2.65 8.12 
Unplanned admission  -2.03 1.17 -1.77 0.08 -4.28 0.28 
Unplanned 0 . . . . . 
Discharge summary 
template 
      
Template of H1 0      
Template of H2 -2.49 3.97 -0.63 0.53 -10.278 5.31 
Template of H3 16.04 4.56 3.52 <0.001 7.11 24.98 
Template of H4 6.78 7.33 0.93 0.36 -7.60 21.15 
Template of H5 -16.75 8.95 -1.87 0.06 -34.30 .807 
Template of community 
hospitals 
-21.33 10.94 -1.95 0.05 -42.79 .130 
Template of other hospitals -1.36 6.64 -0.21 0.84 -14.38 11.67 
*Final step of stepwise backward elimination  
R2=0.13, adjusted R2=0.11  
Table 3.26 Effect of discharge summary template on adherence rate to medication 
information adjusting for age, discharge summary and admission type* 
3.8.3 Predictors of adherence to therapy change information 
Table 3.27 examines the significant predictors of discharge summary adherence to therapy 
change information.  Discharge summary template was the main predictor of discharge 
summary adherence to therapy change information.  The impact of the discharge summary 
template on therapy change information is summarised in Table 3.28.  All templates were 
significant predictors of poor adherence to therapy change information with the exception 
to the template of H3. 
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Variables 
Type III Sum 
of Squares df Mean Square F p 
Corrected Model 171155.39 87 1967.30 1.70 <0.001 
Intercept 96924.28 1 96924.28 83.62 <0.001 
No. of medicines 1803.79 1 1803.79 1.56 0.21 
Age 2920.09 1 2920.09 2.52 0.11 
Hospital stay 2846.69 1 2846.69 2.47 0.12 
Type of discharge summary 853.98 1 853.98 0.74 0.39 
Type of admission 2614.88 2 1307.44 1.13 0.32 
Discharge summary 
template 
15194.84 6 2532.47 2.19 0.04 
Profession type  842.51 3 280.84 0.24 0.87 
Error 2326218.65 2007 1159.05   
Total 7451319.44 2095    
Corrected Total 2497374.04 2094    
df: degree of freedom 
Table 3.27 Predictors of discharge summary adherence to therapy change 
information 
 
Variables B 
Std. 
Error t p 
95% CI 
Lower 
limit 
Upper  
limit 
Intercept 50.55 0.80 63.544 <0.001 48.99 52.11 
Discharge summary 
template 
 
     
Template of H1 0      
Template of H2 -8.71 2.0 -4.353 <0.001 -12.63 -4.79 
Template of H3 14.90 3.50 4.265 <0.001 8.05 21.75 
Template of H4 -3.62 5.47 -0.662 0.51 -14.34 7.10 
Template of H5 -24.16 5.21 -4.642 <0.001 -34.37 -13.96 
Template of community 
hospitals 
-22.86 6.04 -3.785 <0.001 -34.71 -11.02 
Template of other 
hospitals 
-13.68 5.33 -2.565 0.01 -24.13 -3.22 
*Final step of stepwise backward elimination  
R2=0.11, adjusted R2=0.09 
 
Table 3.28 Impact of discharge summary template on therapy change information* 
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3.9 Effect of ward specialty on discharge summary adherence to the total NPC 
minimum dataset  
Wards speciality exhibited potential significant effect (Table 3.21) on discharge summary 
adherence to the total NPC minimum dataset.   
Community and specialist care hospitals are lacking the breadth of specialities which are 
demonstrated by general hospitals and thus it was believed that the influence of ward 
speciality should be investigated across the main general hospitals in the audit.  Therefore, 
a total of 3,383 discharge summaries presenting the five general hospitals in the audit 
were analysed to establish the influence of ward speciality on discharge summary 
adherence to the NPC minimum dataset.  
Table 3.29 examines the influence of ward specialty on discharge summary adherence to 
the total NPC minimum dataset.   
The effect of ward speciality adjusting for discharge summary type and number of 
medicines (Table 3.30) identified orthopaedic ward as a strong predictor of poor adherence 
the adherence to the total NPC minimum dataset. 
Table 3.31 and 3.32 demonstrate the influence of ward speciality on discharge summary 
adherence to patient, admission and discharge information.  Adjusting for the number of 
medicines and type of discharge summary identified orthopaedic wards again as a strong 
predictor of poor adherence. 
Table 3.33 and 3.34 demonstrate the influence of ward speciality on discharge summary 
adherence to medication information.  Adjusting for age and discharge summary type 
higlighted general surgery and gastroentrology wards as significant predictors of poor 
adherence. 
Table 3.35 and 3.36 demonstrate the influence of ward speciality on discharge summary 
adherence to therapy change information.  The effect of ward speciality adjusting for 
hospital stay identified orthopaedic ward to be a strong predictor of poor adherence to 
therapy change information. 
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Variables 
Type III Sum 
of Squares df 
Mean 
Square F p 
Corrected Model 74005.01 195 379.53 3.19 <0.001 
Intercept 395430.14 1 395430.14 3318.70 <0.001 
Age 424.82 1 424.82 3.57 0.06 
No. of medicines 2514.04 1 2514.04 21.10 <0.001 
Hospital stay 94.82 1 94.82 0.80 0.37 
Type of discharge summary 1536.36 1 1536.36 12.89 <0.001 
Type of admission 267.73 2 133.86 1.12 0.34 
Ward speciality  3217.61 12 268.13 2.25 0.01 
Profession type  277.39 3 92.46 0.78 0.51 
Error 338868.38 2844 119.15   
Total 1.609E7 3040    
Corrected Total 412873.39 3039    
df: degree of freedom 
Table 3.29 Influence of ward specialty on discharge summary adherence to the total NPC 
minimum dataset 
 
Variables B 
Std. 
Error t p 
95% CI 
Lower 
limit 
Upper 
limit 
Intercept 77.46 1.11 69.80 <0.001 75.28 79.64 
No. of medicines -0.25 .05 -5.42 <0.001 -.34 -0.16 
Type of Discharge summary  
      
Handwritten discharge summary  -9.51 1.64 -5.79 <0.001 -12.73 -6.29 
Electronic discharge summary  0 . . . . . 
Ward specialities 
      
Discharges from Medicine for elderly wards -0.99 1.19 -0.83 0.41 -3.33 1.34 
Discharged from Orthopaedic wards -5.52 1.42 -3.90 <0.001 -8.30 -2.75 
Discharged from General surgery wards -3.57 1.29 -2.77 0.01 -6.10 -1.04 
Discharged from Urology wards -1.59 1.24 -1.28 0.20 -4.03 0.84 
Discharged from Gastroenterology 
wards 
-4.21 1.57 -2.68 0.01 -7.29 -1.13 
Discharged from Cardiology wards -2.37 1.35 -1.75 0.08 -5.01 0.28 
Discharged from Thoracic wards -1.72 1.33 -1.29 0.20 -4.39 0.89 
Discharged from Paediatric wards -2.38 1.45 -1.65 0.10 -5.22 0.45 
Discharged from Oncology wards -1.51 1.47 -1.03 0.30 -4.39 1.36 
Discharged from Gynaecology wards -3.37 1.48 -2.28 -0.02 -6.27 -0.47 
Discharged from other ward Specialties -2.45 1.23 -1.95 0.05 -4.90 0.01 
Unspecified speciality -6.54 1.56 -4.20 <0.001 -9.59 -3.49 
Discharged from General medicine 0      
*Final step of stepwise backward elimination  
R2 = 0.18, adjusted R2= 0.12 
Table 3.30 Effect of ward speciality on discharge summary adherence to the total NPC 
minimum dataset adjusting for number of medicines and discharge summary type* 
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Variables 
Type III Sum 
of Squares df 
Mean 
Square F p 
Corrected Model 76528.29 195 392.45 3.73 <0.001 
Intercept 422230.15 1 422230.15 4012.44 <0.001 
Age 78.69 1 78.69 0.75 0.39 
No. of medicines 597.29 1 597.29 5.68 0.02 
Hospital stay 107.45 1 107.45 1.02 0.31 
Type of discharge 
summary 
912.24 1 912.24 8.67 0.003 
Type of admission 48.54 2 24.27 0.23 0.79 
Ward speciality  3365.84 12 280.49 2.67 0.001 
Profession types 154.60 3 51.53 0.49 0.69 
Error 299275.28 2844 105.23   
Total 1.859E7 3040    
Corrected Total 375803.57 3039    
df: degree of freedom 
Table 3.31 Influence of ward specialty on discharge summary adherence to patient, 
admission and discharge information 
Variables B 
Std. 
Error t p 
95% CI 
Lower 
limit 
Upper 
limit 
Intercept 79.319 1.05 75.59 <0.001 77.26 81.38 
No. of medicines 0.12 0.04 2.68 0.007 0.03 0.20 
Type of Discharge summary  
      
Handwritten discharge summary  -9.82 1.56 -6.32 <0.001 -12.87 -6.78 
Electronic discharge summary  0 . . . . . 
Ward specialities 
      
Discharges from Medicine for elderly 
wards 
1.32 1.17 1.18 0.24 -0.88 3.53 
Discharged from Orthopaedic wards -3.69 1.34 -2.75 0.006 -6.31 -1.06 
Discharged from General surgery wards -0.06 1.21 -0.05 0.96 -2.45 2.34 
Discharged from Urology wards -0.09 1.18 -0.08 0.94 -2.40 2.21 
Discharged from Gastroenterology 
wards 
-1.79 1.49 -1.20 0.23 -4.70 1.13 
Discharged from Cardiology wards -0.43 1.28 -0.34 0.74 -2.94 2.07 
Discharged from Thoracic wards -0.10 1.26 -0.08 0.94 -2.57 2.37 
Discharged from Paediatric wards -0.54 1.37 -0.40 .69 -3.22 2.14 
Discharged from Oncology wards -1.74 1.39 -1.25 .21 -4.45 0.98 
Discharged from Gynaecology wards -0.29 1.40 -0.21 .84 -3.03 2.46 
Discharged from other ward Specialties -0.32 1.19 -0.27 .79 -2.64 2.00 
Unspecified speciality -5.77 1.47 -3.92 <0.001 -8.65 -2.88 
Discharged from General medicine 0      
*Final step of stepwise backward elimination 
R2= 0.20, adjusted R2 = 0.15 
Table 3.32 Effect of ward speciality on discharge summary adherence to patient, admission 
and discharge adjusting for number of medicines and discharge summary type* 
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Variables 
Type III Sum of 
Squares df 
Mean 
Square F p 
Corrected Model 219639.94 189 1162.12 2.40 <0.001 
Intercept 302009.63 1 302009.63 622.36 <0.001 
No. of medicines 54.54 1 54.54 0.11 0.74 
Age 6203.71 1 6203.71 12.78 <0.001 
Hospital stay 409.31 1 409.31 0.84 0.36 
Type of discharge 
summary  
4810.32 1 4810.32 9.91 0.002 
Type of admission  662.55 2 331.27 0.68 0.51 
Ward speciality  14946.87 12 1245.57 2.57 0.002 
Profession type 311.82 3 103.94 0.21 0.89 
Error 1193757.13 2460 485.27   
Total 1.224E7 2650    
Corrected Total 1413397.07 2649    
df: degree of freedom 
Table 3.33 Influence of ward specialty on discharge summary adherence to medication 
information 
Variables B 
Std. 
Error t p 
95% CI 
Lower 
limit 
Upper 
limit 
Intercept 77.81 2.69 28.97 <0.001 72.54 83.08 
Age -0.08 0.02 -3.39 0.001 -0.126 -0.034 
Type of Discharge summary  
      
Handwritten discharge summary  -17.09 3.46 -4.93 <0.001 -23.87 -10.29 
Electronic discharge summary  0      
Ward specialities 
      
Discharges from Medicine for elderly 
wards 
-4.78 2.62 -1.82 0.07 -9.91 .36 
Discharged from Orthopaedic wards 
-1.58 3.08 -0.51 0.61 -7.62 4.47 
Discharged from General surgery 
wards 
-9.80 2.76 -3.56 <0.001 -15.21 -4.40 
Discharged from Urology wards 
-3.70 2.68 -1.38 0.17 -8.95 1.55 
Discharged from Gastroenterology 
wards 
-9.60 3.37 -2.85 0.004 -16.21 -2.99 
Discharged from Cardiology wards 
-5.11 2.94 -1.74 0.08 -10.87 0.65 
Discharged from Thoracic wards 
-4.52 2.85 -1.59 0.11 -10.11 1.07 
Discharged from Paediatric wards 
-6.04 3.40 -1.78 0.08 -12.71 0.62 
Discharged from Oncology wards -4.08 3.17 -1.29 0.20 -10.29 2.13 
Discharged from Gynaecology wards -7.62 3.21 -2.37 0.02 -13.91 -1.33 
Discharged from other ward Specialties -8.51 2.73 -3.12 0.002 -13.86 -3.16 
Unspecified speciality -5.53 3.59 -1.54 0.12 -12.57 1.51 
Discharged from General medicine 0      
*Final step of stepwise backward elimination  
R2= 0.08, adjusted R2= 0.07 
Table 3.34 Effect of ward speciality on discharge summary adherence to medication 
information adjusting for age and type of discharge summary * 
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Variables 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Corrected Model 291643.46 181 1611.29 1.40 0.001 
Intercept 132816.93 1 132816.93 115.59 <0.001 
Age 1.56 1 1.56 0.001 0.97 
No. of medicines 1781.17 1 1781.17 1.55 0.21 
Hospital stay 6277.79 1 6277.77 5.47 0.02 
Type of discharge 
summary  
1269.10 1 1269.10 1.10 0.29 
Type of admission  1376.67 2 688.33 0.60 0.55 
Ward speciality  20075.32 12 1672.94 1.47 0.03 
Profession type 237.58 3 79.19 0.07 0.98 
Error 2155673.11 1876 1149.08   
Total 7360000.00 2058    
Corrected Total 2447316.57 2057    
df: degree of freedom 
Table 3.35 Influence of ward specialty on discharge summary adherence to therapy change 
 
Variable  B 
Std. 
Error t p 
95% CI 
Lower 
limit 
Upper 
limit 
Intercept 58.89 3.83 15.40 <0.001 51.39 66.39 
Hospital stay -0.18 0.07 -2.62 0.009 -0.31 -0.05 
Ward specialities 
      
Discharges from Medicine for elderly wards -3.74 4.22 -0.89 0.38 -12.00 4.53 
Discharged from Orthopaedic wards -24.08 5.07 -4.72 <0.001 -34.07 -14.08 
Discharged from General surgery wards -14.57 4.43 -3.29 0.001 -23.25 -5.89 
Discharged from Urology wards -5.27 4.40 -1.12 0.23 -13.90 3.36 
Discharged from Gastroenterology wards -10.98 5.42 -2.03 0.04 -21.61 -0.39 
Discharged from Cardiology wards -7.82 4.66 -1.68 0.10 -16.96 1.33 
Discharged from unspecified ward Speciality -6.34 5.01 -1.27 .21 -16.15 3.48 
Discharged from Thoracic wards -6.60 4.63 -1.42 0.16 -15.69 2.49 
Discharged from Paediatric wards -12.20 4.91 -2.49 0.01 -21.82 -2.57 
Discharged from Oncology wards 0.80 5.18 0.16 0.88 -9.36 10.96 
Discharged from Gynaecology wards -8.02 5.37 -1.50 0.14 -18.55 2.51 
Discharged from other ward Specialties -16.0 4.43 -3.61 <0.001 -24.69 -7.31 
Discharged from General medicine 0      
*Final step of stepwise backward elimination 
R 2= 0.12 , adjusted R2= 0.03 
 
 
Table 3.36 Effect of ward speciality on discharge summary adherence to therapy change 
information adjusting for length of hospital stay*  
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3.10 Discharge discrepancies  
3.10.1 Medication discrepancies  
GP held records relating to patient medicines were reviewed for 671 discharge summaries 
to identify medication discrepancies.  Hospitals listed 3,803 medications and when 
reviewing the GP held records it appeared that these patients were prescribed a total of 
4,594 medications.  Thus, hospitals had omitted 791 medications.   
A total of 1,843 medication discrepancies were identified; 559 (83.3%) of discharge 
summaries 95%CI (80.48-86.12) had at least one medication discrepancy.  The median 
(IQ) number of medication discrepancies was 2 (1, 4) per discharge summary.  Table 3.37 
presents the distribution of medication discrepancies between admission and discharge 
summary type, hospitals and wards.   
It can be seen that planned admissions demonstrated a higher rate of medication 
discrepancies with addition discrepancies predominating.  Higher frequencies of omission 
discrepancies, however, can be seen with unplanned admissions.   
Electronic discharge summaries were associated with a higher proportion of discharge 
summaries bearing at least one medication discrepancy with omission discrepancies 
predominating.  Mental hospital trust demonstrated the highest rates of omission and 
addition discrepancies.  
Ear, nose & throat and orthopaedic wards demonstrated the highest rate of medication 
discrepancy with addition discrepancies predominating.   
Consultant discharge summaries demonstrated the highest rate of medication 
discrepancies which were predominantly addition discrepancies. 
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Type of discrepancy 
 N At least one 
medication 
discrepancy  
At least one 
omission: regular 
medications were 
omitted  
At least one 
addition: unstated 
new medications 
were added upon 
discharge 
At least one 
unstated changes 
(dose, frequency 
or formulation) 
At least one 
unstated 
reasons of 
therapy 
discontinuation 
At least one 
unstated 
medication 
substitutions 
Admission type 
Planned  180 158 (87.8%) 67 (37.2%) 109 (60.6%) 16 (8.9%) 3 (1.7%) 7 (3.9%) 
Unplanned  491 401 (81.7%) 202 (41.1%) 201(40.9%) 48 (9.8%) 22 (4.5%) 20 (4.1%) 
Discharge summary 
type 
Electronic  545 464 (85.0%) 232 (42.6%) 317 (58.2%) 58 (10.6%) 23 (4.2%) 22 (4.0%) 
Handwritten  126 95 (76.0%) 37 (29.4%) 84 (66.7%) 6 (4.8%) 2 (1.6%) 5 (4.0%) 
Hospitals  
H1 525 422 (84.2%) 226 (43.1%) 299 (57.1%) 56 (10.7%) 22 (4.2%) 21 (4.0%) 
H2 66 51.0 (77.3%) 12 (18.2%) 48 (72.7%) 1 (1.5%) - 3 (4.5%) 
H4 9 9 (100%) 3 (33.3%) 6 (66.7%) 1 (11.1%) - 1 (11.1%) 
H5  48 36 (75.0%) 20 (40.8%) 33 (67.3%) 4 (8.2%) -3 (6.1) 1 (2.0%) 
Community hospitals  13 6 (48.0%) 2 (15.4%) 7 (53.85) - - 1 (7.7%) 
Mental hospital trust  10 10 (100%) 6 (60.0%) 8 (80.0%) 2 (20.0%) - - 
Wards  
General surgery 121 91 (81.3%) 40 (33.1%) 72 (59.5%) 13 (10.8%) 7 (6.3%) 5 (4.5%) 
Medicine for Elderly 125 103 (77.4%) 60 (48.0%) 81 (64.8%) 13 (10.4%) 5 (4.0%) 4 (3.2%) 
Thoracic 57 50 (84.7%) 18 (31.6%) 32 (56.1%) 7 (12.3%) 2 (3.7%) 4 (7.0%) 
Paediatrics 54 36 (83.7%) 22 (40.7%) 33 (61.1%) 4 (7.4%) - - 
Orthopaedic 36 38 (97.4%) 16 (44.4%) 23 (63.9%) - 2 (5.6%) - 
Urology 41 34 (85.0%) 19 (46.3%) 21 (51.2%) 5 (12.2%) 2 (4.9%) 1 (2.4%) 
Cardiology 27 26 (81.3%) 12 (44.4%) 18 (66.7%0 3 (11.1%)) - 1 (3.7%) 
Gastroenterology 27 24 (88.9%) 7 (25.9%) 18 (66.7%) 3 (11.1% - 2 (7.4%) 
General medicine 24 18 (75.0%) 8 (33.3%) 9 (30.5%) 1 (4.2%) 2 (8.3%) 3 (12.5%) 
Gynaecology 24 17 (81.0%) 6 (25.0%) 13 (54.2%) 1 (4.2%) - - 
Endocrinology 21 16 (72.7%) 8 (38.1%) 14 (66.7%) 2 (9.5%) 1 (4.8%) - 
Oncology 19 19 (95.0%) 9 (47.4%) 7 (36.8%) 1 (5.3%) - - 
Nephrology 18 17 (94.4%) 10 (55.6%) 11 (61.1%) 4 (22.2%) 1 (5.6%) 2 (11.1%) 
Neurology 16 15 (93.8%) 9 (56.3%) 8 (50.0%) 1 (6.3%) - 1 (6.3%) 
Ear, nose & throat 14 13 (100%) 7 (50.0%) 9 (64.3%) 4 (28.6%) - - 
Others* 47 33 (80.5%) 18 (40.1%) 32 (68.1%) 2 (4.3%) 2 (4.2%) 4 (8.5%) 
*E.g. Dermatology, Rheumatology, Ophthalmology, Maternity care and Neonatal  
Table 3.37 Distribution of medication discrepancies between admission type, discharge summary type, hospitals, wards and profession types  
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Type of discrepancy 
 
N At least one 
medication 
discrepancy 
At least one 
omission: regular 
medications were 
omitted 
At least one 
addition: unstated 
new medications 
were added upon 
discharge 
At least one 
unstated changes 
(dose, frequency 
or formulation) 
At least one 
unstated 
reasons of 
therapy 
discontinuation 
At least one 
unstated 
medication 
substitutions 
Profession type         
Doctors+ 151 124 (82.7%) 58 (38.4%) 94 (62.3%) 11 (7.3%) 4 (2.6%) 5 (3.3%) 
Foundation years 301 252 (60.6%) 130 (43.2%) 175 (58.1%) 34 (11.3%) - 13 (4.3%) 
Senior house officers 45 33 (73.3%) 13 (28.9%) 26 (57.8%) 1 (2.2%) 2 (4.4%) 2 (4.4%) 
Registrars  3 2 (66.7%) 2 (66.7%) - - - 1 (33.3%) 
Consultants  29 25 (86.2%) 9 (31.0%) 22 (75.9%) 7 (24.1%) - - 
Pharmacists 10 6 (60.0%) 6 (60.0%) 6 (60.0%) 2 (20.0%) - 1 (10.0%) 
Specialist nurse 
practitioners 
21 11 (52.4%) 11 (52.4%) 11 (52.4%) 3 (14.3%) - - 
Unspecified  111 87 (78.4%) 41 (36.9%) 68 (61.3%) 8 (7.2%) 7 (6.3%) 6 (5.4%) 
+Unspecified training level 
Continued  
Table 3.37 Distribution of medication discrepancies between admission type, discharge summary type, hospitals, wards and profession types 
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Figure 3.3 presents frequencies of prescribed medicines and medicines implicated to 
discrepancies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CNS: central nervous system. GI:Gastroenterology. Classification based on British National Formulary 59 
Figure 3.3 Comparison of prescribed medicines and medicines implicated to 
discrepancies  
It can be seen that, central nervous system medicines were most frequently associated 
with medication discrepancies followed by cardiovascular, gastrointestinal and respiratory 
medications.  However, it can be seen that these also are the most frequently prescribed 
medication classes.  Table 3.38 summarises the nature of medication discrepancies and 
the classes of medicines contributing to discrepancies.   
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Type of discrepancy 
Medication subclass*  Regular 
medicine 
omitted 
n=791 
Unstated 
new 
medicine 
Added 
n=902 
Unstated 
changes (dose, 
frequency or 
formulation) 
n=82 
Unstated reasons 
of therapy 
discontinuation 
n=38 
Unstated medication 
substitutions 
n=30 
Analgesics and Nonsteroidal anti-inflammatory 
drugs 
85 (10.7%) 297(32.9%) 7 (8.5%) 1 (2.6%) 1 (3.3%) 
Bronchodilators 58 (7.2%) 24 (2.7%) 3 (3.7%) - 2 (6.7%) 
Antianginal (nitrate, CCB) preparation  53 (6.7%) 16 (1.8%) 3 (3.7%) 3 (7.9%) 1 (3.3%) 
PPIs and H2-receptor antagonists 44 (5.6%) 46 (5.1%) 4 (4.9%) - 5 (16.7%) 
Laxative 41 (5.2%) 82 (9.1%) 3 (3.7%) 1 (2.6%) 3 (10.0%) 
Lipid-regulating medications 36 (4.5%) 14 (1.6%)  2 (2.4%) - 1 (3.3%) 
Anaemias, vitamins, minerals and bone 
metabolism 
45 (5.7%) 41 (4.6%) 3 (3.7%) 2 (5.3%) 4 (13.3%) 
Hypnotics, anxiolytics, psychosis and Parkinson  48 (6.1%) 26 (2.9%)  3 (3.7%) 1 (2.6%) 1 (3.3%) 
Hypertension and heart failure (BB, ACEI,ARB, 
diuretics) 
54 (6.8%) 29 (3.2%) 14 (17.1%) 18 (47.4%) 5 (16.7%) 
Antiplatelet 31 (3.9%) 46 (5.2%) - 1 (2.6%) - 
Antidepressant 30 (3.8%) 9 (1.0%) 2 (2.4%) 1 (2.6%) - 
Corticosteroids inhaled 29 (3.7%) 12 (1.3%) 3 (3.7%) - 3 (10.0%) 
Corticosteroids oral 7 (0.88%) 41 (4.5%) 6 (7.3%) 2 5.3%) - 
Skin preparation 27 (3.4%)  12 (1.3%) - 1 (2.6%) - 
Anti-diabetic medication  26 (3.3%) 12 (13.3%) 6 (7.3%) 1 (2.6%) - 
Ophthalmic preparation 17 (2.1%) 5 (0.6%)  - - 
Antiepileptic preparation  14 (1.9%) 14 (1.6%) 11 (13.4%) 1 (2.6%) - 
Nausea & vertigo 10 (1.3%) 14 (1.6%) - 1 (2.6%) 2(6.7%) 
Antimicrobial (antibacterial, antifungal, etc.) 16 (2.0%) 118 (13.1%) 1 (1.2%) - 1 (3.3%) 
Anticoagulant  8 (1.0%) 30 (3.3%) 4 (4.9%) 1 (2.6%) - 
Hormones and contraception  16 (2.0%) 2 (0.2%) - - - 
Antihistamines 15 (1.9%) 5 (0.6%) - 1 (2.6%) - 
Others † 81 (10.2%) 8 (0.9%) 7 (8.5%) 2 (5.3%) 1 (3.3%) 
* Classification based on British National Formulary 59. CCB: Calcium channel blockers. PPIs: Proton pump inhibitors. BB: Beta blockers. ACEI:angiotensin-converting-
enzyme inhibitor. ARB: Angiotensin receptor blockers. † Others: nasal preparation, antispasmodic, obstetrics and urinary tract disorders.  
Table 3.38 Medication classes implicated to medication discrepancies 
		
It can be seen that analgesics were associated with a high proportion of both omissions 
and additions.  Paracetamol accounted for 199 (10.8%) of medication discrepancies 
followed by opioid analgesics which were involved in 111 (6.0%) of which codeine 
phosphate accounted for almost 50% of these discrepancies.  Cardiovascular 
discrepancies were largely attributable to aspirin which accounted for 155 (38.5%) of 
cardiovascular discrepancies; these often were due to aspirin being prescribed at 
antiplatelet dosing without any specification on therapy indications or follow up plans.   
The extents to which discharge summaries recorded the duration and the titration plans of 
the medicines associated with increased risk of harm are illustrated in Figure 3.4. 
 
Figure 3.4 Duration and titration plan for antibiotics, clopidogrel, corticosteroids, 
anticoagulant, analgesic and proton pump inhibitors 
Satisfactory communication of antibiotics durations can be seen, however performance 
with the other medicines is poorer.  Additionally, titration plans were often not recorded. 
3.10.2 Factors contributing to medication discrepancies  
The logistic regression model which is summarized in Table 3.39 highlighted that patients 
who were prescribed more medicines had higher odds of having a medication discrepancy; 
with every increase in a prescribed medicine, the potential for a medication discrepancy 
increased by 15%, odds ratio [95%CI] =1.15 [1.10-1.24].  Figure 3.5 illustrates medication 
discrepancy rate with number of medicines.  
As the number of medications increases from 1 through to 5, the likelihood of patients 
experiencing at least discrepancy also increases.  Beyond 5 medicines, there is still a 
gradual but less pronounced increase in medication discrepancy risk.  
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Figure 3.5 Distribution of medication discrepancies and number of prescribed 
medicines 
Additionally, patients who were discharged from orthopaedic wards were almost 11 times 
at higher risk of having a discharge summary with a medication discrepancy, odds ratio 
[95%CI] =10.93 [1.11-107.71].   
Of note, the unadjusted analysis identified handwritten discharge summary as a predictor 
of increased risk to medication discrepancy, however this effect was not significant when 
the model was adjusted to number of medicines.  Similarly, this can be seen for the effect 
of unplanned admission discharge summary.  This highlights the confounding effect 
between variables and the potential benefit of adjusting the model to enable better 
understanding of the true effects of variables on the quality of discharge information. 
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  Univariate analysis Multivariate analysis 
Variable N OR [95%CI] p OR [95%CI] p 
Patient demographics 671       
Age  1.0 [0.98-1.01] 0.49 1.0 0.98-1.01 0.58 
No. of medications  1.10 [1.04-1.17] 0.001 1.15 1.10-1.24 <0.001 
Hospital stay  1.0 [0.98-1.01] 0.81 1.0 0.98-1.03 0.69 
Type of discharge 
summary 
       
Handwritten discharge 
summaries 
129 1.79 [1.11-2.87] 0.02 0.38 0.10-1.46 0.16 
Type of admission a 
Unplanned admission  491 1.61 [0.98-2.66] 0.06 0.80 0.43-1.48 0.48 
Hospitals b 
       
H2 66 0.97 [0.21-4.45] 0.96 1.43 0.32-6.38 0.64 
H4 9 0.62 [0.12-3.1] 0.56 3.27E8 0.00 0.99 
H5 48 2.9E8 0.00 0.99 1.41 0.34-5.86 0.64 
Community hospitals 13 2.9E8 0.00 0.99 2.97 0.23-37.73 0.40 
Mental health or private trust 10 0.55 [0.11-2.82] 0.47 3.93E8 0.00 0.99 
Ward specialities c 
       
Medicine for elderly  133 0.83 [0.35-1.99] 0.68 0.80 0.23-2.77 0.73 
Orthopaedic  38 9.21 [1.09-77.56] 0.04 10.93 1.11-107.71 0.04 
General surgery  122 0.73 [0.22-2.43] 0.61 1.47 0.45-4.88 0.53 
Urology  40 1.05 [0.43-2.58] 0.91 1.55 0.36-6.62 0.56 
Gastroenterology  27 1.37 [0.43-4.39] 0.59 2.62 0.51-13.60 0.25 
Cardiology  31 1.94 [0.47-8.08] 0.36 1.01 0.25-4.17 0.98 
Thoracic  59 1.05 [0.32-3.41] 0.94 1.14 0.30-4.38 0.85 
Paediatric   43 1.35 [0.47-3.85] 0.57 2.15 0.47-9.94 0.33 
Oncology  20 1.25 [0.41-3.82] 0.69 4.17 0.41-42.09 0.23 
Nephrology  18 4.61 [0.53-39.71] 0.17 4.28 0.42-43.75 0.22 
Ear, nose & throat 12 4.12 [0.48-35.70] 0.20 0.00 - 0.99 
Endocrinology  22 3.9E8 0.00 0.99 0.52 0.12-2.33 0.40 
Gynaecology  21 0.65 [0.19-2.18] 0.48 1.38 0.29-6.55 0.69 
Neurology  16 1.03 [0.27-3.92] 0.96 2.92 0.28-30.06 0.37 
Other specialities  41 3.64 [0.42-31.74] 0.24 1.15 0.31-4.29 0.84 
Profession type d 
      0.83 
Core medical training  73 2.10 [0.18-23.99] 0.54 1.91 0.81-4.50 0.14 
Senior house officers 45 2.27 [0.19-26.33] 0.51 0.96 0.36-2.55 0.94 
Consultants  28 3.56 [0.29-43.31] 0.32 1.33 0.40-4.43 0.64 
Registrar  3 2.31 [0.19-28.72] 0.51 0.16 0.004-5.68 0.31 
Doctors of unknown training  226 3.13 [0.23-43.02] 0.39 1.21 0.65-2.25 0.54 
Pharmacists 10 2.13 [0.15-29.66] 0.57 0.75 0.14-4.1 0.74 
Specialist Nurse 
Practitioners 
21 2.76 [0.24-31.23] 0.41 0.94 0.27-3.31 0.93 
Unspecified profession  111 2.0 [0.11-34.82] 0.63 0.95 0.45-199 0.89 
OR: odds ratio. a Compared against planned admission, b Compared to H1, c Compared to general medicine 
wards, d Compared to foundation year doctors  # Bold type face indicates statistically significant model 
predictors (i.e. p<0.05) 
 
Table 3.39 Summary of logistic regression model of factors predicting medication 
discrepancies   
	

The model summarised in Table 3.39 demonstrated good fit to predict medication 
discrepancies (p=0.73, Hosmer & Lemeshow test) and it accounts for 15% (Nagelkerke R 
square= 0.15) of the variances in the predicted potentials for medication discrepancies.  
The model assumptions are checked and presented in Appendix 5. 
3.10.3 Reconciliation discrepancies  
The discharge team provided 241 explicit recommendations for therapy monitoring, 
initiation, changes such as dose, frequency or formulation changes and discontinuation of 
which there was documented evidence that it had been followed in primary care for 194 
(80.5%) occasions.  Reconciliation discrepancies occurred with 175 patients (26.1%) and 
were carried on after patients being discharged up to eight weeks.  Table 3.40 presents 
examples of reconciliation discrepancies. 
With respect to therapy monitoring, there were 23 (9.5%) recommendations, of which 9 
(39.1%) were not followed.  There were 190 (78.8%) therapy initiations recommended of 
which 110 (57.9%) involved prescription only medicines.  There was no evidence of these 
medicines being initiated in 19 (17.3%) cases.  The initiations of over the counter medicine 
medicines were not followed for 11 (13%).   
Changes to dose, frequency or formulation were not followed for two (out of 6) 
recommendations for over the counter medicines and three (out of 11) for prescription only 
medicines.  On two occasions, recommendations to discontinue over the counter 
medicines were made and on neither occasion this was implemented.  Requests to 
discontinue prescription only medicines therapy were implemented on three out of nine 
occasions.   
Following discussion with GPs and primary care pharmacists based on practices, it appeared 
that recommendations predominantly were not implemented due to informed decision.  
This was for 26 (53.1%) cases.  Meanwhile, for 18 (36.7%) cases, this was because the 
recommendations were not brought to the GP attention due to being handled by other 
member of the healthcare team such as the nurse or the pharmacist or due to system or 
person errors.  For 4 (8.2%) recommendations the GP followed the patient preference and 
for one (2.0%) recommendation the GP recalled a conversation with the hospital staff 
agreeing to take an alternate action.   
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3.10.4 Clinical significance of discharge discrepancies 
The mean [95% CI] score 4.3 [3.47-5.13] indicating risk of moderate patient harm.   
Thirteen (65%) of the discrepancies were considered of moderate harm (i.e. average score 
3-7).  Six discrepancies (30.0%) were scored < 3 and thus considered of minor risk whilst 
only one discrepancy was considered of severe harm (i.e. average score > 7).  Table 3.40 
presents examples of discharge discrepancies with their estimated severity.  
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Discharge summary 
discrepancy  
TTO 
information 
Discharge summary information Discrepancy description Severity  
Addition of new medication  
(medication discrepancy) 
Simvastatin 40 
mg ON 
(unknown form) 
PC: Right lacunar infarction 
No comments or further 
information provided regarding 
simvastatin 
Simvastatin was not continued by the GP post 
discharge.  The GP no changes to therapy and 
patient is not taking any other lipid lowering agent.  
 
Moderate 
Change of dose 
(reconciliation discrepancy) 
Prednisolone 
(unknown form) 
30 mg BD PO 
PC: Pulmonary fibrosis and lower 
respiratory tract infection 
Prednisolone was requested to be 
tapered.  
Prednisolone dose was not tapered.  Prednisolone 
30 mg BD is prescribed on repeat screen since 
discharge.  Patient is prescribed omeprazole pre-
admission but no bone prophylaxis.  
Severe 
Addition of new medication  
(reconciliation discrepancy) Atenolol (unknown form) 
50 mg OD PO 
Warfarin 
(unknown form) 
as per INR PO 
PC: Atrial fibrillation 
The GP was requested to continue 
atenolol and warfarin 
Warfarin and atenolol was not prescribed by the GP 
post discharge.  The GP made no changes to 
therapy and patient is not taking any other 
anticoagulants or beta blockers. 
Severe 
Therapy monitoring  
(reconciliation discrepancy) 
Ferrous 
sulphate 2 
tablets BID PO 
PC: Atrial fibrillation 
The GP was requested to check 
anaemia. 
The GP did not check anaemia.  Last results for 
anaemia in primary care held record November 
2010. Patient is regularly prescribed ferrous 
sulphate tablets since 2003. 
Minor 
Change of dose discrepancy 
(reconciliation discrepancy) 
Aspirin 
(unknown form) 
150 mg OD PO 
PC: Femoral neck fractures 
following bed fall  
The GP was requested to continue 
aspirin 150 mg. 
The GP did not increase aspirin dose to 150 mg. 
The GP made no changes to therapy and patient is 
remained on pre-admission aspirin 75 mg OD PO. 
Minor 
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Table 3.40 Examples of discharge discrepancies and their estimated risk 
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Discharge summary 
discrepancy 
TTO 
information 
Discharge summary information Discrepancy description Severity  
Therapy discontinuation  
(reconciliation discrepancy) 
Addition of new medication  
(medication discrepancy) 
Bisoprolol 10 
mg OD PO  
Verapamil 80 
mg TD PO 
PC: Paroxysmal Atrial Fibrillation 
(PAF). 
Bisoprolol was requested to be 
stopped due to wheezing.   
No comments or further 
information regarding verapamil 
Bisoprolol was not stopped by the GP. The GP 
made no changes to therapy and patient prescribed 
both bisoprolol and verapamil on repeat screen. 
Moderate 
Unstated medication 
substitution  
(medication discrepancy) 
 
Amlodipine 
(unknown form) 
5mg OD PO  
 
PC: Extrcapsular left fracture neck 
femur  
No rationale for the drug 
substitution provided. 
The GP did not change lercanidipine to amlodipine. 
The GP made no changes to therapy and patient 
remained on pre-admission lercanidipine 10 mg BD 
Minor 
Addition of new medication  
(medication discrepancy) 
 
Codeine 
phosphate 60 
QDS PO 
(unknown form) 
Paracetamol 
(unknown form) 
1g QDS (PRN) 
PO 
PC: Ovarian cancer 
No comments or further 
information regarding codeine 
phosphate or paracetamol.  
The GP did not add codeine phosphate and/or 
paracetamol. The GP made no changes to therapy 
and patient is not taking any other analgesics. 
 
Moderate 
Therapy monitoring  
(reconciliation discrepancy 
None relevant to 
the discrepancy 
 
The GP did not monitor calcium levels though 
patient was discharged since two weeks.  Serum 
calcium was 3.1 mmol at discharge. 
Moderate 
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Continued 
Table 3.40 Examples of discharge discrepancies and their estimated risk
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3.10.5 Estimated time needed by the GP to confirm necessary action 
For 11 discrepancies the estimated time needed by the GP to confirm the action in 
response to the medication discrepancy was estimated.  The median (IQ) estimated time 
was 1.5 (1, 2) indicating that the time taken to confirm the necessary action was typically 
less than 15 minutes.  None of the discrepancies estimated to require > 30 min.  
3.11 Additional discharge information  
In addition to the NPC minimum dataset, discharge summaries recorded additional clinical 
information related to:  
3.11.1 Laboratory results and procedures 
Discharge summaries recorded information regarding procedures and laboratory tests for 
2,396 (69.6%) and 1,471 (42.7%) patients respectively.  These patients accounted for 
3,920 procedures and 2,394 laboratory tests.  Results were reported for 2,165 (62.9%) 
procedures and 2,127 (88.8%) laboratory tests.  Hospital team comments on these 
procedures and tests were provided only for 1,807 (46.1%) and 1,044 (43.6%), 
respectively.  
3.11.2 Adverse drug reactions during hospitalisation and post admission 
complications 
Discharge summaries reported adverse drug reactions for 453 (13.2%) patients, such as 
hypotension, dehydration and cellulitis.  Post discharge complications were reported for 
663 (19.3%) patients, those were mainly infections 410 (61.8%), deep vein thrombosis 
223 (33.6%) and bleeding 30 (4.5%).  
3.11.3 Contact details if needed by primary care 
Contact details for primary care enquiries such as name, role and contact number of 
person responsible for discharge were recorded for 2,712 (78.7%), 2,686 (78.0%) and 
2,201 (63.9%) discharge summaries respectively.  Nevertheless, ward contact number 
was only provided in 453 (13.2%) discharge summaries.  
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3.12 Variations in the audit data 
Ninety five discharge summaries were selected and re-audited.  Kappa scores [95 % CI] 
related to the audit questions are presented in Table 3.41.  Mean [95 % CI] of kappa 
scores was 0.83 [0.81-0.85] and ranged between good to substantial agreement. 
The greatest variations were with therapy changes including medicines changed, initiated 
and discontinued followed by legibility scoring.  Variations were also apparent with the 
number for days to receive discharge summary by primary care and contact details of the 
person responsible for discharge.  User entry errors and uncompleted questions (i.e. 
blank fields) frequently contributed to these variations.  The latter was the predominating 
reason for the variation with therapy change questions.  A prime contributor to the 
variation in legibility scoring was related to auditors’ judgment of whether a discharge 
summary was considered partially illegible and whether the meaning of the clinical 
message was obscured or not.  Variation related to legibility scoring is further described in 
a later section (3.13).  
Variation in the number of working days needed to receive the discharge summary was 
due to differences in auditors’ interpretation (Table 3.41).  Additionally, discharge 
summaries frequently lacked a nominated person to contact regarding patient 
hospitalisation and therefore auditors varied in inputting this information. 
To obtain further insights on the extents and the rationales of variations within the audit 
data and obtain guidance on the analysis, one to one discussions with six auditors were 
arranged. 
Auditors included two of each profession: GP, primary care pharmacist and primary care 
pharmacy technicians.  Discussions with the two pharmacists and one pharmacy 
technician occurred through face to face conversations, whereas discussions with the GPs 
and one pharmacy technician were over phone.  Discussions lasted on average 20 
minutes.  The key comments from the discussions are summarised in Appendix 17.  Table 
3.41 provides examples on the auditors’ quotes.  
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Information  
Kappa 
[95% CI] Rationale of variations 
Age 1 *  
Hospital 1  
Type of 
discharge 
summary 
1  
Admission date 1  
Correct patient 
name  
1  
Correct date of 
birth 
1  
Presenting 
diagnosis 
1  
Past co-
morbidities 
0.97 
[0.59-1] 
Variations in co-morbidities for which patient prescribed 
medicines vs. co-morbidities with no medications prescribed. 
E.g. ovarian cyst, stroke, etc. 
Gender 0.93 
[0.86-1] 
Inputting errors and incompletion of the field  
Ward specialty 0.93 
[0.87-0.98] 
Auditors deciphered ward speciality from ward name. E.g. 
Pentney ward for cardiac care. Quote “I used to work in this 
hospital and when I was able to work out the speciality I 
reported it” PT1 
ADR during 
hospitalization 
0.88 
[0.70-1]** 
Auditors not completing the related field plus variations in 
sections of the discharge summary ADRs were recorded. 
Type of 
admission  
0.86 
[0.78-0.94] 
Auditors deciphered type of admission from the clinical history 
recorded in the discharge summary. Quote “when the type of 
admission was not specified but yet can be known from the 
clinical information I selected unspecified type of admission with 
comment as free text in the adjacent commentary box” PT1 
Allergy status 0.83 
[0.61-1] 
Variations in drug intolerances/adverse effects vs. actual drug 
allergy/hypersensitivities  
Contact 
number to be 
used by the GP 
for enquires  
0.81 
[0.69-0.93]** 
Variations in the contact number of the health care professional 
responsible for discharge or prepared TTOs list vs. the ward 
consultant.  
Medication 
history  
0.81 
[0.69-0.93] 
Variations in medicines prescribed for regular patient use vs. 
acute or as needed or repeat medicines that are never issued.  
Name of 
professional 
responsible for 
discharge 
0.79 
[0.47-1] 
Variations in the health professional believed to be responsible 
for discharge or prepared TTOs list vs. the ward consultant. 
Consultant 
name  
0.79 
[0.52-1] 
Auditors not completing the related field plus variations when 
more than one consultant is named within the discharge 
summary.  
*Pearson correlation. PT: pharmacy technician. TTO: to take home medicines. ADR: adverse drug reaction  
Table 3.41 Variation in the audit data 
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Information  
Kappa 
[95%CI] Rational of variations  
Was discharge 
summary received 
within 2 working 
days? 
0.78 
[0.65-0.91] 
Auditors not completing the related field plus adding 
weekends and public holidays to the estimated time spent to 
receive discharge  
Does the discharge 
summary clearly 
state all medication 
that has been 
started? 
0.78 
[0.60-0.96] 
Auditors not completing the related field plus variations in the 
response when discharge team had not stated all medicines 
started. Quote “If hospital stated ‘no change to regular 
medication’ I picked yes for being stated and left reason 
blank. I would have responded same if no actual changes 
was done and hospital stated nothing”PT2 
Does the discharge 
summary clearly 
state all medication 
that has been 
changed? 
0.77 
[0.48-1] 
Auditors not completing the related field plus variations in the 
response when discharge team had not stated all medicines 
changed. Quote “If hospital stated ‘no change to regular 
medication’ I answered no. I did the same response when no 
actual changes was done and hospital stated nothing”Ph1 
Ward contact 
number 
0.76 
[0.37-1]** 
 
Variations in ward contact number vs. hospital contact 
number.  
If any drug change, 
is (are) the 
reason(s) reported/ 
specified? 
0.76 
[0.45-1] 
Auditors not completing the related field plus variations in the 
response when discharge team had not stated the reason (s) 
for all medicines changed.  
Discharge date 0.74 
[0.39-1] 
Variations in the date in which the discharge summary was 
prepared vs. the date it was sent to the GP 
Role of professional 
responsible for 
discharge 
0.72 
[0.52-0.92] 
Variations in the role of the health professional believed to be 
responsible for discharge or prepared TTO list vs. the ward 
consultant. 
Does the discharge 
summary clearly 
state all medication 
that has been 
stopped? 
0.71 
[0.34-1] 
Auditors not completing the related field plus variations in the 
response when discharge team had not stated all medicines 
stopped. 
Contact name to be 
used by the GP if 
information 
regarding 
hospitalisation 
required 
0.70 
[0.46-0.94] 
Variations in the health professional believed to be responsible 
for discharge or prepared TTOs vs. the ward consultant. 
PT: pharmacy technician. Ph: pharmacist. TTO: to take out medications. :p<0.05 unless specified 
otherwise.** p≥0.05 
Continued 
Table 3.41 Variation in the audit data  
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Information  
Kappa 
[95%CI] Rational of variations  
If any drug stopped, 
is (are) the 
reason(s) 
reported/specified? 
0.69 
[0.32-1] 
Auditors not completing the related field plus variations in the 
response when discharge team had not stated reason(s) for all 
medicines stopped. 
legibility score 0.67 
[0.43-0.91] 
Variation in auditors’ judgment whether illegibility obscured the 
meaning of the clinical report or not  
If any drug started, 
is (are) the 
reason(s) 
reported/specified? 
0.61 
[0.37-0.85] 
Auditors not completing the related field plus variations in the 
response when discharge team had not stated reason(s) for all 
medicines started. 
:p<0.05 unless specified otherwise indicating statistically significant agreement.** p≥0.05 
Continued 
Table 3.41 Variation within the audit data 
 
The re-audit and the one to one discussions enabled better understanding of the audit 
data quality and the extent of variations associated with the audits’ questions.  The re-
audit and one to one discussions informed the decisions presented in BOX 3.2.  Those 
informed the analysis and interpretation of the audit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BOX 3.2 Decisions informed by the quality assurance of the audit data  
 Questions related to therapy changes (i.e. medicines initiated, changed, 
discontinued) 
Uncompleted (blank) fields were analysed in lights of the auditors’ comments 
(Appendix 17).  Any uncertainty was clarified by contacting auditors. 
 Contact name and number for enquires  
Variations with respect the name and the contact details were neglected.  It was 
believed that these variations won’t be pertinent to practice providing the auditor 
considered there was an accessible name and contact details recorded by the 
discharge summary.   
 Number of days to receive discharge summary  
It was not possible to check whether auditors added weekends and public holiday or 
not to the number of days to receive discharge summary. However, discharge 
summary of patient discharged on weekends and public holiday were checked and 
compared to patient discharged form same hospital and ward to investigate 
anonymities.  Any uncertainty was clarified by contacting the auditors. 
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3.13 Legibility rating agreement   
Weighted Kappa scores [95% CI] was 0.86 [0.59-1] (p=0.001) indicating substantial 
significant agreement.  Disagreement was found with 3 (15%) discharge summaries.   
 
3.14 Summary of the main findings  
In summary, findings from this Trust-wide audit highlighted three years after the 
implementation of the UK minimum dataset for discharge information transfer, the 
requirements are not consistently met.  The deviations identified reflect those of previous 
studies: allergy status, co-morbidities, medication history, details of medicines prescribed 
and rational of therapy changes as common omissions.  
Eight out of ten discharge summaries had at least one discrepancy.  Majority of discharge 
discrepancies had the potential to cause moderate patient harm.  Discrepancies were 
primarily omissions of a pre-admission medicine or additions of new medicines without 
indicating that it is newly initiated or providing a reason for the initiation.  Medicines most 
frequently implicated to discrepancies were also the most frequently prescribed. 
This audit identified that in some instances where information was explicitly provided by 
the discharge team, recommendations were not implemented by the primary care team 
resulting in reconciliation discrepancies which continued up to two months post discharge.   
Considerable variations in the extent of hospital adherence to the NPC minimum dataset 
was demonstrated by the study hospitals with H3 demonstrating the greatest adherence.  
Notably, deviations between hospitals followed a similar pattern to the extent of discharge 
summary template adherence to the NPC minimum dataset.  Templates with high 
adherence incorporated fields to collect information that was otherwise frequently omitted, 
e.g. allergy status and therapy change information.  The explicit presence of these fields 
potentially prompted discharge teams to record this information in the discharge summary. 
Electronic discharge summaries demonstrated better adherence to the NPC minimum 
dataset compared to handwritten discharge summaries.  Diagrammatic representation 
indicated that discharge summary of a patient prescribed five medicines or more were 
associated with an increased risk to experience a medication discrepancy.   
Discharge summary from orthopaedic ward was found a predictor of poor adherence to 
the NPC minimum dataset and contributed to an increased risk of discrepancy.  
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3.15 Audit dissemination  
A comprehensive report presenting the audit findings has been prepared and 
disseminated across all primary care practices in NHS Norfolk primary care trust. 
The audit findings were presented in UK and international conferences in form of 
posters and oral presentations: 
 Hammad E A, Wright DJ, Bhattacharya D, Wood J. Communication of clinical 
information on health interface: An audit pilot. Conference abstract. International 
journal of pharmacy practice. 2011; supp 1:page 48 
 
 Hammad E A, Wright DJ, Bhattacharya D, Wood J. Communication of clinical 
information upon hospital discharge: A regional audit. Conference abstract, 
International journal of pharmacy practice. 2012; supp 1:page 21 
 
 Hammad E A, Wright DJ, Walton C, Wood J, Bhattacharya D. Medicine 
reconciliation: An evaluation of hospital discharge discrepancies in one UK primary 
care trust. Conference abstract. International Pharmaceutical Federation (FIP) 
congress, Amsterdam- Netherland 2012. 
A full paper of the audit findings are currently under review by a peer reviewed journal.  
3.16 Re-audit 
To complete an audit cycle, changes to the practice should be implemented if warranted 
and re-audited to evaluate progress.  This should be done with ample and reasonable 
time frame.  A re-audit was not plausible within the time frame of this thesis.  
Recommendations for the purpose of the re-audit, however, are presented in BOX 3.3.   
  


 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BOX 3.3 Recommendations for the re-audit  
For the purposes of the re-audit, the audit tool requires simplification and amendments 
to facilitate the audit completion and minimise auditors’ variations.  These are outlined 
below: 
1. Addition of an option for not applicable entries, e.g. no therapy changes, no 
allergy, no medicines prescribed 
2. Addition of a field for NHS number compiling with the NPC minimum dataset 
requirements 
 Removal of sections related to procedures and laboratory tests, post admission 
complications.  Those were felt laborious and time consuming.  Additionally, 
auditors felt that the relevance of these details vary between patients and within 
different contexts.  Additionally, without the knowledge on the accuracy of these 
procedures and tests, limited conclusions can be drawn on the quality and the 
significance of these details availability to patient post discharge care. 
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Chapter 4 Quality of Discharge Information 
Audit Discussion  
 
 
 
Discussion 
 
Quality of discharge 
information upon hospital 
discharge: an audit in 
primary care 
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4.1 Extent of adherence to the NPC minimum dataset 
Findings from the Trust-wide audit, on the quality of discharge information transferred to 
primary care presented in chapter three, highlighted that three years post implementation 
of the NPC minimum dataset, requirements were persistently not met.  Deviations 
identified reflected those of previous studies including allergy status, medication and co-
morbidity history, details of medicines prescribed upon discharge and rationales of 
therapy changes.[29, 48, 65, 131, 145] 
The majority of discharge summaries made no reference to drug allergies or 
hypersensitivities despite a record of one or more allergies existing in the primary care 
notes for almost half of those patients.  However, in many cases, whilst labelled as 
allergies, these were drug intolerances or adverse reactions rather than allergies.  When a 
definite allergy was present, it was frequently antibiotic or food related.  If information is 
absent or inaccurate at the point of admission, then it is unlikely that it would be accurately 
communicated upon discharge.[16, 17, 30]  Thus allergy and hypersensitivity information may 
not have been available or accurate during the inpatient stay which is consistent with 
other reports[24, 131] and of concern in terms of patient safety. 
In addition, the audit outlined frequent omissions of pre-admission medicines and co-
morbidity history.  This is consistent with a previous UK audit across 12 primary care 
trusts in 2009,[19] and therefore the lack of progress with discharge information 
communication is of concern.  Persistent deficits can be highlighted with information 
regarding medicine formulation and duration.  However, the recipient of the discharge 
summary, who is the GP, usually has access to a more comprehensive and long term 
patient history, thus the clinical implication is likely to be limited to cases encountered with 
medicines newly initiated during the hospital stay.  In agreement with findings from 
previous studies, the audit found frequent omissions in the details and rationales of 
therapy changes.[29, 48]  This information has been reported by GPs as necessary in order 
to optimise and expedite continuity of care.[40]  GPs might need to spend some time to 
resolve ambiguities in discharge summary and acquiring further contact with hospital 
team.[31] 
The Trust-wide audit investigated the extent to which information additional to the NPC 
minimum dataset, such as laboratory tests and procedures, post admission complications 
and discharge team contact details were communicated.  There was reasonably good 
practice in reporting the results of laboratory tests and procedures, however, hospital 
doctors recorded their comments on those tests or procedures for less than 50% of cases.  
More than 20% of discharge summaries lacked contact details of the person responsible 
for discharge.  This might exacerbate the cost implications related to the time that might 
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be spent by GPs to resolve ambiguities in discharge summary and enquiring further 
details. 
4.2 Discharge discrepancies  
Eight out of ten discharge summaries had at least one medication discrepancy.  This rate 
is comparable to discrepancy rates previously reported.  The nature of these 
discrepancies was also similar to other reports, which were primarily omissions of pre-
admission medicines or addition of a new medicine without providing a rationale for 
initiation.[29, 31, 32, 51, 163, 208, 209] 
Medicines most frequently implicated in discrepancies concurred with previously 
published studies.[13, 29, 31-33, 35, 44]  These medicines were also the most frequently 
prescribed medicines suggesting that discrepancies are arising from generic procedural 
issues.  A possible reason for incomplete therapy change information could be the 
perception of the secondary care team that GPs will decipher these changes from the 
clinical history provided.  It may also be that the medicine is considered of low risk, such 
as analgesics or laxatives and therefore detailed information was considered trivial.[59, 210] 
Noteworthy, the audit identified that in some instances where information was explicitly 
provided by the discharge team, recommendations were not implemented in primary care 
resulting in reconciliation discrepancies.  These discrepancies continued up to two months 
post discharge.  Previous research has suggested that the lack of implementation might 
be largely due to informed decisions made by GPs.[211, 212]  This was in line with the audit 
findings, albeit, for one third of reconciliation discrepancies the lack of implementation was 
due to human errors and deficits in the process of handling incoming communication from 
secondary care.  The current practice for processing incoming communication to GPs 
differs widely.  In some primary care practices, information is processed by administrative 
staff such as the practice receptionist whilst for others it is processed by clinical staff such 
as a nurse or pharmacist.  Primary care practices also use different software to store and 
view incoming communication.  There is also an active NHS intranet providing a direct 
connection to secondary care in some practices whilst for others this is unavailable.  
Inadequate communication of discharge information might lead to unintended changes of 
patient medicines or unnecessary prescribing.[197, 209, 213, 214]  These pose a risk of adverse 
drug events and costs implicated to patient safety and health care resources use.[48, 197]  
Approximately, 65% of the evaluated discrepancies had the potential to cause moderate 
patient harm.  These results are in accordance with a similar study which adapted the 
same validated approach.[35]   
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Incomplete information regarding therapy changes and discharge medicines might also 
confuse primary care providers and compromise continuity of patient care.[49, 50].  GPs 
might need to spend time attempting to establish whether a change was intentional.  This 
audit, estimated that the GP might have spent 15 minutes on average per discrepancy to 
confirm necessary action.  In addition to being time consuming, without having a timely 
and comprehensive discharge notification GPs might feel unable to continue patient care 
and maintain clinical responsibility.[49, 215]   
The audit also explored information on medicines frequently prescribed and considered of 
increased risk to cause patient harm including proton pump inhibitors, anticoagulants, 
clopidogrel, antibiotics and corticosteroids.  There was limited communication of titration 
plans and duration for these medicines.  Research has demonstrated that these 
medicines are often not titrated according to guidelines.[216, 217]  The lack of guidance from 
secondary care may therefore be a contributing factor to such deviation in practice.  
4.3 Predictors of non-adherence to the NPC minimum dataset and discharge 
discrepancies 
The audit attempted to identify factors contributing to discharge summary adherence to 
the NPC minimum dataset and those associated with increased risk of discrepancy.  The 
potential influence of these factors was investigated adjusting for possible confounding 
and covariate effects between variables.  Therefore, predictors of non-adherence to the 
NPC minimum dataset and the characteristics associated with an increased risk of 
discrepancy were explored.   
Considerable variations were seen between hospitals; H3 demonstrated the greatest 
adherence.  Notably, deviations between hospitals followed a similar pattern to the extent 
of discharge summary template adherence to the NPC minimum dataset.  This is 
supported by previous research outlining that the use of a standardised discharge 
summary form resulted in a more comprehensive and accurate communication of 
discharge information.[145, 218, 219] 
Electronic discharge summaries demonstrated better adherence to the NPC minimum 
dataset compared to handwritten discharge summaries.  Electronic production of 
discharge summaries widely reported to be useful in reducing hand transcription and 
allowing faster and uniform recording of discharge information.[61, 63, 64]  However, whilst 
electronic discharge summaries remove the element of illegibility, they are subject to 
errors due to incorrect selection or user entry.[43, 64]  In this audit, an electronic discharge 
summary contributed to a better adherence to the NPC minimum dataset, yet an 
electronic discharge summary predicted an increased risk of omissions.   
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The inverse relationship between the number of prescribed medicines and both 
adherence to the NPC minimum dataset plus increased risk of medication discrepancy is 
intuitive and consistent with previous reports.[16, 30, 32, 35, 52-54]  Diagrammatic representation 
indicated that discharge summaries of patients prescribed five or more medicines were 
associated with an increased risk of medication discrepancy which is consistent with other 
reports.[33, 34, 44, 55] 
A discharge summary from an orthopaedic ward is a predictor of poor adherence to the 
NPC minimum dataset and contributed to an increased risk of discrepancy; this was 
shown by other studies.[220, 221]  Orthopaedic discharge summaries persistently recorded 
no rationales for therapy changes and provided incomplete information related to 
medication and co-morbidity histories.  Short stay admissions for minor risk procedures 
and inattention to secondary conditions unrelated to the surgical procedure could explain 
these frequent deficits.  This is consistent with findings from a recent report in 2012 
highlighting that errors occurred on discharge were more likely attributed to medicines 
unrelated to the primary diagnosis.[222]  Inattention to secondary conditions and 
consequently medicines which is unrelated to primary diagnosis might be of significant 
implications to patient care and safety; a national wide review in USA included over than 
11 million discharged patient from 2003-2004 highlighted that among patients who were 
readmitted within 30 days after a surgical discharge, 70.5% were for unrelated 
condition.[223]  Thus, it is important to devote equal attention to all patient medicines.  
The audit did not find differences between profession types with respect to discharge 
summary adherence to the NPC minimum dataset or risk of discrepancy.  Two large 
reports from UK [13, 66] which is consistent with findings from small studies in USA and 
Europe [28, 45] highlighted foundation year doctor a contributing factor to increased risk of 
error.  The absence of apparent effect of profession type in our audit could reflect the 
limited number of data points among profession types and doctor training, this warranted 
merging subgroups.  Additionally, high proportion of discharge summaries was of 
unspecified profession type or of doctors with no indication of the training level.  Thus, no 
firm conclusion can be drawn on this regard warranting further work.   
Similarly, no discernible differences were demonstrated between planned and unplanned 
admissions; length of hospital stay or patient age and gender were also not identified as 
significant contributors to the quality of discharge information. 
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4.4 Strength and limitations  
This is the first large scale report investigating adherence to the NPC minimum dataset 
across one UK primary care trust.  Whilst this is not generaliseable to the whole of the UK, 
the audit has presented data representing various hospitals and specialities.  This study is 
also the first to evaluate the clinical significance of discharge discrepancies using a 
rigorous approach.  To the best of our knowledge, this is also the first study which has 
attempted to describe reconciliation discrepancies.  Therefore, recommendations were 
proposed on both side of the healthcare interface.  Additionally, this is the first Trust-wide 
audit which thoroughly investigated the predictors of adherence to the NPC minimum 
dataset and risk of discharge discrepancy.   
Of most important, unlike the existing wide scale UK audits,[26, 44] the presenting audit 
assessed the variation contributed by the use of various auditors.  Assessment of 
variation between auditors was important to enable appropriate analysis and interpretation 
of findings.  The quality assurance of the audit data was satisfactory, indicating good to 
substantial agreement.  Thus the audit findings can be presented with confidence. 
However, there are few limitations that warrant discussion.  This study has reported the 
magnitudes of discharge summary adherence to the NPC minimum dataset but it is not 
possible to comment on the accuracy of the information provided by secondary care.  
Therefore, further work to capture the accuracy of discharge information is necessary.  In 
addition, little can be known from the audit findings about the proportion of discharge 
discrepancies that actually led to adverse drug events.  Discharge discrepancies were 
frequently found but these may carry less actual harm to patients.[34]   
This study has identified clear predictors of good adherence and thus allowed 
recommendations to be developed.  These are presented in BOX 4.1.  However, the 
amount of variance explained by regression models was small and thus a substantial 
proportion remains unexplained warranting further work. 
Noteworthy, the discharge summary template was identified as a significant predictor of 
the quality of discharge information.  Such a finding might help to promote the 
implementation of a standardised pro-forma across all NHS trusts.  This conclusion, 
however, might be limited by the variation in templates employed between wards within 
each hospital.  The template representing the majority of discharge summaries generated 
from each hospital was selected for this audit.  The lack of standardisation and use of 
multiple templates may indicate high variation in care standards and patient management.  
Therefore, it is impossible to test to which extent the effect of template is affected by the 
variation in the workflow and staff between hospitals and wards.  Future investigation is of 
value.  
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4.5 Implications for practice   
Interventions to improve the transfer of information upon discharge are likely dependent 
on effective Medicine reconciliation (MR) at patient admission.  Errors within information 
obtained on admission are frequently perpetuated on discharge.[17, 28]  Therefore, 
improving the quality of information received in primary care might be enhanced by 
effective MR practice upon admission and during hospital stay.  
Electronic production and transfer of discharge information may enhance the quality and 
completeness of discharge information; however, user errors and uncompleted fields 
remain pertinent issues.  Hence, attention to update and complete input of information to 
the computer system, user training and IT support are important to minimise these errors. 
[63, 64]  A standardised electronic pro-forma incorporating fields for information frequently 
omitted, such as allergy information, could improve the quality of information transfer upon 
discharge.[64] 
Knowledge regarding which patients who might benefit from MR would help to prioritise 
the service where resources are most scarce.  There could be a prompt to take greater 
care when completing the discharge summary of patients who have been prescribed five 
or more medicines.  
Lack of reconciliation in primary care may be due to the lack of guidance,[19, 21, 224] a 
standard MR process might help to prevent inadvertent failures in implementing discharge 
recommendations in primary care. 
BOX 4.1 Audit recommendations  
 To develop a comprehensive electronic pro-forma 
This potentially might increase adherence to the NPC minimum dataset 
requirements.  However, transcribing and user selection errors are still 
inherited and require great attentions and users training.   
 To prioritise patients prescribed five or more medicine  
These patients may need greater care while completing their discharge 
summaries and therefore future interventions should be targeted at this high 
risk group.  
 To develop guidance for medicine reconciliation (MR) procedures within 
primary care 
This may reduce the proportion of unintentional failures to implement 
secondary care recommendations and smooth the process of care continuity. 
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4.6 Implications for future work  
Further exploration of the factors contributing to variations in performance across wards 
and the reasons why such variations exist is warranted.  This might help to enhance the 
understanding of underlying reasons for variations in practice and the contributions to 
good adherence by others.  One possible way to achieve this would be through interviews 
with care providers involved in care transition tasks  
In summary, this audit identified discrepancies with the information transferred upon 
discharge and highlighted non-reconciled recommendations by primary care team.  The 
findings of this audit showed that the procedures in use for transferring information at the 
health interface are not optimum.  MR is proposed as a solution for health care transition 
deficits.  Optimum implementation of MR during hospital stay might offer the benefit of 
enhancing continuity and quality of information transfer at discharge and thus received in 
primary care.  Efforts to identify the effects and the best practice to implement MR which 
might be translated into national recommendations are of value.  
The next chapter reports findings from the systematic review aimed to summarise the 
available evidence on the effects and resources necessary to implement pharmacy led 
MR interventions in hospital  
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The audit results in the previous chapter, identified that the current process for discharge 
information transfer in not optimal; discrepancies were identified at both sides of the 
health interface.  The audit identified the prevalence and type of discrepancies occurring 
within standard care.  The next stage in developing and evaluating an intervention tailored 
to address such discrepancies was exploring the existing evidence to identify the features 
of effective interventions, the most appropriate outcome measures, the resources 
necessary to deliver such an intervention and the most effective approach to 
implementation.  Medicine reconciliation (MR) is proposed as a solution for health care 
transition deficits thus a comprehensive systematic literature search was of studies 
reporting full implementation of MR was undertaken. 
Additionally, the audit highlighted areas for improvement and contributors to poor 
performance.  This informed the need for future interventions aiming to enhance continuity 
and quality of information transfer at discharge and received in primary care.  Optimum 
implementation of MR during hospital stay would offer the benefit of enhancing post 
discharge care and continuity of information transfer.  Therefore, next step of this thesis 
work was to determine the effect of MR and resources necessary as well as to describe 
the best practice of MR in hospital.   
5.1 Literature search  
The literature search returned 4,065 citations of which 17 studies met the inclusion 
criteria.  The study selection process and number of papers excluded at each stage of the 
review is illustrated in Figure 5.1.  Moderate agreement; kappa [95%CI] =0.48 [0.45-0.51] 
p=<0.001 was achieved at the title screening stage.  Ambiguity and inconsistency in the 
terminology used to describe MR accounted for 62% of disagreements.  Of the screened 
abstracts, one third were retained for full text screening with good agreement, kappa 
[95%CI] =0.63 [0.45-0.51] p=<0.001.  Disagreement was heavily influenced by a paucity 
of information in the abstracts and required full text review to confirm that all elements of 
the MR process were performed. 
At the full text screening stage, agreement between the two independent reviewers was 
much higher, with a kappa value [95%CI] of 0.91 [0.80-1.0], indicating substantial 
agreement.  The main reasons for exclusion of studies are summarised in Figure 5.1. It 
can be seen that studies were excluded most frequently due to lack of implementing all 
elements of the MR process. 
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5.2 Included studies 
There were 10 controlled studies of which six were randomised controlled studies [109, 115, 
118, 135, 225, 226]
,
 two non-randomised prospective observational [227, 228] and two before and 
after design.[113, 229]  The remaining were prospective uncontrolled design. 
Seven studies were based in USA [108, 109, 114, 118, 229] and Canada [230, 231].  Nine conducted 
in Europe of which four were in UK [115, 225, 228, 232], Netherlands [107], Spain [227], two in 
Sweden [113, 135] and France [233].  One study was based in Australia.[226]   
All the included studies were in the English language except one French article.[233]  Table 
5.1 summarises the characteristics of the included studies with respect to study design, 
sample size, duration, measured outcomes, comparator plus the inclusion and exclusion 
criteria. 
5.3 Pharmacy led MR 
Pharmacy led MR was commonly compared with usual care which consisted of standard 
pharmacy care provided by a member of the ward staff.  However, Hellstrom et al. 
evaluated the effect of a full pharmacy led MR intervention extending from admission until 
discharge compared with a discharge MR service which was received by all patients as 
part of the standard care.[113]  In two studies, the standard care included nurse led MR. [118, 
229]
  In one study a nurse verified patient medicines only if it was requested by the 
doctor.[231]   
Table 5.2 describes aspects of pharmacy led interventions between studies.  It can be 
seen that the MR process was frequently supplemented by other clinical pharmacy 
activities such as pharmacotherapy consultation,[107, 109, 114, 115, 135, 228, 230] patient education 
[107, 109, 114, 115, 118, 225-228, 231, 232] and discharge counselling. [107, 108, 135, 229, 230, 232, 233] 
Table 5.3 summarises features of MR process between the included studies with respect 
to settings, time to implement MR, service cover and provider.  The majority of the 
included studies took place mainly in general internal medicine wards and were led by a 
pharmacist of clinical or hospital residency experience.  In two studies MR was 
implemented by pharmacy technicians of which MR was led by a team of pharmaceutical 
consultants who are pharmacy technicians completed an additional three year degree and 
obtained further pharmacotherapy and patient communication training.[107]  The other study 
was performed by pairs of pharmacists and pharmacy technicians.[115]  A pharmacist - 
nurse collaborative approach to implement MR was evaluated in one study.[229]  
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For the purpose of this chapter and the later discussion (chapter six), MR pharmacist 
refers to the MR provider, who could be a pharmacist, a pharmacy technician or a 
pharmaceutical consultant. 
The time point since admission when MR was initiated was reported by six studies.  MR 
was implemented shortly or within 24 hours of admission in three studies.[108, 113, 233]  The 
remaining implemented MR after 24 hours up to 72 hours after admission.[118, 225, 231] 
MR was implemented all weekdays during normal working hours in six studies. [113, 135, 229-
231, 233]  One study reported weekdays and weekends service [225] and few studies reported 
less extensive MR coverage for two to four days per week. [108, 109, 232] 
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*Authors were contacted; no published or unpublished relevant data were available  
MR: Medicine reconciliation 
CINAHL:Cumulative Index to Nursing and Allied Health Literature. CDSR: Cochrane Database of Systematic 
Review. DARE: Database of Abstracts of Reviews of Effects. NHSEED: NHS Economic Evaluation Database. 
CRD: The centre of Reviews and Dissemination. 
NPSA: National Patient and Safety Agency. NPC: National prescribing centre. IHI: Institute of Healthcare 
Improvement  
 
Figure 5.1 Studies selection and reason for exclusion  
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Authors, 
Year 
Study 
design, 
sample size Duration  
Outcomes 
measured Control  Inclusion criteria  Exclusion criteria 
Karapinar-
Carkit 
2012[107] 
Prospective 
uncontrolled, 
262 
 
Nine 
months 
Medication 
costs/savings in 
relation to labour 
costs 
- Age: All adults  
Number of medications: ≥ one 
prescribed medicines  
Condition: Discharged from 
pulmonology department 
  
Transferred from/to other 
wards/hospital: Not included 
Hospital stay: Discharged within 24 
hours or after office hours 
Unable to consent: Physical/mental 
constraints, language restrictions, or 
terminal illness. 
Included from previous admission: Not 
included 
Discharge destination: Discharged to a 
nursing home 
Perennes 
2012[233] 
Prospective 
uncontrolled, 
61 
Five 
months 
Classification 
and 
significance of 
unintentional 
medication 
variances  
- Age: ≥ 65 years old or 
more. 
 
Transferred from/to other 
wards/hospital: Not included 
Hospital stay: Discharged before the 
finalisation of MR 
Unable to consent: Unable to 
communicate and in isolation or 
institutionalised 
Boso-Ribelles 
2011[227] 
Prospective 
uncontrolled 
a
, 675 
Six months Identification of 
drug related 
problems, 
number of 
emergency 
department 
visits and 
hospitalisation 
over three 
months 
- No. of medications: > four 
medicines listed in the first 
hospital prescription 
 
None  
a Number of emergency visits and hospitalisations which were experienced by the patients included in the programme compared against those experienced by patients 
excluded from the programme due to a lack of resources.. MR: Medicine reconciliation 
Table 5.1 Summary of included studies   
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Authors, Year 
Study design, 
sample size  Duration Outcomes measured Control  Inclusion criteria exclusion criteria 
Hellstrom 2011[113] Before and after  
Pre-
implementation 
n=101  
Post-
implementation 
n=109  
Three 
months 
Change in medication 
appropriateness index 
between admission 
and discharge, drug 
related readmissions 
and emergency 
department visits 
within three months 
post discharge 
Standard care 
which included 
only MR upon 
discharge  
Age: ≥ 65 years 
No. of medications: ≥ one 
medicines for regular use 
 
A patient stayed in the 
study wards during one of 
the study inclusion dates b 
Makowsky 2009[230] Multi-centre, quasi 
controlled clinical 
trial 
Intervention 
n=220 Control 
n=231  
12 
months 
Quality score of 
patient care, hospital 
readmissions within 
three and six months 
Usual care 
included 
traditional 
reactive clinical 
pharmacy by 
either ward-
based or 
dispensary-based 
staff pharmacists.  
Age: >18 years  
Condition: Primary 
diagnosis of coronary 
artery disease, 
community acquired 
pneumonia , chronic 
obstructive pulmonary 
disease, heart failure, or 
type 2 diabetes mellitus c 
and not due palliative 
cancer 
Transferred from/to other 
wards/hospital:  Not 
included 
Hospital stay: Admitted for 
two days 
Others: Resided outside 
the capital Health 
catchment area. 
Koehler 2009[118] Randomised 
controlled pilot 
study 
Intervention n=20 
Control n=21 
Four 
months 
Hospital readmissions 
and emergency 
department visits at 
30 and 60 days 
following discharge 
Usual care with 
floor nursing staff 
providing MR 
upon admission 
and discharge 
Age: ≥70 years 
No. of medications: ≥ five 
medicines regularly 
Condition: ≥ three chronic 
co-morbid conditions, not 
admitted primarily for a 
surgical procedure or 
terminal diagnosis 
Hospital stay: an average 
length of hospital stay 
between 5 and 6 days, 
patients who could not be 
enrolled within 72 hours 
following admission 
 
b November 1, 2006 (before the intervention), and March 1, 2007, November 1, 2007 and April 1, 2008 (about 1 month after implementation of the intervention in wards. c 
These disease states were chosen because they are among the most common reasons for admission to the participating teams, are associated with frequent hospital 
readmissions, and have high-quality evidence to contribute to drug related problems. MR: Medicine reconciliation  
Continued  
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Authors, Year 
Study 
design, 
sample size  Duration 
Outcomes 
measured Control  Inclusion criteria Exclusion criteria 
Koehler 2009 
cont. [118] 
- - - - Others: Requirement for assistance 
with one activity of daily living, pre-
admission residence at home or 
assisted living with a reasonable 
expectation of disposition back to 
that domicile. 
Unable to consent: Not conversant in 
English, no reliable phone contact, 
have no proxy caregiver who could 
speak English and be reached by 
phone. 
Discharge destination: Residence in 
a long-term care facility, skilled 
nursing facility or nursing home prior 
to hospitalisation with anticipated 
discharge back to that facility 
Others: Life expectancy six months 
Rabi and 
Dahdal. 
2007[108] 
Prospective 
Uncontrolled, 
150 
One 
months 
Pharmacist’s 
intervention 
resolving 
unintentional 
discrepancies 
- All patients offered intervention 
 
None 
Bayley 2007[114] Prospective 
Uncontrolled, 
99 
Nine 
months 
Type and impact 
of pharmacist’s 
intervention 
- Patient with primary care physician 
employed by the hospital system, 
in-patient stay of at least one day  
 
Hospital stay: Overnight 
“observation” patients 
Unable to consent: With documented 
memory or mental health issues 
Scullin 2007[115] Randomised 
controlled 
study 
Intervention 
n=371 
Control 
n=391  
18 
months 
Length of hospital 
stay, readmission 
rate within 12-
month, health 
care practitioner 
satisfactions  
Usual 
care 
Age: ≥ 65 years 
No. of medications: ≥ four regular 
medications, taking a high risk 
medicine(s) or antidepressant 
Others: A previous hospital 
admission within the last six 
months, prescribed intravenous 
antibiotics on the day of admission 
Scheduled admissions, patients 
admitted from private nursing homes 

Continued  
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Authors, Year 
Study 
design, 
sample size  Duration  
Outcomes 
measured Control  Inclusion criteria exclusion criteria 
Bolas 2003[225] Randomised 
controlled 
study 
Intervention 
n=119 
Control 
n=124  
Two 
weeks d 
Interventions made 
during the 
preparation of 
medication 
histories and their 
clinical significance, 
emergency 
department visits 
within three months 
Usual care 
including standard 
clinical pharmacy 
service, with no 
discharge 
counselling. 
Age: ≥ 55 years 
No. of medications: 
≥ three medicines 
taken regularly 
 
Transferred from/to other 
wards/hospital: Not included 
Unable to consent: Patient or carer 
unable to communicate with 
pharmacist, mental illness or 
alcohol related admission, home 
visit or study follow up was 
declined upon admission 
Discharge destination: Admitted or 
transferred to a nursing home 
Stowasser 2002[226] Randomised 
controlled 
study 
 
Intervention 
n=104 
Control 
n=105  
One 
month e 
Mortality, 
readmission and 
emergency 
department visits, 
change in 
functional health 
status, health 
resource use 
Usual care by a 
clinical pharmacist 
included review of 
medication history 
and current 
medication, 
medication supply, 
counselling on 
medications and 
preparing 
discharge 
medicines 
Patients returning 
to community 
following discharge 
 
Transferred from/to other 
wards/hospital: Not included 
Hospital stay: Discharged within 24 
hours of admission 
Unable to consent: Unable or 
unwilling to consent, unable to 
provide follow up data 
Included from previous admission: 
Not included 
Discharge destination: Discharged 
to hostel or nursing home 
Others: Hospital outpatients 
admission 
d Follow- up 10-14 days post discharge e Follow up 30 days.  
Continued 
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Authors, Year 
Study design, 
sample size  Duration  
Outcomes 
measured Control  Inclusion criteria Exclusion criteria 
Hick 2001[228]  Prospective 
controlled 
50 in each group 
- Number, 
classification and 
clinical significance 
of pharmaceutical 
interventions 
Standard post-
admission pharmacist 
ward visit only, which 
involved checking 
medication charts for 
errors and omissions, 
and making 
interventions when 
deemed necessary 
Age: ≥  29 years  
 
None 
Brookes 2000[232] Prospective 
uncontrolled, 109 
Five 
months 
Medication related 
problems, GP and 
community 
pharmacist 
opinions on the 
service 
- Age: ≥ 60 years 
No. of medications: ≥ 
four drugs 
Others: Admitted via 
the medical admission 
unit 
None 
Kramer 2007[229] Before and after 
study 
Pre-
implementation n= 
147 
Post-
implementation 
n=136  
Six 
months 
Feasibility and 
efficiency of nurse- 
pharmacist MR, 
effect on patient 
safety, and 
satisfaction of 
service users. 
 
Pre-implementation 
phase included 
admission medication 
histories and discharge 
medication counselling 
followed standard care 
process which included 
a nurse led MR 
Age: ≥ 18 years 
 
Transferred from/to other 
wards/hospital: Not 
included 
Hospital stay: Admitted for 
23 hour observation, 
Unable to consent: 
Admission due to 
intentional drug overdose 
Others: Medication history 
was obtained more than 
two hours after admission f 
f The rationale for excluding patients when the nursing medication history was obtained over 2 hours after admission was to avoid confounding factors. MR: Medicine 
Reconciliation. GP: General practitioner 
Continued 
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Authors, 
Year 
Study 
design and 
sample size Duration  
Outcomes 
measured Control  Inclusion  Exclusion criteria 
Gillespie 
2009[135]  
Randomised 
controlled 
study 
Intervention 
n=182  
Control 
n=186  
21 months 
g
 
Hospital visits 
(emergency 
department visits and 
readmission) within 12
months 
Standard care without direct 
involvement of pharmacists at 
the ward level 
Age: All patients 
 
Included from previous admission: Not 
included  
Others: Scheduled admissions 
Vira 
2006[231] 
Prospective 
controlled,60 
one 
month 
Discrepancies in 
patient medication 
upon admission and 
discharge, clinical 
significance of 
unintentional 
medication 
discrepancies 
Pharmacy or nursing 
verification of the patients’ 
medication use history if 
requested by a physician or if 
there were incomplete or 
unusual drug orders. At 
discharge, pharmacists 
provided medication 
education if specifically 
requested by a physician and 
for additional patients as time 
permitted 
All new 
admissions in 
the previous 
24 hours 
 
Patient admitted to rehabilitation and 
chronic care wards 
Spinewine 
2007[109] 
Randomised 
controlled 
study 
 
Intervention 
n= 96 
Control n=90 
19 
months h 
Appropriate of 
prescribing on 
admission, discharge 
and three month post 
discharge using 
Medication 
appropriateness 
index, mortality, 
readmission rate 
Usual care with acute 
geriatric evaluation and 
management care 
All admitted 
patients in the 
study period 
Condition: Not 
due to terminal 
illness 
 
Transferred from/to other wards/hospital: 
Not included 
Hospital stay: Length of stay of 48 hours 
or less or pharmacist unable to perform 
an abstracted chart within 3 days of 
admission because of time constraint 
Included from previous admission: Not 
included 
Others: Life expectancy of less than three 
months, patient had been cared for by 
geriatrician 
h Seven month recruitment and 12 months follow up. g nine month recruitment plus 12 month follow-up. MR: Medicine Reconciliation.  
Continued 
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Study  
All MR 
elements   
Pharmacotherapy 
consultation & 
medication 
review 
Discharge 
counselling/planning 
Patient 
and carer 
education  
Written 
medication 
information 
handed to 
patient 
Phone 
Follow up 
post 
discharge  
Ward 
round 
and 
bedside 
care 
Medicine 
helpline 
Medication 
supply/patient 
own drugs 
management 
Karapinar-
Carkit 
2012[107] 
         
Perennes 
2012[233] 
         
Boso-
Ribelles 
2011[227] 
         
Hellstrom 
2011[113] 
         
Makowsky 
2009[230] 
         
Koehler 
2009[118] 
         
Rabi and 
Dahdal. 
2007[108] 
         
Bayley 
2007[114] 
         
Scullin 
2007[115] 
         
Bolas 
2003[225] 
         
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Study  
All MR 
elements 
Pharmacotherapy 
consultation & 
medication 
review 
Discharge 
counselling/planning 
Patient 
and carer 
education  
Written 
medication 
information 
handed to 
patient 
Phone 
Follow up 
post 
discharge  
Ward 
round 
and 
bedside 
care 
Medicine 
helpline 
Medication 
supply/patient 
own drugs 
management 
Stowasser 
2002[226] 
         
Hick 
2001[228] 
         
Brookes 
2000[232] 
         
Kramer 
2007[229] 
         
Gillespie 
2009[135]  
         
Vira 
2006[231] 
         
Spinewine 
2007[109] 
         
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Authors, Year Settings 
Time to 
implement MR  
Pharmacy 
MR Service 
cover Provider (s) 
Karapinar-Carkit 
2012[107] 
Pulmonary 
medicine 
department 
- No details A team of 
pharmaceutical 
consultants a 
Perennes 2012[233] General Internal 
medicine ward 
25 (41%) within 24 
hours of admission 
31% between 24 -
48 hours of 
admission 
28% >48 hours 
after admission  
Weekdays  An intern hospital 
pharmacist b 
Boso-Ribelles 
2011[227] 
Cardiology and 
cardiovascular 
surgery ward 
- - A Pharmacist  
Hellstrom 2011[113] General internal 
medicine ward 
Shortly after 
admission 
Weekdays A Clinical 
pharmacist 
Makowsky 2009[230] General internal 
medicine and 
family medicine 
wards 
No details Monday-
Friday 
during 
normal 
working 
hours 
Team based 
Pharmacist c 
Koehler 2009[118] General internal 
medicine ward 
Within 72 hours of 
admission d 
- Team of 4 clinical 
pharmacists e 
Rabi and Dahdal. 
2007[108] 
Cardiology ward The same day or 
prior admission 
2- 3 days 
per week 
A college-based 
primary care 
pharmacist 
resident 
Bayley 2007[114] Acute care unit - - A transitional of 
care pharmacist 
doctoral prepared f 
a
 Pharmaceutical consultants: Pharmacy technicians who have completed an additional 3-year bachelor 
degree program, they are specifically trained in pharmacotherapy and communication with patients. b 9 years 
hospital residency programme. c Pharmacists who have a Bachelor of Science in Pharmacy degree, had 
completed a 1-year hospital pharmacy residency and had practiced as hospital-based clinical pharmacists 
prior to study participating; one team-based pharmacist had 8 years of practice experience in an intensive 
care unit, whereas the other had a total of 5 years of experience in intensive care and internal medicine 
settings. d Starting no later than 24 hours after enrolment and continuing up to 1 week following hospital 
discharge. e Upper-level pharmacy residents completing their inpatient clinical rotations. f Doctoral prepared 
with residency training in internal medicine. MR: Medicine reconciliation 
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Authors, Year Settings 
Time to 
implement MR  
Pharmacy 
MR Service 
cover Provider (s) 
Scullin 2007[115] General 
internal 
medicine and 
surgical wards 
- - Team consisted of 
five pairs of clinical 
pharmacists and 
pharmacy 
technicians. 
Bolas 2003[225] Medical 
admission unit 
Within 48 hours of 
admission 
Weekdays & 
weekends 
A community 
liaison pharmacist 
Stowasser 2002[226] - - A clinical 
pharmacist 
A clinical 
pharmacist 
Hick 2001[228] Pre-admission 
clinic visit 
- A pre-
admission 
clinic 
pharmacist 
A pre-admission 
clinic pharmacist 
Brookes 2000[232] Medical 
admission unit 
- 2.5 days per 
week 
A community 
liaison pharmacist 
Kramer 2007[229] - - Monday to 
Friday (7:00 
am-3:30 pm) 
Pharmacist and 
nurse collaboration 
Gillespie 2009[135]  Acute General 
internal 
medicine ward 
- Weekdays 
(8:00 am to 4 
pm) 
Two clinical 
pharmacists 
Vira 2006[231] acute care 
unit 
At least 24 hours 
after admission  
Weekdays A pharmacist 
Spinewine 2007[109] Acute geriatric 
evaluation 
and 
management 
- 4 days per 
week 
A clinical 
pharmacist 
MR: Medicine reconciliation 
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5.4 Targeted patient population 
A wide spectrum of inclusion criteria can be seen in Table 5.1; studies frequently targeted 
patients who are newly admitted and prescribed one or more medicines.  It can be seen 
that most of the studies approached patients within 24 hours of admission.  However, 
Bolas et al. and Koehler et al., however, approached patients between 48 and 72 hours of 
admission to allow inclusion of weekend admissions and to ensure the effect of the MR 
intervention was not obscured by a short hospital stay. [118, 225]  
Generally, studies included patients who were prescribed at least four medicines.[115, 118, 
225, 227, 232]  Medicines were differentiated into regular and as required; frequently studies 
targeted patients who were prescribed at least one regular medicines.[113, 115, 118, 225]  
The main reason for patient exclusion was a short hospital stay of less than 24 or 48 
hours [107, 229, 230, 233], inability to consent for reasons such as language, mental incapacity 
or illness [107, 114, 225, 229, 233] and patients transferred to other ward, care team or health 
facility such as a nursing care facility.[107, 225, 229, 230, 233]  
Table 5.4 summarises the characteristics of the included patients relevant to age, gender, 
number of medicines and type of admission.  All the included studies were conducted in 
adult population with age ranging between 65 years to of 93 years old.  Exception to this 
was the study by Vira et al.[231]  Vira et al. excluded patients from rehabilitation and chronic 
care wards which can might explain the younger population seen in the study compared to 
the rest of the included studies.  Overall, an even gender distribution was seen in all the 
studies except for Perennes et al.[233] and Bayleys et al;[114] those had higher proportion of 
female participants.  
Two studies recorded no details on the number of medicines prescribed to the patient.[108, 
230]
  Six studies reported the total number of medicines prescribed [109, 114, 118, 135, 231, 233] and 
four studies differentiated the number of medicines into admission and discharge. [107, 225-
227]
  Three studies differentiated medicines into regular and as required use. [113, 228, 229]  A 
patient was prescribed more than six medicines on average.  However, patients in the 
study of Vira et al.[231] and Hick et al.[228] were prescribed lower number of medicines; 
mean (SD) were 3.6 (3.5) and 4.36 (2.51) respectively.  Patients in the study by Vira et al. 
were younger and were not under the care of the chronic care wards, this might have 
been attributed to these patients being prescribed fewer medicines.  Patients in the study 
by Hick et al.[228] exhibited a wide age range; 30 to 90 years old and were admitted to a 
general surgery ward via planned admissions.  Those patients might have had a less 
complex medicine regimen.  Details of admission type were not recorded in the majority of 
studies; however, five studies recorded admission type in which they were mostly 
unplanned admissions.[107, 115, 135, 225, 231] 

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Authors, 
Year  Age  
Gender  
(male)  No. of medications 
Type of 
admission 
(planned) 
 Measured 
patients 
Mean (SD) Measured 
patients 
N (%) Measured 
patients 
Mean (SD) N (%)   
Karapinar-
Carkit 
2012[107] 
All patients 65 (17) All patients 131 (50%) Admission 
 
Discharge 
6.6 (3.8) 
 
9.1 (4.7) 
35 (13%)  
Perennes 
2012[233] 
All patients 78 (7.4) 
Range (65-
95) 
All patients 20 (31.2%) All patients 7 (2.9) 
Range (1-15) 
46 (75%) 
Boso-
Ribelles 
2011[227] 
Intervention  
 
Control 
67.7 (14.5) 
 
69.7 (13.9) 
All patients 423 (62.6%)  Admission 
 
Discharge 
7.8 (no details) 
 
8.9 (no details) 
No details 
Hellstrom 
2011[113] 
Intervention  
 
Control 
83.0 (7.0) 
 
81.8 (7.4) 
Intervention  
 
Control 
49 (45%) 
 
50 (49.4%) 
 
Intervention  
 
Control  
 
Intervention 
 
Control 
Regular use medicines*  
8 (5-11) 
 
7 (5-11) 
As needed medicines* 
1 (1-3) 
 
1 (1-3) 
No details 
Makowsky 
2009[230] 
Intervention  
 
Control 
74.9 (13.9) 
 
73.2 (14.7) 
Intervention 
 
Control 
104 (47.1%) 
 
102 (44.2%) 
- No details No details 
*median (IQR) a Two hundred and sixty-four patients were admitted to the cardiology department in the first trimester of 2007; 151 of them were included in the study 
(intervention) versus 113 patients who were excluded (control). SD: Standard deviation. 
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Authors
, Year  Age  
Gender  
(male)  No. of medications 
Type of admission 
(planned) 
 Measured 
patients 
Mean (SD) Measured 
patients 
N (%) Measured 
patients 
Mean (SD) N (%)   
Koehler 
2009[118] 
Intervention  
 
Control 
77.2 (5.3) 
 
79.8 (5.6) 
Intervention 
 
Control 
3 (15%) 
 
8 (38.0%) 
Intervention 
 
Control  
12.0 (5)  
11 (3) 
No details 
Rabi and 
Dahdal. 
2007[108] 
 No details  No details - - No details 
Bayley 
2007[114] 
All patients  
 
Older than 
85  
N (%) 
78.9 (No details) 
Range (60-94) 
 
33 (31%) 
All 35 (33%)  9.8 (No details) No details 
Scullin 
2007[115] 
Intervention 
Control  
70.3 (13.8)  
69.9 (4.8) 
Intervention  
Control 
167 (45.0%) 
192(49.0%) 
- - 100% unplanned 
admission b 
Bolas 
2003[225] 
Intervention  
 
Control  
73 (No details) 
Range (1-27) 
75 (No details) 
Range (1-37) 
Intervention  
 
 
Control 
32(40.0%) 
 
 
31 (39.0%) 
Admission  
Intervention  
 
Control  
Discharge 
Intervention  
 
Control 
6.3 (No details) 
Range (3-21) 
6.2 (No details) 
Range (3-14) 
6.79 (No details) 
Range (2-18) 
6.73 (No details) 
Range (2-16) 
100% unplanned 
admission b 
b Unplanned admissions were excluded. SD: Standard deviation 
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Authors, 
Year  Age  
Gender 
(male)  
No. of 
medications 
Type of 
admission 
(planned) 
 Measured 
patients 
Mean (SD) Measured 
patients 
N (%) Measured patients Mean (SD) N (%)   
Stowasser 
2002[226] 
 
Intervention 
Control 
 
67.4 (13.0) 
65.6 (14.0) 
 
Intervention  
Control 
 
63(56.0%) 
69 (54.0%) 
Admission  
Intervention  
Control  
Discharge: 
Intervention  
Control 
7 (3.7) 
7.2 (3.6)  
 
 
7.6 (3.5) 
7.6 (3.8) 
No details 
Hick 
2001[228] 
Intervention  
 
Control  
 
67.4 (15.5) 
Range (30-91) 
63.0 (16.1) 
Range (30-88) 
Intervention  
 
Control 
21(42.0%) 
 
26 (52.0%) 
Admission regular medicines 
Intervention  
 
Control  
2.78 (2.31) 
 
2.52 (2.58) 
100% planned 
admission  
Admission as needed medicines 
Intervention  
Control 
1.12 (1.08) 
0.50 (0.93) 
Discharge all prescribed 
medicines  
Intervention  
Control  
4.36 (2.51) 
3.60 (3.0) 
Discharge regular medicines 
Intervention  
Control  
3.28 (2.33) 
3.46 (2.44) 
Discharge as needed medicines 
Intervention  
Control 
2.30 (1.39) 
3.12 (1.49) 
SD: Standard deviation  
Continued 
Table 5.4 Characteristics of included patients by study   


Authors, 
Year  Age  
Gender 
(male)  
No. of 
medications 
Type of admission 
(planned) 
 Measured 
patients 
Mean (SD) Measured 
patients 
N (%) Measured patients Mean (SD) N (%)   
Brookes 
2000[232] 
All patients  
 
Older than 
60 n (%) 
75 (no details) 
Range (60-92)  
234 (56%) 
- No details  All patients 8.0 (no details) 
Range (4-14) 
 
No details 
Kramer 
2007[229] 
Intervention  
Control  
 
65.7 (17.6) 
64.4 (16.0) 
Intervention 
Control 
74(51.0%) 
69 (52.0%) 
Total no. of medications  
Intervention  
Control  
 
8.3 (5.2) 
6.0 (4.0) 
No details 
Regular medicines  
Intervention 
Control 
6.2 (4.3) 
4.9 (3.5) 
As required medicines 
Intervention 
Control 
2.0 (1.9) 
1.0 (1.6)  
 
Herbal supplements 
Intervention  
Control 
0.1 (0.6) 
0.1 (0.34) 
SD: Standard deviation  
Continued 
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Authors, 
Year  Age  
Gender 
(male)  No. of medications 
Type of 
admission 
(planned) 
 Measured 
patients 
Mean (SD) Measured 
patients 
N (%) Measured patients Mean (SD) N (%)   
Gillespie 
2009[135]  
 
Intervention  
 
Control 
 
86.4 (4.2) 
 
87.1 (4.1) 
 
Intervention  
 
Control 
 
77(42.3%) 
75 (40.3%) 
Regular medicine  
Intervention 
 
Control 
 
8.7 (4.5) 
 
7.3 (4.4)  
100% 
unplanned 
admission 
Vira 
2006[231] All patients 56.0 (24.0) All patients 30 (50%) 
Admission  
All patients 3.6 (3.5) 13 (22%) 
Spinewine 
2007[109] 
 
Intervention 
 
Control 
 
82.4 (6.9) 
 
81.9 (6.2) 
 
Intervention  
 
Control 
 
27(28.1%) 
 
30 (33.3%) 
Regular medicine  
Intervention  
 
Control 
7.9 (3.5) 
 
7.3 (3.3)  
 
No details 
SD: Standard deviation 
 
Continued  
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5.5 Effects of pharmacy led MR 
5.5.1 Medication discrepancies and the MR pharmacist interventions  
There were considerable variations in the discrepancy rates per patient among the 
included studies (Figure 5.2).  This might reflect differences between studies with respect 
to the intervention and discrepancy measurement.  Additionally, variances in discrepancy 
rate might be attributed to studies reporting only the rate of unintentional discrepancies 
without considering intentional discrepancies as errors.[108, 231, 233] 
 
Figure 5.2 Discrepancies rate per patient by study 
It can be seen in Table 5.2 that the MR pharmacist often provided non-MR care activities 
in addition to MR.  Thus, studies collectively described discrepancies related to MR and 
non-MR interventions.[109, 114, 225-228]  The highest rate was reported by Bayley et al.; [114] the 
MR pharmacist interventions were mainly related to medicine consultations.  Of these only 
20% were related to MR, those were related to allergy clarification. 
The lowest rate of discrepancies was found by Kramer et al.[229]  Ward staff were asked to 
complete the documentation of the MR process and to record interventions using 
computer system; Kramer et al reported that documentation was found incomplete and 
thus the reported rate is likely to underrepresent the actual rate of discrepancy.[229] 
Table 5.5 summarises details of MR discrepancies by study.  There were notable 
variations in the nature of the reported discrepancies.  Some studies reported only 
omission or addition discrepancies, whereas others reported discrepancies such as 
change to frequency, dose, route of administration and allergy information.  
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It can be seen that medication omissions and allergy documentation were the most 
frequent type of discrepancies.[108, 114, 225, 229, 231, 233]  Roughly, equal numbers of 
discrepancies were identified upon admission, during hospital stay and at discharge. [114, 
231]  However, the types of discrepancies varied over the course of the hospital stay.  
Admission discrepancies were mainly omissions of pre-admission medicines.  Clarification 
of allergy information frequently occurred upon admission too; Kramer et al and Bayley et 
al.[114, 229] outlined significant improvement in allergy identification and documentation for 
intervention patients in comparison to control patients.[229]  Discrepancies in medicine’s 
details and additions were identified at a later point of inpatient stay or upon discharge.  
The pharmacist’s role upon discharge was mainly focused on returning the patient to pre-
admission medicines and reconciling the changes occurred during the hospital stay.[109, 114] 
Studies have highlighted a benefit of MR on post discharge medication information; this 
was highlighted by Bolas et al.[225] and Stowasser et al.[226]  Bolas et al.[225] examined 
patient medicines at 10-14 days post discharge and outlined significant improvement in 
the correlation between discharge prescription and home medicines.  Thirty days post-
discharge, Stowasser et al.[226] found fewer medicines changed in the intervention groups 
compared to the control group, 33% and 56% respectively.  However, the proportion of 
patients experiencing medicine changes was similar between the study groups. 
The potential impact of the MR intervention on patient own drugs, i.e. home medicine 
brought with patient upon admission, management and minimising medicines wastage 
was evaluated by Bolas et al.[225]  Pharmacy led MR optimised the management of patient 
own drugs; this was evident by increasing the rate of patient own drugs reconciliation and 
more patients having their patient own drugs returned for use upon discharge.   
5.5.2 Clinical significance of medication discrepancies and MR pharmacist 
interventions  
Seven studies described the clinical significance of discrepancies identified during MR 
process; these studies used various classifications and rating systems.[114, 225, 227-229, 231, 233]  
In four studies, the clinical significance of a discrepancy was determined based on a 
clinical judgment by one or more clinical experts using own developed tools.[114, 225, 231, 233]  
Two studies adapted standardised tools from previous published work.[225, 228]  One study 
used the Dean and Barber visual analogue scale approach.[228]   
A doctor and a pharmacist evaluated the clinical impact of unintentional discrepancies in 
the study of Perennes et al.  More than 50% of the unintentional discrepancies were 
considered clinically significant.[233] The pharmacist considered more discrepancies with 
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low to moderate clinical consequences compared to the doctor who assigned no clinical 
effects or consequences to the same discrepancy.   
Boso- Ribelles et al. employed more generic classification based on a judgment by the 
study pharmacist.  More than 80% of the identified drug related problems were considered 
potential and one out of ten drug related problems were considered actual.[227]  
Bayleys et al. rated pharmacist interventions with respect to length of impact as short or 
long term. Additionally, Bayleys et al. assessed the clinical importance ranging from 
“simple cost saving” to “prevent of morality”.  One out of three interventions prevented 
serious morbidities.[114]  All ratings were based on the study pharmacist’s judgment; 
however, the ratings were reviewed by two independent pharmacists and the variances 
identified were discussed.  
Similar to Perennes et al.,[233] Vira et al. evaluated the clinical importance of unintentional 
discrepancies.  Clinical importance was considered when a discrepancy caused or had 
the potential to cause death, permanent or temporal disability, prolonged hospital stay, 
readmission, need for additional treatment and monitoring to protect the patient from 
harm.  The MR pharmacist intercepted three out of four discrepancies considered 
clinically important before causing patient harm.  This was based on one internist doctor 
judgment.[231] 
A validated system was employed by Bolas et al; using Eadon [234] ratting system grading 
“0” as being detrimental to patient health through to “6” which is potentially lifesaving.  
Discrepancies assessment was performed independently by a consultant and a 
pharmacist.  More than 90% of the interventions were graded as significant or very 
significant resulting in improvement within the standards of care and preventing major 
organ failure or adverse reactions.  The pharmacist again rated interventions with greater 
significance compared to the consultant.[225]   
The work of Hick et al. on the clinical significance was based on Dean and Baber 
approach;[183] using a visual analogue scale with four clinical expert judges.  Four senior 
pharmacists rated the interventions on a visual analogue scale ranging from 0 to10 with 
anchors of life threatening and lifesaving effect.  The study pharmacist interventions 
exhibited more potential positive impact to patients compared to the ward pharmacist’s 
interventions.  Dean and Barber approach is a validated estimate of medication error 
severity; Hick et al believed that the same can be applied to the clinical significance of the 
MR pharmacist interventions.  There was no significant agreement between assessors, 
(p<0.001).  Further to the use of visual analogue scale, Hick et al. graded interventions 
using a standardised scale adapted from a published study in the USA with a few 
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modifications to ensure simplicity of wording.  The tool was devised to assess the clinical 
impact of pharmacist interventions.[235]  Interventions were graded using “1” with adverse 
effect on patient to “6” with potentially lifesaving effects.  The results of the modified 
Hatoum scale [235] were in agreement with Dean and Barbers’ tool.  Again, the study 
pharmacist interventions exhibited significantly more potential impact to improve patient 
care compared to the ward pharmacist interventions.[228] 
Kramer et al. reported their intent to employ the existing policy of errors reporting in the 
study hospital, but due the lack of documentation it was not possible to assess the clinical 
significance.[229] 
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Authors, 
Year Nature of discrepancy N (%) Clinical significance N (%) 
Rater(s), 
agreement 
Karapinar-
Carkit 
2012[107] 
Correction of formulary changes 
Omission of pre-admission medication  
70 (9.0%) 
409 (52.3%) 
-  - - 
Perennes 
2012[233] 
Unintentional a 
Omission of pre-admission medication  
Wrong regimen 
Wrong dosage and incorrect frequency of 
administration  
Intentional  
Undocumented 
 
 
29 (76%) 
6 (16%) 
3 (8%) 
 
 
58 (97%) 
Doctor judgment b: 
Not susceptible to have clinical 
consequence 
19 (50%) A Doctor and a 
pharmacist, no 
details on 
agreement Susceptible to low clinical consequence 17 (45%) 
Susceptible to moderate clinical 
consequence  
2 (5%) 
Pharmacist judgment b: 
Not susceptible to have clinical 
consequence 
 
9 (24%) 
 
Susceptible to low clinical consequence  
 
15 (42%) 
 
Susceptible to moderate clinical 
consequence 
11 (29%) 
Boso-
Ribelles 
2011[227] 
Occurred in the transfer of medical care 
Drug related problem identified during 
admission reconciliation  
Drug related problem identified during 
discharge reconciliation  
76 (87.2%) 
1 (1.2%) 
82 (94.3%) 
Potential DRPs  
Actual DRPs  
73 (83.9%) 
10 (11.5% 
- 
Rabi and 
Dahdal. 
2007[108] 
Improper documentation of allergies 
Medications omission of medication taken 
before admission 
Wrong dose  
Deletion or addition of medication  
26 (46.4%) 
20 (35.7%) 
6 (10.7%) 
4 (7.1%) 
- 
 - 
a Non-prescribed over the counter medications were not taken into account to identify these divergences. b Only unintentional discrepancies were evaluated for clinical 
consequence. MR: Medicine reconciliation 
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Authors, 
Year Nature of discrepancies  N (%) Clinical significance N (%) 
Rater(s), 
agreement 
Bayley 
2007[114] 
Admission interventions  
Allergy Information updated/deleted  
Existing allergy reaction clarified 
New allergy identified  
In hospital interventions  
Allergy Information updated/deleted  
Existing allergy reaction clarified 
New allergy identified  
Intercepting an order of medicine the 
patient is allergic to  
Discharge interventions  
New allergy identified  
Follow up** interventions  
New allergy identified  
Allergy Information updated/deleted  
Intervention decrease morbidity  
Existing allergy reaction  
New allergy identified  
 
27 (13.8%) 
120 (61.2%) 
49 (25.0%) 
 
1 (0.28%) 
4(1.1%) 
4 (1.1%) 
1 (0.28%) 
 
1 (0.38%) 
 
 
1 (0.38%) 
1 (0.37%)  
 
 
22 (8%) 
4 (1%) 
Impact  
Short-term impact  
Long-term impact  
Both short-term and long-term 
impact  
Importance 
Interventions prevented serious 
morbidity 
Interventions prevented potential 
adverse drug event  
Interventions precluded cost (e.g. 
improper product selection)  
 
 
190 (20.5%) 
151 (16.3%) 
583 (62.9%) 
 
 
273 (29.2%) 
 
626 (67.7%) 
 
27 (2.9%) 
All ratting done by 
the study clinical 
pharmacist, the first 
20 patients in the 
study were 
independently 
reviewed by the 
pharmacy manager 
and study author.  
 
 
 
**Follow up care plans with primary care. MR: Medicine reconciliation 
Continued 
Table 5.5 Summary of MR discrepancies and MR pharmacist interventions   
	

 
Authors, 
Year Nature of discrepancies  N (%) Clinical significance N (%) 
Rater(s), 
agreement 
Scullin 
2007[115] 
Discrepancies related to a medicine 
name 
Discrepancies related to a medicine 
form 
Discrepancies related to a medicine 
strength  
Discrepancies related to a medicine 
dose  
Discrepancies related to a medicine 
frequency  
871 (62.7%) 
 
58 (4.2%) 
 
137 (9.9%) 
 
164 (11.8%) 
 
159 (11.4%) 
- - - 
Bolas 
2003[225] 
Drugs missing from patient 
prescription chart 
110 (49% 
 
Consultant C 
An intervention that is detrimental to patient’s 
well-being or patient care  
 
None 
Independently by a 
hospital pharmacist 
and medical 
consultant. No 
details on 
agreement 
Incorrect dose/frequency  46 (20%) An intervention that is significant but does not 
lead to an improvement in patient care  
20 (8.9%) 
 
Clarification of strength or 
presentation   
32 (14%) An intervention that is significant and results 
in an improvement in the standard of care 
171 (76.0%) 
Drug choice query  10 (4.5%) An intervention that is very significant and 
prevents major organ failure or adverse drug 
event  
34 (15.1%) 
Incorrect drug 11 (5%) An intervention that is potentially lifesaving None 
  Pharmacist C  
An intervention that is detrimental to patient’s 
well-being or patient care 
 
9 (4.0%) 
  An intervention that is significant but does not 
lead to an improvement in patient care  
An intervention that is significant and results 
in an improvement in the standard of care 
7 (3.1%) 
 
 
117 (52.0%) 
  
Continued  
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Authors, 
Year Nature of discrepancies N (%) Clinical significance Rater(s), agreement 
Bolas 
2003[225] 
(cont.) 
An intervention that is very significant and prevents major organ 
failure or adverse drug event 
An intervention that is potentially lifesaving 
87 (38.7%) 
 
5 (2.2%) 
 - 
Hick 
2001[228] 
Discrepancies identified by MR pharmacist  
Interactions, previous adverse drug event, drug therapy in ‘Nil 
By Mouth’ periods, the need for long term medication, and 
information documented in medical records 
Dosage discrepancies 
Drug choice/identity discrepancies 
Discrepancies identified by the ward pharmacist 
Interactions, previous adverse drug reactions, drug therapy in 
‘Nil By Mouth’ periods, the need for long term medication, and 
information documented in medical records 
Dosage discrepancies 
Drug choice/identity discrepancies  
 
 
42 (33.9%) 
 
24 (19.4%) 
 
55 (44.3%) 
 
 
 
13 (11.7) 
 
 
47 (42.4%) 
37 (33.3%) 
Visual analogue scale 
Mean (SD) VAS scores for 
intervention 1.6 (0.94) vs. 
for control 1.1(0.59), 
(p=0.003) MWU-test 
Natural log (ln) 
transformed VAS scores, 
(p=0.03) ISTT 
 
Modified Hatoum Scale; 
The median (IQR) grades 
intervention 3 (3 to 4) and 
3 (2 to 3) for control 
(MWU, p=0.005). 
Two methods were used: 
Visual analogue scale; 
Four senior pharmacists 
rated every intervention, 
agreed on the rated 
grades, no significant 
agreement ANOVA p 
<001 
Modified Hatoum Scale; 
second panel (comprising 
four senior pharmacists, 
with equal experience to 
the first), In 85% of cases 
two out of three 
assessors 
Brookes 
2000[232] 
Admission  
66 patients (60.5%) were found to have a discrepancy in their 
medication history on admission as follows: incorrect or 
missing strength of medication, incorrect or missing dose of 
medication, drug omitted from medication history, drug 
recorded but no longer taken by the patient  
Discharge  
In 36 cases (33%) there were problems with the discharge 
Procedure d 
- - - 
VAS: Visual analogue scale. MWU: Mann–Whitney U test. MR: Medicine reconciliation.SD: Standard deviation. IQRinterquartile range. ANOVA: Analysis of variance 
Continued  
Table 5.5 Summary of MR discrepancies and MR pharmacist interventions   


 
Authors, 
Year Nature of discrepancies N (%) Clinical significance 
Rater(s), 
agreement 
Kramer 
2007[229] 
Pre-implementation phased  
Incomplete medicines 
Duplicate medicines  
Dosage changes  
Adverse drug events 
Allergies changed  
Post-implementation phased  
Incomplete medicines 
Duplicate medicines 
Dosage changes 
Adverse drug events 
Allergies identified 
Allergies changed or allergy incomplete  
 
8 (33%) 
5 (20.8%) 
5 (20.8%) 
1 (4.2%) 
5 (20.8%) 
 
4 (8.3%), 
3 (6.3%) 
15 (31.3%) 
1 (2.1%) 
24 (50.0%) 
1 (4.7%) 
Pre-implementation e,f 
two category B errors and 
one category C error.  
Post-implementation e,f 
Three category B errors and 
one category C error.  
- 
Gillespie 
2009[135] 
Transcription errors and faulty omission or addition of 
drugs were frequently detected 
by the pharmacists. 
- - - 
d
 In the pre-implementation phase, admission medication histories and discharge medication counselling followed standard care processes. A nurse obtained each patient’s 
medication history and called the patient’s physician for admission medication orders. The nurse then handwrote admission medication orders in the physicians’ order 
section of the medical record. At discharge, the nurse handwrote each patient’s medication list and provided discharge counselling. In post-implementation pharmacists and 
nurses collaborated to electronically complete admission and discharge medication reconciliation documentation. e Categories A through C classified by National Coalition 
Council Medication Error Reporting Program Taxonomy; category A = circumstances or events that have the capacity to cause error, category B = an error occurred but did 
not reach the patient, category C = an error occurred and reached the patient but did not cause harm. f Severity of potential errors prevented were categorized using the 
hospital’s policy for categorizing medication errors. MR: Medicine reconciliation.   
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Authors, 
Year Nature of discrepancies N (%) Clinical significance N (%) 
Rater(s), 
agreement 
Vira 
2006[231] 
Total g 
Omitted medications 
Incorrect/omitted details (dose, route, 
frequency)  
Medication unintentionally ordered  
Lack of discharge instruction 
regarding medicines changed in 
hospital  
Discrepancies at admission   
Omitted medication/prescription  
Incorrect/omitted details (dose, route, 
frequency)  
Medicines unintentionally ordered  
Discrepancies at discharge  
Omitted medication/prescription 
Incorrect/omitted details (dose, route, 
frequency)  
 
 
80 (59%) 
18 (13%) 
 
4 (3%) 
34 (25%) 
 
 
50 (72%), 
15 (22%) 
 
 
4 (6%) 
 
 
30 (45%) 
3(4%). 
 Overall  
Patients with at least one clinically important 
unintended variance 95% CI 11 (18%) [ 9 to 28]  
Clinically important unintended variances 0.33 per 
patient  
 Intercepted  
 Not intercepted  
Variances leading to harm 0.07 per patient 
 Admission 
Patients with at least one clinically important 
unintended variance 95% CI 9 (15%) [ 6 to 24]  
Clinically important unintended variances 0.17 per 
patient  
 Intercepted  
 Not intercepted  
Variances leading to harm 0.03 per patient 
 Discharge 
Patients with at least one clinically important 
unintended variance 95% CI 5(9%) [ 2 to 16] 
Clinically important unintended variances 0.17 per 
patient 
 Intercepted  
 Not intercepted  
Variances leading to harm 0.03 per patient 
 
 
 
 
15 (75%) 
5 (25%) 
 
 
 
 
 
 
 
8 (80%) 
2 (20%) 
 
 
 
 
 
7 (70%) 
3 (30%) 
An internist  
g Unintentional errors. MR: Medicine reconciliation.  
Continued  
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Authors, 
Year Nature of discrepancies,  N (%) Clinical significance N (%) 
Rater(s), 
agreement 
Spinewine 
2007[109] 
On admission  
At least one unnecessary drug was 
prescribed to 84.4% of control and 
intervention patients on admission.  
On discharge  
Unnecessary drug use in 77.8% of 
control patients and 37.5% of 
intervention patients. 
- - - - 
MR: Medicine reconciliation.  
Continued  
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5.5.3 Length of hospital stay  
Length of hospital stay was reported as a descriptive demographic in eight studies. [107, 113, 
135, 225, 227, 229, 231, 233]  Duration of hospital stay was compared between the intervention and 
the control groups in seven studies, of which four of them included length of hospital stay 
as a measured outcome.[115, 118, 226, 230]  Frequently intervention patients stayed for longer 
time compared to control patients; however this was often not statistically significant all p 
> 0.05.[113, 135, 225, 229]  Mean of hospital stay by study can be seen in Figure 5.3.   
Scullin et al. was the only study which demonstrated a significant reduction in length of 
hospital stay.  The duration of hospital stay was reduced by 2 days on average; mean 
[95%CI] 9.8 [8.8-10.9] days for the intervention group and 7.8 days [7.1-8.6] for the control 
group (p=0.003). [115]  In contrast, Makowsky et al. reported significant increase in length of 
hospital stay of intervention patients compared to control patients; adjusted median ratio 
[95% CI] was 1.16 [1.01, 1.34] (p=0.031).   
 
*Median length of hospital stay  
Figure 5.3 Average length of hospital stay by study 
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5.5.4 Readmissions and emergency department visits 
Details of readmissions and emergency department visits can be seen in Table 5.6.  
Overall, studies reported fewer readmissions and emergency department visits for 
intervention patients compared to control patients; however, this was often not statistically 
significant.  Readmissions and emergency department visits were evaluated at different 
time post discharge which ranged from 30 days up to 12 months.  At 30 days post 
discharge, readmission rate in the intervention group was reduced in the study by 
Stowasser et al; this effect just failed to reach statistical significance.[226]  Mean (SD) 
number of readmissions per patient was 0.12 (4) for the intervention group compared to 
the control group which was 0.46 (1.9) (p=0.055).[226]  Of note, mean planned visits was 
significantly lower in the intervention group compared to the control group; 6.3 vs. 8.61 
respectively p <0.05. 
Koehler et al. found significant reductions in readmission and emergency department 
visits.  This effect appeared 30 days post discharge but was not continued beyond 60 
days.[118]  At three months, unplanned drug related readmissions were significantly 
reduced in the intervention group in the study by Hellstrom et al.  The absolute risk 
reduction [95% CI] was 6.4% [1.2-14.1].[113]  However, the proportions of patients 
experiencing at least one drug related admission were similar between groups.  All cause 
of hospital readmissions combined with emergency department visits were significantly 
reduced three months post discharge in the study by Makowsky et al.  Similar to Koehler 
et al. this significant effect was not carried on six months post discharge.[230]  Conversely, 
at longer follow up of 12 months post discharge, Scullin et al. found a significant reduction 
in hospital readmissions.  The average number of readmissions per patient for the 
intervention group compared to control patients was 0.8 and 1.0 respectively.  Numbers of 
readmissions as well as the proportions of patients readmitted were significantly lower in 
the intervention group compared to the control group.  Additionally, the average duration 
of readmissions was reduced by 3.4 days, (p=0.068) and patients took significantly longer 
time (262 days) to be readmitted to hospital compared to control patients (242 days), 
(p=0.036).[115] 
Koehler et al. also highlighted that the time for readmissions and emergency department 
visits to occur was longer for intervention patients compared to control patients.  Number 
of days for the first readmission or emergency department visit to occur was 36.2 and 15.7 
days respectively, p < 0.05.  Additionally, duration of readmissions was shorter for 
intervention patients with mean (SD) 3.7 (2.1) days compared to patients in control group 
2.2 (2.1).  Koehler et al. was a pilot study of small scale; 20 in each group, there was no 
sufficient power for statistical comparison between groups.[118]  
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Authors, 
Year  
All hospital revisit 
(Readmission & emergency 
department visits) Readmissions emergency department visits 
 Measure  Intervention  
No. patients 
(%) 
Control 
No. patients 
(%) 
Intervention 
No. patients (%) 
Control 
No. patients 
(%) 
Intervention 
No. patients 
(%) 
Control 
No. patients 
(%) 
Boso-Ribelles. 
2011[227] 
Over the first 3 months a 
 
-  - 61 (40.4%) 63 (55.8%) 82 (54.3%) 73 (64.6%) 
Hellstrom 
2011[113] 
Three months post 
discharge **  
6 (5.6%)  12 (12%) 2 (1.9%) b  3 (3%) None  3 (3%) 
Makowsky 
2009[230] 
Three month post 
discharge** 
Six months post discharge* 
80 (36.2%)  
112 (50.7%)  
105 (45.5%) 
130(56.3%) 
- - - - 
Koehler 
2009[118] 
0-30 days post discharge 
** 
31- 60 day post discharge* 
0-60 days post discharge* 
2 (10%) 
1 (5%)  
9 (42.9%)  
 
8 (38%) 
4 (20%) 
6 (30%) 
- - - - 
Rabi and 
Dahdal. 
2007[108] 
Over 1 month study  - 2 (3.6%) - - - 
Scullin  
2007[115] 
12 month follow**c  - 141 (38.0%) 172 (44.0%)  - - 
Bolas  
2003[225] 
Three month post 
discharge 
 -   No details 
about 
frequency* 
 
a Comparing the number of emergency visits and hospitalisations over the first trimester of 2007 which were experienced by the patients included in the programme against 
those experienced by patients excluded from the programme due to a lack of resources. b Unplanned admissions. c Two patients (one intervention and one control) were 
excluded from the analysis due to insufficient medical record data. Numbers to treat, i.e. receiving the study service in order to prevent one readmission 11.7 patients. * NS 
(p >0.05) ** sig (p <0.05).  
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Authors, 
Year Measure 
All hospital revisit  
(Readmission & emergency 
department visits) Readmission Emergency department visits 
  Intervention  Control  Interventio
n  
Control  Intervention  Control  
Stowasser 
2002[226] 
30 days post discharge  
Planned readmissions * 
No. patients (%)  
Unplanned admission* 
No. patients (%)  
No. unplanned admission 
per patient, mean (SD) 
 
 
- 
 
- 
 
 
- 
 
 
- 
 
- 
 
 
- 
12 (11%) 
 
 
9 (8.0%) 
0.08 (0.3) 
17 (13%) 
 
 
12 (9.4%) 
0.13 (0.5) 
- - 
Brookes 
2000[232] 
During the period of the 
study (five months)  
No. patients (%) 
 
 
- 
 
 
- 
 
7 (6.4%) 
 
65 (8.8%) 
- - 
Kramer 
2007[229] 
30 days post discharge*   
No. patients (%) 
- -  
8 (5.7%)  
 
17 (11.6%) 
 
9 (6.1%) 
 
12 (8.8%), 
Gillespie 2009 g
[135]
 
12 months post discharge* 
No. patients (%) 
 
No. per patient, mean (SD) 
 
 
 
1.46 (1.88) 
 
 
1.69 (2.24) 
 
106 (58.2%) 
 
0.049 (0.06)  
 
110 (59.1%) 
 
0.24 (0.32) 
 
 
0.27 (0.35)  
 
 
0.5 (0.66) 
Spinewine 
2007[109] 
12 months post discharge* 
No. patients (%) 
 
- 
 
- 
 
250 (32.6%)   
 
220 (33.7%) 
 
60 (7.9%)  
 
78 (12.0%) 
*NS (P >0.05),** sig <0.05. g Comparison using quotient. SD: standard deviation 
 
 
Continued  
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5.5.5 Health resource use in community  
Stowasser et al. evaluated health resource used in community 30 days post discharge 
using a post survey.  Response rates for the intervention group were 93% and 85% for the 
control group.  Total number of visits to health care professionals were fewer for patients 
in the intervention group compared to control group; mean (SD) were 7.54 (7.4) and 9.94 
(10) respectively (p<0.05).  Health services visits were differentiated into GP, medical 
specialist, community pharmacist and domiciliary nurse; the only significant reduction was 
for the visits of medical specialists; mean (SD) was 0.67 (1.1) for the intervention group 
and 0.94 (1.2) for the control group (p<0.05).  
5.5.6 Health Related Quality of Life  
One study [226] evaluated the impact of pharmacy led MR on health status measured by 
SF- 36.[236]  SF- 36 is a short-form health survey contains 36 questions with eight 
measures: bodily pain, general health, physical functioning, role physical, mental health, 
role emotional, social functioning and vitality.  
Thirty days post discharge, patients in the intervention group showed improvement with all 
health measures except for general health.  However, the only statistically significant 
improvement was for bodily pain and physical functioning, p <0.05.  Control patients 
showed improvement for bodily pain, physical functioning, mental health and vitality which 
was significant for bodily pain, physical functioning and vitality.  Magnitudes of changes in 
the intervention group, however, were more profound compared to the control group, 
except for vitality.  
5.5.7 Mortality 
Impact of the MR intervention on mortality was reported by three studies.[109, 115, 135, 226]  At 
12 months, all three studies found similar death rates between the intervention and the 
control patients.  Although, these conclusions are derived from randomised controlled 
studies, there were significant imbalances between groups.  In two studies, compared to 
the control group, more patients in the intervention group required more complex care.  
Those who were prescribed more medicines were also intervention patients.[109, 135] 
5.6 Cost associated with pharmacy led MR 
Studies reported a range of costs associated with pharmacy led MR interventions (Table 
5.7).  However none of these studies estimated these costs via an economic evaluation 
design.  Only one study performed a form of cost analysis from a health insurer’s 
perspective.[107]  Table 5.8 summarises costs associated with the MR interventions.  
Primarily, costs were related to the additional use of the MR pharmacist [107, 231] medicine 
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use [107, 225, 232], readmissions and emergency department visits [115, 135, 232] and other health 
care professional time.[228, 229]  
The time spent to implement MR was valued in two studies; in the study by Karapinar- 
Carkit et al. the time was converted into labour costs of a pharmaceutical consultant which 
was estimated as €41.04/ patient (sensitivity analysis €25.56-€59.40).  The study also 
valued the time in relation to a clinical pharmacist and a pharmacy technician labour cost 
which was €49.24/ patient and €32.83/ patient respectively (Table 5.8).  Vira et al. valued 
the costs related to pharmacist time spent performing admission MR yielding a cost of 
$10.6/patient.  This estimation was based on the overall time required to perform the 
admission reconciliation which was 1,090 minutes for all patients in the study (n=60).[231] 
Medicine costs/savings were evaluated by Karapinar-Carkit et al.[107]  Three mutually 
exclusive categories of errors were identified (Table 5.5) of which only the correction of 
hospital formulary and therapy optimisation errors were considered of real costs to 
patients prescriptions and consequently to health insurers.  Errors related to discrepancies 
identified between pre-admission and inpatient medicines considered of no costs since 
the patient is taking them prior admission, and therefore these errors were not included.  
Medicine costs/savings were thus estimated as the difference between the labour costs 
and medicines costs related to the correction of hospital formulary and therapy 
optimisation errors.  Discharge medicines intended for chronic use were prescribed for 
one month in the study department and thus medicines costs/savings were estimated at 
one month post discharge.  Additionally, medicines costs/savings were estimated at six 
months period assuming that chronic medicines often continued up to 6 months.  
Medicines contributed to costs for patients but not to insurers were not included and thus 
the costs of the interventions contributed by over the counter and herbal products were 
not estimated.  Those medicines are paid by patients in Netherland.[107]  Karapinar-Carkit 
et al. demonstrated that the net saving in medicine costs contributed by the MR 
interventions was €21.77/patient at one month and €96.65/patient six months.  Savings 
didn’t outweigh the pharmacy labour cost after one month, whereas it overweighed the 
labour costs at six months post discharge with a net saving of €55.62 /patient (sensitivity 
analysis €37.25-€71.10).[107]  The cost savings attributed to a clinical pharmacist and a 
pharmacy technician were estimated; at six months post discharge net savings were 
€47.41/patient (25.37-65.98) for the clinical pharmacist and €63.82/patient (sensitivity 
analysis €49.13-€76.21) for the pharmacy technician.  Similarly, cost savings didn’t 
outweigh the labour costs of the clinical pharmacist and the pharmacy technician at one 
month post discharge.[107] 
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Costs related to reconciliation and management of patient own drugs upon admission 
were evaluated by Brookes et al. and Bolas et al.[225, 232]  The costs of patient own drugs 
returned from wards that were left behind 13 patients after discharge were on average 
£25.22.  Consequently over three weeks and for 35 patients, the wastage related to 
inappropriate management of patient on drugs was estimated more than £15,000 
annually.[232]  Bolas et al. reviewed the medicines which were returned to the pharmacy 
over the study period, the estimated costs of patient own drugs that could have been 
returned and used was over £4,000 annually.   
Savings related to readmissions and emergency department visits can be outlined from 
Table 5.8 in three studies. [115, 135, 232]  Scullin et al. suggested substantial saving in costs 
contributed by reduction in hospital stay.  Cost savings were estimated based on savings 
in beds occupancy which then were extrapolated assuming that 64.5% of patients were 
eligible for the pharmacist intervention.  The potential annual saving was estimated to be 
over £3 million. 
Cost savings related to prevention of readmissions were estimated by Brookes et al.  Over 
four months, 18 readmissions were prevented which extrapolated to an annual base of 72 
readmissions with an estimated average stay of 7.7 days.  Consequently, total cost 
savings for the prevented readmissions was estimated to be £80,000 annually.  Over one 
year, the study by Gillespie et al. estimated the direct costs related to both readmissions 
and emergency department visits balanced with the cost of MR intervention.  Cost of 
intervention was based on the salary of one experienced pharmacist working half time and 
equivalent to nine months with 182 patients.  The unit costs and valuation of readmissions 
and emergency department visits costs were not described.[135]  Costs of readmissions and 
emergency department visits were lower in the intervention group compared to the control 
group which balanced the cost of the intervention and contributed to approximately $250 
savings per patient.[135] 
Saving in nurses’ time was evaluated by Kramer et al.  Approximately one hour of the 
nurse time, which would have been required to document allergies in the computer, was 
spared.  The study also involved doctors and nurses completing different steps of MR 
process primarily in discharge reconciliation report.  No details were reported for the 
estimation or valuation of this time.  Conversely, Koehler et al. reported an increased time 
spent by the nurse care coordinator who worked collaboratively with the MR pharmacist.  
The nurse reported spending additional 20-25 minutes performing wide spectrum of 
clinical activities including counselling patients and families, documentation and faxing of 
the study forms.  Karapinar-Carkit et al. reported no costs or savings related to the time of 
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other health professionals; all tasks were performed independently by the MR 
pharmacist.[107] 
Savings in doctors’ time was reported by one study.[228]  The pharmacist increased time 
commitment to obtain medication histories, transcribe medication and provide patient 
counselling might have spared doctors’ time to perform other activities.  The mean time 
saved for the doctors was 14 minutes per patient which accounted for a total of 63 hours 
per month.  Nevertheless, the time saved for the doctors’ or the nurses’ reported by 
Kramer et al. and Hick et al. was not amounted against to the extra time commitment 
spent by the MR pharmacist.[228, 229]  
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Study 
Overall cost 
of 
intervention
Medication 
errors/ADEs 
patient 
on 
drugs  
use 
Length 
of 
hospital 
stay Readmission 
emergency 
department 
visits 
Pharmacist 
time 
Other 
healthcare 
professional 
time 
Primary 
care use 
Patient 
expenses 
Informal 
care 
Karapinar
-Carkit 
2012[107] 
           
Perennes 
2012[233] 
           
Boso-
Ribelles 
2011[227] 
           
Hellstrom 
2011[113] 
           
Makowsky 
2009[230] 
           
Koehler 
2009[118] 
           
Rabi and 
Dahdal. 
2007[108] 
           
Bayley 
2007[114] 
           
Scullin 
2007[115] 
           
Bolas 
2003[225] 
           
Stowasser 
2002[226] 
           
ADE: Adverse Drug event. MR: Medicine reconciliation  
Table 5.7 Scope of costs measured by study 
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Overall cost 
of 
intervention  
Medication 
errors/ADEs 
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own 
drugs 
use 
Length of 
hospital 
stay Readmission  
emergency 
department 
visits 
Pharmacist 
time   
Other 
healthcare 
professional 
time  
Primary 
care 
use  
Patient 
expenses 
Informal 
care  
Hick 
2001[228]  
           
Brookes 
2000[232] 
           
Kramer 
2007[229] 
           
Gillespie 
2009[135] 
           
Vira 
2006[231] 
           
Spinewine 
2007[109] 
           
ADE: Adverse Drug event. MR: Medicine reconciliation 
Continued 
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Authors, 
Year Variable costs Cost /patient 
Knock on consequence 
costs  
Cost 
/patient 
knock on consequence 
savings  
Cost 
/patient 
Karapinar-
Carkit 
2012[107] 
Labour costs a,b 
Admission and discharge 
medication reconciliation  
Transfer of medication 
information (including 
adjustments in final discharge 
prescriptions   
 
€21.52c 
€2.14c 
 
Medicines related cost 1 
month d 
Total medicine use cost  
 
 
 
€1.51 
 
Medication related 
saving 1 month d  
Total medication saving  
 
 
 
€23.27 
 
Patient counselling (including 
discussion results with 
hospital physician) 
€17.38c  
 
Medicines cost 6 months 
d
 
Total medication cost  
 
 
€7.30 
 
 
Medication related 
saving 6 months  
Total medication saving  
 
 
€103.95 
Scullin 
2007[115] 
 
 
 
 
Length of hospital stay 
reduction e 
Opportunity cost saving £ 
3.3 million per annum 
Reduction of length of 
hospital stay for 
readmissions  
Opportunity cost saving of 
£2.8 million per annum 
£424 
a
 MR process was carried out by a team of pharmaceutical consultants. b Based on a mean yearly salary for a pharmaceutical consultant of €60.000, 44 working weeks, and 
a productivity of 50% (exchange rate: EUR 1 = USD 1.3443). c Based on a mean yearly salary for a pharmaceutical consultant of €50.000, 46 working weeks, and a 
productivity of 70%. d Errors relate to the prevention of medication discrepancies between the pre-admission and in-hospital prescribed medication was considered not to 
represent real costs for society, as the patient was using these drugs before hospitalization. Therefore, these interventions were not included in the cost calculation and only 
the difference between labour costs and hospital formulary induced changes and optimization of pharmacotherapy intervention costs associated with medication 
reconciliation was compared. e A medical bed in the Trust at the study time £212 per day. MR: Medicine reconciliation  
Table 5.8 Summary of MR related costs   
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Authors, 
Year Variable costs 
Cost 
/patient 
knock on consequence costs  
Cost 
/patient 
knock on consequence 
savings  Cost /patient 
Bolas 
2003[225] 
- - Patient own drugs 
The cost of patient own drugs which 
could have been returned to patients 
and reused was estimated as £4582 
per year based on a review of the 
drugs returned to pharmacy and the 
discharge prescription 
- - - 
Brookes 
2000[232] 
- - Patient own drugs 
The value of the patient own drugs 
left ranged from £5.60 - £66.20. In the 
case of 35 patients during a three 
week period £88.70 was wasted 
equivalent to £15.330 annually  
 
£25.22 
Treatment of readmissions 
Opportunity cost saving 
related to reduce rate of 
readmission £83,484 annually 
(i.e. the costs associated with 
the treatment of these re-
admissions) 
- 
Gillespie 
2009[135] 
- - Emergency department visits  
Intervention 
control 
Readmissions per patient 
Intervention 
Control 
Cost of intervention  
 
$160 
$260 
 
 
$12,000 
$12,300 
$170 
Cost savings balanced 
against the cost of the 
intervention was  
$230  
Vira 2006[231] Cost of pharmacist 
time for admission 
reconciliation g 
$10.6 Clinically important medication 
discrepancy detected at admission  
$64   
f Rate of exchange7.15 Swedish Kronor=$1 US on October 25, 2008 and comparison using difference. g This estimate was based on an overall time requirement of 1090 
minutes for admission reconciliation for all 60 patients and the cost of admission reconciliation was calculated by multiplying the number of hours spent by an hourly rate for 
clinical pharmacist time of $35 Canadian. MR: Medicine reconciliation. 
Continued  
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5.7 Resources needed to implement MR 
5.7.1 Time commitment 
An increased pharmacist time commitment was needed in order to implement MR 
interventions.  The estimated times spent by the pharmacist to implement MR varied 
between studies and ranged between 10 to 15 minutes and up to two hours (Table 5.9).  
Variations between studies can be seen; some studies reported the total time spent by the 
MR pharmacist to implement the intervention whilst others described the time spent 
performing MR and non-MR elements.  Approximately, 20-30 minutes were spent by the 
pharmacist to complete admission and discharge MR.[107, 108, 229, 233]  Longer time was 
estimated by few studies; those accounted for the additional time spent in obtaining or 
transfer information to GPs or community pharmacists[114, 118, 233] or performing 
administrative tasks such as printing and computer system updating.[114, 229]  Additionally, 
in some instances the medicine lists prepared by the MR pharmacist enquired validation 
or discussion with doctors or patients, this contributed to an additional time spent by the 
study pharmacist ensuring the completion of the MR process.[114, 118, 228, 229]   
The methods employed to record the intervention time might have contributed to the 
observed variations too. The study by Karapinar- Carkit et al. recorded the time using a 
stopwatch for 59 (22.5%) patients.  Bayley et al. recorded the time using two methods; a 
self-estimated time for each activity over one-week period and an observed time by a 
trained observer who shadowed the MR pharmacist for a day.[114]  Kramer et al. estimated 
the time using two approaches: self-reported and observation by the study investigator.  
Average time to complete the admission medication history timed by the study investigator 
was five minutes less than the self-reported time by the study pharmacist. [229]   No details 
were reported on the approaches followed for the time estimation in the remaining 
studies.[108, 118, 233]  
5.7.2 Training and education 
Education and training comprise potential resources necessary to set up the MR 
intervention.  Table 5.10 summarises details of MR related training and education.  
Training and education of the study team as well as ward staff were reported by five 
studies with contents of the received training and education sessions being described by 3 
studies.[115, 118, 230]  MR education and training was achieved mainly through meetings [118, 
229, 230]
, lectures or workshops [115] posters,[229] one to one communication [114, 229] and by 
written instructions attached to the patient note.[229]  
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The training was related to the targeted diseases[230] and covering various therapeutic 
topics as well as intent, documentation and delivery of the study intervention.[115, 118, 230]  
The MR pharmacist in the study by Bayley et al. spent two days rounding with the medical 
team to become formally integrated in the hospital medical team before commencing the 
study.[114]  The study by Kramer et al., involved pharmacist, nurses as well as doctors 
training on the intervention process and documentation, computer medication order entry, 
medication history interview and phone survey skills.[229] 
The time spent for the purpose of the MR training and education was approximately 2-3 
hours divided over one or more sessions.[118]   
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Author, Year Measure  Activities  
Time per 
patient 
(minuets) 
Karapinar-Carkit 
2012[107] 
Mean 
(SD) 
Total time of intervention  62.7 (14.6) 
Admission and discharge MR  32.9 (6.6)  
Patient counselling  26.6 (9.8)  
Transfer of medication information (including 
adjustments in final discharge prescriptions 
3.3 (2.8) 
Perennes 2012[233] Mean 
(range) 
Total time  
Patient interview or family member  
Obtain medication information from patient 
notes and GP letter  
Obtain faxed copy of the medication 
dispensed by the community pharmacies  
46 (no details) 
16 (5-40) 
12 (5-15)  
 
21 (10-45) 
Boso-Ribelles 2011[227] - Time from intervention identification to 
resolution 
 < 10 min for 97.7% of interventions 
 10 min for 2 interventions 
 None exceed 30 min with any case  
Phone call 
Patient contacted 7 days post discharge to 
resolve any quires, no details on duration 
- 
 
 
 
- 
Koehler 2009[118] Mean  Medication education, reconciliation, and 
optimization of drug therapy by MR 
pharmacist  
20  
 
Patient or carer counselling by the study 
nurse 
20-25 
Phone call 
Patient contacted 5- 7 days post discharge, 
no details on duration 
 
- 
Rabi and Dahdal. 
2007[108] 
Mean  Admission interview 
 
Discharge counselling including list of 
discharge medications prepared by study 
pharmacist and given to patient 
15  
 
10 
MR: Medicine reconciliation 
 
Table 5.9 Time commitment to implement MR 
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Author, 
Year Measure  Activities 
Time per 
patient  
(minuets) 
Bayley 
2007[114] 
Mean (range)  
 
Admission 
Collect historical data, print/read, print/reconcile electronic 
health record, draft care plan, review/document pertinent 
labs,  
Medication history by patient interview, review paper chart 
data, 
Identify patients  
Inpatient 
Daily Rounding, update new labs/culture information, 
assess current progress, ascertain discharge plan, follow 
up interventions  
Discharge 
Type discharge medication list  
Counsel patient  
Prepare printouts  
Write follow up care plan, update medication list, update 
allergies, route final document to primary care physicians  
Enter data on recommendations made  
Phone call a 
3-5 days post discharge to confirm patient understanding 
on medications and answer any questions,  
 
45 (30–60)  
 
 
37.5 (30–45) 
 
37.5 (30-45)  
 
 
75 (60–90)  
 
 
 
22.5 (15–30)  
30 (20–40)  
37.5 (30–45)  
75 (60–90)  
 
12.5 (10–15)  
 
 
(3–5 )  
Bolas 
2003[225] 
- Follow up home visit or telephone  
10–14 days after discharge by either a call 
- 
Hick 
2001[228] 
Mean Pharmacist 
Medication history taking. 
 
Over all additional time commitment  
Doctors  
The mean time saved for the doctor  
Extra 5 
minutes. 
Range (4 to 6)  
11.5 
 
 
14 minutes 
a The MR pharmacist could not provide accurate estimates of the total time spent on patient follow-up calls. 
While each call was brief (3–5 minutes), the calls were interspersed with other activities and often involved 
multiple calling attempts to reach the patient. MR: Medicine reconciliation 
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Author, 
Year Measure  Activities  Time per patient  
Kramer 
2007[229] 
Mean 
(SD) 
Nurses time to input allergies in the computer 
system 
Before MR intervention  
After MR intervention 
 
69.1 (98) 
141.1(238.8) 
  Pharmacist time 
Before MR intervention 
After MR intervention  
Completed admission medication history  
Time to clarify medications  
Time to perform interventions 
 
112.9 (70) 
64.1(38.7)  
12.9 ( 9.34) 
1.18 (5.84) 
1.4 (2.25) 
Gillespie 
2009[135] 
Mean Total time  140 
Vira 
2006[231] b 
Median 
(IQR) 
Admission reconciliation  
 
15 (10–21) 
b Time required for discharge reconciliation was not record. MR: Medicine reconciliation. IQR: interquartile 
range 
 
Continued 
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Author, 
Year Training/education details  
Makowsky 
2009[230] 
A series of education sessions led by local pharmacist experts (1 on each target 
disease state and 1 on documentation of clinical care activities), was conducted with 
the team-based pharmacists prior to commencing the study a 
Koehler 
2009[118] 
Three training meetings (each 45 minutes in duration) regarding the intent and 
delivery of the study intervention and use of study forms. 
Bayley 
2007[114] 
Prior to the onset of the study, the pharmacist rounded with each hospitalist for two 
successive days and became formally integrated into the hospitalist team. 
Scullin 
2007[115] 
A programme of accelerated clinical training covering major therapeutic topics was 
implemented. This consisted of lectures and workshops provided by specialist staff 
(pharmacists, nurses and hospital physicians), and was complemented by study 
days provided by the Northern Ireland Centre for Postgraduate Pharmaceutical 
Education and Training. 
Kramer 
2007[229] 
Nurses education 
Education sessions before study initiation. Nursing education was provided by 
investigators at staff meetings and individually. 
Pharmacist education  
All pharmacists attended a three-hour, hands-on computer education session. Before 
pharmacists were scheduled to work on the study unit, they completed an electronic 
medication order-entry competency evaluation covering admission through discharge 
using a test patient.  
Doctors education 
 Posters were placed on the medical unit to educate physicians about the 
medication reconciliation process.  
 Individual education was provided for physicians who frequently admitted 
patients to the unit.  
 Orange sheets placed in the front of the medical record of patients enrolled with 
written instructions explaining how to view medications, what to complete on the 
reports, and whom to contact with questions. 
 Care coordinator education b 
In-service education to explain the medication reconciliation documentation process. 
Nursing home contact 
Nursing homes and skilled-nursing facilities were contacted to explain the intent of 
the medication reconciliation discharge and patient medication discharge reports and 
to obtain feedback for improvement. 
Pharmacist order entry 
Special order types for home medication and discharge medication were developed 
in the clinical pharmacy care system. c 
Telephone surveyor training 
All researchers conducting telephone surveys completed a questionnaire measuring 
comprehension of a review of survey design methodology, telephone survey 
etiquette,and avoidance of bias in telephone surveys. 
a Most responsible or primary diagnosis of Coronary Artery Disease, community acquired pneumonia, chronic 
obstructive pulmonary disease, heart failure or type 2 diabetes mellitus were included. b Care coordinators are 
either registered nurses or licensed social workers who direct case management activities. Care coordinators 
often assist with compilation of discharge or transfer medication lists. c The special order types prevented 
home medications from being visible to nurses in the electronic medication administration record but allowed 
pharmacists to view the medications throughout each patient’s hospitalization.  
Table 5.10 Details of MR training/education   
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5.8 Quality and design of studies evaluating pharmacy led MR  
Outcomes of quality assessment are illustrated in Figures 5.4 and 5.5  
 
Figure 5.4 Outcomes of risk assessment by bias type 
Overall, studies were susceptible to high risk of design and selection bias.  Additionally, it 
can be seen that studies frequently failed to demonstrate adequate power and were 
presented with concerns on the appropriateness of the statistical analysis.  Appendix 18 
presents detailed description of bias assessment  
5.8.1 Design bias  
The included studies were mainly of non-randomised and/or uncontrolled design; they 
were therefore regarded with high risk of design bias. 
5.8.2 Selection bias  
Incomparability at baseline and ambiguity of patient selection approach were the main 
reason led to high risk of bias judgment.  Koehler et al. and Gillespie et al. are RCTs; they 
were, however, susceptible to selection bias namely due to lacking sufficient evidence to 
assume the study groups were comparable at baseline.[118, 135]  In those studies, 
intervention patients were prescribed more medicines compared to the control group and 
considered of greater illness acuity upon admission.  Those regarded as factors of 
considerable confounding effect on MR. 
No sufficient information describing the process by which patients were identified 
warranted a judgment of high selection bias risk in the study by Brookes et al. and 
Perennes et al.[232, 233]   
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5.8.3 Performance bias  
For five studies, there were insufficient details to precluded risk of performance bias 
relevant to standardised delivery of the MR intervention which warranted “unclear” 
judgement.[107, 114, 227, 231, 232]  A standardised MR delivery was achieved by using 
standardised set of open and closed questions during patient interview,[113, 233] and 
undertaking education sessions prior to the study commencement [229, 230] or attending 
training meetings.[118]  Additionally, studies used standardised operating procedures and 
data collection forms for the delivery and documentation of the MR process.[109, 115, 135, 225, 
228]
  For two studies, the information collected were double checked and verified by other 
health professionals, e.g. ward doctors, community pharmacists or GPs. [226, 233] 
Majority of studies demonstrated no concerns of bias relating to standardised outcome 
measurement.  Standardised outcome measurements was achieved by: blinding 
investigators who were responsible for study analysis,[135] using standard operating 
producers and data collection forms developed by multiple researchers,[109, 113, 230] and 
adapting a previously published standardised approach or employing an existing hospital 
policy. [114, 118, 229]  This was also achieved by an independent review [115] and verification of 
outcome data from multiple sources [226, 233]  
5.8.4 Detection bias  
Only four studies adequately described blinding outcomes assessment, this was achieved 
by blind or independent assessors. [109, 113, 115, 135, 230]  For the majority of studies, outcome 
measurements were performed by the MR pharmacist and therefore it was not possible to 
conceal group allocation.  Non-blinding of outcome measurement relevant to 
readmissions and emergency department visits and mortality was considered not 
concerning, providing outcome data was obtained from a standardised and indisputable 
sources such as: hospital computer system,[118, 226] a national database or reporting 
systems.[118, 230] 
5.8.5 Selective reporting (Incomplete outcome data) 
Majority of studies considered not susceptible to selective reporting bias; all outcomes 
measured were reported with no concerns of missing outcomes data.  However, 
Stowasser et al.[226] reported no details on emergency department visits, meanwhile 
Gillespie et al.[135] reported no sufficient details on drug related emergency department 
visits, omissions and transcribing errors.   
Concerns were presented in the study by Rabi and Dahdal due to incomplete discharge 
data relating to 16 patients.  Fifty six medication histories were conducted upon 
admissions; however, only 40 discharge counselling sessions were reported.  Reasons for 
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the unreported sessions were not discussed and thus it was not possible to preclude risk 
of reporting bias.[108] 
5.8.6 Adequacy of study power & analysis 
Only five of the included studies introduced no concerns regarding the adequacy of the 
study power and the statistical analysis.[109, 113, 115, 135, 230]  Most of the studies reported no 
sample size or study power estimation.  Particular concerns were with those of relatively 
small sample size.[108, 118, 231, 233] 
5.8.7 Validity of economic evaluations  
There was no study of economic evaluation design, and thus it was not permissible to 
assess risk of bias using the domains pre-specified for the purpose of assessing the 
quality of economic evaluations (appendix 9).  One exception was the study by Karapinar-
Carkit et al which attempted cost analysis of pharmacy labour costs in relation to medicine 
use.[107]   
Nevertheless, those studies reported costs, considered limited scope of costs and 
consequences.  Additionally, the costs and the cost savings were not valued based on a 
well-established valuation process and it was not possible to identify whether the unit 
costs were appropriate or of realistic values. 
The cost analysis by Karapinar-Carkit et al., employed a very limited perspective, a health 
insurer’s view, and considered only the cost of pharmacy labour time in relation to 
medicines costs.  Additionally, labour costs were estimated based on a selected sample of 
the study patients without enough information regarding patient selection or 
characteristics. Thus, the quality of the cost measurement is unknown.[107]  However, 
Karapinar-Carkit et al. demonstrated a reliable valuation procedure, clearly identified the 
sources of all cost units, employed justifiable and realistic values, and reported full details 
of the study assumptions.  Additionally, Karapinar-Carkit et al. also examined the 
uncertainty in the costs and cost savings by means of a sensitivity analysis for the factors 
varying medicines and labour costs.[107] Those were the main cost variables. 
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Figure 5.5 Outcomes of risk assessment by study (continued)            No economic evaluation/ cost analysis  Low risk of bias   
  High risk of bias   Risk of bias unclear   
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Overall, there is a scarcity of rigorously designed studies for the effects and the costs of 
pharmacy led MR with only two studies demonstrating low risk for all domains of bias.  For 
the remainder, methodological limitations introduced potential risks of bias and therefore 
conclusions around the questions of the effects and associated costs with pharmacy led 
MR implementation can only be drawn with caution. 
5.9 Summary of main findings 
Medication discrepancies at the time of hospital admission, inpatient stay and discharge 
are common and significant.  Pharmacist involvement in intercepting omission 
discrepancies and ensuring accurate allergy information was evident.  However, 
heterogeneity and methodical limitations do not allow conclusive conclusions on the 
benefits on patient oriented outcomes and post discharge health resource use.  
Only one study demonstrated significant reduction in length of hospital stay; the effect of 
pharmacy led MR on readmissions and emergency department visits was unclear.  
Significant benefits, however, were shown on readmission duration and the time took for 
readmissions to occur.  There was limited evidence for the effect of MR on the quality of 
patient life, though a favourable effect was reported by one study.  In addition, no effect 
was observed on mortality rate up to12 months post discharge.  
Conclusions on the associated cost of MR intervention should be considered with 
hesitation.  Findings reported on costs/savings associated with MR were derived by no 
means of robust health economic evaluation.   
In summary, pharmacy led MR was a useful method for identifying and rectifying 
medication errors at times of transition.  However, the effect on health care resource use 
is less clear.  Only 17 studies evaluated full MR process; those showed considerable 
variations with MR interventions, measures and methods.  Such variances impede 
combining the results to provide an overall indication for the effects and costs of pharmacy 
led MR.  No meta-analysis of the identified evidence was warranted.   
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Chapter 6 Pharmacy Led Medicine Systematic 
Review Discussion  




Discussion 
 
 
Pharmacy led medicine 
reconciliation in hospital 
care: a systematic review  
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6.1 Hospital based pharmacy led MR intervention  
In the previous chapter, pharmacy led MR systematic review of the effects and costs 
associated with pharmacy led MR showed that the transfer of information and thus 
continuity of care could be improved by the MR pharmacist involvement.  However, the 
effects on post discharge health resource use, mortality and quality of life are less certain. 
There was also limited evidence on the associated costs with pharmacy led MR 
implementation. 
Relatively few studies described the implementation of a full MR process despite MR 
tasks being well defined.[72, 73]  This may be because what counts as MR varies between 
organisations and workflows; in some encounters it includes only medication history  
whereas in other encounters it might constitute of more specialised care such as 
medication review and discharge planning.[73, 149]  However, the clarity of MR as a process 
is improving, more recently published studies are increasingly reporting the full MR 
process.[107, 233]  There are a number of reasons cited for why incorporation of the full MR 
process is still a challenge for many hospitals;[237] foremost were highlighted by the 
Institute of Healthcare Improvement in 2011.  The Institute of Healthcare Improvement 
highlighted lack of a clear ownership of the process and absence of a standardised MR 
process.[79]  Medication review is an example of a key part of the prescribing process 
which was clearly defined and standardised across NHS in 2008, which may be partly 
attributable to its wide application.[238]  Similarly, it would be expected that developing well 
defined MR processes would help in optimising the delivery and application of MR. 
Across literature varying terminology was used to describe MR, all of which needed to be 
considered in order to obtain the most comprehensive evidence synthesis.  MR was 
commonly supplemented by other non-MR care activities; and there were considerable 
variations with MR interventions and measurements across the included studies.  Several 
studies focused on process orientated outcomes such as the identification of medication 
discrepancies, MR pharmacist interventions, accuracy and completeness of medical 
notes, or inpatient charts.  Other studies measured more patient orientated outcomes 
such as length of hospital stay, readmission rates and health related quality of life.  
However, no study assessed comprehensively both process and patient orientated 
outcomes.   
Collating the evidence from the included studies; features of the best MR practice and 
foremost outcomes to measure are proposed in BOX 6.1 and 6.2. 
 
  

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BOX 6.1 Features of hospital based MR practice  
 
  Successive steps that include obtaining, verifying and documenting an 
accurate list of medicines the patient is taking and comparing the list with 
inpatient and discharge list to identify and resolve discrepancies [110-112, 116-118, 
121, 137, 237-245]
 
 Led by pharmacist with hospital residency experience or pharmacy technician 
with additional training in pharmacotherapy and communication skills [110-112, 116-
118, 121, 137, 237-245]
 
 Implemented within 24 hours of admission 
	 
 Structured/semi-structured patient and/or carer interview upon admission to 
verify medication history [116, 137, 237, 239, 242, 245] 
 Implemented on weekdays during normal working hours [ 
 Targeted at high risk patients who are prescribed at least one or more regular 
medicines [116, 118, 121, 237, 240] 
 Discrepancies are confirmed using at least two sources of patient information 
[118, 137, 237, 241, 243, 245]
 
 All relevant patient information is collected of such as allergies, previous 
adverse drug events, over the counter medicines and herbal medicine use [111, 
118, 243-245]
 
 Discrepancies are resolved by discussion with doctors and nurses upon 
admission and discharge [116, 118, 121, 244] 
 MR process delivered and documented in  standardised approaches [116, 137, 239] 
 Discharge information is communication to patients, GPs and community 
pharmacists on the day of discharge or shortly afterwards [137, 240, 243, 245]  
 
 
BOX 6.2 Foremost MR related outcomes measured  
 Process oriented  
 Unintentional medication errors [107, 228, 231] 
 Significance of medication errors [114, 225, 227-229, 231, 233]  
 Pharmacist interventions [108, 114, 225, 228] 
 Time commitment [107, 108, 114, 118, 135, 225, 227-229, 231, 233] 
Patient oriented  
 Length of hospital stay [115, 118, 226, 230] 
 Readmission rate [109, 113, 115, 118, 226, 227, 230]  
 Emergency department (ED) visits [113, 118, 135, 225-227] 
 Health resource use in community [226]  
 Health related quality of life [226] 
 Mortality rate [109, 135, 226] 


6.2 Effects of pharmacy led MR  
The involvement of MR pharmacist at the points of care transition was useful for 
identifying and rectifying medication errors and improving the completeness of medication 
history and allergy information.[107, 108, 114, 115, 135, 225-229, 231, 233]  MR was also reported to 
improve the association between discharge prescription and medicines the patient is 
taking post discharge; i.e. post discharge home medicine list was more closely matched 
with discharge list.[225, 226]  The latter effect might have been influenced by the increased 
involvement of the MR pharmacist at discharge; the MR pharmacist was responsible for 
ensuring the accuracy of discharge prescriptions and promptly sent discharge information 
to GPs and/or community pharmacists on the day of discharge or shortly afterward.  This 
may have improved the continuity of care and prevented inappropriate changes to 
therapy.[225, 226]  Nevertheless, these assertions are not conclusive as none of the studies 
investigated the reasons or underlying factors leading to post discharge changes in 
medicines. 
The clinical significance of identified discrepancies and MR related interventions were 
assessed by a number of studies;[114, 225, 227, 228, 231, 233] however, only two studies used a 
standardised validated approach.[225, 228]  In addition, the definitions of clinical significance 
and classification of discrepancies varied widely.  In addition, the definitions of clinical 
significance and classification of discrepancies varied widely.  Two of the included studies 
differentiated discrepancies into intentional and unintentional, the latter were referred as 
error.[231, 233]  Twenty percentage and 50% of unintentional discrepancies were found 
clinically significant by the latter two studies.[231, 233]  This is in line with findings from a 
recent systematic review of 12 studies conducted by Kwan et al. which reported that 34% 
of unintentional discrepancies have the potential to result in clinically significant 
consequences.[138]  Kwan et al., outlined that whilst unintentional errors are common, far 
less number affect patients and have clinical significance on patient health,[138] this was 
also highlighted by other reports.[31, 34, 44, 45]  Due to variation in the range of identified 
discrepancies in this review and varying definitions as well as measurements of 
discrepancies; the effect of MR on reducing clinically significant discrepancies and 
whether those might contribute to actual patient harm is unclear. 
The MR pharmacist played a role in reconciling patient own drugs brought to hospital 
upon admission and ensuring appropriate use during hospital stay and upon 
discharge.[225]  Beside considerable cost savings, this may have a significant impact on 
patient safety; without clear information a patient or carer may duplicate therapy or 
continue with medicines intended to be discontinued.[10, 19]   


Limited evidence was found for the effect of MR on health related quality of life; one study 
reported a favourable but non-significant effect using SF-36.[226]  More studies are required 
to gain further insight on the effect of MR on health related quality of life.  Additionally, EQ-
5D, is the preferred method for the measurement of health related quality of life by the 
National Institute for Health and Care Excellence, the use of EQ-5D is recommended for 
the purpose of the Technology Appraisal Programme.  Thus an evaluation of MR effect on 
health related quality of life using EQ-5D is needed.[172] 
The true effect of MR on length of hospital stay and mortality cannot be assumed without 
more robust evaluation which accounts for confounding factors as well as the effect of 
non-MR clinical activities.  Three studies found no effect of MR on mortality rates up to 12 
months post discharge.  However, the effect of MR on mortality might be difficult to 
establish based on these findings.  Confounding factors might have affected patient 
survival rates such as complexity of medicine regimen and disease progression.[112, 137] 
Only one study demonstrated significant reduction in length of hospital stay of patients 
who received pharmacy led MR.[118]  MR interventions can be expected to shorten length 
of hospital stay by optimising medicines prescribing and preventing adverse drug 
events.[127, 251]  Unexpectedly, length of hospital stay was slightly higher in the intervention 
group compared to control group in most of the included studies, however this effect was 
often not significant.[121, 136, 137, 237]  A possible explanation might be, that the MR 
pharmacist interventions increased the time needed to stabilise patients after proposing 
changes or slightly delayed patient discharge in order to complete discharge 
documentation and counselling.[111, 137, 239, 240, 243]  However, it is not possible to establish 
whether this effect might have been influenced by MR or non-MR aspects of the 
interventions, such as drug consultations, medicines review and patients or carers 
counselling upon discharge.  In addition, length of hospital stay could be influenced by 
various factors that are hard to measure or evaluate such as disease progression, 
seriousness of illness, variance in type and number of medicines as well as the diagnosis 
upon admission.[252, 253] 
Most studies reported lower rates of readmissions and emergency department visits 
among patients who received pharmacy led MR,[109, 113, 135, 226, 229] however, this was often 
not statistically significant.  Nonetheless, significant benefit of MR was evident on duration 
of readmission and the time readmissions or emergency department visits occurred.[115, 
118]  However, the time longevity of these effects cannot be established from the existing 
studies; with readmission and emergency department visits being explored at varying 
time.  The window within which the effect of MR on readmissions and emergency 
department visits can be most evident is not well known.  Omissions and inaccuracies of 


pre-admission medicines are errors commonly identified by MR.  Errors related to long 
term home medicine may result in readmissions and emergency department visits in long 
term and thus a significant effect might not to be expected over a relatively short time 
period.  At 12 months, Scullin et al. found a significant reduction in hospital readmissions, 
readmission duration and the time readmissions occurred.[115]  Assuming that the effect of 
MR would be more evident at longer period of follow up is inconsistent with finding from 
Koehler et al. and Makowsky et al.[118, 230]  Significant reduction was seen at 30 days and 
three months but was not evident at 60 days and six months respectively.[118, 230]  Koehler 
et al. included pharmacy led MR implemented within a multidisciplinary care bundle.  The 
effect shown at such short follow up time, 30 days, might have been augmented by the 
multidisciplinary care bundle.  The systematic review by Kwan et al, pooled three RCTs 
and identified a significant reduction in readmissions and emergency department visits at 
30 days post discharge too.[138]  Similarly, these studies also included non-MR and MR 
tasks provided by other health professionals including IT based applications, a discharge 
nurse advocate, patient education and follow up phone call.[112, 142, 239]  Thus, it is uncertain 
to what extent pharmacy led MR has contributed to this effect.  In addition, without 
detailed investigation of the nature of each readmission and emergency visit, it is not 
possible to account for confounding factors which might contribute to readmissions or 
emergency department visits other than by MR.  Recent changes in NHS polices 
promoted a “30 days discharge tariff”, i.e. making secondary care responsible for patient 
care up to 30 days post discharge, and the target to reduce emergency readmissions 
occurring with 28 days post discharge.[240, 241]  This warrants the need to further exploring 
MR benefits on readmission and emergency department visit and to identify the window 
within which the effect of MR on readmissions and emergency department visits can be 
most evident.  
The use of community health resources at 30 days post discharge was reduced among 
patients who had received MR in one study.[226]  When visits were differentiated, there 
were significantly fewer visits to specialist doctors but not for other professionals such as 
GPs, community pharmacists or domiciliary nurses.  In line with this, one study evaluated 
GP and specialist doctor visits at three months post discharge and found no significant 
change for either type of professional visits.[242]  Further follow up to 6 months found also 
no significant difference in GP visits.[243]  However, the first study of the latter two focused 
on admission MR whilst the other implemented pharmacy led MR upon discharge only.  
Thus, the evidence for full MR process effect on health resource use is lacking. 
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6.3 Costs associated with pharmacy led MR  
Conclusions regarding costs associated with the MR intervention should be drawn with 
caution.  Findings reported by the reviewed studies were not derived from health 
economic evaluations.  One study, attempted a cost analysis of medicine costs in relation 
to the MR pharmacist labour cost.[107]  However, Karapinar- Carkit et al. excluded the cost 
of pre-admission medicine omissions.  Omissions of pre-admission medicines are the 
most common type of MR related errors.
	  Indeed, the majority of the MR-
pharmacist’s time is spent on medication history verification.[114, 229, 233]  Therefore, 
considerable costs were unmeasured by Karapinar- Carkit et al.[107] 
An increased time commitment is needed by the pharmacist to implement MR.  This might 
be the key driver of the costs associated with MR implementation.[107, 231]  Time spent by 
the MR pharmacist varied widely among the included studies; variation within the MR 
interventions did not enable to draw a precise estimation of the average time required to 
implement MR.  Therefore, a time estimate that can be adjusted across different settings 
and workflows was not drawn.   
Nevertheless, the cost of pharmacist time could be balanced by the savings in medicine 
costs,[107, 225] reduction in hospital stay or readmissions and emergency department 
visits.[115, 135, 232]  Costs may be also balanced by freeing the time of other healthcare 
professionals such as junior doctors and nurses.[228, 229]  MR could also require extra time 
for documentation and administrative tasks as well as to contact GPs or community 
pharmacists.[118, 229]  However, the review identified no study which valued the costs of 
increased MR pharmacist time balanced with cost savings in other health care 
professionals’ time and health resource use.  Therefore, conclusions on the overall 
costs/savings of pharmacy led MR are limited due to paucity of the available evidence. 
The identified studies showed that MR interventions required no specialised or complex 
training.  The MR pharmacist usually had no additional clinical training beside education 
concerning MR process and study documentation.[114, 135, 225, 228, 229, 231]  Therefore, no 
additional or advanced skills are needed for pharmacists to perform MR.  However, 
education on the study intent and process should be in place to ensure standardised 
delivery of the intervention. 

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Other costs related to MR implementation were not identified or measured by any of the 
included studies.  Costs requiring consideration include the development of standardised 
forms and study procedures as well as the cost of implementing a new hospital policy plus 
the time of other health professionals in both primary and secondary cares.  This is 
necessary in order to obtain an accurate estimate of the resources necessary for MR 
implementation.[136]  
6.4 The quality of the evidence of pharmacy led MR 
The majority of participants were adult, aged on average 60 years, and mainly from 
general internal medicine wards.  Studies were based mostly in one ward and targeted 
patients with a wide set of characteristics such as: patients admitted in normal working 
hours;[107] prescribed one or more medicines of regular use or pre-specified high risk 
medicines.
Conversely, patients who were discharged to nursing homes or 
transferred to other wards or hospitals,
     short hospital stay,
    
weekends or out-of-hours admissions, planned admissions,[115, 135, 225] non-English 
speakers or mentally incapacitated patients were commonly excluded.[107, 114, 225, 229, 230, 233]  
Those excluded patients might be at increased risk of medication errors and presented 
with greater complexity of care.  Additionally, there might be limited access to primary 
care services or community pharmacists and fewer staff on duty during weekends and out 
of hours admissions.[10, 65]  These differences should be taken into consideration when 
translating this review’s findings into different care areas, populations such as paediatric 
patients or different types of admission, or clinical settings such as outpatients or 
ambulatory care.   
Applicability of the studies’ findings also needs to be considered in light of the differences 
existing between worldwide health care systems, processes for sharing information and 
funding of patient care.  The included studies were conducted in several countries 
including USA, Canada, Europe and Australia.  Non-UK study findings may not be directly 
transferrable to the UK context.  Three UK based studies [115, 225, 232] met the inclusion 
criteria and were all carried out in Northern Ireland.  Differences in patient population and 
workflow between England and Northern Ireland NHS should be considered when 
interpreting these findings.   
In addition, systematic differences in ways likely to affect outcomes of the included studies 
which have been introduced by design and selection bias impede firm conclusions on the 
MR effect.  These were not ruled out in two third of the included studies  The lack of 
details on the use of adequate methods for randomisation and allocation concealment 
might has increased the risk of bias in favour of the intervention.[107, 108, 113, 114, 118, 135, 226-229, 
231-233]
 

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Additionally, although some efforts were made to ‘blind’ the study team, patients and 
doctors; this was usually precluded by the nature of the intervention.  This also increased 
the risk of bias in favour of the intervention.  Herein, blinding of outcome measurements 
was a pertinent issue to consider.  Susceptibility to bias introduced by non-blinded 
assessors could not confidently be ruled out in almost 50% of studies.[107, 108, 114, 225, 227-229, 
232, 233]
  However, this was less concerning where less subjective outcomes were reported 
such as number of hospital readmissions, emergency department visits and mortality 
rates.  This was the case if outcome data were obtained from a reliable reporting system 
or source of information.[118, 226, 230]  There were also concerns on the statistical power and 
thus the meaningfulness of the hypothesis testing which was a dominating concern with 
small scale studies.
 
A positive aspect was that the majority of the included studies demonstrated clearly 
defined interventions and standardised data collection methods as well as outcome 
measurements.  Similarly, the majority of studies were considered free of selective 
reporting bias.  
The lack of any economic evaluation study, ambiguity and heterogeneity in costs 
estimation preclude conclusive answer to the question on the resources necessary to 
implement pharmacy led MR.  Thus, a broad economic evaluation of costs and effects of 
MR is warranted of value.  
Due to limited quality and the heterogeneity of the presented evidence no meta-analysis 
presentation was warranted. 
6.5 Strengths and limitations  
This systematic review has some commonality with the published recent systematic 
reviews on hospital based MR.[137, 138, 244]  There are differences in the scope; those 
reviews described only the effect of pharmacy led MR interventions taking place at any 
point of hospital care, whereas this review focused on the full MR process and aimed to 
investigate the effect as well as costs associated with the intervention.  To the best of our 
knowledge and up to the time of this thesis synthesis, there is no other comprehensive 
review which has systematically considered both aspects. 
There are number of elements strengthen the confidence with this review findings.  The 
evidence of this review was based on a comprehensive search strategy that incorporated 
all key search terms and systematically searched these through all relevant databases.  
Additionally, no limitations were applied on study language, year of publication or design.  
Efforts to capture unpublished research were made by contacting authors and key 
institutions in the UK and USA.  Bibliographies of the included studies and reviews on MR 
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were also hand searched to identify additional references.  SCOPUS database citation 
was also searched and citation alerts were followed through the work on this review up to 
the time of this thesis synthesis.   
A tool based on the Cochrane method for assessing risk of bias was adapted with few 
modifications to fit the purpose of this review.  The tool was validated by senior 
researchers/ systematic reviewers through one to one communication and group 
discussion.  The systematic review protocol was registered on an international database.  
The work progress on the systematic review was kept transparent and up to date.   
The review is, however, subject to some limitations.  Foremost, although applying no 
restrictions on the year of publication allowed an extensive review capturing all possible 
evidence on MR and accounting for variations in terminology over the years, it is important 
to note that the practice of MR is also changing over time.  The Institute of Healthcare 
Improvement outlined in 2011 that MR is not yet optimised but has improved since it was 
first launched 2005.[73]  For most of the included studies, MR was compared with usual 
care.  Usual care related to MR practice was different among settings and it is not 
possible to compare evidence on the effect of pharmacy led MR versus usual care 
between older [225, 226, 228, 232] and newer studies.[108, 109, 113-115, 118, 135, 227, 229, 230]  
Variation in MR terminology could explain five relevant articles found outside the 
prescribed search of which three met the study inclusion criteria.[109, 135, 231]  Additionally, 
Medicine/ medication reconciliation was not always used to describe the intervention and 
arguably this means that the screening for relevant studies was subjective and open to 
individual interpretation.  However, the elements of a full MR process were clearly defined 
in the selection criteria.  Furthermore, two independent reviewers performed screening at 
all stages thereby minimising the risk of personal error.  
The true effect of pharmacy led MR might become unclear in multicomponent/disciplinary 
interventions.  MR was often supplemented by non-MR care and in two studies this was 
implemented within a multicomponent care bundle designed to improve patient 
outcomes.[113, 118]  Thus, this review identifies that there are potential benefits of MR which 
could balance the associated costs.  However, this review is not able to answer whether 
the benefits observed were directly contributed by pharmacy led MR interventions or 
whether MR should be delivered in a multidisciplinary care programme or in supplement 
with other non-MR activities in order to achieve clinical significance on patient outcomes 
and health costs.  This warrants further research. 
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6.6 Implications for further research  
Developing and evaluating a pharmacy led MR is complex and it is essential that all 
resource costs and effects are determined through a rigorously designed study.  More 
robust primary research of randomised design is needed to address questions on the 
clinical effects and costs of pharmacy led MR.  Designing studies of randomised design to 
assess costs and effects is complex; the intervention and outcomes to measure should be 
considered carefully (BOX 6.1 and 6.2). 
The paucity of evidence in the UK and the methodological limitations of the evidence 
available elsewhere underscore the need for robust evidence on pharmacy led MR within 
NHS settings.  Ideally, the evidence in need, as described in BOX 6.3, should be derived 
from a randomised design with blind outcome measurement comprising process and 
patient oriented outcomes (BOX 6.2).  The intervention and measurement methods should 
be standardised and consistent.  A detailed description of usual care, patient screening 
and selection process is also necessary.  It is essential that the evidence would enable a 
precise estimate of MR cost-effectiveness.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This review informed the development of an innovative a pharmacy led MR service 
presented in the next chapter.   
  
BOX 6.3 Features of MR intervention to develop 
 Derived from robust study design   
 Clearly defined and evidence based process 
 Well recognised owner of the process (pharmacist, nurse or doctor) 
 Proven to improve process and patient oriented outcomes  
 Cost-effective 
 Transferrable across different settings and workflows 
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The journey to address the aim of designing a medicine reconciliation (MR) intervention 
and develop a strategy for its evaluation has reached the stage of testing.  The literature 
review, audit and systematic review of chapters one to six have identified the areas of 
sub-optimal current practice, potential strategies for enhancing the transfer of information 
between healthcare interfaces and trial design aspects warranting consideration. 
This chapter focuses on the feasibility of the study design that has been informed by these 
earlier stages.  Additionally, it provides an early indication of the effects and costs/savings 
associated with the intervention. 
7.1 Patient recruitments  
The hospital system was checked daily to obtain a list of all patients admitted within the 
previous 24 hours via accident and emergency department.  One hundred seventeen 
patients were not identified by the daily screen due to lack of hospital record update.  
Thus, the total number of patients admitted to the study wards over the first 3 months of 
the MedRec study was 665 patients of which 105 (15.8%) patients were approached.  The 
main reasons for not approaching patients are summarised in Table 7.1. 
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Reasons  
N (%) 
n=560 
Not eligible for the study inclusion  80 (14.3%) 
Unable to consent consultee within 24 hours of admission  103 (18.4%) 
The study researchers and/or MR pharmacists unavailable 
performing administrative tasks 
87 (15.5%) 
MR pharmacists unavailable due to sick or annual leave, 
weekly off days and performing other clinical activities not 
related to the study 
77 (13.8%) 
Out of the the study researchers working hours  55 (9.8%) 
Not possible to approach patients, e.g. meal time, medical 
round, away from bed, risk of infection 
48 (8.6%) 
RAs unavailable: sickness, annual leave, off days  40 (7.1%) 
Unable to consent patient within 24 hours of admission 25 (4.5%) 
Nurse unavailable to assess patient capacity or willingness to 
speak to the RAs 
16 (2.9%) 
Others* 29 (5.2%) 
*Patient known to RAs, patient with No Fixed Abode, discharged or transferred.  MR: medicine reconciliation  
Table 7.1 Reasons for not approaching patients 
7.1.1 Excluded patients 
Reasons for patients’ exclusion are summarised in Figure 7.1.  Most frequently, patients 
were excluded because they have been seen by the ward pharmacy staff member who 
was frequently a pharmacy technician.  The ward technician mainly checked patient own 
drugs and medicine supplies.  
Patients were also excluded on advice from the nursing team; nurses advised the study 
team not to approach patients who were distressed, unable to cope or overwhelmed.  
Additionally, patients who were prescribed no medicines or anticipated to stay for less 
than 24 hours were also excluded as per the exclusion criteria. 
7.1.2 Consultee identification  
The main barrier for consenting patients was the inability to obtain an informed patient 
decision or consultee declaration within 24 hours of admission.  This was more frequent 
for patients who were admitted with partial or complete lack of mental capacity due, but 
not limited, to dementia, confusion, blindness or alcoholism.   
The consultee was intended to be a person or carer with close relationship to the patient, 
and therefore the study team attempted to approach potential consultees during the ward 
visiting time.  Visiting time at the study site was between 15:00 to 20:00.  To ensure 
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minimum burden and discomfort to the patient, the consultee was approached in the last 
60 or 90 minutes of the visiting hours.  In many instances, this occurred after the study 
researcher and MR pharmacists had departed and frequently by this time the 24 hours 
recruitment window had been passed.  Over the first three months of the MedRec study 
(section 2.3), only one success of consultee (1.7%) enrolment was achieved. 
7.1.3 Unavailability of the MR Pharmacists or the study researchers  
Recruitment was not possible when the MR pharmacists and/or study researchers were 
not available.  Mainly, this was because time was consumed in documenting MR process 
or performing administrative tasks such as filing, printing or faxing.  It was also due to 
sickness, weekly days off or holidays.  
The study MR pharmacists were existing hospital staff members and performed their 
research activities in addition to their usual care duties.  At the study commencement, only 
two MR pharmacists were implementing MR.  At later course of the study, additional three 
MR pharmacists were accredited to perform MR and subsequently they joined the 
research team, this maximised the study cover.   
The senior study researcher (AB) covered 37.5 hours/week and the assistant researcher 
(KH) covered 22.5 hours/week.  KH was an existing pharmacy technician and performed 
her research activities three days/ week.  For one or two hours in the morning she 
provided ward based duties, after which she pursued patient recruitment.  Over the three 
months period, MR pharmacists covered 90% (83 days) and the study researchers were 
available for 83.7% (77 days).  Annual and sick leaves contributed to 57% of the 
uncovered days (n=26 days).  The remaining uncovered days where due to weekly days 
off, bank holidays or database maintenance. 
 


 
HRQL: Health related quality of live. GP: general practitioner. MR: Medicine reconciliation. 
Figure 7.1 The MedRec study diagram 
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7.1.4 Patient declined study participation 
Reasons for declining the study participation can be seen in Figure 7.1.  Most frequently, 
patients declined to take part in the study because they were frail.  
7.2 Recruitment rate  
Patient recruitment can be seen in Figure 7.2.  Overall, recruitment rate was close to the 
intended target; the number of patient recruited fell only 5 patients below the target.  Rate 
for recruitment out of approached patients was 57.1%.  Meanwhile, the recruitment rate 
out of eligible patients (n=88) is 68.2%.  The later rate was estimated after deducting 
ineligible patients identified after conversing with the patient or the nurse, i.e. prescribed 
no medicine or seen by the ward pharmacist. 
It can be seen that, at the first two weeks the study recruitment rate was achieving the 
target.  A notable decrease occurred at the third week of the study commencement; this 
was due to unavailability of the study team for pre-booked annual leave and summer 
holidays.   
 
 
Figure 7.2 Recruitment rate compared to target rate  
Five recruits were targeted per week; however the study team attempted to exceed the 
target to 8-10 patients per week.  In practice, this was not achievable and constrained by 
difficulties related to patient identification and time constraints.  Details of recruitment 
barriers can be seen in (Appendix 19).  
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7.3 Feasibility of implementing the MR Process  
The MedRec process was implemented as intended (section 2.3.7.1).  Due to limited 
study cover at the early stage of the study, discharge MR was implemented 
retrospectively after the patient discharge.  However, the additional MR pharmacists cover 
enabled the team to follow up and identify patients planned for discharge on daily basis.  
Discharge medicines were reconciled at the time of patient discharge and GPs were sent 
discharge letters promptly on the day of discharge. 
7.4 Feasibility of data collection  
All the study data collection tools were ensured to be comprehensible and appropriate.  
Additionally, standard operating procedures were developed to guide data collection and 
input.  There were, however, few challenges in data collection process which were not 
anticipated.  These are presented in Appendix 19. 
7.5 Feasibility of data management  
The study database was tested to ensure user utility and ease of data input and 
extraction.  System errors and break down were reported promptly once occurred.  
Deficits with the database were discussed with the IT supporting team.   
The database layout is yet not optimised; the medicines section requires adjustment and 
the layout could be modified to facilitate comparing medicine lists at the different time 
points.  Appendix 20 summarises amendments suggested for the MedRec database. 
7.6 Acceptability of the intervention and study process 
The question for the acceptability of the intervention can’t be fully answered at this stage 
without comprehensible insight from patients and ward staff.  However, it can be outlined 
that patient consent and the randomisation approach appeared to be feasible.  Although, 
the time pressure for consenting consultees should be of note.   
Patients agreed to be randomised and endorsed the concept of randomisation.  The study 
information leaflet and the consent form found understandable and clear.  Additionally, the 
study researchers identified the best way for providing a suitable explanation and eliciting 
informed decision for patients.  
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7.7 Follow up rate 
7.7.1 Death 
Five patients died in both groups during the study follow up period; i.e. three months post 
discharge.  Two patients were in the intervention and three in the control groups.  Two 
intervention patients did not receive full MR of which one patient discharged before 
receiving discharge MR and the other died during hospital stay (Figure 7.1).   
7.7.2 Withdrawal 
Minimum burden to patients was anticipated by the MR intervention; none of the study 
patients withdraw while in hospital stay or during three month post discharge.  However, 
one patient withdrawn beyond the three month period; the patient lacked mental capacity 
at the latter time and the consultee advised the study team with patient withdrawal. 
7.7.3 Medicines prescribed to patients in primary care three months post 
discharge 
At three months post discharge, in total 48 (87.3%) medicine lists held by GPs were 
available for both groups (Figure 7.1).  Lists were not available for the deceased patients, 
i.e. six patients of which five died during the study follow up and one beyond the three 
months window.  Additionally for 4 (7.3%) patients, the primary care practices did not 
respond to the study team requests up to the point of this analysis.  In one case, the 
primary care practice declined the RA request indicting that the GP time that would be 
spent processing the request was more than the value offered as a complementary fund 
by the study; i.e. £5.  The three months list was not available too for the patient who had 
withdrawn beyond three months of discharge; the GP list was not received up to the point 
the patient was withdrawn and thus no further contact made to obtain the medicines list.   
Twenty seven GP lists were received following the first request by fax (56.3%).  For the 
remainder (n=21), the study team initiated a second contact to prompt primary care 
practices to send these.  Median (IQ) days to receive GP list was 9 (2, 32) days and 
ranged between same day up to 95 days.  Median (IQ) days upon the first contact was 4.5 
(1, 11) days ranging from same day to 44 days.  Upon the second contact the median (IQ) 
days was 5 (2, 9) ranging from same day to 42 days. 
Christmas and New Year holidays slightly increased the days needed to receive the GP 
list, adjusted medians (IR) were 9 (2, 34) days for Christmas and New Year compared to 8 
(1,29) days.  Additionally, when adjusting for Christmas and New Year, it was noted that 
the study researchers were more likely to initiate a second request 14 (43.8%) compared 
to 7 (30.4%) during the holiday season.   
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7.7.4 Health related quality of life and Health resource use at 3 months 
In both groups 35 (63.6%) patients returned health related quality of life and health 
resource use questionnaires.  Three month health related quality of life and health 
resource use questionnaires were not available for the deceased patients (n=6) and the 
patient who was withdrawn and two patients who had moved (Figure 7.1).  More details 
on those patients are described in Appendix 21. 
Patients returned health related quality of life and health resource use with a median (IQ) 
of 18 (11, 42) days ranging from six to 85 days.  Twenty three (65.7%) of returned 
questionnaires were received following the first contact (i.e. sending questionnaire by 
post) with a median (IQ) of 12 (10, 18) days ranging between six to 26 days.  A reminding 
letter was sent after one month of the first contact, eight (66.7%) patients responded and 
returned the questionnaire with a median (IQ) of 10 (3, 19) days ranging between one to 
29 days.  The study researchers called non-responders after four weeks of sending the 
reminding letter.  In total the study researchers called 18 patients.  Consequently, four 
questionnaires were returned with a median (IQ) of seven (3, 10) days following the call 
and ranging between two to 10 days. 
7.8 MR in the control group 
Three MR control forms were not retained in the ward folder and 12 were returned 
uncompleted.  The review of patients’ medical notes showed: 
 One patient received MR with no details on the time and the person who provided MR   
 One patient received patient own drugs check by a pharmacy technician  
 Eight patients received control MR   
In total 24 (80%) patients in the control group received MR by the ward pharmacy team as 
per the study site policy.  Table 7.2 summarise details of MR in the control group. 
 
  
	

Control MR  n=23a 
Time MR delivered within 24 hours 9 (39%) 
 Within 48 hours 6 (26.1%) 
 Within 72 hours 2 (8.7%) 
 More than 72 hours 6 (26.1%) 
Duration b 
10 minutes 12 (80%) 
 
< 30 minutes  3 (20%) 
 >30 minutes  - 
Provider c Pharmacist  8 (38.1%) 
 
Pharmacy technician  12 (57.1%) 
Source of information Patient  3 (13.0%) 
 
Laminated list with 
patients 1 (4.3%) 
 
Patient own drugs 15 (65.2%) 
 GP referral letter  1 (4.3%) 
 GP list  2 (8.7%) 
 Outpatient clinical letter  2 (8.7%) 
 Repeat prescription  5 (21.8%) 
a For one patient no details on timing or duration. b No details on time spent to provide MR for 8 patients. 
 
c No details on MR provider for 3 patients. MR: Medicine reconciliation. GP: general practitioner.  
Table 7.2 Details of MR in control group 
It can be seen that control MR was often implemented after 48 hours and mainly by 
pharmacy technicians and took frequently 10 minutes.  Only one source of information 
was used with patient own drugs being the primary source.  
7.9 Patient characteristics 
Table 7.3 summarise patient characteristics in both study groups.  Both groups were 
similar with respect to all baseline characteristics.  Additionally, both groups were similar 
with respect to the baseline health related quality of life measures (Table 7.4).  However, 
intervention patients had higher baseline mean of EQ-5D score compared to control 
patients. 
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Characteristics  Measure 
Intervention  
n=30 
N% 
Control  
n=30 
N%  
Demographics  
Female  N (%) 15 (50%) 19 (63.3%) 
Age Mean (SD) 63.0 (20.6) 56.2 (24.3) 
No. medicine on admission Median (IQ) 10 (6.8,14) 10 (7,15) 
No. medicine on discharge  Median (IQ) 8 (4.8,11.3) 8 (6,15) 
Reason for admission  N (%)   
Abdominal pain, nausea and vomiting   3 (10%) 8 (26.7%) 
Chest pain and tightness   6 (20%) 3 (10%) 
Collapse and fall   4 (13.3%) 4 (13.3%) 
Confusion  3 (10%) - 
Exacerbation of asthma, SOB due to 
chest infection  
 3 (10%) 5 (16.7%) 
Leg, shoulder or knee pain  1 (3.3%) 4 (13.3%) 
Others*  10 (30%) 6 (20%) 
Day of admission  
Weekdays N (%) 22 (73.3%) 25 (83.3%) 
Time of admission  
Working hours N (%) 5 (16.7%) 8 (26.7%) 
*Worsening or renal function, skin ulceration and cellulitis, ethanol abuse and seizure.SD: Standard deviation. 
IQ: Interquartile 
Table 7.3 Baseline characteristics   
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Health related quality of life 
measures at baseline Measure 
Intervention 
N=30 
Control  
N=30  
Mobility 
No problem 
Some problem  
Confide to bed 
N (%)  
11 (36.7%) 
14 (46.7%) 
5 (16.7%) 
 
4 (13.3%) 
19 (63.3%) 
7 (23.3%) 
Self-care 
No problem 
Some problem  
Unable of self-care 
N (%)  
20 (66.7%) 
8 (26.7%) 
2 (6.7%) 
 
18 (60.0%) 
10 (33.3%) 
2 (6.7%) 
Usual activities 
No problem 
Some problem  
Unable to perform any unusual 
activity 
N (%)  
9 (30.0%) 
12 (40.0%) 
9 (30.0%) 
 
6 (20.0%) 
17 (56.7%) 
7 (23.3%) 
Pain & discomfort 
No pain  
Moderate  
Extreme  
N (%)  
8 (26.7%) 
17 (56.7%) 
5 (16.7%) 
 
7 (23.3%) 
15 (50.0%) 
8 (26.7%) 
Depression/anxiety  
I am not anxious or depressed 
I am moderately anxious or 
depressed 
I am extremely anxious or 
depressed 
N (%)  
12 (40%) 
15 (50.0%) 
3 (10%) 
 
18 (60%) 
10 (33.3%) 
2 (6.7%) 
EuroQol VAS Mean (SD) 52.3 (24.2) 51.4 (25.9) 
EQ-5D score Mean (SD) 0.49 (0.38) 0.36 (0.39) 
VAS: Visual analogue scale 
Table 7.4 Baseline health related quality of life measures   
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7.10 Outcomes measured 
7.10.1 Medication errors 
In total 438 discrepancies were identified in both groups of which 145 (26.3%) were 
unintentional errors.  Inter-rater agreement kappa score of discrepancies identification 
was 0.66, indicating good agreement.  Variances identified with discrepancy identification 
were discussed with the study principal investigator and consequently the process was 
standardised. 
A total of 60 errors were identified at admission in the control group affecting 24 (80.0%) 
patients with a median (IQ) of 2 (1, 3).  A total of 58 errors were identified at discharge 
affecting 20 (69%) patients with a median (IQ) of 2 (1, 3).  Table 7.5 summaries the nature 
of unintentional errors in the control group.  It can be seen; most unintentional errors 
occurred on admission and were due to omissions.  Majority of admission omissions were 
carried on until discharge.  Only 12 (20%) discrepancies, of which 10 omissions, affecting 
nine patients were resolved before discharge.  Of these, four which occurred in three 
patients were intercepted by ward pharmacy staff during control MR.  
In the control group, three months post discharge, 25 (56.8%) of errors occurred on 
discharge were translated into primary care.  It was not possible to know the outcome of 
16 errors because GP lists were not available at the time of this analysis: 
 Three patients were deceased accounting for five errors  
 One patient transferred to other hospital patient accounting for two errors.  
 Three patients had their GP lists not received upto the time of this analysis, this 
accounted for nine errors. 
Table 7.6 describes discharge errors at three months in the control group.  Fifteen 
omissions identified at three months were confirmed by only one source of patient 
information.  Nine of these omissions were listed by the GP list only, four omissions were 
identified from patient own drugs alone and in two discrepancies medicines were listed in 
repeat prescriptions only.   
It can be seen in Table 7.6 that GPs often retained medicines as prescribed pre-
admission presumably assuming changes or omissions were not intended.  
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Time point  
Type of 
discrepancy  
No. 
patients  N (%) Examples 
Within 24 
hours of 
admission  
Pre-admission 
medicine omitted 
from administration 
chart 
22 58  
(80.5%)* 
Pre-admission: Simvastatin 40 mg 
 OM  
Inpatient:  omitted 
 Dose, frequency or 
formulation 
inadvertently 
changed 
2 2  
(2.8%) 
 
Pre-admission: Senna 2 tablet
  ON PRN 
Inpatient:  Senna  2 tablet 
 ON  BD 
Upon 
discharge 
Pre-admission 
medicine omitted 
from discharge 
summary 
17 49 
(70.8%) 
Pre-admission: Alendronic Acid 
 70mg once weekly 
Inpatient:  Omitted  
Discharge:  Omitted 
 Dose, frequency or 
formulation 
inadvertently 
changed 
4 4  
(5.6%) 
Pre-admission: Amitriptyline  10mg 
  OM  
Inpatient:  Amitriptyline 10mg 
 OM 
Discharge: Amitriptyline  20mg 
 OM 
 Prescribed medicine 
discontinued 
 
1 3 
(4.3%) 
Pre-admission: Ezetimibe  10mg 
 OD  
Inpatient:  Ezetimibe  10 mg 
 OD 
Discharge: Not prescribed  
 New medicine 
incorrectly added to 
discharge summary  
 
1 2 
(2.8%) 
 
Pre-admission: Digoxin  62.5 mcg 
 OD 
Medical note:  Digoxin stopped for 
 bradycardia  
Discharge: Digoxin  62.5 mcg 
 OD 
*38 were omission stated by only one source of patient information.  48 admission omissions continued until 
discharge. OD: Once a day. BD: Twice a day. OM: in the morning. ON: #$. PRN: as required  
Table 7.5 Nature of unintentional errors in the control group   
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Error type No. patients 
N (%) 
n=44 
Medicines omitted in discharge summary  
  
Medicine present in GP repeat list at 3 months post discharge 9 16 (36.4%) 
Medicine not present in GP repeat list at 3 months post 
discharge, i.e. omission perpetuated 
12 21*(47.7%) 
Dose, frequency or formulation Changed in discharge 
summary 
  
Dose, frequency or formulation retained as pre-admission in GP 
repeat list at three months post discharge 
3 3 (6.8%) 
Dose, frequency or formulation changed in GP repeat list at 
three months post discharge, i.e. unintentional change 
perpetuated 
1 1 (2.3%) 
Discontinuation  
  
Medicine not present in GP repeat list at three months post 
discharge, i.e. discontinuation perpetuated 
1 3 (6.8%) 
*15 omissions identified by one source of patient information. GP: general practitioner 
 
Table 7.6 Unintentional errors at three months post discharge in the control group 
 
7.10.2 Clinical significance of medication errors  
Medications errors in the control group were stratified by the type of error and the time at 
which the discrepancy occurred.  A random selection of 20 was rated by an expert panel 
of four assessors from the following professions: one hospital consultants, one primary 
care pharmacist and two hospital pharmacists.  
The mean (SD) of visual analogue scale (VAS) scores was 2.3 (1.16) indicating minor 
severity.  No discrepancy was considered to cause severe harm, 5 (25%) discrepancies 
we scored with moderate potential of harm (score ≥ 3).  Appendix 22 presents examples 
of errors in the control arm and their risk. 
7.10.3 Medication errors in the interventions group 
The MR pharmacist performed a total of 225 interventions intercepting medication 
discrepancies in the intervention group, median (IQ) was 7 (5, 10).  Seventy three 
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interventions intercepted unintentional errors occurring in 22 (73.3%) patients.  Table 7.7 
describes the nature of the MR pharmacist interventions. 
It can be seen that the majority of the MR pharmacists’ interventions occurred at 
admission and were related to omissions or inaccuracies in medicines the patient is taking 
before admission.  Upon discharge, the MR pharmacist frequently intervened to resolve 
unintentional therapy changes and discontinuation. 
One medication error was not intercepted in the intervention group by the study MR 
pharmacists.  Pre-admission, the patient was prescribed Seretide 500 Accuhaler for 
Asthma; dose was two puffs twice a day.  While the patient in hospital for 20 days, 
Seretide was prescribed as one puff twice a day.  Unintentionally this was continued 
upon discharge; Seretide was transcribed into discharge prescription as one puff twice a 
day.  At three months post discharge, this inadvertent dose change was not translated into 
primary care; the GP retained Seretide as pre-admission dose (i.e. of two puffs twice a 
day). 
7.10.4 Intentional medication discrepancies 
In total there were 293 intentional discrepancies in both groups of which 141 (48.1%) 
discrepancies were identified in the control group with 91 (64.5%) undocumented 
intentional discrepancy.   
In the intervention group, the MR pharmacists established intentional discrepancies by 
discussion with the medical team in 114 instances of which 56 (49.1%) discrepancies 
required further communication to the nursing team or the primary care to enable correct 
or safe prescribing.  The majority of intentional discrepancies were performed upon 
discharge 33 (58.9%); the MR pharmacists prepared discharge medicines list, clarified all 
changes occurred during hospital stay and recorded clear instructions to primary care 
team.  Appendix 23 presents examples of intentional discrepancies in the intervention 
group.  
7.10.5 Post discharge medication changes  
Three month post discharge, a total of 48 medicine changes were identified in both 
groups.  The majority of changes occurred in the intervention group 36 (75%).  
Additionally, higher proportions of patients in the intervention group had at least one 
medicine changed 13 (43.3%) compared to 6 (23.3%) control patients.  Changes in post 
discharge medicines occurring in the intervention groups were commonly in response to 
the MR pharmacists’ discharge instructions.   
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Time point  
Type of 
discrepancy  
No. 
patients  
N 
(%) Examples 
Within 24 
hours of 
admission  
Pre-admission 
medicine omitted 
from administration 
chart 
15 25 
(34.2%) 
Pre-admission: Lisinopril  10 mg 
 OD 
Inpatient:  Omitted 
 Dose, frequency or 
formulation 
inadvertently 
changed 
8 17 
(23.3%) 
Pre-admission:  Nicorandil 
 10mg   BD 
Inpatient:  Nicorandil  10mg 
 OD 
 Illegibility 2 2  
(2.7%) 
Dose of amlodipine was clarified  
 Omitted dose, 
frequency  
6 16 
(21.9%) 
Dose of chlordiazepoxide 10 mg was 
reconciled  
 Wrong dose, 
formulation, 
frequency 
2 2  
(2.7%) 
Pre-admission: Digoxin  6.25 
Mcg  od  
Inpatient:  Digoxin  6.25 mg od  
Upon 
discharge 
Dose, frequency or 
formulation 
inadvertently 
changed 
3 3 
(4.1%) 
Pre-admission: Sodium valproate 
MR  700 mg BD 
Inpatient:  Sodium valproate 
MR  700mg  BD 
Discharge: Sodium valproate
 700 mg BD 
 
 Prescribed medicine 
discontinued  
 
2 6 
(8.2%) 
Pre-admission:  Zopiclone 3.75 
mg  ON 
Inpatient:  Zopiclone 3.75 mg 
 ON 
Discharge:   Not prescribed  
 New medicine 
incorrectly added to 
discharge summary  
1 1 
(1.4%) 
Inpatient: GTN spray 2 puffs  
 PRN 
Discharge: GTN spray 2 puffs  
 OD 
 Wrong dose, 
formulation or  
frequency  
1 1 
(1.4%) 
Inpatient:  Domperidone 10 mg 
 PRN for nausea 
Discharge:  Domperidone 10 mg   
 for regular use 
BD: Twice a day. OD: once a day. PRN: as required. OM: In the morning. ON: In evening time. GTN:Glyceryl 
trinitrate. MR: Modified release  
Table 7.7 Pharmacist interventions to resolve unintentional errors   
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7.10.6 Length of hospital stay  
Distributions of length of hospital stay by study group are illustrated in Figure 7.3 and 7.4.  
It can be seen that length of hospital stay (hours) is positively skewed.  The box plot 
presentation (Figure 7.4) shows that patients in the intervention group exhibited wider 
range of length of hospital stay with three patients outside the whiskers (i.e. beyond 800 
hours).  The distributions of log length of hospital stay are illustrated in Figure 7.5 and 7.6.  
Log transformation of length of hospital stay resulted in a more symmetric distribution for 
both groups.  However, the intervention group yet exhibited wider variation compared to 
the control group. 
 
Figure 7.3 Histogram presentation of hospital stay in hours by study group 
 
Figure 7.4 Box plot of hospital stay in hours by study group 


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Figure 7.5 Histogram presentation of Log length of hospital stay in hours by study 
group 
 
 
Figure 7.6 Box plot of Log length of hospital stay in hours by study group 
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It is shown from the box plot presentation, four outlaying data points might be suspected.  
Those appeared incompatible with the rest of the data.  Table 7.8 summarises details 
related to these data points.  Those data points were carefully reviewed; there was no 
evidence of a user or data entry errors.  Therefore they were not altered or excluded 
Study 
group  
Study 
no. 
Admitting 
diagnosis  
Age 
(years) 
Admitting 
Ward 
Admission 
date 
Admission 
discharge 
Hospital 
stay 
(hours) 
I 029 Bilateral leg 
ulceration 
83 W1 a 24/08/2012 04/10/2012 981 
I 051 Sepsis 85 W1 25/09/2012 Deceased 
05/11/2012 
1000 
I 019 Bibasal 
pneumonia 
40 W2b 09/08/2012 
 
22/08/2012 
 
1075 
C 016 Exacerbation 
of heart failure 
and cellulitis 
86 W1 02/08/2012 
 
06/09/2012 860 
aW1 care for the Elderly specialising in caring for dementia and Parkinson’s disease. b W2 Renal and Diabetes 
& Endocrinology with general medicine.  
Table 7.8 Details of suspected outlying data points 
Mean (SD) Log length of hospital stay for the intervention and control groups were 4.9 
days (4.26) and 5.49 days (1.11), p > 0.05.  The estimated Coben’s effect size of the 
MedRec intervention was 0.22 95% CI [-0.77-1.95] indicating a potential small effect size. 
7.10.7 Readmission episodes identified by hospital records  
In total 17 (28.3%) patients were readmitted on one or more episodes in both groups.  
Total number of readmissions was 50 episodes.  Table 7.9 summarises readmissions 
between the study groups.  
Higher number of readmissions occurred in the control group compared to intervention 
group.  Median (IQ) of readmissions experienced by patient was 2 (1, 3) for the control 
group and 1 (1, 2) for intervention group.  This effect was not statistically significant, p 
>0.05. 
Nevertheless, intervention patients took longer time to be readmitted compared to control 
patients with mean (SD) of 43.3 (20.2) and 34.3 (28.4) hours respectively.  However, this 
was not statistically significant, (p=0.46).  Number to treat in order to prevent one 
readmission was 7.5 patients.  
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Readmission  
Intervention  
n=28 
Control  
n=29 
Total number of readmission  19 31 
Patients readmitted 7 (25%) 10 (34.5%) 
Planned readmission  
Number of planned readmissions 10 10 
Patients readmitted with at least one planned 
admission  
4 (14.3%) 4 (13.8%) 
Unplanned readmission  
Number of unplanned readmissions 9 21 
Patients readmitted with at least one unplanned 
admission 
3 (10.7%) 11 (37.9%) 
 
Table 7.9 Readmission episodes in both groups 
The Kaplan-Meier estimate of readmission time is illustrated in Figure 7.7. 
 
Figure 7.7 Kaplan-Meier survival function of time to readmission  
Kaplan-Meier test showed that intervention patients took significantly longer time to be 
readmitted to the hospital compared to control patients.   


The median [95% CL] survival function time, the smallest survival time for which the 
participant probability of being readmitted is more or equal to 0.5 was 56 days [14.9-97.1] 
for the intervention group and 31 days [15.2-46.8] for the control group; log rank test 
(p=0.016).  
There were no significant differences between the number of planned admission neither 
the proportion of patients readmitted via planned admission in both the intervention and 
control groups.  Whereas, there were significantly more unplanned admissions in the 
control group compared to intervention (p=0.028).  Patient in the control group were three 
times more likely to experience at least one unplanned admission compared to the 
intervention arm.  This effect almost approached statistical significance (p=0.07). 
7.10.8 Patient self-reported use of NHS and personal and social services (PSS) in 
hospital 
7.10.8.1 Readmission episodes reported by patients 
Seventeen (28.3%) patients reported 34 readmissions; median (IQ) length of hospital stay 
of readmissions was 2.5 (0, 7).  Table 7.10 summarises patient-reported readmissions in 
both study groups. 
Control patients reported higher number of readmissions compared to intervention 
patients; 2.3 (0.43) and 0.79 (0.43) respectively (p=0.14).  Additionally, on average those 
patients reported longer hospital stay; 5 (0.75, 9.8) days compared to intervention patients 
3 (0.24, 2.6) days.  This was not statistically significant (p=0.28). 
Patients self-reported readmissions and readmissions identified by the hospital records 
were matched.  Readmissions identified by reviewing the hospital system and reported by 
patients were not matching for 18 readmissions reported by seven patients of which four 
reported lower number compared to the number identified by the hospital system.  
Additionally, eight patients reported not being readmitted at all, but yet they were identified 
with at least one or more readmissions by the hospital record.  This occurred with 15 
readmissions of which four readmissions occurred in three intervention patients and the 
remainder occurred in five control patients.  Eleven readmissions were reported by 
patients but not identified by the hospital record which occurred for seven intervention 
patients accounting for seven readmissions and with two control patients accounting for 
four readmissions.  
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7.10.8.2 Emergency department visits  
Twelve patients reported 22 visits to emergency department of which twelve reported by 
five control patients and seven were reported by intervention patients (p=0.92).  The 
proportions of patients reporting emergency department visits in both groups were similar 
(p=0.75). 
7.10.8.3 NHS walk in centre 
Only one control patient reported a visit to NHS walk in centre.   
7.10.8.4 Outpatients visits 
Nineteen patients reported attending outpatient clinics for at least or more visit in both 
groups in which nine were control patients.  Patients in both study groups also reported 
similar number of outpatient visits (p=0.66).   
Wards  
Intervention  
N=18 
Control  
N=17 
General medicine  
Number of readmissions 
 
4  
 
3  
Total length of hospital 
stay (day) 
20 12 
Oncology Number of readmissions 1  2  
 Total length of hospital 
stay (day) 
9 23 
Cardiology Number of readmissions 1  1  
 Total length of hospital 
stay (day) 
9 14 
Respiratory  Number of readmissions 1  - 
 Total length of hospital 
stay (day) 
7 - 
GI& colorectal  Number of readmissions 2  4  
 Total length of hospital 
stay (day) 
9 16 
Surgical  Number of readmissions - 1  
 Total length of hospital 
stay (day) 
- 1 
Others* Number of readmissions 2  12  
 Total length of hospital 
stay (day) 
7 13 
Total  Patient readmitted 
Total length of hospital 
stay (day) 
9  
11 
 
8  
23 
 
*Observation and programmed investigation unit ward 
Table 7.10 Patient self-reported readmissions and readmission duration  
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7.10.9 Patient self-reported use of NHS and personal social services in community 
Intervention patients trended to have fewer number of visits to NHS and personal social 
services (PSS) workers 1.5 (0, 8.5) compared to control patients 3.5 (1.10).  This was not 
statistically significant (p=0.29).   
The most frequent health workers visited were GPs 116 (39.2%) followed by practice 
nurses 56 (18.9%). and often these visits took place in GP clinics.  Table 7.11 
summarises details of NHS and PSS visits in the intervention and control groups. 
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Worker  Measure 
Intervention 
n=11 
Control  
n=14 
GP Total number of GP visits N 35 81 
Patient visited GP N (%) 9 (81.8%) 11 (78.6%) 
Place of most visits 
GP clinic 
Home 
Telephone consultation  
N (%)  
7 (77.8%) 
2 (22.2%) 
- 
 
9 (81.8%) 
1 (11.1%) 
1 (11.1%) 
Practice nurse  Total number of practice 
nurse visits 
N 13 43 
Patient visited practice 
nurse 
N (%) 5 (45.5%) 8 (57.1%) 
Place of most visits 
GP clinic 
Home 
N (%)  
4 (80.0%) 
1 (20%) 
 
8 (100%) 
- 
District nurse Total number of district 
nurse visits 
N 26 29 
Patient visited district nurse N (%) 3 (27.3%) 4 (28.6%) 
Place of most visits 
GP clinic 
Home 
N (%)  
- 
3(100%) 
 
1 (25%) 
3 (75%) 
Specialist Nurse Total number of specialist 
nurse visits 
N - 19 
Patient visited specialist 
nurse 
N (%) - 2(7.1%) 
Place of most visits 
Hospital  
N (%) - 
- 
- 
2 (100%) 
Dietician   Total number of dietician 
visits 
N 1 4 
Patient visited dietician N (%) 1 (9.1%) 3 (21.4%) 
Place of most visits 
GP clinic 
Telephone consultation  
Hospital  
N (%)  
1 (100%) 
- 
- 
 
1 (33.3%) 
1 (33.3%) 
1 (33.3%) 
Physiotherapist Total number of 
physiotherapist visits 
N 4 5 
Patient visited 
physiotherapist 
N (%) 1 (9.1%) 2 (14.3%) 
Place of most visits 
GP clinic 
Home  
N (%)  
- 
1 (100%) 
 
1 (50%) 
1 (50%) 
Care assistant* Total number of visits N 31 5 
Patient visited other N (%) 2 (9.1%) 1(33.3%) 
Place of most visits 
Hospital 
Home  
N (%)  
1 (50%) 
1 (50%) 
- 
- 
1 (100%) 
Total NHS and PSS worker visits  110 186 
:4*:%!
Table 7.11 NHS and PSS worker visits   
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7.10.10 Patient self-reported use of social and informal care  
None of the patients were admitted to residential home, nursing home.  Meanwhile, one 
patient in the control group reported six visits to a day centre.  Four patients needed home 
help or community assistant, of which two patients were in the control group with an 
average time of 40 minute per visit.  For intervention patients, the average time per visit 
was 25 minutes. 
Eight patients of which four were control patients needed support with everyday activities 
from friend or relative carer who lives with them.  This occurred in 24 times over a week 
with an average duration of 26 minutes.  For intervention patients, this occurred in 34 
times with an average duration of 44 minutes. 
Four patients, two control and two intervention patients, needed help from a friend or a 
relative who does not live with them.  This occurred in one and two times per week with 
average duration of 60 and 240 minutes for the control patients.  For the intervention 
patients, this occurred one and six times with duration of 30 and 120 minutes.  None of 
those carers had to take time off work.  None of the patients reported using meals on 
wheels. 
7.10.11 Health Related Quality of Life  
Health related quality of life measures at three months post discharge are summarised in 
Table 7.12.  No significant difference was seen between the study groups.  Health status 
EuroQoL VAS and EQ-5D scores were higher for intervention patients compared to 
control patients.  However, this was not statistically significant.  Change on health related 
quality of life measures between baseline and three months post discharge was not 
significant for all measures too, all p values > 0.05.   
However, intervention patients showed more profound but not significant change in 
EuroQoL VAS scores; mean change (SD) was 16.4 (22.4) compared to 12.2 (21.7) for 
control patient, p =0.58.  Similarly, mean (SD) change in EQ-5D was slightly higher in 
intervention patients 0.22 (0.29) compared to 0.20 (0.38) for control patients, yet again 
this was not significant (p=0.85). 
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Health related quality of life  Measure 
Intervention 
N=18 
Control  
N=17  Sig 
Mobility 
No problem 
Some problem  
Confide to bed 
N (%)  
9(50.0%) 
9 (50.0%) 
- 
 
9 (52.9%) 
8 (47.1%) 
- 
NS 
Self-care 
No problem 
Some problem  
Unable of self-care 
N (%)  
15 (83.3%) 
3 (16.7%) 
- 
 
14 (82.4%) 
3 (17.6%) 
 
NS 
Usual activities 
No problem 
Some problem  
Unable to perform any unusual 
activity 
N (%)  
7 (38.9%) 
11 (61.1%) 
- 
 
9 (52.9%) 
7 (41.7%) 
1 (5.9%) 
NS 
Pain & discomfort 
No pain  
Moderate  
Extreme  
N (%)  
6 (33.3%) 
11 (61.1%) 
1 (5.9%) 
 
8 (47.1%) 
7 (41.2%) 
2 (11.8%) 
NS 
Depression/anxiety  
I am not anxious or depressed 
I am moderately anxious or 
depressed 
I am extremely anxious or 
depressed 
N (%)  
10 (55.6%) 
8 (44.4%) 
- 
 
11 (64.7%) 
4 (23.5%) 
2 (8.3%) 
NS 
EuroQoL VSA score Mean (SD) 71.3 (16.3) 68.9 (19.8) NS 
EQ-5D score Mean (SD) 0.72 (0.22)  0.66 (0.31) NS 
NS: not statistically significant. SD: Standard deviation 
Table 7.12 Health related quality of life measures three months post discharge in both 
groups 
7.10.12 Mortality rate 
Mortality rates were similar between groups; 6.7% for intervention group and 10% for 
control group, p >0.05. 
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7.11 Resources necessary to implement pharmacy led MR service 
 Pharmacist time 
The total time spent by the MR pharmacist implementing MR was 899 minutes, median 
(IQ) 29.5 (15.8-43.5) minutes per patient.  Table 7.13 summarises details of the time 
spent implementing MR.  It can be seen that admission MR took longer than discharge 
MR, with the largest proportion of MR pharmacist’s time spent collecting and verifying 
medication histories.  The MR pharmacist spent the time on discharge mainly reconciling 
medicine changes occurred during hospital stay into discharge prescriptions.  
 
 
Point of 
care  Pharmacist activities 
Mean (SD) 
per patient 
% of MR 
pharmacist 
spent time Range 
Admission Collection of data on medication history from 
source(s) other than patient own drugs* 
11.5 (7.0) 31.3% 3-30 
 Documentation of discrepancies 6.3 (4.1) 14.7% 2-15 
 Discrepancies identification 4.0 (2.4) 10.1% 0-10 
 Checking patient own drugs 3.6 (2.6) 6.8% 0-10 
 Establishing unintentional discrepancies with 
medical staff 
3.5 (1.5) 5.9% 2-5 
 Rectifying unintentional discrepancies  3.0 (3.3) 6.7% 0-5 
 Intentional discrepancies clarified with 
medical team as a result of the pharmacist 
query 
2.3 (4.6) 0.8% 1-5 
Discharge Rectifying unintentional discrepancies with 
medical staff 
2.3 (4.9) 12.2% 1-5 
 Discrepancies identification 4.0 (4.2) 6.7% 1-15 
 Clarification of discrepancies identified on 
discharge with medical staff 
7.4 (4.6) 5.0% 5-10 
 Documentation of discrepancies 3.9 (2.8) 3.9% 1-10 
 Recording of any changes as a result of 
discussion with medical staff 
3.8 (2.95) 1.8% 1-10 
 Establishing unintentional discrepancies with 
medical staff 
2.3 (1.9) 1.6% 1-6 
 Intentional discrepancies clarified and 
recorded on electronic discharge summary 
3.5 (4.4) 1.6% 1-10 
*Mainly patient or carer interview. MR: Medicine reconciliation. SD; standard deviation  
 
Table 7.13 Pharmacist time (minutes) spent on MR upon admission and discharge 
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 Doctor time  
The doctors who were responsible for preparing admission charts spent approximately 
two minutes (range 1-5) per patient responding to the MR pharmacist interventions.  
Likewise, 1.5 minutes (range 1-3) were spent per patients by the doctors responsible for 
discharge.    
7.12 Cost estimation 
The MedRec study evaluated a broad scope of costs and consequences.  The main costs 
consumed were related to the time commitment by MR pharmacists.  Consequence costs 
included burden on hospital bed occupancy, NHS and PSS services worker visits, social 
and informal care. 
The unit costs and assumptions used in cost estimation are presented in Tables 7.14, 
7.18, 7.20 and 7.23. 
Assumptions* Cost unit  
Time commitment a 
Hospital pharmacist  £41 per hour 
Foundation year doctor  £37.5 per hour b 
Registrar  £58 per hour 
Unintentional errors  
 4.8% 95% CI [3.7-6.1] of errors occurring upon patient 
transfer of hospital lead to adverse drug events 
 Patients admitted with an adverse drug events had a median 
stay (IQ) 8 [4,18] [11] 
 The average cost of an excess bed day is £264  
£2,112 per adverse drug event 
Readmissions  
 The average cost of an elective inpatient stay excluding 
excess bed days  
 The average cost of a non-elective inpatient short and long 
stay combined excluding excess bed days  
£3,215  
£1,436  
* Costs estimate based on mean (SD).  Unit costs are taken from Personal Social Services Research unit 
(PSSRU) unit costs 2012 and Department of Health reference costs 2011-2012; financial year 2011/2012. a 
Costs without qualifications. b Mean foundation year 1 and year 2 doctors. MR: Medicine reconciliation. CI: 
Confidence interval. IQ: interquartile. 
 
Table 7.14 Unit costs and assumptions for MR pharmacist time, doctor time, length of 
hospital stay, unintentional errors and readmissions   
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7.12.1 Costs associated with pharmacist time 
Based on the unit costs and assumptions stated in Table 7.14, the costs associated with 
the MR pharmacists’ activities are summarised in Table 7.15.  The estimated cost 
attributed to the increased pharmacist time commitment is £23.59 per patient ranging 
between £0 to £54.83.   
Point of 
care  Pharmacist activities (n=30) Cost per patient Range  
Admission  Collection of data on medication history from 
source(s) other than patient own drugs* 
£7.85  £2.34-£23.4 
 Documentation of discrepancies £4.28 £1.58-£11.7 
 Discrepancies identification £2.72 £0-£8.7 
 Checking patient own drugs £2.38  £0-£8.7 
 Establishing unintentional discrepancies with 
medical staff 
£2.38 £1.6-£3.9 
 Rectifying unintentional discrepancies  £2.04  £0-£3.9 
 Intentional discrepancies clarified with 
medical team as a result of the pharmacist 
query 
£1.56 £0.8-£3.9 
Discharge  Rectifying unintentional discrepancies with 
medical staff 
£1.56 £0.8-£3.9 
 Discrepancies identification £2.72  £0.8-£11.7 
 Clarification of discrepancies identified on 
discharge with medical staff 
£5.03 £3.9-£7.8 
 Documentation of discrepancies £3.65 £0.8-£8.7 
 Recording of any changes as a result of 
discussion with medical staff 
£2.55 £0.8-£8.7 
 Establishing unintentional discrepancies with 
medical staff 
£ 1.56 £0.8-£4.7 
 Intentional discrepancies clarified and 
recorded on electronic discharge summary 
£2.38 £0.8-£8.7 
*Mainly through patient or carer interview.MR: Medicine reconciliation 
7.15 Cost associated with pharmacist time commitment 
7.12.2 Costs associated with doctor time 
The role of the person who prepared admission medical charts and discharge summaries 
was identifiable for 47 of medical charts and 25 of discharge summaries.  Foundation 
doctors prepared admission charts in 76%, meanwhile registrar doctors prepared 
discharge summaries in 68%.  The cost associated with doctor time upon admissions 
assumed based on the unit cost of a foundation doctor; whereas a registrar doctor unit 
cost was assumed upon discharge.    
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The cost associated with doctor time upon admission was £1.58 per patient ranging 
between £0.73 and £3.96.  On discharge, the cost associated with the doctor time was 
£1.78 per patient ranging between £1.18 and £3.55. 
7.12.3 Costs associated with unintentional errors 
Costs of unintentional errors are summarised in Table 7.16.  It can be seen, considerable 
costs were saved in the intervention group as errors were intercepted and resolved by the 
MR pharmacist.   
 
Assumptions 
Intervention  
Mean [95% CI] 
N=30 
Control  
Mean [95% CI] 
N=30 
Estimated number of adverse drug events 
contributed by unintentional discrepancies 
3.50 [2.7-4.4] 3.46 [2.7-4.4] 
Length of hospital stay in days of adverse 
drug events related admissions 
28 [21.6-35.6] 27.6 [21.6-35.1] 
Cost of unintentional discrepancies £7,392 [5,702-9,398] £7,286 [5,702-9,266] 
Cost of unintentional discrepancies 
intercepted by routine care  
- £1,013 [781.44-1,288] 
Cost of unintentional discrepancies 
intercepted by the MR pharmacists 
interventions 
£7,392 [5,702-9,398]] - 
Overall cost of unintentional discrepancies £7,392 [5,702-9,398]* £6,273 [4,920-7,978] 
*Cost saved as errors were intercepted. MR: Medicine reconciliation. 
7.16 Costs of unintentional discrepancies in the control and intervention groups 
7.12.4 Costs of hospital stay  
Mean difference in length of hospital stay between intervention and control groups was 
2.97 days.  Excess bed stay cost is estimated on average £264 per day, and therefore the 
MR intervention constituted to additional cost of £784.08 per patient.  When extrapolating 
the extra costs of length of hospital stay to include the 30 patient received MR, the costs 
of excess bed stay amounted to £23,522 in the intervention group. 
7.12.5 Costs of readmissions 
Cost related to readmissions identified from hospital records can be seen in Table 7.17.  It 
can be seen that the cost of excess day bed in control group exceed the cost in the 
intervention group.  This also can be seen when readmissions are differentiated into 
planned and unplanned.  The cost of unplanned readmissions in the control group were 
more than two times the cost in the intervention group. 
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Readmissions Intervention Control  
 N=7 N=10 
Total number of readmissions  19 31 
Total duration of readmission (days) 
Mean per patient 
Range  
72.1 
10.3  
0.20-49.90 
145.40 
13.20  
0.11-42.90 
Total cost of readmissions excess bed day  
Mean cost per patient 
Range (days) 
£19,034.40 
£2,719.20 
£52.80-£13,173.60 
£38,385.6  
£3,484.80 
£27,04-£11,325.60 
Planned admissions a N=4 N=4 
Total number of planned readmissions 
Mean per patient  
Range (days) 
10 
2.50  
1-7 
10 
2.50  
1-6 
Total cost of planned admission excluding excess 
bed days  
Mean cost per patient 
Range (days) 
£32,150 
 
£8,037.50 
£3,215-£22,505 
£32,150 
 
£8,037.50 
£3,461-£19,29 
Total duration of planned readmission (days) 
Mean per patient 
Range (days) 
14.30 
3.60  
0.10-7 
31.20 
7.80  
0.10-40.46 
Total cost of planned inpatient stay including 
excess bed days 
Mean cost per patient 
Range (days) 
£35,925.20 
 
£8,987.90 
£3,241.4-£24,353 
£40,386.80 
 
£10,096.70 
£3,241.4-£29,971.44 
Unplanned admissions b N=6 N=10 
Total number of unplanned readmissions 
Mean per patient 
Range (days) 
9 
1.5 
1-2 
21 
1.9  
1-4 
Total cost of unplanned inpatient excluding excess 
bed days  
Mean cost per patient 
Range (days) 
£12,924 
 
£2,154 
£1,436-£2,872 
£30,156 
 
£2,728.40 
£1,436-£5,744 
Total duration of unplanned readmission (days) 
Mean per patient 
Range(days) 
25.9 
8.6  
1-14 
57.8 
19.3  
0.60-49.9 
Cost of unplanned inpatient including excess bed 
days 
Mean cost per patient 
Range  
£19,761.60 
 
£4,424.40 
£1,700-£6,568 
£45,415.2 
 
£7,823.60 
£1,594.40-£18,917.60 
a
 Elective inpatient stay. b non-elective inpatient short and long stay combined. 
Table 7.17 Cost related to readmissions in both study groups 
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7.12.6 Costs of NHS and PSS worker visits 
The unit costs and assumptions for NHS and PSS worker visits are summarised in Table 
7.18 
Workers a  
Place of 
most visits Unit 
cost* 
Cost per hour 
of 
employment 
Assumptions and comments 
GP GP clinic £23.01 £118 Per consultation lasting 11.7 
minutes for general medical 
service 
 home £91.26  Per out of surgery visit lasting 23.4 
minutes 
Including travel expense  
 Telephone 
consultation  
£22  Per telephone consultation lasting 
7.1 minutes 
Practice nurse  GP clinic £6.83 £35 Assumed same duration of a GP 
consultation  
 home £13.65  Assumed same duration of a GP 
out of surgery visit 
District Nurse  GP clinic £12.04 £42 Assumed same duration of a GP 
consultation  
 home £16.38  Assumed same duration of a GP 
out of surgery visit 
Specialist nurse GP clinic £13 £52 Assumed length of consultation 15 
minutes 
 Hospital  £8.75 £35 Assumed hospital staff nurse and 
assumed length of consultation 15 
minutes 
Dietician GP clinic £16.45 £30 Assumed same duration of hospital 
physiotherapist lasting 32.9 
minutes 
 Hospital £11.65  Assumed same duration of hospital 
physiotherapist clinic visit lasting 
23.3 minutes 
 Telephone 
consultation  
£6.55  Assumed same duration of hospital 
physiotherapist lasting 13.1 
minutes 
Physiotherapist  GP clinic £16.45 £30 Assumed same duration of hospital 
physiotherapist lasting 32.9 
minutes  
 home £12.09  Assumed same duration of GP out 
of surgery visit lasting 23.4 
minutes 
Care assistant  Home £24.57 £63 Assumed same of health visitors 
per hour of home visit 
Assumed same duration of GP out 
of surgery visit lasting 23.4 minutes 
Including travel expense  
*Unit costs are taken from Personal Social Services Research unit (PSSRU) unit cost of health and social care 
2012, financial year 2011/2012. a Costs without qualification. GP: General practitioner.   
Table 7.18 Units cost and assumptions related to NHS and PSS worker visits 
Costs of NHS and PSS worker visits for both study groups are summarised in Table 7.19.  
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Workers  Intervention  Control  
GP  N=7 N=9 
Number of GP visits in GP Clinic  
Mean per patient 
Range  
29 
4.14  
1-13 
75 
8.33  
1-30 
Total cost of GP visits in GP Clinic 
Mean cost per patient 
Range 
£667.29 
£95.26 
£23.01-£299.13 
£1,725.75 
£191.67 
£23.01-£690.3 
 
N=2 N=1 
Number of GP visits at patient home  
Mean per patient 
Range  
6 
3  
2,4 
1 
- 
1 
Total cost of GP visits in patient home 
Mean cost per patient 
Range 
£547.56 
£273.78 
£182.52,£365.04 
£91.26 
- 
£91.26 
 
- N=1 
Number of GP telephone consultation   - 1 
Total cost of GP telephone consultation   - £22 
Practice Nurse  
Number of practice nurse visits in GP clinic 
Mean per patient 
Range 
N=5 
12 
2.5  
1-7 
N=2 
33 
16.5  
3,30 
Total cost of practice nurse visits in GP clinic 
Mean cost per patient 
Range 
£120.36 
£25.08 
£10.03-£70.21 
£330.99 
£165.50 
£30.09,£300.9 
 N=1 N=6 
Number of practice nurse visits at patient home  
Mean per patient 
Range 
1 
- 
- 
10 
1.7  
1-4 
Total cost of practice nurse visits at patient home 
Mean cost per patient 
Range 
£13.65 
- 
- 
£136.50 
£23.21  
£13.65-£54.6 
GP: General practitioner 
Table 7.19 Costs of NHS and PSS worker visits  
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Workers  Intervention  Control  
District nurse  
Number of district nurse visits in GP clinic 
- N=1 
Total cost of district nurse visits in GP clinic  - £12.04 
 N=3 N=4 
Number of district nurse visits at patient home  
Mean per patient 
Range 
26 
8.7 
1-24 
27 
7  
1-20 
Total cost of district nurse visits at patient home 
Mean cost per patient 
Range 
£425.88 
£142.51 
£16.38-£393 
£442.26 
£114.66 
£16.38-£327.6 
Specialist nurse  
Number of specialist nurse visits in GP clinic  
- 
- 
N=1 
15 
Total cost of specialist nurse visits in GP clinic  - £195 
 
- N=1 
Number of specialist nurse visits in hospital - 4 
Total cost of specialist nurse visits in hospital - £35 
Dietician  
Number of dietician visits in GP clinic 
N=1 
1 
N=1 
1 
Total cost of dietician visits in GP clinic £16.45 £16.45 
 
- N=1 
Number of dietician visits in hospital  - 1 
Total cost of dietician visits in hospital  - £11.65 
 
- N=1 
Number of dietician telephone consultations   - 2 
Total cost of dietician telephone consultations   - £13.10 
Physiotherapist  
Number of physiotherapist visits in GP clinic 
- 
- 
N=1 
1 
Total cost of physiotherapist visits in GP clinic - £17 
 
- N=1 
Number of physiotherapist visits at home 4 4 
Total cost of physiotherapist visits at home £48.36 £48.36 
GP: General practitioner  
Continued 
Table 7.19 Costs NHS and PSS worker visits   
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Worker  Intervention  Control  
Care assistant  
Number of care assistant visits at home 
Mean per patient  
Range 
N=2 
31 
15.5  
6,25 
N=1 
5 
- 
- 
Total cost of care assistant visits at home 
Mean cost per patient 
Range 
£761.67 
£380.84 
£147.42,£614.25 
£122.85 
- 
- 
Continued 
Table 7.19 Costs of NHS and PSS worker visits 
The total cost associated with NHS and PSS worker visits in the intervention was 
£2,601.22; whilst the total cost in the control group was £3,185.21. 
7.12.7 Costs of hospital service use 
Unit costs and assumptions for hospital service use are summarised in Table 7.20. 
Assumptions Cost unit* 
Weighted average of emergency 
department visit (not admitted) 
£112 average visit  
Weighted average of walk in service (not 
admitted) 
£41 average visit 
Weighted average of all outpatient 
procedures 
£139  
*Unit costs are taken from Personal social services research unit (PSSRU) unit cost of health and social care 
2012, financial year 2011/2012.   
Table 7.20 Units cost and assumptions for hospital service use 
Costs of emergency department visits can be seen in Table 7.21. 
Emergency visits 
Intervention  
N=7 
Control  
N=5 
 
  
Total emergency department visits  
Mean per patient 
Range 
10 
1.43  
1-3 
12 
2.4  
1-3 
Total cost of emergency department visits  
Mean cost per patient 
Range 
£1,120 
 
£160.16 
£112-£336 
£1,344 
 
£268.8 
£112-£336 
 
Table 7.21 Costs of emergency department in both study group 
The cost of emergency department visits in the control group exceeded the cost in the 
intervention group.  
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None of intervention patients used NHS walk in centre service, where one control patient 
visited NHS walk in centre with an estimated cost of £41. 
Costs of outpatient visits are shown in Table 7.22. 
Outpatient visits 
Intervention  
N=10 
Control  
N=9 
Total outpatients visits  
Mean  
Range 
27 
2.7  
1-8 
21 
2.4  
1-3 
Cost of outpatients visits  
Mean  
Range 
£3,753 
£375.3 
£139-£1,112 
£2,919 
£333.6 
£139-£417 
Table 7.22 Cost of outpatient visits  
The total weighted cost of outpatients’ visits in the intervention group exceeded the cost in 
the control group. 
7.12.8 Costs of social and informal carer  
Cost units and assumptions related to social and informal care use can be seen in Table 
7.23.  No costs were associated with patients’ admissions to residential or nursing home 
and the use of meal on wheels service in both groups.  None of the informal carer took 
time off work and thus no costs valued for productivity loss.  Costs associated with social 
and informal care use are shown in Table 7.24. 
The costs of day centre attendance and home help in the control group exceeded the 
costs for intervention patients.  The time spent by informal carers who live with patients 
amounted for more costs in the intervention group, whereas, the costs of the time spent 
by carers who do not live with patients, including travel expenses, were similar. 
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Social and informal care  Unit cost*  Assumption and comments 
Day centre attendance  £41 per 
attendance 
Assumed that the number of reported 
day centre attendances for the week in 
question was equivalent to the average 
per week across all weeks in the past 3 
months 
Home help or community care 
assistant 
£23 per hour  
 
Assume day time weekday visits a 
Face to face contact  
Assumed a visit lasted 30 minutes 
Opportunity cost of the time spent 
by the informal care givers  
£4.38 per hour b Only includes costs attributed to carer 
time and excludes patient time. the value 
of the opportunities forgone by care 
givers as a result of time spent on care 
giving 
Assumed travel cost for each visit 
for a friend or relative who don’t 
live with the patient 
£4c Assumed the use of public transport, 
return journey 
*Unit costs are taken from Personal Social Services Research unit (PSSRU) unit cost of health and social care 
2012, financial year 2011/2012. a Higher fee for weekends. b Taken from the National Minimum Wage rates 
2011/2012 available at: https://www.gov.uk/national-minimum-wage-rates . c Taken from the Annual Bus 
Statistics: Great Britain 2011/12: Table BUS0401b, published by the department of transport. 
Table 7.23 Cost units and assumptions for social and informal care service use  
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Social and informal care Intervention  Control  
Social care  N=1 
Day centre attendance  
Number of day centre attendance 
Costs of day centre attendance  
-  
6 
£216 
Home help or community care assistant 
Number of times home help or community care assistant 
needed per week 
Total minutes  
Mean duration per patient 
Range  
N=2 
9 
 
55 
27.5  
10,45 
N=2 
13 
 
80 
40.0  
20,60 
Total costs of home help or community care assistant 
Mean cost per patient 
Range 
£21.08 
£10.54 
£3.83,£17.25 
£30.67 
£15.33 
£7.67,£23a 
Informal care (i.e. help with everyday activities) 
  
Carers who live with the patient  
Number of times help needed per week 
Total minutes  
Mean duration per patient  
Range  
N=3 
34 
980  
44  
20-90 
N=3 
24 
550 
26.3 
20-30 
Total cost of time spent by carers who live with patients  
Mean cost per patient 
Rang 
£71.54 
£3.21 
£1.46-£6.57 
£40.15 
£1.92 
£1.5-£2.19 
Carers who do not live with the patient b 
Number of times help needed per week  
Total minutes  
Mean duration per patient 
Range (minutes) 
N=2 
7 
300 
42.86 
30, 120 
N=2 
3 
360 
120  
60,240 
Total cost of time spent by carers who don’t live with the 
patient  
Mean cost per patient 
Rang 
£38.95 
 
£7.13 
£26.19-£12.76 
£38.28 
 
£12.76 
£12.38-£21.52 
a One visit lasted one hour and 12 visits each in average lasted 20 minutes. b Travel expense added 
Table 7.24 Costs of social and informal care service use   
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In response to the question on items incurred out of the patient pocket, i.e. paid by a 
patient as a result of his/her health in the last three months, twelve patients responded 
that they have incurred out of pocket expenses.  Total expense for control patients was 
£104 and for intervention patients was £185.  Details of incurred items can be seen in 
Table 7.25. 
Out of pocket expenses 
Intervention 
Per patient  
N=7 
Control  
Per patient  
N=5 
Bus tickets & transport £3.86 £2.80 
Car travel expenses £3.57 £8.80 
Car parking  £5.43 £4.20 
Prescription and medicines  £13.14 £1 
Mouth wash - £0.80 
Bottle of sterile water  - £1.20 
Micropore - £0.40 
Antiseptic wipes x4 - £1.60 
Table 7.25 Expenses incurred by patients in the intervention and control groups  
It can be seen that intervention patients reported incurring more expenses with mean of 
£37.6 ranging between £5 and £85.  Meanwhile, control patients incurred a mean of £15.6 
ranging between £5 and £50.   
7.12.9 Costs of control MR  
To estimate the cost of MR received by control patients, it was assumed based on Table 
7.2 that on average control MR took 20 minutes and was provided by pharmacy 
technicians.  The unit cost assigned to one hour employment of pharmacy technician 
taken from the National Career Service information and based on an average earning of 
£23,000 per year [196] was £11.64. 
The average cost of control MR was estimated as £3.88 per patient and ranging between 
£1.93 and £5.82.  For the 24 patients received control MR, the total cost was estimated as 
£93.12 ranging from £46.32 and £139.68. 
7.13 Cost-effectiveness of pharmacy led MR 
Quality- adjusted life-year (QALY) gained diagram can be seen in Figure 7.8.  Methods for 
QALY estimation with and without baseline estimation are illustrated in Box 7.1. 
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BOX 7.1 QALY estimation  
 
Figure 7.8 QALY gained over three months in both groups 
 Without baseline adjustment  
Total area under the curve (intervention) =0.5 (0.49+0.72) *0.25 = 0.15 
Total area under the curve (control) =0.5 (0.36+0.66)*0.25 = 0.13 
Incremental QALY gain/loss= QALY (intervention)-QALY (control) = 0.02 
 
 With baseline adjustment  
Total area under the curve (intervention) = 0.5(0.72-0.49) *0.25 =0.029 
Total area under the curve (control) =0.5 (0.66- 0.36)*0.25 = 0.038 
Incremental QALY gain/loss = QALY (intervention)-QALY (control) = - 0.0088 

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Table 7.26 summarises incremental costs/ savings (intervention –control) per patient.  It 
can be seen, from NHS and PSS perspective, the MR intervention contributed to savings 
of almost £3,000 per patient.   
Costs 
Costs per 
patient  
Intervention  
Cost per 
patient  
Control  
Incremental 
cost/saving 
per patient  
Time commitment     
Pharmacist time £23.59  £3.88 19.71 
Doctor time £3.36 - £3.36 
Hospital service use 
   
Hospital stay costs £3,102.30  £2,318.80  £783.50 
Cost of unintentional errors burden on 
hospital bed 
£70.40a £209.10  -£138.70 
Unplanned readmission b,c  £4,424.40 £7,823.60  -£3,399.20 
Emergency department visits  £160.16 £268.80 -£108.64 
Outpatients visits £375.30 £333.60 £41.70 
NHS walk in centre - £41 -£41 
NHS and PSS workers   
  
GP visits  £369.04 £304.93 £64.11 
Practice nurse visits £38.73 £188.71 -£149.98 
District nurse  £142.51  £126.70  £15.81 
Specialist nurse  - £230 -£230 
Dietician  £16.45 £41.20 -£24.75 
Physiotherapist  £48.36 £65.36 -£17 
Care assistant  £380.48 £122.85 £257.63 
Social care costs 
  
 
Day care  - £216 £216 
Home care  £10.54 £15.33 -£4.79 
Total costs excluding informal care  £9,213.56 £12,340.10 -£3,126.54 
Total costs including informal care 
and items incurred out of patient 
pocket 
9,213.56 £12,2994.10 -£3,085.54 
a one unintentional error was not intercepted in the intervention group. b Planned admissions were not a main 
cost drive. [245, 246] c Readmissions reported from the hospital record  
Table 7.26 Summary of costs/saving associated with the intervention and control group  
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The MedRec intervention appeared less costly compared to the standard care.  The costs 
saved were mainly attributed to savings in unplanned readmissions and NHS and PSS 
worker visits.  The addition of informal care and items incurred out of patient pockets did 
not alter the finding.  The change in utility was less evident, adjusting for baseline 
imbalances showed a change in QALY gained in favour of the control group.  Incomplete 
outcome data on the use of health resources at three months (only 35 returned 
questionnaires in both groups) hindered precise estimate of utility change, it was agreed it 
would be too speculative to calculate an incremental cost-effectiveness ratio at this stage.   
7.14 Summary of the MedRec interim analysis findings 
This is mainly a descriptive analysis with the focus on the feasibility and integrity of the 
study protocol.  Pilot studies by their nature and being of small scale may not produce 
significant results [169, 171] and it is important to interpret hypothesis testing with caution.  
Additionally, this was also focused on ensuring that the process of recruitment, 
intervention delivery and follow up all run smoothly.  The reported results are not inclusive 
and the full analysis of the pilot will provide a further insight on the effects and the 
resources necessary to implement pharmacy led MR within inpatient settings.   
 
  


 

Chapter 8 Medicine Reconciliation at the 
Health Interface Discussion  



Discussion 
Medicine reconciliation at 
the health interface: The 
MedRec Study  
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8.1 Feasibility of the MedRec study 
Over all the study process, data collection and analysis all appeared feasible.  Learning 
points on the feasibility of the MedRec study are summarised in BOX 8.1.   
Recruitment rate was satisfactory; approximately two thirds of the approached patients 
consented.  This rate increases when ineligible patients are excluded from the 
denominator, i.e. patients who were seen by ward pharmacy staff and/or prescribed no 
medicines.  Without conversing with the patient and the nursing team it was not possible 
to identify the latter patients.  Additionally, the research team needed to allocate time to 
perform administrative research activities which were time consuming.  Within these 
limitations, it was not possible to exceed the recruitment target of five patients per week.  
Time constraint was the main barrier for consenting patients.  This was of particular 
concern with consultee recruitment.  Previous reports have highlighted that patients with 
incomplete mental capacity are at frequent risk of inappropriate inclusion or exclusion 
from research.[247]  This is due to variation in the extent and type of illness or methods for 
assessing mental capacity.[247, 248]  This study is the first to highlight time constraints as a 
barrier to consent these patients; this could underline an important consideration when 
developing studies aiming to target such population. 
Similarly, patient retention in the study was reasonable with death being the main reason 
for losing patients to follow up.  Mortality rate was comparable between the study groups 
and there was no reason to believe that the intervention caused any significant burden or 
harm to patients. 
Collection of outcome data at three months post discharge was also found feasible; 
practices responded to the study researcher requests for details on patient medicines at 
three months post discharge for almost 90% of patients (excluding deceased patients).  It 
is notable that for 50% of patients, a second contact was required to prompt practices to 
send information requested.  Follow up non-responders team increased responses by 
20% but did not expedite responses.  This again underlines an important time 
consideration when developing studies acquiring follow up data across healthcare 
settings. 
The response rate of health related quality of life and health resource use questionnaires 
was again reasonable; three out of five patients returned the questionnaires within 
approximately two weeks.  Notably, sending reminder letters and calling patients 
increased and expedited responses.  This is consistent with a systematic review of 
methods to improve health questionnaires response rates, which found that the use of 
follow up contact significantly Improved the response rate.[249]  
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BOX 8.1 Feasibility of the MedRec study 
 Recruitment rate and MR implementation  
Recruitment and MR implementation were found feasible. The intended patient 
population can be identified following the study procedure.  The delivery of MR was 
implemented well and in time manner.  There are; however few unforeseen 
challenges warranted considerations: 
o Consultee recruitment  
Consultee recruitment was difficult to achieve; frequently this was limited by time 
constraints and unavailability of the research team.   
o Proportion of patients approached/ recruited  
Recruitment rate was satisfactory (68%) and fell only five patients below the target.  It 
was not possible to exceed the agreed target per week mainly due to time constraints. 
 Data collection  
Data collection was found feasible, however, it is laborious and time consuming. 
Standard operating produces and personal communication and periodic meetings 
between the study team are required to ensure uniform data collection and entry.   
 Control MR   
Eighty percentage of control patients received control MR.  This was believed due 
mainly to the pressure in the Trust to increase routine MR rate.  It was, however, 
believed partially to be due to patients being highlighted to the ward staff by the study 
process.  Control forms were relocated and patient study number was used in instead 
of name and date of birth. This would not make it obvious to the staff that MR had not 
been performed.   
 Database 
The study database was helpful and facilitated data analysis and processing.  
However, amendments are needed to optimise usability. Refinements to the MedRec 
database have been proposed. 
 

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During the development of the MedRec study and before commencing the study, it was 
determined via an audit and formal discussion, that approximately 50% or less of patients 
at the study site receive MR as a part of the usual care.  Additionally, the study wards 
were identified as those with less pharmacy staff cover; this was intended to keep MR 
contamination minimal in the control group.  By the time the study was implemented 80% 
of control patients received control MR.  Whilst this was mainly due to pressure within the 
trust to increase the MR rate, it was partially believed to be due to patients being 
highlighted to the ward staff by the study process.  It is therefore important to ensure that 
such trials do not inadvertently highlight control patients and measures effectively 
introduced to prevent this.  To resolve this, it was agreed to relocate the control MR forms 
and to use patient study number rather than full name and date of birth.   
When MR took place within the control group it was limited frequently to patient own drugs 
check and medication history taking (Table 7.2).  In addition, patient medicines were 
verified using one source of information and MR was frequently implemented beyond 24 
hours of admission and by pharmacy technicians.  Subgroup analysis of true and partial 
control patients is also planned at the time of the full pilot analysis.  
BOX 8.1 Feasibility of the MedRec study (continued) 
 Follow up rate 
Attrition of participants was similar between groups (Figure 7.1).  
o Three months GP held medicine lists 
Details of medicines the patient is taking three months post discharge was attainable to 
a reasonable extent (87.3%). A second contact by the study team increased response; 
however it did not expedite responses. 
o Health related quality of life and health resource use  
Health related quality of life and resource use questionnaires returned within four weeks 
to six weeks by 63.6% of patients.  The reminding letters sent to non-responders 
increased response but did not expedite responses.  Phone contacts to non-
respondents expedite the questionnaire return by three days on average. 
 Randomisation  
The study randomisation was successful; groups are comparable at baseline.  
However, baseline imbalances between groups with respect to EQ-5D were of note 
when the incremental QALY gained was estimated. This warrant adjustment to baseline 
imbalances if this continued to exist when the full data is available for full pilot analysis. 

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Ensuring a standard delivery of the MedRec intervention is of need to enable future wide 
implementation of recommendations across NHS trusts.  The MedRec pilot study tests a 
novel MR service described in (BOX 2.3.2).  This service was informed by literature 
(chapter 1 and five) and discussion with care stakeholders.  MR pharmacists were trained 
prior the study commencement by performing at least 30 MR episodes observed by the 
study principal investigator.  The interim analysis aimed to develop and refine standard 
operating procedures and checklists for the delivery and documentation of MR, those 
were to ensure the intervention can be transferred and preformed consistently across 
settings or hospitals.  The final pro-forma for optimum MR implementation and 
documentation still under development.  Further refinement will be gained by the end of 
the full pilot study.  Then, this will enable us to describe a standard pro-forma for MR 
implementation and documentation to promote widely across hospitals. 
8.2 Initial findings of the MedRec study 
Pharmacy led MR tended towards favourable effect on Log length of hospital stay, 
readmissions, medication errors, heath resources use and health related quality of life.  
Length of hospital stay was the primary outcome.  It could be seen from the small interim 
analysis that intervention patients had a shorter log hospital stay.  Log transformation was 
planned a priori and was informed by a similar study in Dublin in 2007.[4]  Additionally, Log 
transformation was justified by the skewed distribution of hospital stay and the variation 
seen between intervention patients.[250]  Few data points were potential outliers; those 
suspected were reviewed to identify anomalies with data entry or user error but none was 
found.  Findings from literature on the effect of MR on length of hospital stay are 
inconsistent.  Scullin et al., in a Northern Ireland study, demonstrated a significant 
reduction in length of hospital stay [115] which is supported by findings from the USA,[251]. 
whilst Makowsky et al. in Canada showed a significant increase in length of hospital stay 
[230]
 and Stowasser et al. from Australia reported no significant effect on length of hospital 
stay.[226]  In all these studies, the pharmacist completed discharge reconciliation upon 
consultation with patients, thus it is unclear whether this might have delayed the discharge 
process.  The MR pharmacist in Makowsky et al’s study provided patients or carers with 
counselling upon discharge and this might explain the significant increase in length of 
hospital stay.  Nevertheless discharge counselling and patient consultation upon 
discharge was not a feature of the MedRec intervention.  Thus, there is little reason to 
believe that this was caused by the MR pharmacist involvement in the discharge process.  
More insight can be gained on the change in the length of hospital stay when the full 
dataset is available for the full pilot analysis. 
 


The study intervention group was associated with lower readmission rates; it also took 
longer for readmissions to occur in the intervention group compared to the control group.  
This is consistent with other studies.[115, 118]  There was a significant difference in favour of 
the intervention group in the number of unplanned admissions which almost achieved 
statistical significance.  This might have major cost and health implications; studies have 
demonstrated that adverse drug events are common cause of preventable unplanned 
admissions which are estimated to cost the NHS a total of £500 million annually.[11, 245, 246]  
Consistent with previous studies showing medication errors at care transition are 
common,[17, 29, 31, 222, 231] the interim analysis highlighted high rates of medication errors at 
admission and discharge.  The nature of these medication errors was also similar with 
omissions being the main type of unintentional errors which adds to the findings from 
previous studies.[29, 31, 32, 51, 163, 208, 209]   
The majority of admission errors recurred in discharge summaries; 20% of MR related 
errors were intercepted by the ward pharmacy staff.  This highlights that the MR 
pharmacist is useful in detecting and rectifying medication errors at the point of admission 
as well as preventing error recurrence in discharge summaries.   
A novel aspect of this study is that discharge errors were assessed three months post 
discharge to identify the proportion of errors translated into primary care.  When it was 
possible to identify the outcome of discharge errors at three months (n=44 errors), these 
were translated into primary care in almost 50% of cases.  However, the majority of errors 
were omissions assumed by one source of information.  And thus these should only be 
defined as errors after discussion with GPs.  This is planned for the full pilot analysis. 
A random selection of 20 errors, identified by the interim analysis, showed that the 
majority of errors were considered of minor severity.  A similar study, by Grimes et al. in 
Ireland in 2011, employed the Dean and Barber approach to assess the potential harm of 
non-reconciled medicines at hospital discharge; the majority were regarded to be of 
moderate harm.[35]  There are two important differences between the MedRec interim 
analysis and the aforementioned study; firstly, in Grimes et al. non-reconciliation 
medicines were judged with no reference to prescriber intention, meanwhile in the 
MedRec interim analysis intentional discrepancies were not considered errors.  Secondly, 
the information on whether errors perpetuated at three months or not was not available for 
the assessors in the study by Grimes et al.; therefore they might have rated errors with 
higher clinical significance assuming discharge errors have reached patients. 
Although few reports investigated the consequence of admission errors on patients during 
hospital stays and upon discharge,[17, 28, 29] to our knowledge this interim analysis is the 
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first to acquire information on discharge errors after three months.  Therefore this can add 
new knowledge on whether it is appropriate to assume that errors in discharge summaries 
result in patient harm.  A recent systematic review outlined that unintentional 
discrepancies are common but few have clinical significance.[138]  With the knowledge of 
discharge error consequences in primary care, it would be possible to gain insight into 
actual patient harm and thus achieve a better understanding of the clinical implications 
and effects of MR on patient safety and continuity of care.  Discussion with GPs is 
planned for the full pilot analysis which will enable us to evaluate actual patient harm and 
obtain a more realistic measure of MR clinical significance to patient care.  
Intentional changes in medicines were often not documented; these were not considered 
errors.  However absence of this information might create ambiguity and impede optimum 
continuity of patient care.[39, 50]  It is noteworthy that 50% of undocumented intentional 
changes required subsequent actions or communication to nursing teams or GPs.   
The MR pharmacist ensured complete and clear communication of undocumented 
changes to ward staff.  Additionally, the MR pharmacist ensured comprehensive 
documentation of medicines changed in discharge summaries and prepared 
comprehensive discharge instructions sent promptly to primary care on the day of 
discharge.  This highlights an added value of the MR pharmacist in enabling care 
coordination and appropriate prescribing.  
In addition, enhancing the clarity of discharge information and ensuring a full record of 
discharge instructions could ensure continuity of care post discharge; this has been 
suggested in previous studies.[225, 226]  Both studies highlighted that discharge MR 
improved the correlation between discharge lists and medicines prescribed post 
discharge.  It was suggested that patient therapy was optimised by the pharmacist during 
hospital stay and thus GPs needed to do few number of changes to therapy. [225, 226]  
Those studies reported fewer numbers of post discharge changes, i.e. discharge lists and 
home medicines were more closely matched for intervention patients.  However, the 
reasons underlying post discharge changes were not investigated.  The interim analysis 
supports these suggestions; however, more medicines were changed in the intervention 
group compared to control patients at three months post discharge.  These changes were 
mainly actions taken in response to the MR pharmacist discharge instructions; 
comprehensive discharge instructions and full details of medicine changes during hospital 
stays might have empowered GPs to make additional and appropriate changes when 
needed and thus enhanced effective continuity of care.  Further insight on such an 
assertion can be gained after discussions with GPs. 
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The addition of the MR pharmacist appeared to improve health related quality of life 
measures; EQ-5D scores and EuroQol VAS scores were higher for intervention patients at 
three months post-discharge.  However, this conclusion is limited by the fact that these 
were based on findings from only 35 patients.  Additionally, baseline imbalances in EQ-5D 
scores is worthy of further consideration.  Thus no firm conclusion can be drawn without 
gaining further insight into health related quality of life measures when the full pilot dataset 
is available. 
The interim analysis also showed that intervention patients tended to have fewer visits to 
NHS and PSS workers and hospital service use at three months post discharge.  The 
need to visit health professionals in community and in hospital might have been influenced 
by the MedRec intervention; the MR pharmacist verified medication histories and 
intercepted errors which potentially optimised patients’ care during hospital stay and upon 
discharge.  In addition, comprehensive and timely discharge information communication 
might have optimised post discharge management and thus minimised number of visits.  
This is supported by findings from other studies.[115, 118, 226]  
Of note is the number of mismatches that were found between the number of 
readmissions identified by hospital records and those self-reported by patients.  Byford et 
al. evaluated the accuracy of data collected from GP records and those reported by 
patients on the use of health services and reported variability in agreement across 
services.[176]  Byford et al. suggested that there might be a systematic underestimation of 
inpatient visits in GP records compared to patient reports; GPs might be well aware of 
planned admissions but they might be less aware of other inpatient stays (unplanned 
admissions) unless informed by the hospital.  Thus patient self-reports were suggested to 
provide a more accurate estimation of inpatient use compared to GP records. [176]  A 
similar investigation comparing the accuracy of patient reports and hospital records on 
physiotherapy services use found patient self-reports a more reliable method.[252]  The 
interim analysis found 44 discrepancies in readmissions data between hospital records 
and patient reports.  It is not possible to comment on the accuracy of either source; 
readmissions data identified by hospital records was related to the complete dataset of the 
interim analysis (n=60) patients, while data from patient self-reports was related to 35 
patients.  Nevertheless, it is most likely that data obtained from the hospital records would 
capture patient readmissions to CUFHT but not readmissions to other hospitals in the 
area.  It is possible also that patients might recall additional visits outside the reference 
period of three months.  More insight will be gained once the full dataset is available for 
the full pilot analysis.  Furthermore, details of patients’ health resource use will be 
collected from GP practices at the end of the MedRec study which will provide valuable 
insight on the accuracy and comparability of these data sources.  
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8.3 Resources necessary to implement pharmacy led MR  
The main resource requirement is the increased time commitment by the MR pharmacist.  
The interim analysis estimated that the MR pharmacist took half an hour on average to 
implement MR.  This lies in the range reported by literature.[114, 228, 229]   
The MedRec study is one of the few studies to describe the time spent by the MR 
pharmacist performing different MR tasks, [114, 229] this enables to highlight the most time 
consuming steps thus efficiently prioritising pharmacist time.  Admission MR took longer 
time than discharge MR; the majority of the MR pharmacist time was spent verifying 
medication history during patient or carer interview.  Findings on the MR pharmacist 
activities and the time spent for each MR step would help to identify how to implement MR 
optimally.  This is of great implication where pharmacy services are limited. 
It is important to note that the study researcher obtained information on patients’ 
medicines from GP practices, medical notes, patient own drugs and hospital records in 
advance of the MR pharmacist visits and these were given to the MR pharmacist to avoid 
duplication of effort.  Thus the time spent by MR pharmacist could have been longer if 
such time was considered.  However, the use of administrative staff to collate information 
may be a more efficient use of resources and pharmacist’s time could be prioritised to 
perform more patient centred MR tasks. 
8.4 Cost-effectiveness of pharmacist-led MR 
Patient safety continues to be a driving force in healthcare.  Length of hospital stay, 
readmissions and emergency department visits and resource use in community are the 
major elements that make up the cost of patient care.[251]   
Pharmacy led MR was associated with a longer mean length of hospital stay and hence 
increased costs related to increased hospital bed occupancy.  More insight can be gained 
on length of hospital stay change and thus costs at the time of full pilot analysis. 
The interim analysis showed that the MR intervention can preclude the burden of adverse 
drug events on bed occupancy and thus contribute to considerable cost savings for the 
NHS.  This is in line with the cost savings estimated in literature.[107]  However the cost of 
medicine use attributed to identifying omitted pre-admission medicines and patient own 
drugs use and the cost savings attributed to optimising therapy such us stopping 
unintentional addition of medicines were not estimated.  The interim analysis aimed to 
provide a rough estimation of costs/savings related to medication errors; a broader scope 
of costs is planned for the full pilot analysis.  


With the majority of hospital re-visits related to medicines being unplanned, [245, 246] it is 
expected that MR would demonstrate significant cost savings related to unplanned 
admissions.  This is consistent with the findings from this interim analysis and other 
studies.[135, 232]  
The estimated cost of pharmacist time was £23.59, adding in the time spent by doctors 
responding to the MR pharmacist’ interventions resulted in a total cost of £27.22.  This 
however did not increase the overall health expenditure.  The MedRec intervention was 
less costly compared to usual care; overall savings were estimated as £3,000 per patient.  
This indicates that the MedRec intervention did not shift patient care to community; the 
number of visits and thus costs to NHS and PSS workers were reduced.  The MedRec 
intervention reduced the cost of social care but not informal care; however there is little 
reason to believe that the MedRec intervention shifted care to the later carers.   
No other study estimated the cost of pharmacy led MR intervention using similar broad 
scope of costs and consequences.  Herein, the estimated savings associated with the 
MedRec intervention cannot be compared to those in a previous UK investigation.[136] 
Nevertheless, the primary focus of this analysis was to identify whether it would be 
achievable to obtain data on the costs and consequences of MR to enable a robust 
economic evaluation.  This analysis ensured feasibility of costing and a cost-effectiveness 
estimation.  Broader costing strategies will be employed for the full pilot analysis.  These 
are summarised in BOX 8.2.  
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BOX 8.2 Costing strategies planned for the full pilot analysis 
 Allowance for differential timing of cost 
Allowance will be needed to make for the differential timing of costs and consequence. 
This can be done by inflating unit costs using the predicted inflation indices for 2013.[175]  
 Systematic handling of missing data 
For the purposes of the interim analysis, “Available Case analysis” was used.  This is 
considered a simple approach to handle missing data.[180] Available Case analysis 
estimates the mean for the complete cases for each variable. The major disadvantage is 
that different samples are used across the analysis, i.e. the sample base varies from one 
variable to another since a different set of patients contribute to the estimation of different 
variables. This leads to problems of comparability across variables.[180]  
Another method which is also considered a naive method to handle missing data is 
“Complete Case analysis”. Complete-case analysis or list wise deletion of cases is the 
default method in most statistical software packages. It involves discarding cases where 
any variables are missing. The advantages of using this method are that it is easy to do 
and that the same set of data (albeit a reduced set) is used for all analyses. However, it 
is inefficient in that it excludes data that are potentially informative for the analysis.  
Complete-case analysis will be biased if the complete cases systematically differ from 
the original sample. Complete Case analysis is an acceptable method with small 
amounts of missing information. Thus providing this would be the case at the time of the 
full pilot analysis, Complete Case analysis is planned. Otherwise missing data will be 
imputed to produce a complete dataset. 
 Estimating indirect or non-contact time of MR pharmacist 
There might be unmeasured costs of time spent by the MR pharmacist performing 
activities which do not include patients contact such MR interview preparation, team 
discussions, writing up notes.  The estimation of non-contact time will help to provide 
more precise estimate of the time required for effective MR implementation.  It is 
estimated for a hospital pharmacist that for each one hour of contact there is an 
additional 0.43 hours of non-contact time. [180]   
Additionally, the time spent by the study researcher collecting relevant MR information, 
faxing and contacting primary care practices, that otherwise would have been spent by 
the MR pharmacist could add to the cost associated with the MedRec intervention.  
Those warrant valuation by the full pilot analysis. 
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Although the MedRec intervention appeared less costly, the conclusion on effectiveness 
should be drawn with tentative consideration.  The value of QALY changed over time is 
highly correlated to baseline utility; baseline EQ-5D scores are a strong contributes to 
QALY calculation.  Additionally, baseline utility is expected to be a predictive of 
individual’s utility value at follow up time, this is because although some aspects of health 
would change but many others would not.  Thus, imbalances in baseline utility should be 
handled explicitly.  Failure to control for such imbalance can result in a misleading 
incremental cost effectiveness ratio as it can be very sensitive to quite small changes in its 
denominator.[199]  There was a small imbalance between groups at baseline.  Albeit, this 
was not significant it required careful notification.  Estimating QALY gained without 
baseline adjustment resulted in mean incremental QALY gain in favour of pharmacy led 
MR intervention; QALY (intervention)-QALY (control) = 0.02.  Whereas, when the main 
gain of QALY estimated with baseline adjustment, the incremental QALY gain was in 
favour of the control group, i.e. QALY (intervention)-QALY (control) = - 0.0088.  It is 
important to note that both approaches led to opposite conclusions.  The use of area 
under the curve approach where no allowance is made for imbalance in baseline utility 
can lead to incorrect results regardless of whether these differences are statistically 
significant.[35]  Therefore, adjustment for baseline imbalances is warranted at the time of 
the full pilot analysis if such imbalances continue to exist when the full pilot data is 
available.   
Multiple regression analysis is recommended to be a more appropriate method for dealing 
with baseline imbalances.  It can be used to generate appropriate estimates of 
incremental QALYs gained and sampling variability while adjusting for differences in 
baseline utility between groups.  The regression based approach generates unbiased 
estimates of incremental QALYs gain and increases the precision of the intervention effect 
size estimate.[253]  This approach will be employed for the full pilot analysis if deemed 
appropriate. 
8.5 Strengths and limitations  
The interim analysis had clear aims; those kept on focus while performing the analysis 
and interpreting findings.  It was understood that this was a pilot study which should be 
mainly descriptive.  We were aware that this analysis was most likely not powered enough 
to detect statistically significant differences.  Thus our focus was to gain insight on the 
study process and foresee any challenges if larger study would be warranted. 
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The MedRec study evaluated a full MR process implemented within 24 hours of patient 
admission.  The process implemented in the study found feasible and implemented in time 
manner.[72]  MR is the main focus of the MedRec study intervention, i.e. it was not 
supplemented with other additional non-MR care activities.  Thus, it would be plausible to 
assume that observed benefits would be most likely contributed by MR.   
Additionally, the MedRec study estimate the time spent by the MR pharmacist performing 
different tasks of MR, thus the best MR practice can be described and promoted across 
other care areas if proven cost-effective. 
To date, up to the time of thesis synthesis, there is no other UK study of randomised 
controlled design employing similar broad scope of health outcomes, costs and 
consequences.  MedRec also the first comprehensive cost-effectiveness analysis of 
pharmacy led MR within NHS setting which employs NHS and PSS perspective.  In 
addition, the Med Rec study takes into consideration the possibility of shifting care cost to 
community, social and informal care.  If a large scale study would be warranted, this 
would inform the decision whether to accept pharmacy led MR services across NHS.    
However, the MedRec study has a number of potential limitations that warrant discussion.  
Although, recruitment rate was satisfactory, only three out of 20 admitted patients were 
approached which account in total to 15% of patients admitted in the first three months of 
the MedRec study.  A greater proportion of patients approached might indicate better 
generalisability and more representative sample.  Inevitably, it was not possible to 
approach a large proportion of patients due to time constraints.  Additionally, the study 
wards were selected pragmatically and those wards were caring for general medicine and 
medicine for older patients.  Thus, findings of the MedRec might not be generaliseable to 
other care areas such as paediatric or general surgery.  However, it most likely to be 
generaliseable to trusts of similar resources and service profile in the area.[26] 
Variability with length of hospital stay, the primary outcome, necessitated log 
transformation.  In addition, outliers were suspected.  However with small sample size, a 
small deviation within the data would exert more profound effect on data distribution.  
Such effect might disappear when the full pilot dataset is available for analysis.  Worth 
noting, the MedRec is a pilot study with the aim of informing the design of a definitive trial 
if warranted and to determine the best outcome to measure.  Thus, alternate primary 
outcomes, such as readmission rate, might be found more appropriate outcome for a 
definitive trial.  This however, can be fully determined at the time of the full pilot analysis.  
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There were frequent ambiguities and omitted responses with retuned health resource use 
questionnaires.  Mostly, those were related to the question on outpatient visits (Appendix 
16).   
There might be two factors contributed to variations and omissions; firstly, the relevant 
grid table layout might have been confusing to patients.  Modification to simplify the 
questionnaire might be warranted.  This can be investigated further through patients’ 
discussion which is planned at the end of the MedRec study using focus group approach.   
The second reason might be related to difficulties with patient recalling outpatient 
appointments; it might be difficult to recollect details of departments visited and 
procedures carried out.  Nonetheless, the study researchers clarified ambiguities by 
phone calls when this was possible.  Additionally, systematic approach for missing data 
imputation is planned for the full pilot analysis. 
The MedRec obtained follow up data at three months post discharge.  This time window 
was informed by the systematic literature search on pharmacy led MR (chapter five).[113, 
225, 227, 230]  It was believed that short follow up time such as 30 days might not be ample to 
assess the benefit of MR on patient safety and health resource use.[138]  Three months in a 
pilot design was believed sufficient to explore the potential benefits and costs of MR as 
well as the feasibility of an incremental cost-effectiveness analysis.  We are aware that a 
longer follow up period has been implemented up to 12 months,[115, 135, 138] this is 
warranted for consideration if a larger scale study is presumed feasible. 
Concealing the study allocation was not possible for patients, doctors, the study 
researcher and MR pharmacists.  The rest of the ward team and UEA team were blinded.  
The thesis author (EH) was not blind to patient allocation for the purpose of the interim 
analysis.  However, the analysis was supported by members of the team who were blind 
to patient allocation (DW, IN, GB) and were not involved in the intervention.  Efforts will be 
maintained to ensure the UEA team who will be involved in the full pilot analysis will be 
blinded to study allocation for the full pilot analysis.  The data from the interim analysis 
was not presented to the hospital team or the principle investigator until after the study 
was finished to ensure that these did not alter the delivery of the intervention. 
Identification of medication errors in the control group was done retrospectively and 
without interviewing patients or carers.  Ethically, knowledge of errors or possible 
interventions that could optimise patient care cannot be withheld from the team caring for 
control patients.  Thus, this was felt to be the best approach to identify discrepancies in 
control group with minimum risk of bias.   
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No data was collected on baseline use of health resources.  It is plausible to assume that 
patients in both groups were comparable at baseline with respect to their use of health 
resources since their EQ-5D and EuroQol VAS scores were similar.  However, obtaining 
baseline health resource use would enable more precise estimate of cost change between 
groups.[193]  This might be considered if larger scale study deemed warranted.  
The interim analysis attempted to produce a rough estimate of the costs associated with 
unintentional errors using assumptions based on related studies.[11, 197]  However, it should 
be outlined that here is considerable uncertainty around these assumptions; firstly the 
proportion of unintentional errors at care transition that might lead to adverse drug events 
was based on a USA study; differences in the reporting system could influence 
transferability to the UK context.  Additionally, equal weight was assumed for all type of 
adverse drug events, i.e. all events were assumed to lead to similar consequences on 
health care.  Some type of adverse drug events might contribute to minor or minimum 
harm and thus will not require any intervention or care.[11]  Secondly, the consequences of 
adverse drug events were assumed to place costs only on hospitals but not on community 
services or informal care.  Nevertheless, those assumptions were justifiable by the lack of 
UK figures; however, more realistic and reliable estimate of the costs/savings related to 
medication errors is planned for the full pilot analysis. 
8.6 Implications for the full pilot analysis 
The interim analysis has several important implications that informed the full pilot analysis.  
Subgroup analysis of true and partial control patients is believed of value.  The effect of 
the MedRec intervention might have been partially masked by a potential benefit of control 
MR. 
Further qualitative research might be undertaken to gain insight on the time spent and the 
quality of control MR.  Qualitative research also could be of value to assess why some 
practices responded promptly to the study researcher requests of patient information and 
the reasons underlying that other practices took longer time.  It would be of value also to 
gain insight on why some patients returned the questionnaire promptly compared to 
others.  This might inform the need to modify methods of data collection or mode of 
contact.[254]  
Within the limited resources, it might be necessary to target patients at increased risk or 
most likely to benefit from pharmacy led MR.  Multivariate and regression analysis to 
identify patient related risk factors is planned for the full pilot analysis.  This would help to 
prioritise MR services were recourses are most constraints. 
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Cost related to medicine use and the use of patient own drugs managements were not 
estimated; these believed key contributors to costs/savings related to MR.  Broader 
costing strategies are planned for the full pilot analysis (BOX 8.2).  Additionally, although 
employing a broad-brush costs and consequences evaluation is an element of strength for 
the MedRec study, the selection of key cost drivers is necessary.  This will help to focus 
data collection where data is more relevant and informative which would help to save 
research time and efforts.  This might also help to improve response rate and thus result 
in more precise estimate for resource use; patients are more likely to complete short and 
concise questionnaires.[249]   
Studies which aim to perform economic evaluation should account for uncertainty 
surrounding the key estimates and assumptions relating to costs and outcomes.[172, 173, 204]  
If dominance was not apparent at the time of the full pilot analysis, an incremental cost-
effectiveness ratio will be estimated.  Sensitivity analysis would be planned then to 
account for uncertainty around the point estimate of incremental cost-effectiveness ratio 
and cost-effectiveness acceptability curve would be constructed to assess uncertainty 
around the cost-effectiveness decision. 
The interim analysis performed unadjusted comparisons of patient outcomes according to 
study group.  This was useful to gain insight on the initial findings; however, adjustment of 
the outcome analysis for important predictors or factors to allow for chance imbalances 
between study groups at baseline is warranted for the full pilot analysis.  Of most 
important, hence randomisation was stratified by ward, a factor that might contribute to 
imbalances between patients in the study groups, it is, therefore, planned to adjust the 
analysis with a factor for ‘wards’ included as an explanatory (or ‘x’) variable.  It would be of 
interest to evaluate the effect of such adjustment on results or conclusions. 
In summary, this interim analysis helped to gain insight on the initial findings of the 
MedRec study and plan the analysis of the full pilot.  This also enabled to assess the 
feasibility of the study process and familiarised the research team with the protocol.  The 
interim analysis was a starting point in the analysis of the MedRec study.  A lot has been 
learned which improved the research team understanding of the MR process and enabled 
well preparation for the full pilot analysis.  BOX 8.3 summarises gains from the interim 
analysis. 
The journey of this thesis for answering the question on the methods for optimisation MR 
at the health interface finished with the interim analysis.  The interim analysis findings 
offered new knowledge on the cost and effect of pharmacy led MR in the UK and added to 
the existing literature worldwide.  However, these should be considered tentatively; lots 
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yet left to explore at the time of the full pilot analysis and if a definitive trial would be 
warranted of value.   
 
 
 
 
 
  
BOX 8.3 Gains from the interim analysis 
The MedRec interim analysis:  
 Helped to plan the full pilot analysis  
 Enabled to estimate recruitment, retention and follow up rates 
 Familiarised of the research team with the study protocol 
 Assisted to refine of the study design and measurements 
 Helped to standardise the study intervention and data collection  
 Assessed randomisation procedure 
 Identified areas of ambiguity  
 Identified possible key cost drivers 
 Ensured MR acceptability  
 Assessed the feasibility of cost analysis  
 Assessed the feasibility of utility and QALY calculation  
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Chapter 9 Conclusions 
 
 
Conclusions  
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9.1 Main findings 
This thesis, when considered within the context of published UK and international 
research, adds to the existing evidence supporting pharmacy led MR practice and offers 
new knowledge regarding methods to optimise MR use at the healthcare interface. 
National guidance for the minimum dataset of information transferred at care transition 
has been in existence for over four years.  However, the Trust-wide evaluation of the 
quality of information received in primary care following patient discharge found frequent 
omissions and inaccuracies in discharge communication.  These were similar to those 
identified by reports published pre- and post-national guidance implementation [10, 22-26, 44]  
Therefore, the lack of progress in UK practice of MR was of concern and warranted further 
investigation of methods to optimise MR use at the health interface. 
In order to identify the most effective method to optimise MR, a systematic review to 
determine the effects and costs associated with pharmacy led MR was conducted.  There 
were a limited number of studies implementing the full MR process; those available had 
methodological flaws that limited the ability to draw conclusions about MR effectiveness 
and the resources necessary for effective implementation.  No study adopted outcomes 
that addressed both process and patients oriented outcomes.  Additionally, the identified 
evidence was largely non-UK.  There was, therefore, a need for more high quality, UK 
relevant data to define the most appropriate study design plus determine the effects and 
cost-effectiveness of pharmacy led MR interventions.   
Chapter Seven reported the MedRec study which adopted a randomised controlled design 
informed by the findings of the pharmacy led MR systematic review.  The MedRec study 
focused on implementing a full MR intervention led by a pharmacist within 24 hours of 
admission to hospital and investigated process and patient oriented outcomes, costs and 
consequences.  Developing and evaluating a pharmacy led MR service was recognised 
as a complex process requiring careful consideration of the most appropriate intervention 
components and outcome measures.  The Medical Research Council recommends 
piloting to gain insight on the effect size of the intervention and to determine whether a 
larger scale trial is feasible before large scale evaluation.[160]  This thesis presented the 
findings from the interim analysis of the MedRec pilot study.   
The interim analysis identified potential benefits of pharmacy led MR service compared to 
usual care in terms of enhancing the accuracy and transfer of information to primary care, 
prevention of potential harm associated with adverse drug events and reduction in use of 
health resources post discharge.  This, however, required an increased time commitment 
by the pharmacist.  It was difficult to draw a definitive conclusion on the cost-effectiveness 
without further analysis of the full dataset.  
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9.2 Lack of collaboration between secondary and primary care providers 
Because a patient is attended by various health care providers in each setting, effective 
communication between providers is essential.  Lack of communication might result in a 
patient receiving unintended therapy or missing out on a treatment altogether.[19, 21, 40]  
However, the interim analysis of the MedRec study highlighted that in many cases, GPs 
did not act upon information communicated from secondary care.  This may be because 
the rationale for changes to pre-admission therapy were not expressly described and thus 
GPs might have presumed these were unintentional changes.  This is of significance 
since most therapy changes at discharge are reported to be intentional despite rationale 
not being documented explicitly on the discharge summary.[17, 29, 222]  The Trust-wide audit 
identified cases where information was explicitly provided by the discharge team but 
recommendations in some instances were not implemented in primary care.  In many 
cases, lack of implementation was due to undocumented informed decisions by GPs but 
in some instances this was due to human error and shortcomings in the process of 
handling incoming communication from secondary care.   
Withstanding the above, the MedRec study reflects the findings from the systematic 
review highlighting that the pharmacist has an important role in medication history 
verification using patient or carer interviewing and information from GPs or community 
pharmacies as well as providing comprehensive details of medicines prescribed and 
changed upon discharge.  The poverty of explicit communication between providers on 
both sides of the health interface despite clear guidance regarding the set of minimum 
data to communicate requires consideration.  Lack of formal training or education on 
medical note documentation, the lack of standardised methods of communication, the 
hurried environment and the assumption that changes can be deciphered by the recipient 
may be contributing factors.[21, 210]  It is of great importance, therefore, to highlight gaps in 
communication between providers and identify barriers to effective communication.   
9.3 Best possible medication history  
The best possible medication history is considered the cornerstone MR.  The World 
Health Organisation states “The key to the success of MR at all interfaces is to first have a 
process working effectively at admission to the healthcare facility”.  Appropriate admission 
MR is the foundation to support and facilitate efficient and appropriate reconciliation at 
internal transfer and discharge.[99]  
 
Accurate sources of information may be difficult to identify at the time of care transition 
unless one has taken the time to explore and test different sources of information.[73]  The 
Trust-wide audit identified deficits in discharge information sent to the primary care team 
and also in the processing of discharge instructions by the primary care team.  Similarly, 
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the MedRec study found disparities between different sources of patient information such 
as GP lists, patient own drugs and patients repeat prescriptions.  Previous studies 
highlighted the lack of a gold standard list containing all medicines the patient is taking; 
none of the patient information sources including GPs records, which provide long term 
medication history, was found to be the most accurate source of information.  Thus, it was 
recommended to use as many as possible sources to match patient information each time 
the patient transfer.[24, 25, 115, 225, 233]  Variances between information sources could arise 
due to poorly informed patients, multiple prescribers or use of multiple pharmacies.[233, 255]  
This necessitates a change in the existing process for organising and sharing patient 
information between providers and to place recommendations to maintain a gold standard 
list of patient medicines transferred with the patient across health settings. 
9.4 Optimising resource use for effective MR implementation  
Evidence from pharmacy led systematic review and the MedRec study indicates that 
pharmacists need to invest additional time to implement full MR.  Whilst providing a 
comprehensive pharmacy led MR service to all patients may be desirable, given limited 
resources, alternative strategies may be a current necessity.   
A potential strategy could be reallocation of existing resources by involving less costly 
administrative staff such as ward clerks or receptionists to deliver the non-clinical MR 
tasks.  Those could include collecting information from GPs or community pharmacies, 
obtaining previous medicine or allergy information from hospital records and faxing 
discharge summaries to primary care practices.  This may improve the cost-effectiveness 
of MR by ensuring pharmacist time is dedicated to the patient centred, clinical aspects of 
MR. 
Additionally, identifying the situations most likely to benefit from pharmacy led MR would 
enable targeting the areas where impact would be maximised.  The pharmacy led MR 
systematic review identified no study investigating the patient characteristics associated 
with greatest benefit from MR.  The Trust-wide audit did, however, explore the factors 
associated with increased risk of discharge discrepancy and identified that patients 
prescribed more than five medicines and discharged from specific wards such 
orthopaedics are at increased risk.  Further investigation to identify other patient-related 
factors and highlight areas where there is the potential for maximal benefit from pharmacy 
led MR is warranted for the full dataset of the MedRec study.  This would inform the 
decision of prioritising MR services where benefit is most pronounced.  
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9.5 Thesis recommendations  
Despite the potential for improved outcomes, there are many challenges to effectively 
executing MR.[7, 149, 150]  This thesis informs the following recommendations: 
 The use of a standardised electronic pro-forma that complies with the national 
guidance for information transfer at care transition points.   
 Patients who are prescribed more than five medicines are recommended to receive 
attention at care transition; one useful suggestion might be the use of reminders 
placed in medical notes or inpatient charts to highlight these patients for the care 
team.  A similar approach could be used to highlight medicines requiring titration 
plans, specified durations, frequently associated with omissions and considered of 
potential for patient harm. 
 The Trust-wide audit showed that the process in place to transfer information at 
healthcare interfaces is insufficient.  Lack of clear agreement on the process of MR 
and lack of national legislation to formalise MR as well as the lack of linking MR to 
funding decisions might be contributing to this insufficiency.  In the USA, MR is 
designated as a national safety goal and considered one of the criteria for health 
organisation accreditation.[97]  Similar linking of MR to funding and commissioning 
decisions in the UK NHS such as the Quality and Outcomes Framework scheme for 
primary care practices and NHS incentive schemes for hospitals, may enforce better 
implementation. 
 Highlighting organisations that have successfully implemented MR implementation 
through a national reward scheme may encourage more organisations to define their 
MR process and adopt MR within their routine workflows. 
 Promoting the use of MR via a monthly bulletin highlighting examples of good clinical 
practice might also help organisations to share experience of optimum use of MR.  
Additionally, national workshops or discussion forums engaging professionals from 
primary and secondary care might enhance continuity of care and collaboration 
between care providers; this could raise awareness of the effects of MR on patient 
outcomes 
 The development of an NHS universal secure interactive medical record system that 
can be viewed by all care providers at any time during the patient care journey 
between health settings may resolve many of the information transfer issues.  Studies 
have highlighted the usefulness of similar applications,[141, 142] however, user training 
and IT support would be of great importance to achieve successful implementation.   
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 The development of guidance in primary care might minimise inadvertent 
shortcomings in discharge instruction reconciliation and enable effective sharing of 
information between providers.  This guidance must be based on discussions with 
managerial, administrative and clinical staff from practices of different size and 
workflows to account for the variation between practices in processing and sharing 
information. 
 More UK studies of robust design, larger and multi-centred should be conducted to 
confirm whether the benefits of pharmacy led MR services are generaliseable across 
institutions and trusts. 
 
 The National Institute for Health and Care Excellence (NICE) guidance Principles for 
Best Practice in Clinical Audit provides valuable guide through the development and 
conduction of clinical audits.[158]  The NICE guidance also provide valuable guide on 
data analysis; however, we would recommend NICE to place an emphasis within this 
guide on the usefulness and importance of evaluating variation in clinical audits data. 
 
 The interim analysis of the MedRec study was useful to identify unforeseen 
challenges with the process and measurement of the intervention.  It also helped to 
ensure feasibility of data collection and cost-effectiveness analysis.  In line with the 
Medical Research Council recommendations,[160] a lesson from this thesis is that 
piloting is an important step to ensure effective evaluation of complex clinical 
interventions.  
9.6 Research needs  
The Trust-wide investigation presented an indication of the predictors of adherence to the 
NPC minimum dataset and medication discrepancies, however, further work remains.  
More research is needed to better understand the effect of profession type and ward 
speciality and determine the reasons underlying substandard areas of practice.  Subgroup 
analyses of ward and profession types were limited by the available number of data 
points.  Merging of small subgroups led to loss of valuable information on factors 
contributing to variation in practice between wards and professionals.  Larger studies are 
therefore necessary to ensure better representation of these smaller groups.   
Furthermore, qualitative investigations with managerial, administrative and clinical staff to 
describe current practice across different wards and professions plus explore barriers to 
effective information transfer may inform effective MR practice guidance.  Conduct of such 
qualitative studies would be of value from both the primary and secondary care 
perspective of the health interface. 


Additionally, given that a high proportion of discharge summaries are written by foundation 
year doctors,[13, 21]  investigation of any changes in quality of information sent to primary 
care between the period when foundation doctors start their training (August) and a few 
months later after gaining knowledge and experience on wards (January/February) may 
be of value.   
 


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Appendix 1 Literature variation in 
discrepancy classification, clinical 
significance and inter-rater agreement 
assessment 



Author, year country Discrepancy classification Clinical relevant or impact Inter-rater reliability  
Perren [1] 
2009 
Switzerland Omitted medication: Unintentionally not 
prescribing a drug for a clinical condition for 
which medication is indicated; the judgement 
was based on common recommendations or 
online literature 
Defendable omission: Intentional omission, 
that is, omission justified by a potential and 
documented  contraindication 
Un-defendable omission: Omission without 
documented contraindication 
Potentially harmful omission: Omission 
presumably leading to increased mortality or 
morbidity  
Unjustified medication: Prescribing a drug 
for which there is no indication for that patient  
Potentially harmful unjustified medication: 
A medication which, for a given patient, could 
have resulted in an ADE 
Harmless unjustified medication: Largely 
prescribed and generally well-tolerated 
medication 
Medication errors were judged 
to be potentially harmful if it 
could result in increased 
mortality /morbidity or ADE: 
into fatal, life threatening, 
serious or significant. 
Two internists independently examined 
the same 40 discharge summaries. 
Reliability across reviewers was 
subsequently assessed by a third doctor 
and scored utilising a previous reported 
scale. Agreement was determined to be 
nearly equivalent for the classification of 
unjustified medication (k=0.85), and 
substantial for the reviewers’ judgements 
of diagnoses implicating rug therapy and 
diagnoses with drug omission (k=0.74 
and 0.76, respectively). 
Reliability was only moderate for the 
reviewers’ classification of defendable 
drug omission (k=0.39).Two internists 
jointly performed the analysis in order to 
improve agreement of low k-values 
(defendable drug omission). Thus, 
differences between the reviewers’ 
judgements were resolved by discussion, 
and a consensus was achieved 
Kwan [2] 2007 USA Postoperative discrepancy defined as any 
medication clarification related to home 
medications that were made. Medication 
discrepancies associated with any of the 
following: drug, dosage, duration, frequency, 
formulation, route of administration, and 
appropriateness of restarting medications, 
orders requesting the pharmacist to clarify 
medications, illegible orders, and 
miscellaneous items. 
Discrepancy need clarification: 
• Omission of medication  
• Commission of medication 
• Different dosage,  route or frequency 
Different medication 
Independently by 3 pharmacy 
clinician evaluators. For each 
postoperative medication 
discrepancy, the degree of 
effect was based on the 
potential 
that the discrepancy could 
result in “unlikely,” 
“possible,” or 
“probable” patient discomfort 
and/or clinical deterioration if 
the discrepancy was not 
identified and addressed.  
 
Inter-rater reliability for assessing the 
severity of the medication discrepancy 
was analysed using the mean of Cohen 
k scores; Pairwise k scores for a sample 
of 46/ n=464 medication discrepancies 
were calculated and ranged from 0.78 to 
0.89; the mean k score was 0.84. 
ADE: Adverse drug event. 1. Perren A, Previsdomini, M., Cerutti, B., Soldini, D., Donghi, D., Marone, C. Omitted and unjustified medications in the discharge summary. 
Quality and Safety in Health are. 2009;18(3):205. 2. Kwan Y, Fernandes OA, Nagge JJ, et al. Pharmacist Medication Assessments in a Surgical Pre-admission Clinic. Arch 
Intern Med. May 28, 2007 2007;167(10):1034-1040 
  


Author, year country Discrepancy classification Clinical relevant or impact Inter-rater reliability  
Bergkvist [3] 
2009 
Sweden Defined as: occurrence of discrepancy with 
the lack of documentation to indicate that 
change was deliberately; 
• medication was missed in the 
medication list from the community 
health care. 
• medication had been added to the 
medication list from the community 
health care. 
• The total dosage over 24 h had been 
changed in the medication list from 
the community health care. 
• Generic substitution of a medication 
was not considered an error in the 
reconciliation process. 
• Reason for change not reported 
• Indication of new medication not 
reported 
-  Identification of discrepancies 
was done by two pharmacists 
independently, disagreement 
resolved by consensus  
Grimes [4] 
2008 
Ireland No doses specified on discharge summary 
No frequencies specified on discharge 
summary  
No medication listed on discharge summary  
Discharge summary not completed 
Drug omission  
Strength inconsistency  
Choice of drug inconsistency  
Strength omission 
Frequency inconsistency  
Frequency omission  
Commission discrepancy  
Prescription of discontinued medicines 
Validated VAS scale between 1 (no 
harm) and 10 (death) 
The mean score for each error was 
calculated and categorised as: 
potential to cause none or minor 
(mean score <3), 
moderate (mean score 3–7),  
or severe (mean score >7patient 
harm 
Five healthcare professionals 
independently scored the clinical 
importance of every error. ( no 
inter-rater agreement assessed) 
3.Bergkvist A, Midlöv, P., Höglund, P., Larsson, L., Bondesson, Å., Eriksson, T. Improved quality in the hospital discharge summary reduces medication errors—LIMM: 
Landskrona Integrated Medicines Management. European Journal of Clinical Pharmacology. 2009;65(10):1037-1046. 4. Grimes T, Delaney, T., Duggan, C., Kelly, J., 
Graham, I. Survey of medication documentation at hospital discharge: Implications for patient safety and continuity of care. Irish Journal of Medical Science. 
2008;177(2):93-97 VAS: Visual analogue scale . 


Author, year country Discrepancy classification Clinical relevant or impact Inter-rater reliability  
Pippins [5] 
2008 
USA Intentional:  
Documented vs. Undocumented 
Unintentional: 
No potential for harm vs. potential for harm 
Potential for harm:  
History error vs. Reconciliation error 
 
1. Potential for harm 
Confidence about that the identified error 
had the potential to cause harm if not 
corrected 
i. Little or no confidence (e.g., 
omission of multivitamin) 
ii. Slight to modest confidence  
iii. Less than 50–50 but close call  
iv. More than 50–50 but close call  
v. Strong confidence  
vi. Virtually certain confidence  
2. Potential severity: significant , 
serious, life threatening 
Two pharmacists independently. 
Disagreement was resolved by 
consensus or third assessor. 
Kappa= 0.95 
Wong [6] 2008 USA Unintended vs.  undocumented intended 
Unintentional : actual vs. potential  
Actual unintentional: made by physician to 
add or change or omit  
Potential unintentional: direction on home 
medicine were omitted or not explicitly. 
• Omission: formulation, frequency or 
route 
• No indication: medication no longer 
required was reordered on hospital 
discharge. 
• Therapeutic duplication  
• Inappropriate route 
• Need of prescription refill was not 
addressed 
• Inappropriate duration  
• Incorrect dose 
• Dose not renally adjusted 
• Incorrect frequency  
• Incomplete prescription that may lead 
to delay in starting medication. 
• Misspelled drug name 
• Illegible order  
Unlikely to cause patient discomfort 
and/or clinical deterioration if not 
identified or addressed 
Possible  to cause patient discomfort 
and/or clinical deterioration if not 
identified or addressed 
Probable to cause patient discomfort 
and/or clinical deterioration if not 
identified or addressed 
Three independent raters (two 
pharmacists and one general 
internist) who were blind, a 
majority consensus was 
required. kappa was 
sustainable. Pair wise k 
score.72-.8  
5. Pippins JR, Gandhi, T. K., Hamann, C., Ndumele, C. D., Labonville, S. A., Diedrichsen, E. K., Carty, M. G., Karson, A. S., Bhan, I., Coley, C. M.,. Classifying and predicting errors of 
inpatient medication reconciliation. Journal of general internal medicine. 2008;23(9):1414-1422. 6. Wong JD, Bajcar, J.M., Wong, G.G., Alibhai, S.M.H., Huh, J.H., Cesta, A., Pond, 
G.R., Fernandes, O.A. Medication Reconciliation at Hospital Discharge: Evaluating Discrepancies (October). The Annals of pharmacotherapy. 2008;42:1373-1379
 



 
 
 
 
 
 
 
 
 
Appendix 2 Discharge information audit tool 


Medication discrepancies assessment tool 
Patient audit number   Date   
Age 
 
Gender  Male    Female  
Ward specialty Medicine for elderly Orthopaedic 
General medicine  Gastroenterology  
General surgery  Cardiology   
Urology   Unspecified  
If other please specify: 
 Hospital name  NNUH  West Suffolk Hospital  
QEH James Paget 
Addenbrooks  Papworth 
Hellesdon  community hospital  
If other please specify: 
Type of admission Emergency  Planned  
Unspecified   
Is the discharge summary typed?  
Yes 
 
No  
Comment in discharge summary legibility if hand written 
If the discharge summary is handwritten, is it: 
Illegible (most or all words impossible to identify) 
  
Comment in discharge summary legibility if hand written 
Most words illegible; meaning of report unclear 
  
Some words illegible, but report can be 
understood by a clinician  
  
 

 
 
 
 
 
 
 
 

 






Medicines reconciliation Items 
 
 
Specify whether the 
following information  
was stated in the 
discharge summary 
Details 
Admission date Yes No  Enter the admission date 
Admission time  Yes  No  Enter the admission time 
Discharge date Yes  No  Enter the discharge date 
Discharge time Yes  No  Enter the discharge time 
Name of professional responsible for discharge Yes  No  Enter name if provided 
Role of professional responsible for discharge Yes  No  Enter the role of person Dr., FY1, Pharmacist. 
Contact name to be used by GP if information 
regarding hospitalization required 
Yes  No  Enter Name if different from professional responsible for discharge  
Contact number to be used by GP if information 
regarding hospitalization required 
Yes  No  Enter  Contact number to be used by GP 
Was the discharge summary received within 2 
working days? 
Yes  No  Enter number of working days post discharge 
Patient name  Yes  
 
No  
Patient name is correct? Yes  
 
No  
Date of Birth Yes 
 
No  
Date of Birth is correct? Yes 
 
No  
Consultant name Yes 
 
No  
Ward contact number Yes 
 
No  
Allergy status Yes 
 
No  
ADR during hospitalization Yes 
 
No  




































Presenting medical complaint on admission Yes 
 
No  
Past medical history/co-morbidities Yes 
 
No  
Complete past drug history and current medications Yes No  

Does the discharge summary clearly 
state all medication that has been 
changed including (dose, 
formulation,...)?  
 
Yes 
 
No  
If any, is (are) the reason(s) reported/ 
specified?  
Yes                                     
 
No   
Does the discharge summary clearly 
state all medication that has been 
stopped?  
 
Yes 
 
No  
If any, is (are) the reason(s) 
reported/specified?  Yes                                     
 
No   
Does the discharge summary clearly 
state all medication that has been 
started?  
 
Yes 
 
No  
If any, is (are) the reason(s) 
reported/specified?  Yes                                      
 
No 

Medication  Name Dose Frequency Route Duration  Formulation  
1- E.g. Bisoprolol  Generic  
 Brand    
 Both 
 
Yes   
 No           
 
Yes   
 No           
 
Yes   
 No                        
 
Yes           No        Pre admission drug 
 
Yes   
 No           
2- 
 Generic  
 Brand    
  Both 
 
Yes   
 No           
 
Yes   
 No           
 
Yes   
 No           
 
Yes           No        Pre admission drug 
 
Yes   
 No           
3- Generic  
 Brand    
 Both 
 
Yes   
 No           
 
Yes   
 No           
 
Yes   
 No           
 
Yes           No        Pre admission drug 
 
Yes   
 No           



 
 
 














State if procedures have been reported on the discharge summary 
Name Results & Comments 
 
Procedure (s) name Result(s) Hospital practitioner remarks E.g.ECG Atrial fibrillation, warfarin therapy was commenced 
Yes   No  
 
Yes  
 
No  
 
Yes  
 
No      
 
Yes  
 
No  
 
Yes  
 
No  
 
Yes  
 
No      
 
Yes  
 
No  
 
Yes  
 
No  
 
Yes  
 
No      
Post admission complications; please indicate if any of the 
following have been reported  
Complication/management 
E.g. Patient had experienced chest infection; proper management with 
antibiotics was commenced. 
Infection  
 
Yes  
 
No   
Bleeding 
 
Yes  
 
No    
DVT 
 
Yes  
 
No    
Others 
 
Yes  
 
No    

Please indicate if you expect or need any additional laboratory assessment or monitoring for this patient, you believe it is required by the 
primary health care team to achieve the optimum continuity of care. 
E.g. A patient with CKD admitted due to a potential drug induced worsening of kidney function.  Would therefore have expected to see renal function test 
results. 
Any additional comments on discharge summary information:  
E.g. Bendroflumethiazide was missed from discharge summary medications list, yet was not specified among stopped drugs.  A call for hospital staff was 
needed to clarify that it was unintentionally omitted from the list. 
 










 
 
 
Appendix 3 Discharge information audit 
guidance 



Overview 
You will be recording the information that is provided on discharge summaries that you 
receive during the audit period.  Ideally, this information is recorded in an excel 
spreadsheet to allow the data to be collated. 
 
STEP 1 – Identification of patients 
 
1.1 Based on list sizes, each practice has been allocated a number of discharge 
summaries to audit. If you do not know what the number is for your practice, please 
your NHS Norfolk Prescribing Advisor. 
 
1.2 Set a start date for the audit in January 2011.  
1.3 From the practice designated start date, ask the member(s) of the practice team 
responsible for receiving and sorting discharge summaries to set them aside once they 
have been processed. 
 
1.4 Collect the discharge summaries until the allocated target number is reached. 
 
1.5 The audit is only of discharge summaries where the patient was hospitalized for longer 
24 hours. Please check admission dates and discharges dates to determine patient 
hospital stay, exclude all other discharge summaries. 
 
STEP 2 – Audit guidance 
 
2.1 You have been sent an electronic folder which includes the required number of excel 
documents for the number of discharge summaries you need to audit. You must complete 
one document for each discharge summary. 
 
2.2 The document has option boxes for you to click and in some cases, specific details are 
required.  These cases are indicated by the boxes which are shaded gray and guidance 
regarding the information required in these boxes is in italic font. You can simply type over 
this writing. 
 
2.3 Use the guidance below for the following questions: 
2.3.1 Is the discharge summary typed? 
You do not need to complete rows 20-30 if the discharge summary is typed. 
2.3.2 Was the discharge summary received within 2 working days? 
Please exclude weekends and public holidays. 
2.3.3 Allergy status 
From your records, indicate in the grey box whether or not the patient has any allergies.  
2.3.4 Past medical history/co-morbidities 
 
2.3.4.1 Answer yes only if all patient co-morbidities are stated on the discharge summary. 
2.3.4.2 If no, from your records, indicate in the grey box whether or not the patient has any 
past co-morbidity. Type “no co- morbidities” if none are present. 


2.3.5 Complete past drug history  
 
2.3.5.1 Answer yes only if all patient pre admission medications are stated on the 
discharge summary. 
2.3.5.2 If no, from your records, indicate in the grey box whether or not the patient had any 
prescribed medication prior to hospital admission. Type “no pre-admission medication” if 
none were prescribed. 
2.3.6 Medication  
In the grey box, fill in the name of medications as provided on the discharge summary. See 
box 53. 
2.3.7.1 Does the discharge summary clearly state all medication that has been 
changed?  
Answers yes only, if all change (s) is (are) clearly stated on the discharge summary. 
2.3.7.2 If any, is (are) the reason(s) reported/ specified? 
Answer yes only, if reason (s) for all change (s) is (are) clearly stated on the discharge 
summary. 
2.3.8.1 Does the discharge summary clearly state all medication that has been 
stopped?  
Answer yes only, if all medication (s) stopped is (are) clearly stated on the discharge 
summary. 
2.3.8.2 If any, is (are) the reason(s) reported/ specified? 
Answer yes only, if the reasons for all medication (s) stopped is (are) clearly stated on the 
discharge summary. 
2.3.9.1 Does the discharge summary clearly state all medication that has been 
started?  
Answers yes only, if all medication(s) started is (are) clearly stated on the discharge 
summary. 
2.3.9.2 If any, is (are) the reason(s) reported/ specified? 
Answer yes only, if the reason(s) for all medication (s) started is (are) clearly stated on the 
discharge summary. 
2.4 If you feel that the discharge summary information is lacking in some way that was not 
identified above please add details about the information that would have been beneficial 
to you in box 93 and 95. 
Step 3 – Submitting your audit 
3.1 Once you have completed a spreadsheet for each of your discharge summaries, return 
them electronically via NHS Eman Hammad e.hammad@uea.ac.uk 
3.2 You do not need to do anything further with your data. The results will be collated with 
other practices and a report produced. 
3.3 Please retain all hard copies of the discharge summaries that you have included in your 
audit until you are advised that they can be disposed of.  
 
3.4 Maintain and retain a list of patients audit ID & NHS numbers to allow subsequent 
quality assurance following the audit 
 



 
 
 
 
 
 
 
 
 
Appendix 4 Discharge information 
reconciliation sheet 


Collated patient medications list * GP action+  
  
Drug code Drug 
name 
Dose Frequency Route Formulation Duration A B C Discrepancy type Comments 
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Appendix 5 Multiple and logistic regression 
assumption check 
  

Checking assumptions* of the multiple regression model presented in Table 3.17: 
Assumption  Assumption 
met/violated  
Comment  
All predictors are continuous or 
categorical in two categories 
Met Dummy variable used for 
categorical variable >2 
No perfect multicollinearity (i.e. no 
perfect linear relationship between 
two or more  predictors) 
Met - Correlation matrix: 
checked none of the 
predictors highly 
correlated, i.e. r>0.8 
- VIF**: None of VIF values 
> 10. The Average VIF 
2.03 which is not 
substantially greater than 
1  
Homoscedasticity (i.e. equality of 
residual variances) 
Met - Plot of standardised 
residuals vs. 
standardised predicted 
values: No funnelling of 
data point (Figure A). 
ZRESID vs. ZPRED 
appeared like a random 
array of dots evenly 
distributed around zero. 
 
Linearity (i.e. the mean value of 
the outcome for each increment of 
the predictor lie along a straight 
line) the relation that is modelled is 
a linear one  
Met - Plot of standardised 
residuals vs. 
standardised predicted 
values: No curviness 
(Figure A) 
ZRESID vs. ZPRED 
showed no trend of the 
data points for curvilinear 
relationship 
Independence  Met - Data points are not related 
to the same patient in 
different occasion or time 
Independent of the errors (i.e. for 
any two observation the errors or 
residual are independent)   
Met - Durbin-Watson test: 
None of the values were 
<1 or >3. The model value 
=1.75 (the closer to 2 is 
better) no concerns 
Normally distributed errors 
(residuals) 
Met - Bell shaped curve (normal 
distribution) of the 
histogram of residuals 
(Figure B) 
- All points lie in the line 
indicating limited deviation 
of residual from Normality 
(Figure C) 
*Based on: Field A. Discovering statistics using SPSS statistics. Third edition, 2009.** VIF: 
Variance inflation factor 

 
ZRESID: The standardised residuals or errors 
ZPRED: The standardised predicted values of the dependent variable based on the model  
Figure A: Plot of ZRESID vs. ZPRED for modelling adherence to the total NPC 
minimum dataset 
 
Figure B: Histogram presentation of residuals of total adherence to NPC minimum 
dataset 

 
Figure C: Normal P-P Plot (probability–probability plot) of Regression Standardized 
Residual  
  

Checking assumptions* of the multiple regression model presented in Table 3.18: 
Assumption  Assumption 
met/violated  
Comment  
All predictors are continuous or 
categorical in two categories 
Met Dummy variable used for 
categorical variable >2 
No perfect multicollinearity (i.e. no 
perfect linear relationship between 
two or more  predictors) 
Met - Correlation matrix: 
checked none of the 
predictors highly 
correlated, i.e. r>0.8 
- VIF**: None of VIF values 
> 10. The Average VIF 
1.94 which is not 
substantially greater than 
1  
Homoscedasticity (i.e. equality of 
residual variances) 
Met - Plot of standardised 
residuals vs. 
standardised predicted 
values: No funnelling of 
data point (Figure D). 
ZRESID vs. ZPRED 
appeared like a random 
array of dots evenly 
distributed around zero. 
 
Linearity (i.e. the mean value of 
the outcome for each increment of 
the predictor lie along a straight 
line) the relation that is modelled is 
a linear one  
Met  - Plot of standardised 
residuals vs. 
standardised predicted 
values: No curviness 
(Figure D) 
ZRESID vs. ZPRED 
showed no trend of the 
data points for curvilinear 
relationship 
Independence  Met - Data points are not related 
to the same patient in 
different occasion or time 
Independent of the errors (i.e. for 
any two observation the errors or 
residual are independent)   
Met - Durbin-Watson test: 
None of the values were 
<1 or >3. The model value 
=1.67 (the closer to 2 is 
better) no concerns 
Normally distributed errors 
(residuals) 
Met (some 
concern) 
- Bell shaped curve (normal 
distribution) of the 
histogram of residuals 
(Figure E) 
- All points lie in the line 
indicating limited deviation 
of residual from Normality 
(Figure F) 
*Based on: Field A. Discovering statistics using SPSS statistics. Third edition, 2009.** VIF: 
Variance inflation factor 
 

 
 
Figure D: Plot of ZRESID vs. ZPRED for modelling adherence to patient, admission 
and discharge information 
 
 
Figure E: Histogram presentation of residuals of patient, admission and discharge 
information 

 
 
Figure F: Normal P-P Plot (probability–probability plot) of Regression Standardized 
Residual of patient, admission and discharge information 
 
 
  

Checking assumptions* of the multiple regression model presented in Table 3.19: 
Assumption  Assumption 
met/violated  
Comment  
All predictors are continuous or 
categorical in two categories 
Met Dummy variable used for 
categorical variable >2 
No perfect multicollinearity (i.e. no 
perfect linear relationship between 
two or more  predictors) 
Met - Correlation matrix: 
checked none of the 
predictors highly 
correlated, i.e. r>0.8 
- VIF**: None of VIF values 
> 10. The Average VIF 
1.86 which is not 
substantially greater than 
1  
Homoscedasticity (i.e. equality of 
residual variances) 
Met - Plot of standardised 
residuals vs. 
standardised predicted 
values: No funnelling of 
data point (Figure G). 
ZRESID vs. ZPRED 
appeared like a random 
array of dots evenly 
distributed around zero. 
 
Linearity (i.e. the mean value of 
the outcome for each increment of 
the predictor lie along a straight 
line) the relation that is modelled is 
a linear one  
Met  - Plot of standardised 
residuals vs. 
standardised predicted 
values: No curviness 
(Figure G) 
ZRESID vs. ZPRED 
showed no trend of the 
data points for curvilinear 
relationship 
Independence  Met - Data points are not related 
to the same patient in 
different occasion or time 
Independent of the errors (i.e. for 
any two observation the errors or 
residual are independent)   
Met - Durbin-Watson test: 
None of the values were 
<1 or >3. The model value 
=1.48 (the closer to 2 is 
better) no concerns 
Normally distributed errors 
(residuals) 
Met  - Bell shaped curve (normal 
distribution) of the 
histogram of residuals 
(Figure H) 
- All points lie in the line 
indicating limited deviation 
of residual from Normality 
(Figure I) 
*Based on: Field A. Discovering statistics using SPSS statistics. Third edition, 2009.** VIF: 
Variance inflation factor 
 

 
 
Figure G: Plot of ZRESID vs. ZPRED for modelling adherence to medication 
information 
 
 
Figure H: Histogram presentation of residuals of medication information 
 
 

 
Figure I: Normal P-P Plot (probability–probability plot) of Regression Standardized 
Residual of medication information 
  

Checking assumptions* of the multiple regression model presented in Table 3.20: 
Assumption  Assumption 
met/violated  
Comment  
All predictors are continuous or 
categorical in two categories 
Met Dummy variable used for 
categorical variable >2 
No perfect multicollinearity (i.e. no 
perfect linear relationship between 
two or more  predictors) 
Met - Correlation matrix: 
checked none of the 
predictors highly 
correlated, i.e. r>0.8 
- VIF**: None of VIF values 
> 10. The Average VIF 
1.96 which is not 
substantially greater than 
1  
Homoscedasticity (i.e. equality of 
residual variances) 
Met - Plot of standardised 
residuals vs. 
standardised predicted 
values: No funnelling of 
data point (Figure J). 
ZRESID vs. ZPRED 
appeared like a random 
array of dots evenly 
distributed around zero. 
 
Linearity (i.e. the mean value of 
the outcome for each increment of 
the predictor lie along a straight 
line) the relation that is modelled is 
a linear one  
Met  - Plot of standardised 
residuals vs. 
standardised predicted 
values: No curviness 
(Figure J) 
ZRESID vs. ZPRED 
showed no trend of the 
data points for curvilinear 
relationship 
Independence  Met - Data points are not related 
to the same patient in 
different occasion or time 
Independent of the errors (i.e. for 
any two observation the errors or 
residual are independent)   
Met - Durbin-Watson test: 
None of the values were 
<1 or >3. The model value 
=1.76 (the closer to 2 is 
better) no concerns 
Normally distributed errors 
(residuals) 
Met  - Bell shaped curve (normal 
distribution) of the 
histogram of residuals 
(Figure K) 
- All points lie in the line 
indicating limited deviation 
of residual from Normality 
(Figure L) 
*Based on: Field A. Discovering statistics using SPSS statistics. Third edition, 2009.** VIF: 
Variance inflation factor 
 

 
Figure J: Plot of ZRESID vs. ZPRED for modelling adherence to therapy change 
information 
 
Figure K: Histogram presentation of residuals of therapy change information 
 
 
 

 
Figure L: Normal P-P Plot (probability–probability plot) of Regression Standardized 
Residual of therapy change information 
  

Checking assumptions* of the logistic regression model presented in Table 3.39: 
Assumption  Assumption 
met/violated  
Comment  
All predictors are continuous or 
categorical in two categories 
Met Dummy variable used for 
categorical variable >2 
No perfect multicollinearity (i.e. 
predictors should not be highly 
correlated. 
Met - Collinearity diagnostics 
Eigenvalues were fairly 
similar  
- VIF**: None of VIF values 
> 10. The Average VIF 
2.01 which is not 
substantially greater than 
1  
Linearity (i.e. there is a linear 
relationship between continues 
predictors and the logit of the 
outcome. 
Met  Log interaction terms 
The interaction terms of 
continues variable (age, 
no. of medications and 
hospital stay) with their 
logs were checked; all p 
>0.05 indicating 
assumption met 
Independent of the errors (i.e. for 
any two observation the errors or 
residual are independent)   
Met - Data points are not 
related and  
*Based on: Field A. Discovering statistics using SPSS statistics. Third edition, 2009.** VIF: 
Variance inflation factor 
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Appendix 6 Pharmacy led medicine 
reconciliation systematic review search 
strategies  
 

Appendix 6A: Search terms applied for EMBASE and MEDLINE Ovid database in 
23.03.2012 
 
 
 
Search terms Number of 
retrievals 
1. medicine$.ti,ab. 655,284 
2. Medication$.ti,ab. 375,197 
3. drug$.ti,ab. 2,184,362 
4. 
medicament$.ti,ab  9,837  
5. prescription$.ti,ab.  111,893  
6. (medic$ adj2 chart$).ti,ab.  8,620  
7. (medic$ adj2 record$).ti,ab.  113,559  
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 3,233,797  
9. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 reconciliation).ti,ab.  807  
10. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 management).ti,ab.  9,874  
11. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 assessment).ti,ab.  
 
5,111 
 
12.  ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 review$).ti,ab.  40,775  
13. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 histor$).ti,ab.  15,931  
14. information.ti,ab.  1,410,099  
15. (information adj2 transfer$).ti,ab.  6,930  
16. information adj2 continu$).ti,ab.  1,625  
17. ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 system$).ti,ab.  44,490  
18 ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 congruence$).ti,ab. 23  
19 ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 
communication).ti,ab.  
1,151  
20 (information adj2 communication).ti,ab.  4,803  
21 ((medicine$ or medication$ or drug$ or medicament$ or prescription$ or 
(medic$ adj2 chart$) or (medic$ adj2 record$)) adj2 liaison).ti,ab.  100  
22 
care.ti,ab.  1,643,248  

23 (seamless adj2 care).ti,ab.  328  
24 discrepanc$.ti,ab.  4,102,001 
25 Error$.ti,ab.  346,734 
26 transition$.ti,ab.  404,601  
27 9 or 10 or 11 or 12 or 13 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 23 or 
25 or 26  
965,588 
28 Secondary adj1 care).ti,ab.  6,717  
29 hospital$.ti,ab.  1,639,428  
30 inpatient$.ti,ab.  123,976  
31 interface$.ti,ab.  189,253  
32 dicharge$.ti,ab.  57  
33 
admission$.ti,ab.  271,361  
34 28 or 29 or 30 or 31 or 32 or 33  1,993,872  
35 pharmacist$.ti,ab.  50,114  
36 pharmacy.ti,ab.  58,512  
37 pharmacies.ti,ab.  14,249  
38 35 or 36 or 37 102,050  
39 27 and 34 and 38 4,608 
40 Remove duplicate from 39 3,046 
41 Export to Endnote and further remove of duplicate  2,981 
 
  

Appendix 6B: Search terms applied CINAHL database in 19.04.2012 
 
 Search terms Number of 
retrievals 
1. TI Medicine OR AB Medicine 62,405 
2. TI Medication OR AB Medication 45,882 
3. TI drug OR AB drug 102,505 
4. TI medicament OR AB medicament 185 
5. TI prescription OR AB prescription 14,745 
6. TI (medic* N2 chart) OR AB (medic* N2 chart)  15 
7. TI (medic* N2 record) OR AB (medic* N2 record) 474 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 201,986 
9. TI (8 N2 reconciliation) OR AB (8 N2 reconciliation) 298 
10. TI (8 N2 management) OR AB (8 N2 management) 2,648 
11. 
TI (8 N2 assessment) OR AB (8 N2 assessment). 
 
731 
 
12.  TI (8 N2 review*) OR AB (8 N2 review*)  2,627 
13. TI (8 N2 histor*) OR AB (8 N2 histor*)  1,563 
15. TI (information N2 transfer*) OR AB (information N2 transfer*) 464 
16. TI (information N2 contin*) OR AB (information N2 contin*) 359 
17. TI (8 N2 system*) OR AB (8 N2 system*)   2,664 
18 TI (8 N2 congruence*) OR AB (8 N2 congruence*) 3 
19 TI (8 N2 communication) OR AB (8 N2 communication) 196 
20 TI (information N2 communication) OR AB (information N2 
communication) 1095 
21 TI (8 N2 liaison) OR AB (8 N2 liaison) 31 
23 TI (seamless N2 care) OR AB (seamless N2 care) 186  
24 TI Discrepanc* OR AB Discrepanc* 4,690 
25 TI Error* OR AB Error* 20,468 
26 TI transition* OR AB transition* 16,239 
27 9 or 10 or 11 or 12 or 13 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 23 
or 25 or 26  
52,242 
28 TI (Secondary N1 care) OR AB (Secondary N1 care) 1,450 
29 TI hospital* OR RA hospital* 165,610 
30 TI inpatient* OR RA inpatient* 16,853 
31 TI interface* OR RA interface*  5,092 

32 TI discharge* OR AB discharge* 525,523 
33 TI admission* OR AB admission* 24,989 
34 28 or 29 or 30 or 31 or 32 or 33  198,196 
35 TI Pharmacist OR AB Pharmacist   5,388 
36 TI pharmacy OR AB pharmacy  6,506 
37 TI pharmacies OR AB pharmacies 1,317 
38 35 or 36 or 37 11,592 
39 27 and 34 and 38 565 
 
Appendix 6C: Search terms applied in Cochrane library which included Cochrane 
Database of Systematic Review (CDSR), Database of Abstracts of Reviews of 
Effects (DARE) and the NHS Economic Evaluation Database (NHSEED) database in 
26.04.2012 
 
Search term  Retrieval  
(((medication*or medicine*or drug*or medicament*or prescription* or 
(medic* NEAR/2 chart*) or (medic* NEAR/2 record*)) NEAR/2 
(reconciliation or management or assessment or review*or histor* or 
system*or congruence*or communication or liaison)) or (information 
NEAR/2 (transfer or continu* or communication)) or (seamless NEAR/2 
care) or discrepanc* or error* or transition*) AND  ((secondary NEAR/1 
care) or hospital* or inpatient* or interface* or discharge* or admission*) 
AND (Pharmacist* or pharmacy or pharmacies) 
48 
 
Remove duplicate  45 
Export to collated data and remove duplicate  6 
 

Appendix 6D: Search terms applied in the centre of Reviews and Dissemination 
(CRD); search date in 28.04.2012 
Search term  Retrieval  
((medication*or medicine*or drug*or medicament*or prescription* or 
(medic* NEAR/2 chart*) or (medic* NEAR2 record*)) NEAR2 
(reconciliation or management or assessment or review*or histor* or 
system*or congruence*or communication or liaison)) or (information 
NEAR2 (transfer or continu* or communication)) or (seamless NEAR2 
care) or discrepanc* or error* or transition* 
AND  
(secondary NEAR1 care) or hospital* or inpatient* or interface* or 
discharge* or admission* 
AND  
Pharmacist* or pharmacy or pharmacies 
193 
Export to the collated database and remove duplicate  183* 

Note: Using any field (Title, author, journal, keywords) because there was no search 
within abstract choice  
 
Appendix 6E: Search terms applied in PHARMLINE which is provided by the 
National electronic Library for Medicines (NeLM); search date in 2/05/2012 
Search term Retrievals  
medic* reconciliation OR drug* reconciliation OR prescription*reconciliation OR 
medic* management OR drug* mamangement OR prescription*management 
OR medic* assessment or drug* assessment OR prescription* assessment OR 
medic* review* OR drug* review* OR prescription*review* OR medic* histor* 
OR drug* history* OR prescription* histor* OR medic* system* OR drug* 
system* OR prescription* system* medic* congruence* OR drug* congruence* 
OR prescription* congruence* OR medic* communication* OR drug* 
communication* OR prescription* communication* OR medic* liaison* OR 
drug* liaison* OR prescription* liaison* OR information transfer* OR 
information continu* OR “information communication” OR “seamless* care” OR 
discrepac* OR error* OR transition* Pharamc*  
32,197 
 
NelM area: evidence > Medicines management 22,599 
NelM category: National Health service > hospital trust  261 
NelM category: National Health service > hospital trust > hospital pharmacy  219 
Remove duplicate  216 
Remove duplicate from collated data file 161 
  

 
 
 
 
 
 
 
 
 
 
Appendix 7 Pharmacy led medicine 
reconciliation review screening tools  


Abstract screening tool (in MS Excel sheet) 
End 
note 
ID  
Authors Year  Title  Intervention 
included all 
MR elements 
led by 
Pharmacy 
Intervention a 
pharmacist or 
pharmacy 
technician or 
pharmacy 
student 
Implemented 
in inpatient 
setting 
Qualitative 
evaluation   
Decision 
    
Y/N Y/N Y/N Y/N Y/N
         
         
Full text screening tool (in MS Excel sheet) 
Endnote 
ID 
Author Year Title Confirm: 
Intervention  
includes all MR 
elements 
Confirm: 
Intervention is 
pharmacy led  
Confirm: 
Intervention 
in inpatient 
setting? 
Provide any 
report of 
costs 
associated 
with the 
intervention 
Decision 
   
Y/N Y/N Y/N Y/N Y/N 
   
    
 

 
 
 
 
 
 
 
 
 
 
Appendix 8 Pharmacy led medicine 
reconciliation review extraction tool  
 

Please complete details as appropriate Study 
details 
Endnote ID  
  Author   
  Year   
  Country  
  Language  
  Study design  
  Study period (Month)  
  Randomisation if any    
  Randomisation description  
  unit of allocation   
 
Intervention  Person led MR  
  Time to  initiate MR  
  Service cover days/week  
 
Control or 
comparator  
   
 Sample size  Sample size (no. patients for 
analysis) 
 
  Intervention (no. patients for 
analysis) 
 
  Control (no. patients for 
analysis) 
 
  Inclusion Criteria  
  Exclusion criteria  
Please complete age average estimate 
indicating whether measure is mean 
or median as appropriate 
Age Average Age (over all 
sample) 
 
Average Age intervention   
Average Age control  
Please complete in the gender & 
planned admission proportions as 
appropriate 
 
Gender Intervention % male  
 
 control male%  
 
Admissi
on  
Planned %  
Number of medications might be 
reported as total number prescribed or 
broke down into regular or PRN use 
and admission, inpatient or discharge; 
please complete details as appropriate  
No. meds Intervention  
Control  
Please complete speciality 
proportions as appropriate 
Speciality 
  
Medication discrepancies might be 
reported as total number of 
discrepancies or broke down into 
admission, inpatient or discharge 
discrepancies; please complete 
details as appropriate. All rates to be 
recorded  per patient (no. of 
discrepancies/no. patients) 
Medication 
discrepancie
s  
Intervention    
control  

 

Nature of medication discrepancies 
might be differentiated into 
admission, inpatient, discharge or 
post discharge discrepancies; Please 
complete details on the nature of 
discrepancies, all rates to be 
reported per patient (no. of 
discrepancies/no. patients) 
Nature of 
discrepancy  
Intervention   
control  
Discrepancy severity might be 
reported employing many tools. In 
texts please describe all rates per 
patient (no. of discrepancies/no. 
patients) for intervention and control 
group 
Discrepancy 
severity 
Tool used  
n. Rater(s)  
Inter-rater 
agreement 
 
Hospital visits might be reported as 
total hospital visits or broke down 
into inpatient readmission and ED. 
This might be reported at different 
follow up time, i.e. 3 months, 6 
months, etc. Please complete details 
and all rates to be recorded per 
patient (no. of discrepancies/no. 
patients) 
Hospital visit 
(Readmission 
& ED or both 
as 
appropriate)  
Intervention   
Control  
Please complete the details of other 
health care professional visits. In 
texts please describe all rates per 
patient (no. of discrepancies/no. 
patients) for intervention and control 
group 
Other health 
professional 
(HCP) visits  
Intervention   
Control  
Please complete the average 
estimate of length of hospital stay for 
the index admission and 
readmission(s) as appropriate 
length of 
hospital stay  
 
Readmission 
duration  
Intervention  
Control   
Intervention   
Control  
Please complete details on  rate of 
death in both group, all rates per 
patient (no. of discrepancies/no. 
patients) 
Death 12 
months 
n/patient 
intervention  
control  
Please complete details of health 
related quality of life. In texts please 
describe different measures of 
quality of life for intervention and 
control group 
health related 
quality of life 
Tool used  
Intervention  
Control   
Please complete details related to 
cost saving if reported. Saving might 
be reported at different follow up 
time, i.e. 3 months, 6 months. All 
savings to be reported per patient 
(total saving / no. patients) 
Cost saving  
 
 

Please complete details related to costs 
per patients as appropriate.  
Perspective 
of cost if 
applicable 
e.g. NHS/ 
societal 
Unit cost  
 Currency  
 n. Patient included 
in  cost analysis 
 
Please complete details related to time 
spent by MR pharmacist per patients as 
appropriate.  
 Mean time  
 range min  
 range max  
Please complete details related to time 
spent/saved by other professionals per 
patients as appropriate. 
Time 
saved/spent  
 
  
 

 
 
 
 
 
 
 
 
 
Appendix 9 Pharmacy led medicine 
reconciliation review risk assessment tool  


Domain Low risk High risk Unclear 
1. Design bias (focus study 
question & design) 
• The study clearly described all of the following: 
• Targeted population  
• The intervention 
• The comparator 
• Outcomes measured 
• The study design is the best to answer the question, 
e.g. RCT for intervention  
• The study addressed the intended research 
question 
The study is not fulfilling any of 
these criteria  
Insufficient information to 
permit judgment of ‘Low 
risk’ or ‘High risk’ 
2. Selection bias (external and 
internal variations)  
• The study sample is representative of the intended 
population 
• There is nothing special about the sample with any 
potential to effect intervention or outcomes 
• All patients were included/ excluded as per the 
stated inclusion and exclusion criteria 
• The study groups are comparable at baseline 
The study is not fulfilling any of 
these criteria  
Insufficient information to 
permit judgment of ‘Low 
risk’ or ‘High risk’1 
3. Selection bias 
(randomisation) 
The investigators describe a random component in the 
sequence generation process 2 
The description of the 
sequence generation involve 
some systematic but non- 
random approach 3 
Insufficient information 
permit judgment of ‘Low 
risk’ or ‘High risk’ 
4. Selection bias (allocation 
concealment) 
Participants and investigators enrolling participants 
could not foresee the study group assignment 4 
Participants and investigators 
enrolling participants could 
possibly foresee the study 
group assignments 5 
Insufficient information 
permit judgment of ‘Low 
risk’ or ‘High risk’ 
5. Performance bias 
(Standardised intervention 
delivery) 
The investigators used a standardised process which 
followed by all the service providers delivering the 
intervention 6 
The process of intervention 
delivery was not standardised  
Insufficient information to 
permit judgment of ‘Low 
risk’ or ‘High risk’ 
6. Performance bias 
(Standardised outcome 
measurement) 
The investigators used a standardised process which 
followed by all investigators recording and measuring t 
outcomes7 
The process for recording 
/measuring outcomes was not 
standardised 
Insufficient information to 
permit judgment of “‘Low 
risk’ or ‘High risk’ 
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Domain Low risk High risk Unclear 
1. Detection bias (Blindness of 
the outcomes) 
• Blinding of outcome assessment ensured, and 
unlikely it was broken. 
• No blinding of the outcome assessment, but 
this unlikely to influence outcome assessment 
Outcomes measurement was not 
blind 8 
Insufficient information to 
permit judgement of ‘Low 
risk’ or ‘High risk’ 
2. Incomplete outcome data  • No missing outcome data and all study 
participants accounting for at conclusion 9  
• All pre-specified (primary and secondary) 
outcomes have been reported  
• The reported outcomes are appropriate to 
answer the study question 
The study is not fulfilling one or 
more of these criteria  
Insufficient information to 
permit judgement of ‘Low 
risk’ or ‘High risk’ 
3. Adequacy of study power 
(appropriate Statistical 
analysis)  
• The study used appropriate/justifiable 
statistical testing 
• Power calculation or sample size calculation 
was performed 
• Results do not match up or add up but with no 
major concern 
The study is not fulfilling one or 
more of these criteria 
Insufficient information to 
permit judgement of ‘Low 
risk’ or ‘High risk’ 
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Additional criteria for Economic evaluation : Validity of the economic evaluation 
 Low risk  High risk  Unclear risk  NA 
1. Perspective  The investigator(s) specified/established the 
perspective of the economic evaluation  
The study is not 
fulfilling one or more 
of these criteria 
Insufficient information to 
permit judgement of ‘Low risk’ 
or ‘High risk’. 
Study is not an economic 
evaluation  
2. Cost measure 
 
• capital costs as well as operating costs 
were included  
• Appropriate cost unit was used  
• The unit(s) used was of a realistic value (s) 
• Appropriate method(s) was employed to 
drive the value(s) of costs and 
consequences 
• All the study assumptions with respect to 
cost estimation are reported and justified 
The study is not 
fulfilling one or more 
of these criteria  
Insufficient information to 
permit judgement of ‘Low risk’ 
or ‘High risk’. 
Study is not an economic 
evaluation 
3. Variability of the 
estimate 
Adequate sensitivity analysis was reported for 
the primary estimate 
Sensitivity analysis 
of the primary 
estimate was not 
performed 
Insufficient information to 
permit judgement of ‘Low risk’ 
or ‘High risk’. 
Study is not an economic 
evaluation 


 
 
 
 
 
 
 
 
Appendix 10 Medicine Reconciliation at the 
health interface patient information leaflet 

 
  

Invitation: 
You are invited to take part in a clinical research study.  To help you decide if you want to 
take part in the study, it is important for you to understand why the study is being done 
and what it will involve.  Please take your time to read the following information carefully 
before making up your mind.  Please ask about anything that is not clear or if you would 
like more information. 
What is the purpose of the study? 
The purpose of the study is to carry out a small project to see whether it is a good use of 
NHS money for a pharmacist to check patients’ medicines history when they come into 
hospital. All patients are seen by a Doctor and their medicines are prescribed. We are 
trying to find out whether it is a good idea that all medicines are also checked by a 
Pharmacist. The results of the study will be used to inform the best design of a larger 
study to look at the cost and effect of an extended pharmacy service. 
Why have I been chosen? 
You have been chosen because you have been admitted to the ward within the previous 
24 hours under the care of a medical team at Addenbrooke’s hospital and have not yet 
had your medicines history looked at by a pharmacist. 
Do I have to take part? 
No. Your participation in this study is voluntary and it is entirely up to you if you decide to 
take part or not.  If you do decide to take part you will be given this information sheet to 
keep and will be asked to sign a consent form to confirm that you understand what is 
involved in the study.  If you decide to take part but later change your mind during the 
study, you are free to withdraw at anytime without giving a reason.  This will not in any 
way affect the care or services you subsequently receive by Addenbrooke’s hospital staff. 
How many patients will be in the study? 
This is a relatively small pilot study involving 200 patients. One hundred patients will 
receive usual care and 100 will have their medicine history taken by a pharmacist in 
addition to that taken by a doctor. 
Which group I will be in? 
All patients who consent to take part will be randomly allocated (like flipping a coin) to 
receive the pharmacist service or usual care. By agreeing to take part in the study you 
have a 50/50 chance of receiving the extra pharmacist service  
For all patients in both groups  
• A research assistant will talk with you about your medicines (including any 
medicines that you might buy over the counter at a pharmacy or from a health shop)  
• Your own medicines will be checked and the  boxes copied 
• Your prescription charts while you are in hospital will be copied 
• Your GP will be contacted to obtain details of your medicines 

• Relevant data will be collected from your hospital records 
• Your hospital record and discharge letter will be reviewed 3 months after discharge 
• You will be asked to complete a health-related quality of life questionnaire which 
consists of five questions following your consent to be in the study 
• You may receive a copy of your discharge letter and you may receive a copy of a 
medication chart. A medication chart summarises the drugs you are taking and at 
what time of day you should take them 
• The same health-related quality of life questionnaire as previously will be sent to you 
three months after discharge from hospital. We will also send a questionnaire asking 
about your use of any health or social care services since discharge. This will be 
followed up with a letter or a phone call   
• Some patients who were recruited in the first 3 months of the study will be invited to 
take part in a discussion group to help us better understand how the project has 
worked.  This will be a meeting with other patients where you will be asked for your 
comments about the experience of being in the trial.  Participation in this is entirely 
voluntary.  Your travel expenses and use of the car park will be reimbursed. Audio 
recordings of the discussion  group will be stored in a secure location at the UEA 
and destroyed no later than five years after the study has finished 
If you receive the pharmacy service 
• A Pharmacist will talk with you so that he or she can produce a complete list of all 
the medicines that you are taking  
• Any differences between medicines taken before admission and those currently 
being taken will be discussed with your GP/and or your Doctor on the ward 
• You will receive a copy of your discharge letter and you will receive a medication 
chart. 
Will my GP be informed that I am taking part? 
Yes, your GP will be informed that you are taking part in a study. 
What are the risks involved/disadvantages in taking part in the study? 
We do not anticipate any risks or disadvantages to you taking part in this study.  
What are the benefits? 
Taking part in this study may not be of direct benefit to you.  The information we gain from 
this study may improve the future management of medicines in the NHS. It will also help 
to inform the running of a large scale trial. The results may be published in scientific 
journals or presented at meetings.  A summary of the study results will be sent to you if 
you wish after the research has been completed. 
After 3 months, we will check your discharge letter with our records to see if errors 
occurred at the time of discharge.  If we find any, we will contact your doctor to make sure 

that you are receiving the correct medications. Also at 3 months, we will post a 
questionnaire and short survey, which may be followed up with a telephone call. 
What if something goes wrong ? 
In the very unlikely event of any harm occurring by taking part in this research study there 
are no special compensation arrangements.  If you are harmed as a result of someone’s 
negligence then you may have grounds for legal action but you may have to pay for it.  
Regardless of this, if you wish to make a complaint or have any concerns about any 
aspect of the way in which you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms are available to you. 
You can contact the local  
Patient Advice Liaison Service at: pals@addenbrookes.nhs.uk or Tel: 01223 216 756. 
Has the study been approved? 
This study has been developed by a team from Cambridge University Hospitals and 
University of East Anglia.  This study has been approved by Essex Ethics Committee. 
Who is paying for the study? 
National Institute for Health Research: Research for Patient Benefit Programme 
www.nihr.ac.uk 
Are there any payments to subjects? 
You will receive no payment for taking part in this study. There will be expenses available 
for travelling to any discussion group at the end of the study. 
Will my participation in the study be kept confidential? 
Yes. If you consent to taking part in this study, your medical records will only be 
accessible to study clinical or research staff involved in the research.  Non-clinical 
research staff will have access only to anonymised information from medical records.  The 
data will be stored in a computer for research purposes and won’t be in any way directly 
linked or identify you. 
As part of European law it may be necessary for details of your treatment to be disclosed 
to an official body. Even so, confidentiality will be maintained and your identity will not be 
disclosed. The results of the meeting may be used in presentations or be published in 
scientific reports. Any presentation report based about the study will not name or 
otherwise identify you.  The focus group discussion will be tape-recorded and listened to 
by the research team at the UEA.  Any data that can identify you will not be published and 
no-one outside the research team will be able to access any information you give us. 
Where can I get more information? 
If you have any concerns about any aspect of this research then please contact either 
Amanda Bale, Senior Research Assistant, Cambridge University Hospitals NHS 
Foundation Trust on 01223 217980 or email: amanda.bale@addenbrookes.nhs.net  OR 
Brit Cadman, Consultant Pharmacist, Cambridge University Hospitals NHS Foundation 
Trust on 01223 217980 or email: brit.cadman@addenbrookes.nhs.ne  

 

 
 
 
 
 
 
 
Appendix 11 Medicine Reconciliation at the 
health interface patient informed consent 
form 
  

 
 
 
 
 
 
Patient Consent Form 
Medicines reconciliation at the interface: A pilot randomised controlled 
trial to determine the costs and effects of a pharmacy provided service 
 
Please initial each box and sign at the bottom if you agree to participate  
1. I confirm that I have read and understand the Patient Information Sheet 
(version 2, date 1 may 2012), for the above study. I have had the 
opportunity to consider the information, ask questions and have these 
answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free  
to withdraw at any time without giving any reason. 
 
 
3. I agree to take part in the above study 
 
 
4.  I have been informed that the confidentiality of the information I will 
provide will be safeguarded. 
 
  
5. I understand that I am free to ask any question at any time before and 
during the study, and I have the contact details of the researchers if I 
wish to discuss any aspect of the study  
 
6. 
I understand that relevant sections of my data collected during the study 
may be looked at by individual from regulatory authorities where it is 
relevant to my participation in this research. I give permission for these 
individuals to have access to my records. 
 
7. 
I understand that a letter will be sent to my GP to inform them of my 
participation in the study. 
 
8. I understand that I will be asked to complete a quality of life questionnaire 
upon admission to hospital. A questionnaire and survey will be posted 3 
months after discharge. This will be followed up with a telephone call 
 
9. I have been provided with a copy of this form and the participant 
information sheet. 

Participant number: _________ 
 
Name:                Signature  Date 
Please tick the box if you would like to receive details of the results of the study  
  
Cambridge University Hospitals 
Foundation Trust 
Hills Road 
Cambridge 
CB2 0QQ 
Phone: 01223 245151 
School of Pharmacy 
University of East Anglia 
Norwich 
NR4 7TJ 
Phone: 01603 5931996 











 
 
 
 
 
 
 
 
 
Appendix 12 Medicine Reconciliation at the 
health interface consultee information 
leaflet 

 
 

Invitation: 
We feel that your relative/friend is unable to decide for him/herself whether to participate 
in this research project so we’d like to ask your opinion as to whether or not they would 
want to be involved. You will be acting as a Personal Consultee under the Mental 
Capacity Act 2005. It is important for you to understand why the study is being done and 
what it will involve.  Please take your time to read the following information carefully 
before making up your mind.  Please ask about anything that is not clear or if you would 
like more information. 
Personal Consultees under the Mental Capacity Act 2005 
You are being asked to consider whether your friend or relative would be content to take 
part or whether doing so might upset them. You are being asked to give your opinion on 
what the past and present feelings and wishes of your relative or friend may be about 
taking part in the study. You are asked to consider the risks, benefits and practicalities of 
what taking part will mean for him/her. 
You are not being asked for your personal views on participation in the project, or on 
research in general. You must set aside any views that you may have about the research 
and consider only the views and interests of your friend or relative.  
At any stage you can advise the researcher that your friend or relative would not want to 
remain in the project. Your advice will be respected by the researcher. 
We are asking you because you are interested in your friend/relative’s welfare. 
If you feel unable to give this advice then please tell the Research Assistant or a member 
of the care team. 
You may want to seek further advice regarding this role. More information can be gained 
by contacting your GP. You could also discuss the role with an Independent Mental 
Capacity Advocate- one can be contacted through the Patient Advice and Liaison Service 
on 01223 216 756.You could also contact Voice ability on 01223 555800 or the 
Department of Health Public Guardian on 0845 330 2900. 
What is the purpose of the study? 
The purpose of the study is to carry out a small project to see whether it is a good use of 
NHS money for a Pharmacist to check patients’ medicines history when they come into 
hospital. All patients are seen by a Doctor and their medicines are prescribed. We are 
trying to find out whether it is a good idea that all medicines are also checked by a 
Pharmacist. The results of the study will be used to inform the best design of a larger 
study to look at the cost and effect of an extended pharmacy service. 
Why has my relative/friend been chosen? 
Your relative/friend has been chosen because he/she has been admitted to the ward 
within the previous 24 hrs under the care of a medical team at Addenbrooke’s hospital. 
He/she has not yet had their medicines history looked at by a pharmacist. 
  

Does my relative/friend have to take part? 
No. If however you do decide that he/she would  take part you will be given this 
information sheet to keep and will be asked to sign a consultee declaration form to confirm 
that you understand what is involved in the study and to say that you think that your 
relative/friend would want to take part in the study.  If you later change your mind during 
the study, you are free to withdraw your relative/friend at anytime without giving a reason.  
This will not in any way affect the care or services you or your relative/friend subsequently 
receive from Addenbrooke’s hospital staff. 
How many patients will be in the study? 
This is a relatively small pilot study involving 200 patients. One hundred patients will 
receive usual care and one hundred will have their medicine history taken by a pharmacist 
in addition to that taken by a doctor. 
Which group will my relative/friend be in? 
All patients who take part will be randomly allocated (like flipping a coin) to receive the 
pharmacist service or usual care. By agreeing to their taking part in the study they have a 
50/50 chance of receiving the extra pharmacist service  
For all patients in both groups  
• Their own medicines will be checked and the  boxes copied 
• Their prescription charts while they are in hospital will be copied 
• Their GP will be contacted to obtain details of their medicines 
• Relevant data will be collected from their hospital records 
• Their hospital record and discharge letter will be reviewed 3 months after discharge 
• You will be asked to complete a health-related quality of life questionnaire which 
consists of five questions following your agreeing to your relative/friend being 
involved in the study. This questionnaire has been approved for use by patients’ 
relatives or friends 
• The same health-related quality of life questionnaire as previously will be sent to you 
three months after discharge from hospital. We will also send a questionnaire asking 
about your relative/friend’s use of any health or social care services since discharge. 
This will be followed up with a phone call   
If your relative/friend receives the pharmacy service 
• Any differences between medicines taken before admission and those currently 
being taken will be discussed with his/her GP and/or the Doctor on the ward 
  

Will my relative/friend’s GP be informed that they are taking part? 
Yes, their GP will be informed that they are part of a study. 
What are the risks involved/disadvantages in being involved in the study? 
We do not anticipate any risks or disadvantages to being involved in this study.  
What are the benefits? 
Taking part in this study may not be of direct benefit to your relative/friend.  The 
information we gain from this study may improve the future management of medicines in 
the NHS. It will also help to inform the running of a large scale trial. The results may be 
published in scientific journals or presented at meetings.  A summary of the study results 
will be sent to you or your relative/friend if you wish after the research has been 
completed. 
After 3 months, we will check your relative/friend’s discharge letter with our records to see 
if errors occurred at the time of discharge.  If we find any, we will contact their GP to make 
sure that they are receiving the correct medications 
What if something goes wrong ? 
In the very unlikely event of any harm occurring by taking part in this research study there 
are no special compensation arrangements.  If your relative or friend  is harmed as a 
result of someone’s negligence then you or they may have grounds for legal action but 
you or they may have to pay for it.  Regardless of this, if you wish to make a complaint or 
have any concerns about any aspect of the way in which you or they have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you. You can contact the local Patient Advice 
Liaison Service at: pals@addenbrookes.nhs.uk or Tel: 01223 216 756. 
Has the study been approved? 
This study has been developed by a team from Cambridge University Hospitals and 
University of East Anglia.  This study has been approved by Essex Ethics Committee. 
Who is paying for the study? 
National Institute for Health Research: Research for Patient Benefit Programme.  
Are there any payments to subjects? 
Neither you nor your relative/friend will receive payment for being part of this study. There 
will be expenses available for travelling to any discussion group at the end of the study. 
Will my relative/friend’s participation in the study be kept confidential? 
Yes. Their medical records will only be accessible to study clinical or research staff 
involved in the research.  Non-clinical research staff will have access only to anonymised 
information from medical records.  The data will be stored in a computer for research 
purposes and won’t be in any way directly linked to or identify you or your relative/friend. 
As part of European law it may be necessary for details of your relative/friend’s treatment 
to be disclosed to an official body. Even so, confidentiality will be maintained and their 

identity will not be disclosed. The results of the meeting may be used in presentations or 
be published in scientific reports. Any presentation report based about the study will not 
name or otherwise identify them.  The focus group discussion will be tape-recorded and 
listened to by the research team at the UEA.  Any data that can identify them will not be 
published and no-one outside the research team will be able to access any information 
you or they give us. 
Where can I get more information? 
If you have any concerns about any aspect of this research then please contact either 
Amanda Bale, Senior Research Assistant, Cambridge University Hospitals NHS 
Foundation Trust on 01223 217980 or email: amanda.bale@addenbrookes.nhs.net  OR 
Brit Cadman, Consultant Pharmacist, Cambridge University Hospitals NHS Foundation 
Trust on 01223 217980 or email: brit.cadman@addenbrookes.nhs.net 
 

 
 
 
 
 
 
 
 
 
Appendix 13 Medicine Reconciliation at the 
health interface consultee declaration form 
  

 
 
 
 
 
Consultee Declaration Form 
Version 2, 1 may 2012 
Title of the project: 
Medicines reconciliation at the interface: A pilot randomised controlled trial 
to determine the costs and effects of a pharmacy provided service 
Please initial each box and sign at the bottom if you agree  
1. I, …………….................................., have been consulted about 
……………………………………..’s participation in this research project. I 
have had the opportunity to ask questions about the study and 
understand what is involved. 
 
2. In my opinion he/she would wish to take part in the above study  
3. I understand that I can request that he/she is withdrawn from the study at 
any time, without giving any reason and without his/her care or legal rights 
being affected. 
 
4.  I understand that relevant sections of his/her care record and data 
collected during the study may be looked at by responsible individuals 
from Cambridge University Hospitals NHS Foundation Trust or from 
regulatory authorities, where it is relevant to their taking part in this 
research. I give permission for these individuals to have access to his/her 
records 
 
5. I understand that I am free to ask any question at any time before and 
during the study, and I have the contact details of the researchers if I wish 
to discuss any aspect of the study  
 
6. I agree to their GP being sent a letter informing them of participation in the 
study 
 
7. I agree that, if he/she becomes able to consent then consent will be 
sought 
 
8. I have been provided with a copy of this form and the “Consultee 
information sheet” (version 2, dated 1 may 2012.) I have read and 
understood this information sheet 
 
Name of Consultee 
Signature Date:                        Relationship to participant 
Please tick the box if you would like to receive details of the results of the study  
  
Cambridge University Hospitals 
Foundation NHS Trust 
Hills Road 
Cambridge 
CB2 0QQ 
Phone: 01223256256 
School of Pharmacy 
University of East Anglia 
Norwich 
NR4 7TJ 











 
 
 
 
 
 
 
 
 
Appendix 14 Medicine Reconciliation at the 
health interface pharmacist time recording 
form 
  

Subject number: ___________ 
 
Name of pharmacist 
RECORDING DURATION OF INTERVENTION ACTIVITY  
Job title Actions Time spent 
on activity 
(minutes) 
Com
ment
s 
Pharma
cist 
Admission 
 Checking of patients own medication (POD)    
 Collection of data on medication history from source(s) 
other than PODs 
(record source in comment section) 
  
 Discrepancies identification    
Job title Actions Time spent 
on activity 
(minutes) 
Com
ment
s 
 Documentation of discrepancies   
 Establishing unintentional discrepancies with medical staff    
   Rectifying unintentional discrepancies with medical staff     
 Establishing allergies/sensitivities   
 
Discharge  
  Discrepancies identification      
 Documentation of discrepancies (amendment of discharge 
letter, new copy printed) 
  
 Establishing unintentional discrepancies with medical staff    
   Rectifying unintentional discrepancies with medical staff     
   Intentional discrepancies clarified and recorded on EDS  
following discussion with medical staff 
    
 Recording of any changes as a result of discussion with 
medical staff 
  
 

 Medical 
doctor 
Admission 
  Rectifying unintentional discrepancies as a result of the 
intervention pharmacist query 
    
   Intentional discrepancies clarified as a result of the 
intervention pharmacist query 
    
 
Discharge 
  Discrepancies on discharge clarified and amended as 
appropriate as a result of intervention pharmacist query 
    
 Confirming/clarifying allergies/sensitivities information   
Administrat
or  
Discrepancies identification      
Job title Actions Time spent 
on activity 
(minutes) 
Com
ment
s 
 Documentation of discrepancies   
 Establishing unintentional discrepancies with medical 
staff  
  
   Rectifying unintentional discrepancies with medical 
staff 
    
   Intentional discrepancies clarified and recorded on 
EDS   
    
  Clarification of discrepancies identified on discharge  
with medical staff  
    
 Recording of any changes as a result of discussion with 
medical staff 
  
 
  

 
 
 
 
 
 
 
 
Appendix 15 Medicine reconciliation at the 
health interface control MR form 
  

Patient addressograph: 
 
 
 
 
 
 
 
Date patient admitted:……………. 
 
Time patient admitted:……………. 
 
Time when MR delivered following patient admission: 
Please tick  
<24 hours <48 hours <72 hours >72hours 
    
 
Time taken to deliver MR  
Please tick  
10 minutes <30 minutes >30 minutes >60 minutes 
    
 
Comments: 
 
 
 
 
Completed by: 
………………………………………………………….Pharmacist  
  

 
 
 
 
 
 
 
 
 
Appendix 16 Medicine reconciliation at the 
health interface three month health related 
quality of life and health resource use 
questionnaire 
  



 
The following questions ask about your health status today, please indicate which 
statements best describe your own health state today. 
 
1 Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
2 Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
3 Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
4 Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
5 Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
  
Section 1:    Health Related Quality of Life 

  
 
 
 
 
 
 
 
 
 
 
 
 
Please do this by drawing a line from the box below to whichever point on  
the scale indicates how good or bad your health state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own 
health state 
today 
 To help you say how good or bad your health state is, we have 
drawn a scale (rather like a thermometer) on which the best state 
you can imagine is marked 100 and the worst state you can 
imagine is marked 0. 
 
 We would like you to indicate on this scale how good or bad your 
own health is today, in your opinion
 
 
 
 
 
	 
 
 
 

K!
$#3%

=
$#3%

 
The following questions ask about health care services you may have used in the community. 
6.During the last 3 months have you seen, or been visited by, a health or social care worker? 
Yes    No    
If Yes, please complete the table below.  If No, please go to question 7. 
  Number of visits in 
the previous 3 
months 
Place of most visits 
(1= GP clinic; 2 = 
Home;  
3 = telephone 
consultation) 
E.g. GP 6 1 
GP (General practitioner)   
Practice nurse   
District nurse   
Care assistant   
Dietician   
Physiotherapist   
Occupational therapist    
Social worker   
Speech and language therapist   
 


The following questions ask about health care services you may have used from hospital services. 
7.How many times have you been admitted to the hospital in the last 3 months?  [If none, please 
put ‘00’ in the boxes and go please to question 8] 
If you have been admitted to hospital, please complete the following for each inpatient stay.  
Admission number  Ward admitted to Length of stay in hospital 
1 e.g. respiratory ward 4 days 
2   
3.   
4.   
   
Section 2B Health care service use: Hospital services 
Section 2A   Health care service use: Community 

8.How many times have you visited the Accident and Emergency department (‘Casualty’) in the last 
3 months?    [If ‘none, please put ‘00’ in the boxes and go please to question 9] 
9.How many times have you visited an NHS ‘walk-in’ centre in the last 3 months?  [If none please 
put  ‘00’ in the boxes and go please to question 10] 
10.How many times have you had an appointment in an outpatient clinic in the last 3 months?  [If 
none, please put ‘00’ in the boxes and go to question 11] 
If you have been to an appointment, please complete the following for each outpatient 
appointment.  
Number  Hospital department visited if you had to have an investigation e.g. x-ray, ct 
scan, blood test etc please state these as well 
1 e.g. respiratory clinic Chest X-ray 
2   
3   
4   


The following questions ask about services you may have used from social care services. 
11.How many times have you been admitted to a residential home in the last 3 months?  [if none, 
please put ‘00’ in the boxes and go please to question 12] 
12.How many times have you been admitted to a nursing home in the last 3 months?  [If none, 
please put ‘00’ in the boxes and go please to question 13] 
On average, how long was each stay?                                           Days 
13. How many times per week have you attended a day centre in the last 3 months?  [If ‘NO’, put 
‘00’ in the boxes and go please to question 14] 
14.How many times per week have you had a home help or community care assistant in the last 3 
months?  [If not at all, answer ‘00’ in the boxes and go please to 15] 
How long do they stay?                                                                           mins 
             (minutes approx., average time per visit, last week)                              
15.In the past week, how many times has anyone who lives with you had to help you with everyday 
activities (For example, housework, shopping, and taking you to appointments)?  [If none, please 
put ‘00’ in the boxes and go please to 16] 
For how long? )                                                                              mins 
           (minutes approx., on average, last week)  
Section 3    Social care service  

Did they have to take time off work to help you?          Yes     No     N/A  
16.In the past week, how many times has a friend or relative who does not live with you had to 
come and help you with everyday activities (For example, personal care tasks, housework, 
shopping and taking you to appointments)? [If none, please put ‘00’ in the boxes and go please to 
question 18] 
For how long?                                                                                              mins 
               (minutes approx., average time per visit, last week) 
Did they have to take time off work to help you?          Yes     No     N/A  
17.Has a relative or friend had to give up work completely to look after you in the last 3 months?  
                                                                                      Yes               No   
18.How many meals on wheels have you had in the past week?   [If none, please put ‘00’ in the 
boxes and please go to 20] 
If you had to pay for these yourself, how much did they cost you?  £________
19.Have you incurred any out of pocket expenses (those you have had to pay for yourself) as a 
result of your health in the last 3 months? This could include travel or parking costs to attend health 
care visits, over the counter medications, equipment etc)                                                     Yes                   
No  
If yes, please specify the item and cost incurred by you in purchasing it 
Item Estimate of the cost incurred by you (£) 
E.g. Bus ticket £4.20 
  
  
  
  
  
  
 
 
Thank you for completing the questionnaires. Please place the questionnaire booklet in the 
envelope and post back to the research team   

  
 
 
 
 
 
 
 
 
Appendix 17 Summary of auditors’ comments 
on the discharge information audit 

Examples of auditors’ commonts on the process and handling the discharge information 
tool  
Question Auditor  Comment  
It would be valuable if you could share 
with us your thoughts on the audit. 
Clarity of aims (what do you think it was 
designed to achieve? 
Ph1 
 
 
Ph2 
The audit was detailed enough to pick 
the quality of hospital information. 
  
Where students did the audit practice 
staff have not been informed well with 
regard the audit 
Audit importance to the current practice 
(how it may affect your practice?) 
PT1 Surgeries will benefit when report 
disseminated 
Please comment on the ease of audit 
tool completion and handling 
 
Excel sheet format (Check boxes) vs. 
paper form 
PT2 
 
 
 
 
GP1 
Was bit tricky as formulation check 
boxes were out of the page screen 
scale.  However, it is nice not to have 
pile of paper. 
Switching between screens was hard 
(practices print out discharge 
summaries) 
Exchange, transfer, return  Ph2 Small practice needed small folders had 
no trouble but larger folders needed to 
learn how to use zip software 
Order and nature of questions  Ph2 Make sense with the way discharge 
summary was written 
If any, additional questions (missed or 
were not adequately addressed 
PT1 Time when discharge summary was 
sent from hospital ( how long it took for 
hospital staff to process) 
PT2 
 
If patient was readmitted to hospital 
would have been of interest. Time frame 
to audit was not stipulated ( how long 
following discharge to audit discharge 
summary 
Ph2 
 
If they were clinically checked by 
pharmacist before being sent to 
practices 
Roughly, how long did it take you to 
complete each audit? 
GP,PT,PH 10-45 minutes 
Which parts needed the most time and 
effort 
o Number of medications, 
o Hospital stay  
o Specialty 
o Other factors  
GP 1 Medications list, it was hard to know 
which to list 
GP2 
 
No. of medication , style of DS , number 
of medication changes, surgical and 
orthopaedic were simpler and more 
straight forward compared to medical 
wards 
PT1 Cardiology and orthopaedic wards 
needed longer time, they weren’t clear 

Examples of auditors’ commonts on the process and handling the discharge information 
tool
Question Auditor  Comment  
Specifically, can you describe your 
answers with regard the following 
felids: 
o Type of admission, where it 
was not specified but can be 
known by the clinical context 
o Ward specialty (ward number 
or name)  
o Medicines whether listed as 
per discharge summary or GP 
record 
GP1 
 
For unspecified speciality or type of 
admission commented on the 
commentary box 
PT1 
 
I worked out speciality and type of 
admission from the clinical history in 
discharge summary and recorded this 
what I was able 
GP, Ph, 
PT 
Medicines as listed in discharge 
summary 
There were 3 questions following the 
medications part about drugs changed, 
started and stopped; would you please 
describe any uncertainty you may have 
in answering them?  
o All changes stated and all 
reasons  
 
o Answer where no medicine 
changed, initiated or 
discontinued 
 
o Identifying drug changes , 
initiation or discontinuation 
(comparing against GP held 
record) 
GP1 
 
Not sure/ remember, No, will be the 
answer if some changes are not stated 
Ph2 Yes,only if all changes (start or stop) 
were stated 
PT2 
 
If hospital stated ‘no regular changes to 
medication’ she picked no. Same 
response if no actual changes was done 
and hospital stated no thing 
GP2 
 
 
Ph2 
Yes, checked discharge list with our 
record 
 
Cross refreshing with GP record and was 
time consuming 
 
The audit tool contains many free text 
fields that required you to type in 
details such as PMH, presenting 
diagnosis, etc. Could you tell please 
how you responded to them? 
o Missing PMH , pre admission 
medication  
 
 
o Procedures and tests 
PT, GP, 
Ph 
 
 
PT2 
 
 
PT1 
Missing ones were listed 
 
 
Summary of main results not too much 
detailed 
 
Cut and paste was possible all details 
were included but if not she typed in that 
results were in DS 

Examples of auditors’ commonts on the process and handling the discharge information 
tool
Question Auditor  Comment  
Legibility of handwritten DSs was 
scored using a 4 point scale (illegible 1 
to 4 legible)  
o Do you recollect any 
uncertainty in determining the 
legibility?  
 
o Were the distinction between 4 
&3 or 2 &3 clear to you? 
PT1 
 
It was fine, majority of discharge 
summary were electronic 
GP2 All were handwritten ( legality was not 
poor as usual) 
GP2 It was clear to distinguish between , the 
hard bit was related to DS themselves 
not to the scoring points 
Do you have any other thoughts or 
comments that you would like to add 
related to the audit? 
Ph1 Differences between practices as 
different person completed ( some had 
help and some had not), the result will  
be interesting to know 
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Appendix 18 Pharmacy led medicine 
reconciliation systematic review description 
of risk of bias assessment  

Karapinar-Carkit et al. 2012 
Domain  Bias Author 
judgement 
Support of judgement  
Design bias Focus study question & design High risk This a uncontrolled study from one department (i.e. Pulmonology) 
Selection bias External and internal variations 
of study sample  
High risk Sampling method  
No details on how patients were identified and screened for study legibility.  
Quote “In brief, all adults discharged with at least one prescribed drug from 
the Department of pulmonology were included” 
For labour related cost the data used were for 59/262 patient, there was no 
sufficient details on the rational and the selection of such subset sample.  
Quote “The pharmaceutical consultants recorded the time needed for 
reconciliation of the drugs of 59 patients by using a stopwatch” 
Randomisation High risk No randomisation  
Allocation concealment  High risk No Allocation 
Performance 
bias  
 
Standardised intervention 
delivery 
Unclear No sufficient details to establish whether delivery of MR intervention was 
standardised between the team of the study pharmaceutical consultants.  
Quote “In this study the medication reconciliation process was carried out by a 
team of pharmaceutical consultants who were trained in medication 
reconciliation before this study was conducted” 
 Standardised outcome 
measurement 
Unclear No sufficient details to establish whether identification and classification of 
intervention was standardised. 
Quote “After medication reconciliation, the pharmaceutical consultant registered 
every change made by the hospital physician to the pharmacotherapy at 
hospital admission and discharge and after patient counselling. The 
classification of 
interventions was based on the first 2 steps in medication 
reconciliation that could influence medication costs” 
Detection bias Blinding of outcome 
measurement 
High risk Uncontrolled study and potentially there was no blinding for the study 
pharmaceutical consultants, recording and classification of the intervention 
which is the main contribute for the main outcome (i.e. medication related cost ) 
was done by the study pharmaceutical consultants.  
Quote:” After medication reconciliation, the pharmaceutical consultant 
registered every change made by the hospital physician to the 
pharmacotherapy at hospital admission and discharge and after patient 
counselling. The classification of 
interventions was based on the first 2 steps in medication 
reconciliation that could influence medication costs” 
 

Karapinar-Carkit et al. 2012 (continued)  
 
Domain  
Bias Author 
judgement 
Support of judgement 
Selective 
reporting  
Incomplete outcome data High risk Outcome data for labour costs were based on 59/262 patients as such not all study 
participants accounting for study conclusions. 
Quote: “The pharmaceutical consultants recorded the time needed for 
reconciliation of the drugs of 59 patients by using a stopwatch” 
Thought it was not considered of real cost, errors relating to preventions of 
medication discrepancies between pre-admission and inpatient medications was 
not described in sufficient details. 
Quote:” Eliminating discrepancies is an important aspect of medication 
reconciliation but does not represent real costs for society. Therefore, these 
interventions were not included in the cost calculation. .......... Estimates of costs 
per adverse drug event range from €900 to €1800. For our study this would mean 
an additional cost savings of €18,000-€36,000 (€69-137/patient), as we eliminated 
409 discrepancies, of which 20 would theoretically cause an adverse drug event” 
Adequacy of 
study power & 
analysis  
Powered and appropriate 
statistical analysis 
Unclear There is no sufficient information to establish whether the study was sufficiently 
powered. 
Validity of 
economic 
evaluation  
Perspective High risk Very limited perspective though it was clearly established. 
Quote “The medication-related costs were analysed from a health insurer’s 
perspective. In the Netherlands, the health insurer pays for most medications 
except over-the-counter drugs and herbal products. The payments made to 
dispensing community pharmacies by health insurers are based on the cost of 
the medication dispensed plus a fixed dispensing fee of €6.10 to cover the routine 
pharmaceutical services” 
 Cost identification, 
measurement and valuation 
Unclear-high 
risk 
Labour costs were estimated based on a selected sample of the study patients 
without enough information regarding patient selection or characteristics. Thus, 
the quality of the cost measurement is unknown. Quote “To estimate the costs, 
the mean yearly salary of a pharmaceutical consultant (€50,000) was used. When 
assuming 46 annual working weeks and an efficiency rate of 70%, the 1-hour 
salary was€ 39.25. The efficiency rate of 70% was based on time not directly 
related to specific medication reconciliation activities, such as courses, meetings, 
and instructions to new hospital physicians”. Valuation process was considered of 
law risk 
 

Karapinar-Carkit et al. 2012 (continued) 
Domain  Bias Author judgement Support of judgement 
Validity of 
economic 
evaluation cont. 
Variability within the 
estimate 
Low risk Adequate sensitivity analysis was described. 
Quote “We performed a sensitivity analysis to examine best and worst-
case scenarios. To investigate the robustness of the assumptions 
regarding the medication costs, we varied the factors on reducing the 
medication costs with 50%. Thus, for the sensitivity analysis, 10% and 
30% reduction on medication costs was applied for hospital formulary–
induced interventions (initial reduction was 20% based on previous 
studies” 
 
Perennes et al. 2012 
Domain  Bias Author 
judgement 
Support of judgement 
Design bias Focus study question & design High risk Uncontrolled study in a general medicine ward on army hospital  
Selection bias External and internal variations 
of study sample  
Unclear No details on how patients were identified and screened for study legibility.  
Quote ”patients of 65 years old or more hospitalised in the ward were 
included in the study.” 
Randomisation High risk No randomisation  
Allocation concealment  High risk No Allocation concealment 
Performance bias  
 
Standardised intervention 
delivery 
Low risk The study described a standardised method for interviewing patient during 
admission and discharge reconciliation. 
Quote: “the meeting with patient was done in a standardised manner with a 
succession of open and closed questions alternatively” 
Standardised outcome 
measurement 
Low risk There is no sufficient details to establish whether identification of 
discrepancies was standardised however it was done by single reviewer. 
Additionally, unintentional discrepancies were confirmed at least by a 
minimum of two information sources 
 

Karapinar-Carkit et al. 2012 (continued) 
Detection bias Blinding of outcome 
measurement 
Unclear As uncontrolled design, potentially there was no blinding while the 
evaluation of the potential clinical impact of discrepancies. This was done 
by with two assessors; a doctor and a pharmacist.  There is no details 
whether the assessors where independent of the study neither a measure 
for the extent of agreements between raters.  
Selective reporting  Incomplete outcome data Low risk There are no concerns with regard any incomplete outcome data 
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
High risk No details whether sample size or power calculation was performed by the 
study investigators.  There are potential high risk for bias with relatively 
small sample size (n=61) 
No concerns related to the statistical analysis used 
 
Boso-Ribelleset al. 2011 
Domain  Bias Author 
judgement  
Support of judgement 
Design bias Focus study question & design High risk This is a prospective and not a real controlled study design carried out in 
cardiology and cardiovascular surgery department.   
Selection bias External and internal variations 
of study sample  
High risk Sampling method  
Patient were identified and screened for study by means that potentially 
contribute to high risk of bias. There is no details to establish whether the 
sample obtained by these means is a proper representation of the population  
Quote:” Patients were identified by means of an electronic prescription program 
and selected by date of admission, clinical service and more than four drugs 
listed in the first hospital prescription”  
Baseline comparability  
Comparator was a sample of patients not included in the study. there is no 
enough details to establish whether this comparison is valid 
Quote:” Patients with respect comparing the number of emergency visits and 
hospitalisations over the first trimester of 2007 which were experienced by the 
patients included in the programme against those experienced by  
 

Boso-Ribelles et al. 2011 
Domain  Bias Author 
judgement  
Support of judgement 
Selection bias 
cont. 
External and internal variations 
of study sample  
High risk Patients excluded from the programme due to a lack of resources. 
Baseline comparability  
Quote:” Two hundred and sixty-four patients were admitted to the cardiology 
department in the first trimester of 2007; 151 of them were included in the 
pharmaceutical care programme (average age 67.7 ± 14.5 years) versus 113 
patients (average age 69.1 ± 13.9 years) who were excluded” 
Randomisation High risk No randomisation  
Quote:” Patients were identified by means of an electronic prescription 
program and selected by date of admission, clinical service and more than four 
drugs listed in the first hospital prescription”  
Allocation concealment  High risk No allocation concealment 
Performance 
bias  
 
Standardised intervention 
delivery 
Unclear  There is no enough details to establish whether the delivery of MR was 
standardised 
Standardised outcome 
measurement 
Unclear There is no enough details to establish whether the identification of 
discrepancies was standardised 
Quote: “Discrepancies were evaluated as ‘justified’ or ‘not justified’. 
Discrepancies which were not justified were discussed with the prescribing 
physician or nurse” 
Quote:” A global analysis and validation of the prescribed treatment was 
carried out and the discharge medication list was compared with the last 
hospital prescription” 
There is no details on the means of obtaining outcome data related to 
emergency department visits and hospitalisation  
Detection bias  Blinding of outcome 
measurement 
Unclear There are no details on the means of obtaining outcome data related to 
emergency department visits and hospitalisation. Blinding of such measures 
were agreed not to influence reported outcomes  (methods, 3.2.9) 
DRP and medication errors classification and pharmaceutical interventions 
were done by the study pharmacist and consulted with physicians, nurse and 
patients who are not part of the study personal. This could potentially preclude 
bias but there are no enough details confirming whether this was the case or 
not. 
 

Boso-Ribelles et al. 2011 
Domain  Bias Author 
judgement  
Support of judgement 
Selective reporting  Incomplete outcome data Low risk There are no concerns with regard any incomplete outcome data 
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
Unclear No details whether sample size or power calculation was performed by the 
study investigators.  The study was of large sample size (n=675).   
There are no sufficient details however to establish whether study was 
powered to detect differences related to readmissions and emergency 
department visits. There was no statistical testing of significance reported 
for these outcomes 
Quote “Two hundred and sixty-four patients were admitted to the cardiology 
department in the first trimester of 2007; 151 of them were included in the 
pharmaceutical care programme (average age 67.7 ± 14.5 years) versus 
113 patients (average age 69.1 ± 13.9 years) who were excluded” 
 
Hellstrom et al. 2011 
Domain  Bias Author 
judgement  
Support of judgement 
Design bias Focus study question & design 
 
High risk This is “before and after” study design. The authors reported a 
controlled prospective deign with patient receiving the study 
intervention upon admission.  However, patient was identified for 
study participation by retrospective review  
Quote “All patients in wards A, B and C received the intervention 
after it had been implemented, but the patients evaluated 
retrospectively for eligibility for inclusion” 
Selection bias External and internal variations 
of study sample  
High risk Sampling method  
No enough details to establish whether the sample is representative 
of the patients received the service or admitted to study wards. 
Variations can be contributed by sampling at different time periods 
from each of the study wards, i.e. March 2007 to April 2008.  
  

Hellstrom et al. 2011    
Domain  Bias Author 
judgement 
Support of judgement 
Selection bias cont. Randomisation High risk No randomisation  
 Allocation concealment  High risk No allocation concealment 
Performance bias  
 
Standardised intervention 
delivery 
Low risk  The investigators described a standardised delivery of intervention 
using questionnaire which was previously published  
Quote:” The admission medication reconciliation was performed on 
weekdays, shortly after the patient had been admitted, using the 
LIMM Medication Interview Questionnaire parts 1-3”.  
Standardised outcome 
measurement 
Low risk The investigators described a standardised collection of outcome 
data related to drug related hospital visits 
Quote:” In the reviewing process, we combined clinical judgment 
with the use of predetermined triggers, namely combinations of 
drugs and symptoms or certain ‘high-alert’ medications.... The cases 
were further classified by using the World Health Organisation 
criteria for causality” 
Detection bias Blinding of outcome 
measurement 
Low risk The reviewers were blind to study allocation  
Quote: “All reviewers in the initial and final reviews were blinded to 
group allocation” 
Selective reporting  Incomplete outcome data Low risk There were no concern on missing data outcomes; intention to treat 
analysis was performed as well as pre protocol. Similar attrition rates 
were found between two groups 
Quote: “Fifteen patients in the intervention group did not receive the 
complete intervention due to a short length of stay in hospital, the 
absence of a clinical pharmacist during the weekends or closed 
wards due to an infection outbreak among the patients. In addition, 
12 intervention patients (including 2 who did not receive the 
complete intervention) and nine control patients died during the 
initial hospital stay. Eighty-four intervention patients and 92 control 
patients were therefore included in the per protocol.  
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
Low risk Power of calculation was performed for the primary outcome (MAI) 
using ITT as the MAI analysis as well as per protocol analysis 
No concerns on analysis related to drug related hospital visits 
MAI: Medication Appropriateness Index. ITT: Intentional to treat  

Makowsky et al. 2009 
Domain  Bias Author 
judgement 
Support of judgement 
Design bias Focus study question & design Unclear It is a multi-centre randomised and controlled study. Randomisation 
is on the level the care team rather than patient level 
Quote:” a 2 site “on-off” study design for 4 sites (ie, 4 teams). This 
design was chosen to allow for the presence of a comparable control 
group. Two pharmacists were recruited and each was assigned to 
rotate between a CTU team and PHCT team. For 3 months at a time 
in sequential order patients admitted to the CTU team received team 
care (“On” period) while patients on the corresponding PHCT team 
received usual care (“Off” period). At the end of each 3 month block, 
the status was reversed, and the patients admitted to the PHCT 
team received team care while patients admitted under the CTU 
team received usual care. Since the intervention was team-based 
care, the unit of randomization was at the level of the team rather 
than the patient” 
Selection bias External and internal variations 
of study sample  
High risk Sampling method 
Patients were allocated to either care teams per the usual hospital 
procedures and they were recruited in sequential order upon 
admission over 3 months period of time. Though allocation of care 
team was randomised, patients were not and this might contributes 
to selection bias.  
Baseline comparability  
Quote “Baseline demographic and clinical characteristics were 
similar in the 2 groups, however, there were more internal medicine 
patients  and fewer patients admitted with a most responsible or 
primary diagnosis of HF in the usual care group”  
Randomisation High risk Randomisation was on the level of care team rather than patients 
Quote” The unit of randomization was at the level of the team rather 
than the patient and the participating teams were randomized as to 
which would receive pharmacist team care first by flip of a coin.  
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Makowsky et al. 2009 
Domain  Bias Author 
judgement 
Support of judgement 
Selection bias cont. Randomisation High risk The unit of randomization was at the level of the team rather than the 
patient and the participating teams were randomized as to which 
would receive pharmacist team care first by flip of a coin. However, 
no randomisation on patient level 
Allocation concealment  High risk Allocation was not concealed to on or of study period 
Quote "Allocation of patients to specific patient care teams occurred 
as per usual hospital procedures" 
Performance bias  
 
Standardised intervention 
delivery 
Low risk Period to study commencing the pharmacists undertook educational 
sessions 
Quote "A series of education sessions led by local pharmacist 
experts 
(1 on each target disease state and 1 on documentation of clinical 
care activities), was conducted with the team-based pharmacists 
prior to commencing the study” 
Standardised outcome 
measurement 
Low risk A standardised process was described for secondary outcomes 
related to readmission data outcome and pharmacist intervention 
were collected 
Quote "3-month and 6-month all-cause hospital readmission was 
determined prospectively via linkage with the Capital Health regional 
admissions database. The number, type, acceptance rate, and 
expected clinical impact of pharmacist recommendations for the 2 
team-based pharmacists was reported. This descriptive data were 
captured prospectively 
using the Regional Pharmacy Services Benchmarking form” 

Makowsky et al. 2009
Domain  Bias Author 
judgement 
Support of judgement 
Detection bias Blinding of outcome 
measurement 
Low risk Blinded reviewer was reported for primary outcomes related to 
quality of care indicators. No details on who recorded the data 
related to readmission and emergency department neither whether if 
it was by blind reviewers. However, unbinding unlikely to influence 
the report of readmission or emergency department visits. 
Selective reporting  Incomplete outcome data Low risk There are no concerns about missing data outcomes 
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
Low risk The investigators perform sample size calculation; a sample size of 
650 patients was aimed however this number was not achieved 
(=452) due to funding.  The findings were found statistically 
significant though which indicates a true difference between groups. 
There are no concerns about the appropriateness of statistical 
testing, OR analysis was used adjusting to confounding factors. 
 
 
Koehler et al. 2009 
Domain  Bias Author 
judgement  
Support of judgement  
Design bias Focus study question & design Low risk A randomised controlled study 
Selection bias External and internal variations 
of study sample  
High risk  Sampling method 
Patient were screened daily to establish eligibility of study, which 
was done by study personal 
Quote " Study personnel performed daily chart review to establish 
eligibility criteria” 
Baseline comparability 
Groups were comparable in general. However, the intervention 
group trended toward higher severity of illness and mortality and 
more patient prescribed medications commonly implicated in 
adverse events (65% vs. 45%). The later was not significant.  These 
variation might influence readmissions/ED  

Koehler et al. 2009
Domain  Bias Author 
judgement 
Support of judgement 
Selection bias cont. External and internal variations 
of study sample  
High risk  Quote “...on APR-DRG measures relating to acuity of illness and 
mortality risk, patients in the intervention group trended toward 
higher severity. Likewise, although it was not a statistically 
significant difference, 13 of 20 patients in the intervention group 
were taking medications from >2 drug 
classes commonly implicated in adverse drug events (warfarin, 
insulin, diuretics, sedating agents) as part of their discharge 
medication regimen compared to 10 of 21 patients in the control 
group” 
 Randomisation Low risk No concerns about the random component described by 
investigators 
Quote “patients were randomized to intervention or usual care arms 
in permuted blocks of 8 via a random number generator and sealed 
opaque envelopes” 
Allocation concealment  Low risk No concerns about the allocation concealment component 
described by investigators 
Performance bias  
 
Standardised intervention 
delivery 
Low risk  The process described for the study intervention was standardised 
between the service providers.  
Quote “training for both study CCs and CPs was limited to a series 
of 3 meetings (each 45 minutes in duration) regarding the intent and 
delivery of the supplemental care bundle, including use of study 
forms” 
 Standardised outcome 
measurement 
Low risk There are no concerns on the process by which data outcomes 
related to readmissions or emergency department visits obtained. 
Quote “Data on length of hospital stay, illness severity (APR-DRGs), 
and unplanned hospital 
readmission or emergency department visitation at 30 and 60 days 
post discharge were collected via Boston University Medical Centre 
electronic reporting systems” 
Detection bias Blinding of outcome 
measurement 
Low risk Unbinding likely not to influence recording outcome data related to 
readmission or emergency department visit 
CC: Care coordinator. CP; clinical pharmacist

Koehler et al. 2009
Domain  Bias Author 
judgement 
Support of judgement 
Selective reporting  Incomplete outcome data Low risk No concerns about missing outcome data 
Adequacy of study power 
& analysis  
Powered and appropriate 
statistical analysis 
High risk It is a pilot study of small size; It is most likely not statistically 
powered. Insufficient power for statistical comparison was reported. 
the overall sample size is small (n=41) 
Quote “Resource and time constraints necessitated a sample size 
that would allow implementation of the intervention despite a limited 
number of study CCs and pharmacists. To accommodate these 
conditions while still generating pilot data, and priori decision was 
made to enrol up to 80 patients” 
CC: Care coordinator  
Rabi and Dahdal. 2007 
Domain  Bias Author judgement  Support of judgement  
Design bias Focus study question & design High risk This is uncontrolled observational study in cardiology consult 
service 
Selection bias External and internal variations 
of study sample  
High risk Sampling method  
All admitted patients provided the service using admission list each 
morning. However, pharmacist provided a cover of 10 days and 
there is no way to establish the variation between included and 
excluded patients  
Quote “Each morning the pharmacist would obtain the admission 
list for the unit and conduct the service on all patients admitted that 
day and the previous day...... At the end of the 4 weeks, the 
pharmacist provided a total of 10 days of coverage. Fifty-six 
medication admission histories were conducted from the 150 
patients who were admitted during the 4 weeks 
(28 days)” 
Randomisation High risk No randomisation  
Allocation concealment  High risk No allocation concealment 
  

Rabi and Dahdal. 2007 
Domain  Bias Author judgement  Support of judgement  
Performance bias  
 
Standardised intervention 
delivery 
Low risk No details whether the process of intervention delivery was 
standardised. However, this was done by a single reviewer (i.e. 
college-based primary care pharmacist resident) 
Standardised outcome 
measurement 
Unclear  No details to establish whether the process of intervention 
recording and classification  
Detection bias Blinding of outcome 
measurement 
Unclear  No details on who did the intervention classification or any effort 
which probably done by the study pharmacist. 
Selective reporting  Incomplete outcome data High risk Though 56 medication histories were conducted, there was only 40 
discharge counselling sessions reported. There are no enough 
details to establish whether this might influence outcome or the 
time estimated for discharge counselling or whether the reported 
sessions are different to one that are not (n=16).  Investigators 
reported no rational for the mission 16  
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
High risk No power of calculation. This also a with a small sample size study 
(n=56) comprising only 37.3% of patients admitted and 35.7% of 
days over the study period. 
 
Bayley et al. 2007 
Domain  Bias Author judgement  Support of judgement  
Design bias Focus study question & design High risk Uncontrolled prospective design study 
Selection bias External and internal variations 
of study sample  
High risk Sampling method 
Quote “Potential study subjects were identified from the 
hospitalist admitting census list, and were assigned for evaluation 
and follow-up by a study pharmacist.... During the course of the 
study, 105 patients were eligible or treatment by the study 
pharmacist, ninety-nine (99) of these patients were seen “ 
 Randomisation High risk No randomisation  
Allocation concealment  High risk  No allocation concealment 
Performance bias  
 
Standardised intervention 
delivery 
Unclear The study pharmacist role was developed from two pilot projects. 
However, there are no details if the delivery was standardised. 
Quote “Their role was developed from two pilot projects and an 
FMEA (Failure Mode and Effects Analysis) on medication 
information transfer across care settings” 
  

Bayley et al. 2007 (continued) 
Bias Author judgement  Support of 
judgement  
 
Performance bias cont. 
 
Standardised outcome 
measurement 
Low risk Intervention classification followed a scheme previously published. 
Estimating the time needed by the study pharmacist was recorded 
using two methods. 
Quote “Interventions made by the pharmacist were classified using 
a scheme adapted from Hatoum et al (1988)” 
Quote “Time spent on TCP interventions was assessed mid-point in 
the study period using two methods. First, the TCP was queried to 
estimate the time spent on each of the above activities in a typical 
day. She reviewed her work over a 1-week time period and 
approximated the amount of time on each activity, providing a 
range, e.g. 30 to 45 minutes. Second, a trained observer shadowed 
the TCP for a day to understand these estimates and identify any 
time commitments the TCP had overlooked. 
Time estimates were revised at study close, to take into account 
feedback from these observations and also the increased efficiency 
with the maturation of the TCP program 
Detection bias Blinding of outcome 
measurement 
High risk The process of rating intervention was standardised using a sample 
of 20 patients. Nevertheless this is done by the study pharmacist  
Quote “Classification into the “prevented serious morbidity” versus 
“prevented potential ADE” was based on the pharmacist’s judgment 
as to both the severity of potential harm to the patient and the 
probability that a specific c medication would result in harm.  
 Blinding of outcome 
measurement 
High risk The clinical pharmacist performed all of these ratings. The 
process was standardised "To verify the reasonableness of the 
ratings, ratings for the first 20 patients in the study were 
independently reviewed by the pharmacy manager and study 
author" 
Selective reporting  Incomplete outcome data Low risk No concerns about missing data outcome  
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
High risk There is no power or sample size estimation reported. No 
statistical comparison was attempted and all descriptive estimate 
related to time were reported as average with no measure of 
variation (SD, CI)   
TCP: Transitional care pharmacist. SD: standard deviation. CI: Confidence Interval. ADE: adverse drug events 
  

Scullin et al. 2007 
Domain  Bias Author judgment  Support of judgment  
Design bias Focus study question & design Low risk Randomised controlled study  
Selection bias External and internal variations 
of study sample  
Low risk Patient selection was randomised and both groups appeared similar 
at baseline  
Randomisation Low risk No concerns about the randomisation component described 
Quote “Patients meeting the eligibility criteria were randomly 
assigned 
to the study group or normal care group, using block randomization 
coupled with a closed envelope technique. Randomization was 
carried out in blocks of 20 (each block contained 10 intervention and 
10 normal care allocations). 
Allocation concealment  Low risk Allocation concealment was done by closed envelop technique 
Performance bias  
 
Standardised intervention 
delivery 
Low risk Through all the study process the use of SOPs and customised data 
collection form was reported 
Quote “For each stage, standard operating procedures and 
customized data collection forms were used” 
Standardised outcome 
measurement 
Low risk  Intervention grading was audited by a pharmacist independent of 
the study. The outcome data related to readmission obtained from 
the hospital system. 
Quote “The grading of all interventions was independently audited 
and reviewed by a non-project clinical pharmacist....12-month 
follow-up period, readmission data for the two groups were collected 
from the hospital computer system and included assessment of the 
time to a further hospital admission as well as the number of 
readmissions” 
Detection bias Blinding of outcome 
measurement 
Low risk Intervention grading was audited by a pharmacist independent of 
the study. Unbinding unlikely to influence outcome data related to 
readmission (methods 2.4.9) 
Selective reporting  Incomplete outcome data Low risk No concerns about missing outcome data  
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
Low risk No power or sample size calculation reported however the pilot of 
the service indicate providing service for 50%. Though there is no 
enough details to estimate study power, sample size is large 
(n=762) and differences were found statistically significant indicating 
a potential real effect the study was able to detect  
 
  

Bolas et al. 2003 
Domain  Bias Author 
judgement  
Support of judgement  
Design bias Focus study question & design Low risk Randomised controlled design 
Selection bias External and internal variations 
of study sample  
Low risk  Both study group were comparable  
Quote “Patients were matched in the study and control group for sex, 
age length of hospital stay, social circumstances, average number of 
drugs on admission, average number of drugs on discharge and the 
number of changes made to therapy during the hospital stay” 
Randomisation Low risk No concerns about the randomisation component reported by 
investigators 
Quote “patients were randomized into study or control group by 
allocation of a computer generated random number” 
Allocation concealment  Low risk It was not possible to foresee the study allocation  
Performance bias  
 
Standardised intervention 
delivery 
Low risk Medication history and data collection was standardised. 
Quote “drug history data collection form was used to record details of 
drug treatment. A standard drug history data collection form.... A form 
was designed to assess patient recall of their treatment and the labelling 
of dispensed medication under the same headings for the follow up” 
Standardised outcome 
measurement 
Low risk Interventions were graded using a validated tool and this was done 
independently by a hospital pharmacist and medical consultant. 
However, the study provided no estimate of assessor agreement 
Quote “Interventions made during the preparation of the medication 
history were graded using the Eadon system (0 being detrimental to 
patient health through to 6 which is potentially lifesaving). The outcome 
scores were awarded independently by a hospital pharmacist and 
medical consultant” 
Detection bias Blinding of outcome 
measurement 
Unclear  No details whether assessors of interventions were blind to study 
allocation 
Selective reporting  Incomplete outcome data Low risk Data outcomes related to ED rates was not reported completely. 
Investigators only reported statistical significance  
Quote “There was no significant differences (P > 0.05) in the number of 
readmissions between groups nor in the average length of stay during 
readmission” 
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
High risk No power or sample size calculation reported.  
  

Stowasser et al. 2002 
Domain  Bias Author 
judgement  
Support of judgement  
Design bias Focus study question & design Low risk Random controlled study from 12 medical and 5surgical units 
Selection bias External and internal variations 
of study sample  
Low risk No significant differences between groups at baseline.  
Quote “ At baseline there were no significant differences between 
study intervention group and control with respect to demographic 
and clinical variables, number of medications, medications omitted 
from the discharge summary and SF-36 scores” 
Randomisation Low risk Patient were randomly selected  
Quote “ patient was selected from daily admissions list using a 
random number generation and systematic sampling” 
Allocation concealment  Unclear  There are no enough details to establish allocation concealment. 
Using systematic sampling might allow the foresee of allocation  
Performance bias  
 
Standardised intervention 
delivery 
Low risk A clinical pharmacist obtained a comprehensive medication history 
on admission which was confirmed by the admitting doctors. 
Standardised outcome 
measurement 
Low risk There are no concerns about outcome measurement. Outcome data 
was obtained via postal questionnaires and computer system check  
Quote “Computer information system were reviewed one month after 
discharge to identify any readmission within 30 days. Subject who 
died were identified through this computer system or through 
notification by the carer” 
Detection bias Blinding of outcome 
measurement 
Low risk  No details whether obtaining outcome data was done by blind 
assessor. However, this unlikely to influence outcomes. 
Quote “Post discharge outcome were obtained by postal survey. 
Computer information systems were reviewed one month after 
discharge to identify any readmission within 30 days. Subject who 
died were identified through this computer system or through 
notification by the carer.  
Selective reporting  Incomplete outcome data High risk Missing outcome data related to emergency department visits 
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
High risk No power or sample size calculation reported 
 
 
 

Hick et al. 2001 
Domain  Bias Author 
judgement  
Support of judgement  
Design bias Focus study question & design High risk Non-randomised controlled observational study  
Selection bias External and internal variations 
of study sample  
Unclear Both groups were matched; however there was high potential for 
selection bias. Patients in both groups were selected from different 
consultant list, and selected consecutively.  
Quote “For the intervention (PAC) group, a sample of consecutive 
eligible patients was taken from one consultant’s list. The first fifty 
patients on that list (aged over 29 years) were seen by a pharmacist 
in the PAC. For the control (ward) group, an equal number of 
consecutive eligible patients were taken from the list of another 
consultant with similar case mix. Control and intervention groups 
were matched as far as possible for type of procedure and age, and 
the same pharmacist was responsible for their pharmaceutical care” 
Randomisation High risk No randomisation  
Allocation concealment  High risk No allocation  
Performance bias  
 
Standardised intervention 
delivery 
Low risk Intervention delivery was standardised  
Quote “Pharmaceutical PAC assessment comprised: taking a 
written patient medication history using standard documentation; 
writing each patient’s usual” 
 Standardised outcome 
measurement 
Unclear Interventions was rated using two tools; VAS and Modified Hatoum 
scale.  
Though using two tools was aimed to minimise potential bias plus 
using four senior pharmacists rating every intervention. Agreement 
was found  
not significant for VAS. The second tool was modified and thus it is 
unclear whether it would be valid to give reproducible results. 
Quote “Analysis of variance (ANOVA) showed no significant 
agreement between different assessors’ VAS scores (p<0.001). 
Second panel (comprising four senior pharmacists, with equal 
experience to the first) graded interventions using a 1 (adverse 
effect on patient) to 6 (potentially lifesaving) scale..... the modal 
grade obtained from three assessors was deemed the severity 
index for each intervention. The fourth assessor’s mark was used as 
a casting vote where there was no agreement”.  
 

Hick et al. 2001    
Domain  Bias Author 
judgement  
Support of judgement  
Selective reporting  
Adequacy of study 
power & analysis  
Incomplete outcome data Low risk No concerns about missing outcome data  
Powered and appropriate 
statistical analysis 
High risk No power or sample size calculation.  

Brookes et al. 2000 
Domain  Bias Author 
judgement  
Support of judgement  
Design bias Focus study question & design High risk Non randomised and uncontrolled design 
Selection bias External and internal variations 
of study sample  
Unclear  No details on who and how patients were identified or screened  
Quote “The patients in the study (109) contributed 15% of all 
patients over 60 years of age admitted” 
Randomisation High risk  No randomisation  
Allocation concealment  High risk No allocation concealment  
Performance bias  
 
Standardised intervention 
delivery 
Unclear  There are no details whether the intervention delivery was 
standardised. 
Standardised outcome 
measurement 
Unclear There are no details whether the outcome measurement was 
standardised.  No details how outcome data related to readmission 
data was obtained 
Detection bias Blinding of outcome 
measurement 
Low risk There are no details whether outcome measurement was blinded.  
However this unlikely to influence outcomes measured related to 
readmission rate 
Selective reporting  Incomplete outcome data Low risk There are no concerns about missing outcome data 
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
High risk  Power or sample size calculation was not reported. 
 
  

Kramer et al. 2007 
Domain  Bias Author 
judgement  
Support of judgement  
Design bias Focus study question & design High risk  Before and after design  
Selection bias External and internal variations 
of study sample  
High risk Patient selection and screening was guided by triggering question by 
study nurse. There were differences between the two phases 
patients at baseline related to no. of medication  
Quote “Potential study participants were identified through a set of 
trigger questions that the nurse asked patients during the admission 
assessment” 
 
Quote “significantly more patients in the post-implementation group 
were taking seven or more Medications (p < 0.0001; 95% CI, 
0.5284–0.7604) and had a history of coronary artery disease (CAD) 
(p < 0.0001; 95% CI, 0.3274–0.5444)” 
Randomisation High risk No randomisation  
Allocation concealment  High risk No allocation concealment 
Performance bias  
 
Standardised intervention 
delivery 
Low risk The study intervention was standardised via educational session for 
all health care staff involved. 
Quote “nurses and pharmacists attended education sessions before 
study initiation. A flow chart was created to guide nurses through the 
admission and discharge medication reconciliation documentation 
process. All pharmacists attended a three-hour, hands-on computer 
education session” 
Standardised outcome 
measurement 
Low risk Outcome measurement was standardised  
Quote “The number and type of potential errors prevented at 
admission and discharge were identified by the mean number and 
type (intervention subcategory) of reconciliation interventions or 
discrepancies documented in the computerized database. Severity of 
potential errors prevented were categorized using the hospital’s 
policy for categorizing medication errors and the 30-day readmission 
rate”  
 

Kramer et al. 2007 
Domain  Bias Author 
judgement  
Support of judgement  
Detection bias Blinding of outcome 
measurement 
High risk This is after and before study, blinding is not possible as such for data 
on intervention categorisation though it was using the hospital policy and 
30 day readmission rate.  
Selective reporting  Incomplete outcome data High risk Missing details on medication errors and potential impact. 
Quote “attempts were made to determine potential medication errors, 
the effect of the medication reconciliation process on medication errors 
could not be determined due to the lack of intervention documentation in 
both 
study phases” 
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
High risk No power or sample size calculation 
 
 
 
Gillespie et al. 2009 
Domain  Bias Author 
judgement  
Support of judgement  
Design bias Focus study question & design Low risk Randomised controlled design 
Selection bias External and internal variations 
of study sample  
Unclear  Differences between the two groups related to no. of prescribed 
medication and history cerebral vascular lesion. However, this was one 
medication difference on average  
Quote “The groups were well balanced except in 2 respects. First, more 
patients in the intervention group had a history of cerebral vascular lesions 
(20.9% vs. 10.2%, P=.006). Second, the intervention group patients were 
taking more prescription drugs (8.7 vs. 7.3, P=.004).  
 Randomisation  No concerns about randomisation component 
Quote “Randomization was performed in blocks of 20 (each block 
contained 10 intervention and 10 control allocations) and using closed-
envelope  
 Allocation concealment  Low risk Closed-envelope technique was used 
  

Gillespie et al. 2009 
Domain  Bias Author 
judgement  
Support of judgement  
Performance bias  
 
Standardised intervention 
delivery 
Low risk Intervention delivery was standardised. 
Quote “Standard operating procedures for the enhanced service were 
prepared by the study pharmacists (U.G. and A.A.) during the preceding 
pilot study and were peer reviewed in an open forum multi-professional 
discussion and revised accordingly.  
 Standardised outcome 
measurement 
Low risk Classification of related to drug related readmission were performed by a 
blind assessor. Additionally, analysing readmission data was done by 
blind researchers.  
Quote “The electronic medical records were used to establish the reasons 
for readmission and the current medication list for each readmission. The 
physician in charge of the patient was required to document in the medical 
record if readmissions were drug related. The physicians making this 
decision were blinded as to whether the patients were study participants. 
The researchers (U.G. and A.A.) responsible for analysing readmission 
data were blinded regarding the group to which the patients had been 
randomized”  
Detection bias Blinding of outcome 
measurement 
Low risk Rating and analysing readmission outcome data was done by blind 
investigators 
Selective reporting  Incomplete outcome data High risk  There are missing outcome data related to transcription errors and 
omission 
Quote “Transcription errors and faulty omission or addition of drugs were 
frequently detected by the pharmacists. There was limited information in 
the case notes about reasons for visits and about patients’ medication use 
before visits. Therefore, analyses of drug-related emergency department 
visits were not possible” 
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
Low risk The sample size calculations were based on results from a previously 
performed pilot investigation and from a study conducted by Scullin et al. 
To detect a 15% reduction in hospital visits with 80% power, we needed to 
enrol 162 patients in each group. As such the study was sufficiently 
powered  
 
  

Vira T et al. 2006 
Domain  Bias Author 
judgement  
Support of judgement  
Design bias Focus study question & design High risk  Patient were selected randomly but the study is not controlled  
Selection bias External and internal variations 
of study sample  
Low risk Patients were randomly selected with 60 patients selected from 168 
admissions. 
Randomisation Low risk Random number table was used 
Quote “A random number table was used to select patients from all 
new admissions to the units in the previous 24 hours” 
Allocation concealment  High risk No allocation concealment 
Performance bias  
 
Standardised intervention 
delivery 
unclear No details whether intervention delivery was standardised.  
Standardised outcome 
measurement 
Unclear  No details whether outcomes measurement was standardised 
Detection bias Blinding of outcome 
measurement 
High risk No details whether the assessor of discrepancies was blind but the 
study is not controlled as such there was no blinding 
Quote “An internist reviewed each unintended variance to assess 
the potential and/or actual clinical importance. Unintended variances 
were classified as clinically important if they caused or had the 
potential to cause death, permanent or temporary disability, 
prolonged hospital stay, readmission, or the need for additional 
treatment or monitoring to protect the patient from harm” 
Selective reporting  Incomplete outcome data Low risk  No concerns about missing outcome data.  
Quote “Of the 60 patients enrolled, 56 were followed until discharge, 
two had not been discharged at the end of the study period, and two 
died in hospital; the latter four patients were excluded from 
discharge medication reconciliation analysis.  
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
High risk No sample size calculation  
 
 

Spinewine et al. 2007 
Domain  Bias Author 
judgement  
Support of judgement  
Design bias Focus study question & design Low risk Randomised controlled design study  
Selection bias External and internal variations 
of study sample  
Low risk  Both group comparable and where screened by independent person  
Quote "A pharmacist external to the main study checked inclusion 
criteria and assigned participants to their groups.... No significant 
differences were present in the characteristics of patients at 
baseline” 
Randomisation Low risk Randomization was alternate and stratified for age (<85 vs.≥ 85), 
number of prescribed medicines (<5 vs. ≥5), and identity of the 
resident in charge of 
the patient 
 Allocation concealment  Low risk Using alternate and stratified selection might undermine concealment, 
however screening against inclusion and exclusion criteria was done 
by person independent from the study 
Performance bias  
 
Standardised intervention 
delivery 
Low risk The study pharmaceutical care from admission to discharge 
according was performed by a validated scheme  
Quote "The intervention consisted of a clinical pharmacist (AS) 
providing pharmaceutical care from admission to discharge according 
to a validated scheme described in detail elsewhere” 
 Standardised outcome 
measurement 
Low risk The process followed for outcomes measurement was standardised 
Quote "Additional outcome measures were collected after discharge. 
All patients were followed up 1 month, 3 months, and 1 year post-
discharge through telephone calls performed by two trained hospital 
pharmacists (SA and SB) who were blinded to group assignment and 
not involved in patient care. One of these two pharmacists (SA) and 
the main investigator (AS) developed the questionnaire” 
 

Spinewine et al. 2007 
Domain  Bias Author 
judgement  
Support of judgement  
Detection bias Blinding of outcome 
measurement 
Low risk Outcome measurement was blinded and collected by two pharmacists. 
Outcome data related to hospital revisits were also doubled checked when 
applicable. 
Quote "All patients were followed up 1 month, 3 months, and 1 year post-
discharge through telephone calls performed by two trained hospital 
pharmacists (SA and SB) who were blinded to group assignment and not 
involved in patient care. Data, which the person preparing the medications 
(patient or caregiver) provided, included the following: mortality, 
readmission or visit to an emergency department (double checked with 
the hospital record when applicable)”  
Selective reporting  Incomplete outcome data Low risk No concern about missing outcome data, attrition rate was similar 
between groups. Attrition rates for both groups (control vs. intervention) 
was; (10% vs. 6.8% lost to follow up), (2.2% vs. 1%) at 1 month, (2.2% vs. 
1.1%) at 3 month (3.5% vs. 5.3%) at 1year. 
 Incomplete outcome data Low risk Quote "The percentages of patients for whom data were available after 
discharge were as follows: at 1 month, 98% (88/90) of control and 99% 
(95/96) of intervention patients for clinical data and 84% (72/86 patients 
alive) of control and 83% (79/95 patients alive) of intervention patients for 
pharmaceutical data; at 3 months, these percentages were 96% (86/90) 
and 98% (94/96) and 86% (68/79 patients alive) and 85% (75/88 patients 
alive), respectively; and at 12 months, 92% (83/90) and 93% (89/96) 
Adequacy of study 
power & analysis  
Powered and appropriate 
statistical analysis 
Low risk  Sample size calculation was performed.  ITT analysis was not performed; 
however differences between groups for outcomes related to mortality, 
readmissions and emergency department visits were found not statistically 
significant. 
ITT: Intention to treat.  

 
 
 
 
 
 
 
 
 
 
 
 
Appendix 19 Medicine reconciliation at the 
health interface data collection and 
recuitement barriers 
 

Data collection process challenges 
Process Issue Solution  
Control MR forms Higher number than anticipated for patients possibly receive 
usual care MR.  
Control forms relocated so as not to make it oblivious to the 
staff that MR had not been performed 
 Uncompleted (blank) control MR forms The study researchers realised that they need to check 
medical notes in addition to MR forms as these very often not 
completed 
Allergy information  Lack of a field in the intervention form to record the time 
spent by the pharmacist clarifying allergy information  
The form was amended to record details of allergy 
interventions. 
 
Time to photocopy post 
intervention notes and 
charts 
The study researchers photocopied post intervention charts 
shortly after the MR pharmacist visit.   
The study researchers realised that they need to photocopy 
post intervention charts allowing ample time After MR 
intervention 
Obtaining at least two 
updated sources of patient 
information  
It was not accessible to obtain GP lists during weekends.   
 
The study researchers attempted to identify other sources of 
information.   
 No other updated source was attainable (i.e. only very old 
discharge letter, no patient own drugs).   
The MR pharmacist relied on patients or carers and obtained 
the GP list on Monday and re-checked the history reconciled. 
 Patient had no previous admissions or had been discharged 
over one year ago.   
It was agreed that a discharge letter dated more than one 
year ago from the study admission not to be considered an 
updated source of medicine information.   
 Discrepancies between patient sources of information 
identified three month post discharge in control patients, i.e. 
absences of a third source of information  
An omission discrepancy was considered if the medicine was 
listed by at least two sources. Omissions of pre-admission 
medicine identified by only one source of information were 
considered with caution as that patient might be no longer 
taking it. 
Post discharge health 
resource use  
Omissions and ambiguities within the returned 
questionnaire 
The study researchers called patients to clarify the omitted or 
unclear responses.   
 Mismatches in readmissions identified by hospital system 
details between self- reported and  
The study researchers called patients to clarify the discrepancy 
in the information  
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Data collection process 
Process Issue Solution  
Post discharge health 
related quality of life 
Patient was in hospital at the time 3 month health related 
quality of life was due.  
 
The questionnaire was not sent until patient discharged.  This 
was two weeks beyond the intended time point.   
 GP practice took 6 weeks (4 weeks when adjusting for 
Christmas and new year holidays) to confirm patient not 
being deceased 
questionnaire was sent 6 weeks beyond the intended time 
point 
 
 One patient withdrawn beyond the three months point of his 
discharge 
Questionnaire was sent to the patient on time.  Beyond the 
point he withdrawn no future contact was intended.   
 One patient died beyond the 3-months point of his 
discharge 
Questionnaire was posted to the patient at the time it was due.  
Beyond the point he was deceased no further contact was 
done. 
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Barriers to recruitment related to patient identification and time constraints 
Process Issue Solution  
Patient identification  
 
Lack of hospital system update and inaccuracies  The study researcher to contact ward clerks to clarify patient 
eligibility for the study.   
 Confirming a patient was prescribed at least one medicine 
or not seen by a pharmacy staff was not possible without 
conversing with patient 
The nurse was asked to obtain a verbal consent from the 
patient enabling the study team to approach patients. 
Patient and nurses 
unavailability 
 
patient meals, sleeping, medicines, medical rounds, 
procedures or self-care  
- 
 Busy nursing staff - 
Obtaining patient 
information from the GP 
GP practices did not response promptly  The study researchers initiate one or more phone contacts 
and/ or fax to obtain the GP list 
Obtaining patient Medical 
notes and medicine chart 
Obtaining the patient medical notes and medicine charts  The study was not to interfere with the medical rounds or the 
clinical team use of medical notes and medicine charts.   
 
It was time consuming to locate the medical notes of 
discharged or transferred patients; this required the  
The study researchers sought an access to the hospital 
medical notes library or/and contacting the ward clerks and 
outpatient clinics. 
Photocopying, scanning 
and fax use 
 
Photocopying and scanning of medical notes, medicine 
charts, patient own drugs was time consuming 
Liaison with the wards clerks or the nursing staff to facilitate the 
use of the ward fax machine. 
 
 Shortcoming with paper, ink or maintenance added to the 
time consumed by the study the study researchers to 
perform these tasks. 
 
Outcomes data collection 
and entry 
The task of inputting outcomes data to the database was 
laborious.   
Time was committed to develop standard operating procedure 
guiding the data collection and entry.   
 The study database was underdevelopment with respect to 
layout and user utility.   
The study researchers devoted time to test the database by 
inputting actual data followed by feedback and discussion with 
the IT supporting team 
Communication with other 
health professionals and 
patients  
 
Considerable time was committed to communicate with the 
ward nurses or pharmacy staff to facilitate recruitment or 
consenting.   
 
- 
 Time was spent posting follow up questionnaires and 
contacting GP practices to obtain a list of medicines the 
patient is taking 3 month 
 
 In addition, time was spent by the RAs posting letters to 
informing the GPs of the patient enrolment. 
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Appendix 20 Amendments suggested for the 
MedRec database 
 
  


Issue Description Suggestion/ solution 
No opt to construct a 
standard goal list of patient 
medicines collated from the 
different sources 
This is mainly relevant for control 
patients, without constructing this 
list the patient’s medication 
history can’t be verified 
efficiently.  For the interim 
analysis these lists were 
constructed manually.  
Modify database to facilitate 
construction of gold standard 
medicines list collating 
information from different 
sources 
Instability of the database  System errors frequently occurred 
and as a consequence the user 
ought to restart the Internet 
Explore application 
Issue has been reported to 
the IT team  
User entry errors 
 
The first three months data was 
inputted by the study RAs and the 
thesis author (EH).  Upon the 
discrepancies analysis 
inaccuracies with medicines 
information entry was found 
common and related mainly to 
differences between users 
inputting similar details in different 
ways, human errors and typo 
errors.  
 
o Standard operating 
procedures were 
developed to guide data 
entry; however, user 
training is crucial.   
o A part- time researcher 
joined the study to support 
administrative tasks 
related to data entry 
o Database user interface 
should be revised and 
organised in simpler, easy 
to fill manner 
o The database is equipped 
with an option to copy 
medicine lists across the 
different study time points, 
i.e. admission, discharge 
and three months post 
discharge.  Inappropriate 
use of this option 
contributed to errors and 
inaccuracies.  The usability 
of the copy option should 
be revised 
Data extraction 
 
The database is equipped with an 
extraction option into an excel 
format.  This assisted data 
analysis to a great extent; 
however, the excel output can be 
refined 
o Medicines details are 
extracted into columns; 
transposing extracted data 
into rows would be easier 
to analyse and export to 
data processing software  
 
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Issue Description Suggestion/ solution 
Data extraction cont.  o Details on duration, 
readmissions, person 
prepared admission chart 
and discharge letter, 
allergy and co-morbidities 
cannot be extracted.  An 
extraction option to these 
detailed is desired 
Maintenance support 
 
System errors and unavailability 
of maintenance support hindered 
recruitment in few instances. 
Additionally, IT support was not 
available during weekends or out 
of working hours.   
o Maintenance and IT 
helpline to cover 
weekends is demanded 
  

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Appendix 21 Details of unreturned health 
related quality of life and health resoucre use 
questionniares  
  


Issue*  No. of patient  Description  
Address changed Two patients Patients moved and consequently the contact details of 
those patients and the GP practices were lost to follow up. 
One of those two patients was readmitted and an updated 
contact address was obtained from the hospital system.  
The questionnaire was posted to the patient new address 
at the point of 6 weeks of his discharge.   
For the other patient, a phone contact was available and 
the questionnaire was re-sent upon confirming the new 
address.  However, this was 4 weeks beyond the 
intended time point.   
Hospitalisation  One patient The patient was in hospital at the time health related 
quality of life and health resource use was due.  As such, 
the questionnaire was not sent until patient discharged.  
This was two weeks beyond the intended time point.   
 
GP practice 
delayed response  
One patient The GP practice took 6 weeks (4 weeks when adjusting 
for Christmas and new year holidays) to confirm patient 
not being deceased and therefore the questionnaire was 
sent beyond the intended time point. 
Withdrawn One patient The patient Withdrawn beyond the three months point of 
his discharge, the questionnaire was sent to the patient 
on time. Beyond the point he withdrawn no future contact 
was intended.   
Death One patient One patient died beyond the three months point of his 
discharge and similarly the questionnaire was posted to 
the patient at the time it was due.  Beyond the point he 
was deceased and no further contact was done 
*Up to the time of this analysis none of these patients returned the questionnaires. GP: General practitioner 
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Appendix 22 Examples of medication errors 
identified by the MedRec interim analysis 
  


Description of errors Score 
Patient: Age: 86 years; Co-morbidities: Type 2 diabetes mellitus, 
hypercholesterolemia & osteoporosis; Presenting diagnosis: chronic cardiac failure; 
Length of hospital stay: 12 days 
Point of care: Admission  
Error type: Changed dose                         
Error Details:      
 
 
 
3.5 
Patient: Age: 74 years; Co-morbidities: hypertension, chronic kidney disease & 
history of deep vein thrombosis; Presenting diagnosis: Acute gout; Length of hospital 
stay: 4 days 
Point of care: Discharge 
Error type: Changed dose                         
Error Details:   
 
 
 
 
3.5 
Patient: Age: 71 years; Co-morbidities: chronic cardiac failure hypothyroidism, 
recurrent falls & atrial fibrillation; Presenting diagnosis: Shortness of breath; Length of 
hospital stay: 23 days 
Point of care: Discharge 
Error type: Addition                         
Error Details:      
 
 
 
4.75 
Patient: Age: 86 years; Co-morbidities: Type 2 diabetes mellitus, 
hypercholesterolemia & osteoporosis; Presenting diagnosis: Chronic heart failure ; 
Length of hospital stay: 12 days 
Point of care: Admission  
Error type: Omission                         
Error Details:  
 
 
2 
Patient: Age: 53 years; Co-morbidities: End stage renal failure, ischaemic heart 
disease, Chronic pancreatitis, hypertension, Type 2 diabetes mellitus; Presenting 
diagnosis: Troponin negative chest pain; Length of hospital stay: 3 days 
Point of care: Discharge  
Error type: Changed formulation                         
Error Details: 
 
 
 
2.75 
POD: Patient own drugs. bd:twice daily.od: once daily. MR: modified release.od:once daily 
Pre-admission (PODs, GP list): Metformin 1000 mg 2 tablets bd 
Inpatient &Discharge    Metformin 1000 mg 1 tablets bd 
GP list 3 months post discharge: Metformin 1000 mg 2 tablets bd 
Pre-admission (GP list only):  Doxazosin 4 mg  2 tablets om 
Inpatient &Discharge:   Doxazosin 4 mg  1 tablets om 
GP list 3 months post discharge: Doxazosin 4 mg  2 tablets om 
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Pre-admission (GP list only):  Tolterodine tartrate MR  4 mg capsule od 
Inpatient & Discharge:   Omitted  
GP list 3 months post discharge: Not prescribed 
Inpatient:    Oxycodone MR  40 mg 1 tablet  bd  
Discharge:    Oxycodone  40 mg 1tablet  bd  
GP list 3 months post discharge: Oxycodone  40 mg 1tablet  bd 


Description of errors score 
Patient: Age: 66 years; Co-morbidities: Diverticular disease, Previous transient 
ischemic accident, hypertension, hypercholesterolemia & left total knee 
replacement; Presenting diagnosis: Bleeding, abdominal pain, dizziness; Length of 
hospital stay: 4days 
Point of care: Discharge 
Error type: Discontinuation 
Error Details: 
 
 
4.5 
Patient: Age: 71 years; Co-morbidities: Parkinson's disease, Previous chronic 
cardiac failure; presenting diagnosis: shortness od breath; length of hospital stay: 
9days 
Point of care: Admission 
Error type: Changed dose                         
Error Details: 
 
 
 
 
2 
Patient: Age: 66 years; Co-morbidities: Diverticular disease, breast cancer 
(mastectomy) & hypertension; Presenting diagnosis: Fall; Length of hospital stay: 4 
days 
Point of care: Discharge 
Error type: Discontinuation                        
Error Details:  
 
 
 
 
 
 
1 
Patient: Age: 86 years; Co-morbidities: Chronic cardiac failure., prostate cancer, Type 
2 diabetes mellitus, peripheral neuropathy & hypertension; Presenting diagnosis: 
Exacerbation of chronic cardiac failure; Length of hospital stay: 4 days 
Point of care: Admission 
Error type: Omission                         
Error Details:  

 
2 
om: in morning. on: in evening. bd: twice daily  
Pre-admission (PODs, GP list): Exemestane  25 mg 1tablet  om  
Inpatient:    Exemestane  25 mg 1tablet  om 
Discharge:    Omitted  
Pre-admission (PODs, GP list): Amitriptyline  10 mg 1 tablet  on 
Inpatient & Discharge:   Amitriptyline  20 mg 1 tablet  on 
GP list 3 months post discharge: Amitriptyline  20 mg 1 tablet  on 
Pre-admission (PODs, GP list): Piroxicam  gel bd  
Inpatient:    Piroxicam  gel bd 
Discharge:     Omitted 
6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Pre-admission (GP list, previous discharge summary): Latanoprost  eye drop  2 drops  both eyes 
Inpatient & Discharge: Omitted 
GP list 3 months post discharge: Latanoprost  eye drop  2 drops  both eyes 


 
 
 
 
 
 
 
 
Appendix 23 Examples of intentional 
discrepancies 
 
 
  

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Description of discrepancy  Classification 
Patient: Age: 87 years; Co-morbidities: Atrial fibrillation; 
Presenting diagnosis: Collapse of unknown reason; Length of 
hospital stay: 3 days 
Point of care: Discharge 
Discrepancy type: Discontinuation  
Discrepancy Details: 
 
 
 Undocumented 
Patient: Age: 87 years; Co-morbidities: Atrial fibrillation; 
Presenting diagnosis: Collapse of unknown reason; Length of 
hospital stay: 3 days 
 
Point of care: Discharge 
Discrepancy type: Change 
Discrepancy Details: 
 
 
 
 Documented 
Patient: Age: 65 years; Co-morbidities: Pancreatic cancer, 
previous pericarditis, obstructive jaundice stent; Presenting 
diagnosis: Stent related infection/sepsis; Length of hospital 
stay: 8 days 
Point of care: Discharge 
Discrepancy type: Change                        
Discrepancy Details:  
Inpatient: Dalteparin 5000 unit  SC od 
Discharge: Omitted  
GP list 3 months post discharge: - 
 
 Undocumented 
Patient: Age: 65 years; Co-morbidities: Pancreatic cancer, 
previous pericarditis, obstructive jaundice stent; Presenting 
diagnosis: Stent related infection/sepsis; Length of hospital 
stay: 8 days 
Point of care: Discharge 
Discrepancy type: Discontinuation                         
Discrepancy Details:  
 
 
 Undocumented 
Patient: Age: 86 years; Co-morbidities: Diverticular disease, 
previous transient ischemic accident, hypertension, 
Hypercholesterolemia & Left total knee replacement; 
Presenting diagnosis: Abdominal pain/ dizziness; Length of 
hospital stay: 4 days 
Point of care: Discharge 
Discrepancy type: substitution                          
Discrepancy Details:  
 
 
 
 
 undocumented 
GP: General practitioner. qds: four times a day. Bd: twice time a day. SC: subcutaneous. tds: three times a 
day 
Inpatient: Codeine phosphate 30-60 mg as required 
+	
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Inpatient  Cyclizine  50 mg  tds as required 
 Discharge: Omitted 
GP list 3 months post discharge: - 
Inpatient: Chlordiazepoxide 10mg   qds 
Discharge: Chlordiazepoxide 10 mg  bd  
6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9ot known 
Pre-admission Navispare 2.5mg/250mcg   od 
Inpatient  Navispare 2.5mg/250mcg   od 
Discharge: Substitution into co-amilofruse 5/40 od 
GP list 3 months post discharge:  Co-amilofruse  5/40 mg  od 


 

